nct_id,brief_title,page_rank_score_brief_title,page_rank_score_brief_title_summary_combined
NCT01762020,Barrier Film vs. Standard Skin Care in Preventing Dermatitis in Women With Breast Cancer Receiving Radiation,0.00024442990340196755,0.00022898777246379992
NCT01728506,An Internet-based Weight Loss and Exercise Intervention for Breast Cancer Survivors,0.00032942409823572607,0.00035381636805163037
NCT01731769,Preventing Seroma Formation After Axillary Lymph Node Dissection for Breast Cancer by Early Vacuum Assisted Closure,0.000272711134440421,0.0002424524976172291
NCT01785420,Pre Operative Trastuzumab in Operable Breast Cancer,0.00048375288864420873,0.0004830463779709904
NCT01758445,Proton Radiation for Stage II/III Breast Cancer,0.00034429257137097186,0.0003094921981197849
NCT01752907,Effect of Patient Education on Reported Bone Pain in Breast Cancer Patients Receiving Chemotherapy and Pegfilgrastim,0.0003010072438272308,0.0003196033110914862
NCT01788839,Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma,0.00028543200094982747,0.00028812007046329134
NCT01766297,Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer,0.00025776184284088456,0.00031120657571604587
NCT01784120,A Phase II Trial of Doxorubicin and Genexol-PM in Patients With Advanced Breast Cancer,0.0003329072118393578,0.00028108180806533847
NCT01777958,HELENA Study: An Observational Study of Perjeta (Pertuzumab) in First-Line Treatment in Patients With Her2-Positive Advanced Breast Cancer After Adjuvant Herceptin Therapy,0.00035387124945453116,0.00036037962235874107
NCT01777802,"Immune Responses in Prostate, Lung, Melanoma and Breast Cancer Patients Following Stereotactic Body Radiotherapy (SBRT), Intensity Modulated Radiotherapy (IMRT) or Brachytherapy",0.00029254614212880094,0.00019761273125899208
NCT01727362,Evaluation of Effectiveness of Acupuncture on Quality of Life in Patients With Breast Cancer Receiving Chemotherapy,0.0003093956061427856,0.00038623853746170406
NCT01723774,PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer,0.00025336444330415387,0.0003038274216927732
NCT01723592,The Ability of Orally Administered Lactobacillus Species to Improve the Quality of the Vaginal Flora of Women With Breast Cancer and Chemotherapy.,0.00025188538015698985,0.00028533418774836605
NCT01723943,Educational Counseling in Improving Communication and Quality of Life in Spouses and Breast Cancer Patients,0.00031252855030881166,0.0002780678327377191
NCT01767168,Study to Test the Value of a Pain Modulation Test in Predicting Persistent Postoperative Pain After Breast Cancer Surgery,0.00027626945714800304,0.0002780688941418933
NCT01776008,Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer,0.00029474449169525786,0.0003269744174723754
NCT01791998,Magnetic Resonance Thermal Image Guided Laser Interstitial Thermal Therapy in Treating Patients With Breast Cancer,0.0002915198922817289,0.00027574900280438183
NCT01791985,AZD4547 & Anastrozole or Letrozole (NSAIs) in ER+ Breast Cancer Patients Who Have Progressed on NSAIs (RADICAL),0.00035508006092601285,0.0003603404033667332
NCT01736605,The Effect of Meditation and Massage Therapy for Breast Cancer Patients Undergoing Tissue Reconstruction,0.0002931941975511276,0.0002850848485396725
NCT01736306,Biomarkers for Breast Cancer Risk in African American Women,0.0004709342382672909,0.0002798419435267018
NCT01755208,Light-Scattering Spectroscopy for Detection of Breast Cancer,0.00032869607615644656,0.0003242981195295075
NCT01795612,Adapted Physical Activity Effect on Aerobic Function and Fatigue at Home in Patients With Breast Cancer Treated in Adjuvant or Neoadjuvant Phase,0.0003004744111974476,0.00034955892674670436
NCT01740271,A Study of Genetic Based Chemotherapy Dosing for Breast Cancer Patients,0.00036574732416125495,0.00035174543707587597
NCT01740323,Phase II Study of Curcumin vs Placebo for Chemotherapy-Treated Breast Cancer Patients Undergoing Radiotherapy,0.0003418185787313646,0.0003350091349085613
NCT01740427,A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2),0.0003134682951001344,0.0003277563759543436
NCT01741883,Side Effect Prevention Training (SEPT) for Nocebo Effects in Breast Cancer Patients,0.000312783068831031,0.00037872459265748574
NCT01732939,Phase II Study of Neoadjuvant Chemotherapy Regimen Choice in Breast Cancer,0.0003309500064769815,0.00035156873696269163
NCT01729884,Vaccine Therapy in Treating Patients With Stage IV Hormone Receptor Positive Breast Cancer,0.00030309589532223326,0.00033268650007870664
NCT01729832,Stereotactic Image-Guided Navigation During Breast Reconstruction in Patients With Breast Cancer,0.00029165752476271946,0.0002738693663625676
NCT01737970,A Study to Correlate Ultrasound Elastography With Histopathology to Monitor the Response of Locally Advanced Breast Cancer to Neoadjuvant Chemotherapy,0.00030655958041529355,0.0004003981095768476
NCT01779206,ADAPT - Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer,0.0002802560733808459,0.0004015692036993895
NCT01779050,Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells,0.0003020625848185405,0.0003575703183959237
NCT01789684,Cluster Randomized Trial Comparing Interventions to Enhance Genetic Counseling Among Breast Cancer Patients,0.0002941201481734252,0.00022201658712868975
NCT01790399,IDENTIFICATION OF SENTINEL NODE(S) IN BREAST CANCER,0.000328147309837614,0.00037955339407338284
NCT01792726,A Comparison of Intra-operative Radiotherapy Boost With External Beam Radiotherapy Boost in Early Breast Cancer.,0.00027404879243127147,0.0002620394820034982
NCT01706016,Local Treatment by Thermic Destruction of Primitive Breast Cancer,0.00036435508150890067,0.0003491435201672924
NCT01724606,Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastases (BCBM),0.000258841081266357,0.0003294833354898245
NCT01724866,Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients,0.0003278414690984829,0.00035634998344913723
NCT01724242,Vaginal DHEA for Women After Breast Cancer,0.0003282449237617844,0.0002453956089947676
NCT01743573,"Effects on Physical Fitness, Immunity, and Quality of Life of Yoga Training in Breast Cancer Survivors.",0.0002432033797821257,0.00026218777427549836
NCT01771666,Pilot Indocyanine Green™ Imaging for Mapping of Arm Draining Lymphatics & Nodes in Breast Cancer,0.00023960868264700776,0.00019949300883305828
NCT01708798,Study of the Effect of Eplerenone on Heart Function in Women Receiving Anthracycline Chemotherapy for Breast Cancer,0.000280755126019592,0.0003494083183559447
NCT01716247,Comparison of Contrast Enhanced Mammography to Breast MRI in Screening Patients at Increased Risk for Breast Cancer,0.0002889289957271975,0.00030183975674543935
NCT01797354,Impact of a Group Intervention on Breast Cancer Patient's Adjustment and Emotion Regulation at the End of Treatment,0.0003107730179812716,0.0003222918004875867
NCT01799031,Educational Intervention for Reducing Work Disability in Breast Cancer Survivors,0.00032769025367967406,0.00033963962824763385
NCT01764789,Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer,0.0003126586214452076,0.00038365302405196015
NCT01764802,Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer,0.0003624853719040002,0.00040111772949534384
NCT01780064,Psychosocial Support to Facilitate the Return to Employment of Women With Breast Cancer,0.0004603590742105769,0.0004099934397448696
NCT01753908,Broccoli Sprout Extract in Treating Patients With Breast Cancer,0.0003453078996883455,0.00032249788733290874
NCT01754519,Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer Undergoing Surgery,0.0002804060393877308,0.00038302643956536665
NCT01772472,A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE),0.0003343222945406161,0.000362002400034038
NCT01796444,Axillary Lymph Node Dissection Versus no Dissection in Breast Cancer With Positive Sentinel Lymph Node,0.00025864873868147053,0.0002876228538392243
NCT01796041,Intraoperative Imaging of Breast Cancer With Indocyanine Green,0.000327963695100993,0.00024304524348616645
NCT01763931,DIG-HIF1 Pharmacodynamic Trial in Newly Diagnosed Operable Breast Cancer,0.0004728040577709801,0.00048528104885216917
NCT01793948,Metformin Hydrochloride vs. Placebo in Overweight or Obese Patients at Elevated Risk for Breast Cancer,0.00028544234279039796,0.00029310045340734864
NCT01775514,"A Non-Interventional Study of the Occurrence Rate of Non-Small Cell Lung Cancer, Colon Cancer, Breast Cancer, Gastric Cancer and Malignant Melanoma in Turkey, and Diagnosis and Treatment Characteristics",0.00029103734380026095,0.0003171208146594293
NCT01775085,Group Interventions for Breast Cancer Survivors,0.00033001363316923236,0.000298331819622932
NCT01734499,The Change Cycle Intervention for Improving Quality of Life in Breast Cancer Survivors,0.0002816778708502352,0.0003010705801538002
NCT01705691,Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer,0.000283291450281128,0.00034467008067233567
NCT01757327,LDE225 in Treating Patients With Stage II-III Estrogen Receptor- and HER2-Negative Breast Cancer,0.000349139579615984,0.0003542238161943453
NCT01781338,Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer,0.0002802560733808459,0.0004015692036993895
NCT01725386,An Observational Study of Xeloda (Capecitabine) in Participants With Metastatic or Advanced Breast Cancer,0.000291686355387561,0.0003591534997650416
NCT01709370,"Letrozole and CDK 4/6 Inhibitor for ER Positive, HER2 Negative Breast Cancer in Postmenopausal Women",0.0002516743329304713,0.00035094828081533877
NCT01782274,Proteome-based Immunotherapy of Brain Metastases From Breast Cancer,0.00033121474466257377,0.00025987111954898573
NCT01742975,Efficacy Study of Ifabond in Breast Cancer Surgery,0.000405702192318445,0.00027303290612687106
NCT01717261,Single Pre-Operative Radiation Therapy (SPORT) for Low Risk Breast Cancer,0.00028330141249065916,0.00036038326821079367
NCT01717131,Axillary Node Dissection Versus no Dissection in Breast Cancer With Positive Sentinel Lymph Node,0.00025864873868147053,0.0002566642865951585
NCT01745965,"A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol.",0.0002976763381968568,0.00023386373729583515
NCT01730833,"Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer",0.0003121994384374426,0.0003596772846442586
NCT01738685,Intervention to Improve Self-Care of Symptoms in Breast Cancer Survivors on Adjuvant Endocrine Therapy,0.00025789647162149644,0.00019470863953138142
NCT01750073,Paclitaxel and Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Patients With Previously Untreated Stage I-III Breast Cancer,0.00031814577220481196,0.00036932628153651904
NCT01750164,Patient Derived Breast Cancer Xenografts,0.00034551056599524535,0.00037671425546004716
NCT01712815,PET/CT in Evaluating Response to Chemotherapy in Patients With Breast Cancer,0.0003346018370860108,0.0003967951855726486
NCT01712893,"Simultaneous Versus Sequential Use of Adjuvant Chemotherapy and GnRHa in Treating ER+,Premenopausal Breast Cancer",0.00033454800540450377,0.00029960729740256836
NCT01783444,A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer.,0.0002920324033000221,0.0003270714798305664
NCT01783756,"Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis",0.0002582765758592767,0.000326229684474531
NCT01702571,A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment,0.00030537022187926096,0.00036982070034223275
NCT02890316,Assessment of Fatigue During Radiotherapy for Breast Cancer With and Without Homeopathy Treatment,0.0002717864252728963,0.00030072421733845815
NCT02890082,"Preservation of Fertility by Ovarian Stimulation Associated With Tamoxifen, Prior Chemotherapy for Breast Cancer",0.00023874559817609864,0.00028142616512672966
NCT02866994,Project Connect Online: An Internet-based Intervention for Women With Breast Cancer,0.0003346855203473141,0.00021538629680677255
NCT02895178,Lifestyles Of Health And Sustainability for Breast Cancer Survivors,0.00046242777069681454,0.0003659745054990691
NCT02895724,Hyperbaric Oxygen Therapy to Reduce Lymphedema After Breast Cancer -an Explorative Clinical Trial,0.00027754784362580393,0.00036748936144637373
NCT02876640,Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer,0.00031822169457340475,0.00032580607689364845
NCT02876627,Effect Aerobic Training on Women With Breast Cancer After Chemotherapy,0.00035754261266246874,0.00027202446184586206
NCT02876497,Study of Trans-tissular Migration of Macrophages Associated to Human Breast Cancer,0.0003168794841579431,0.00025761619325025413
NCT02855775,Monoclonal Antibodies Elimination in Breast Cancer Patient,0.0003088931724321295,0.00034234250708417883
NCT02860000,"Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer",0.00030992220946709213,0.00033656333143940913
NCT02825810,Cervical Motor Control in Long-term Breast Cancer Survivors,0.00032805711434546423,0.000281802051129936
NCT02896504,"Chemotherapy Effect on Brain Structure, Neurophysiology and Psychomotor Behavior in Breast Cancer Patients",0.0003083667785259098,0.0003555880239800279
NCT02836093,Exercise Testing for Early Stage Breast Cancer Patients Receiving Radiation Treatment,0.00033078402066832267,0.00037651522920937285
NCT02817724,Integral Strategy to Supportive Care in Breast Cancer Patients,0.0003459480714208733,0.00040208068330750034
NCT02817334,A Prospective Clinical Study for Evaluation of Safe Resection Margin in Breast Conserving Surgery in Breast Cancer,0.0002776554506962953,0.00025909849114658866
NCT02863146,Efficacy of the Use of Refrigerant Helmet to Prevent Alopecia in Patients Treated With Eribulin for Breast Cancer,0.00029201904151797696,0.00033810968608808306
NCT02844335,Combination of Cryosurgery and NK Immunotherapy for Advanced Breast Cancer,0.0002760866547881578,0.00039845924685902784
NCT02879513,Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response to Neoadjuvant Chemotherapy,0.00032006691035451457,0.0003047872114682658
NCT02875626,Role of Indocyanine Green (ICG) for Detection of Sentinel Nodes in Breast Cancer,0.00024958162625809483,0.0003255266894643808
NCT02875951,"Investigating Patient Satisfaction With Oral Anti-cancer Treatment in Patients With Hormone-receptor Positive, HER2-receptor Negative, Advanced Breast Cancer",0.0003301201491664855,0.0004027832528267945
NCT02819921,Desvenlafaxine for Treatment of Hot Flashes in Women With Breast Cancer Taking Tamoxifen,0.0002754820648203533,0.0003503634437154473
NCT02804308,Combined Training on Body Composition of Postmenopausal Women Undergoing Treatment for Breast Cancer,0.00028196382776962686,0.0002227920856473948
NCT02840344,Couples-Based Mindfulness for Young Breast Cancer Survivors,0.00046229057229774123,0.0002401371219912878
NCT02840890,Osteopathy and Prevention of Gastrointestinal Side Effects in Women Treated for Breast Cancer,0.00024962977302738843,0.0002597388370438786
NCT02802098,Abrogation of Chronic Monoclonal Antibody Treatment-induced T-cell Exhaustion With DURVALUMAB in Advanced HER-2 Negative Breast Cancer,0.00026786492626517435,0.00027043367872717135
NCT02802748,Phase 0 Study of Metronomic Oral Vinorelbine and Letrozole in HR+/HER2-negative Early Breast Cancer Patients (VENTANA),0.00035366762703889227,0.00037865879746487157
NCT02802826,Studying Tailored Exercise Prescriptions in Breast Cancer Patients,0.000349173741070237,0.0003628819454434417
NCT02850419,Heat-Activated Target Therapy of Local-Regional Relapse in Breast Cancer Patients,0.000374334426339651,0.0004259359006335144
NCT02850939,Improving Adherence to EHT Among Breast Cancer Patients,0.000604818613718354,0.00031735816172844434
NCT02894398,"Efficacy/Quality of Life Study of Postmenop. Women With Advanced Breast Cancer, Treated With Letrozol and Palbociclib",0.0002976602259342552,0.0003659327991962858
NCT02834494,"Assessment of Response to Neo-adjuvant Chemotherapy for Patients With a Locally Advanced Breast Cancer With 3D Elastography (Shear Wave),",0.00032574994531612997,0.00031947174806144297
NCT02888366,A Prospective Validation Study of a Rapid Point-of-Care Breath Test for Breast Cancer,0.0003167408446578516,0.00025879291296015576
NCT02859168,Myofascial Induction in Breast Cancer Survivors,0.00046090517012062376,0.0002456891344414672
NCT02816125,Effects of Omega-3 Fatty Acids on Risk Factors for Breast Cancer in Pre-menopausal Women,0.00027538224851137593,0.00018238309986091171
NCT02812277,Retrospective Analysis of Effectiveness and Safety Profile of Anastrozole and Letrozole in HR+ Breast Cancer Patients,0.0002992521063608231,0.0003525791059407366
NCT02884284,Prospective and Retrospective Breast Cancer Database,0.0003279520799336598,0.0002434414140048875
NCT02808598,Breast Cancer Trials Education Program,0.0003339704601640725,0.00036047975994676305
NCT02807597,LS301 Uptake in Tumors of Patients Undergoing Partial Mastectomy and Sentinel Lymph Node Biopsy for Breast Cancer,0.0002958435914056162,0.0003003068518973131
NCT02806817,ME-344 in Early HER2-negative Breast Cancer With Antiangiogenic-induced Mitochondrial Metabolism,0.00032796056870899285,0.00032315046226522785
NCT02806544,Neoadjuvant Tamoxifen in Locally Advanced Breast Cancer in a Low/Middle Income Country,0.00027018571764679945,0.00029821431468742823
NCT02800317,RISAS Procedure in Node Positive Breast Cancer Following NAC,0.00029201382170343347,0.00025654555784958397
NCT02869607,Institut Paoli Calmettes Breast Cancer Database,0.00046076332334122244,0.000522750116270829
NCT02848989,Qigong For PPSP In Breast Cancer Pain In Breast Cancer Survivors,0.00032983172511300316,0.00023610108303655407
NCT02803593,To Enhance Breast Cancer Survivorship of Asian Americans,0.0008829212022672371,0.0003722681269616705
NCT02858856,Clinical Trial of Deciten Granule on Immunity of Breast Cancer Patients,0.00031097017232563633,0.00040023337164261035
NCT02858934,Feasibility Study of Accelerated Preoperative Radiotherapy for Early Breast Cancer,0.00034218898870587173,0.00032894187213155965
NCT02830282,Surveillance Markers of Utility for Recurrence After Neoadjuvant Chemotherapy for Breast Cancer,0.0002689931548132446,0.00032678870663277926
NCT02820961,Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer,0.00027458164044107564,0.00031861047819923427
NCT02833766,Anti-EGFR-immunoliposomes Loaded With Doxorubicin in Patients With Advanced Triple Negative EGFR Positive Breast Cancer,0.0003164646756416716,0.00028426451441278255
NCT02833233,A Study of Pre-Operative Treatment With Cryoablation and Immune Therapy in Early Stage Breast Cancer,0.00030118792081265693,0.0004277596071510374
NCT02846389,Trial of Exercise to Reduce Cancer Related Fatigue in Breast Cancer,0.0002574790392234438,0.0002982881909126628
NCT02846428,To Evaluate the Efficacy and Safety of Capecitabine Prior to Surgery in Women With Breast Cancer,0.00030003557312764905,0.00032965877267448405
NCT02831582,Omega-3 Supplementation in Prevention of Aromatase Inhibitor-Induced Toxicity in Patients With Stage I-III Breast Cancer,0.0002951326796044052,0.0002941826798738299
NCT02831530,Randomized Short-term Pre-surgical Study to Assess the Effects of Abemaciclib (LY2835219) in Early Breast Cancer Patients,0.0003408499482298045,0.00039094588806092126
NCT02831439,A Statewide Intervention to Reduce Use of Unproven or Ineffective Breast Cancer Care,0.0004701954466120917,0.00033760918806195885
NCT02827370,CAREFOR: Precision Medicine Driving Precision Nutrition for the Treatment of NeoAdjuvant Breast Cancer,0.00027034239905404054,0.00041454112530699795
NCT02861703,Online vs In-Person Lifestyle Intervention for Weight Management and Improved Quality of Life in Breast Cancer Survivors,0.00024415543188629655,0.0002607418824388671
NCT02861859,Individualised Versus Standard Care for Breast Cancer Patients at High-risk for Chemotherapy-induced Nausea and Vomiting The ILIAD Study,0.00033641467092201087,0.00037036164367463
NCT02898376,Clinical Benefit of Spa Care on Severe Radiation-induced Fibrosis After Postoperative Radiotherapy for Breast Cancer,0.0002571995766642429,0.0002733982184012875
NCT02839668,The Impact of Intravenous Anaesthesia on Angiogenesis in Patients With Breast Cancer (TIVA/TCI-BC),0.0003093772836410955,0.0002674745416784463
NCT02897934,CWI and Discharge After Breast Cancer Surgery,0.00034699694320981935,0.00022766609274414555
NCT02829021,Dynamic Infrared Thermography in Breast Cancer Diagnostics,0.0003358867903341848,0.0003332460276775406
NCT02829008,Low -Dose-bevacizumab and Pemetrexed Versus TPC in Metastatic HER2-negative Breast Cancer Patients,0.0003005712434710934,0.00022701872695325508
NCT02826512,"A Feasibility Study of Niraparib for Advanced, BRCA1-like, HER2-negative Breast Cancer Patients",0.00033096008941660204,0.0002783876040953831
NCT02838225,DA Versus DAC as Postoperative Adjuvant Treatment for Early-stage Breast Cancer,0.0003795977640168182,0.00044478722356252985
NCT02838238,X Versus Placebo as Postoperative Adjuvant Treatment for Elder Breast Cancer,0.00036699846305258483,0.0003973755766493034
NCT02838823,Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Patients With Advanced Breast Cancer,0.0003106876895162594,0.000390665821067136
NCT02838173,Serratus Plane Block for the Prevention of Chronic Pain After Breast Cancer Surgery,0.0002622477731040814,0.00032408644012161305
NCT02882581,"Metformin in Breast Cancer, Visualized With Positron Emission Tomography",0.0003338088783538722,0.00021221170370048573
NCT02867644,Conversational Hypnosis in Women Undergoing Imaging for Breast Cancer,0.0003326082211223259,0.0003154699517324164
NCT02810093,Big Data and Text-mining Technologies Applied for Breast Cancer Medical Data Analysis,0.00027165176770268433,0.00020076688921850523
NCT02810873,Positron Emission Tomography Imaging Using Copper Cu 64 TP3805 in Patients With Breast Cancer,0.00031492232577961924,0.0002960186729231867
NCT02810743,Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer,0.0004677686376374999,0.0003685103465763659
NCT02870699,Efficacy of Evonail® Solution in the Prevention of Nail Damage Induced by Docetaxel in Patients With Breast Cancer.,0.0003165486381874116,0.00032292802725698367
NCT02878057,Multicenter Phase II Study of Apatinib in Patients With Advanced Breast Cancer,0.00036857138200611456,0.0003444955333872801
NCT02856503,Effect of High Dose Vitamin D on Cancer Biomarkers and Breast Cancer Tumors,0.00024811004304474453,0.00022100317421297702
NCT02889458,Hong Kong Breast Cancer Study,0.0005475118996500432,0.00030771812744731064
NCT02889874,EXamining PErsonalised Radiation Therapy for Low-risk Early Breast Cancer,0.00034284652983245336,0.0001939677752157675
NCT02805153,PEG-rhG-CSF in Patients With Breast Cancer Receiving Chemotherapy,0.0003265521330765207,0.0004845689208204878
NCT02805205,PEG-rhG-CSF in Patients With Breast Cancer Receiving Chemotherapy to Prevent Neutropenia,0.0002999869344719184,0.0004038059145338058
NCT02871167,Risk of Infertility Related to Adjuvant Chemotherapy for Early Breast Cancer: Oocyte/Embryo Cryopreservation,0.00025070911765576876,0.00031237528092046906
NCT02871388,Addressing Modifiable Breast Cancer Risk Factors With Project CONECT,0.000272487437902581,0.0001882627695402219
NCT02872103,Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy,0.0002959057114803937,0.0004369624678732461
NCT02872064,Treatment of Primary Breast Cancer Using PDT,0.0005152476714020549,0.0005061719727907831
NCT02824016,Evaluation of Hypothyroidism Incidence After Breast Cancer Supraclavicular Irradiation,0.00026194326187475316,0.0002422572128657158
NCT02865148,Behavioral Symptom Management Program for Breast Cancer in Singapore and The US,0.0002767992656411746,0.0002685429494562336
NCT02893761,Bergonie Institute Breast Cancer Database,0.00046076332334122244,0.00031851221644596555
NCT02862990,Evaluation of the Attitude of Pre Menopausal Women With Breast Cancer Faced With the Risk of Fertility Loss Caused by Chemotherapy,0.00025918609714516914,0.00030796989304763465
NCT02842658,Exercise Preconditioning and Breast Cancer Cardiotoxicity,0.00027638085924024835,0.00029593763813654314
NCT02842099,Standard Chemotherapy Followed by Capecitabine as Prolonged Postoperative Adjuvant Treatment for Breast Cancer,0.000278216051097437,0.0004049052782424552
NCT02823015,Acute Pain Trajectories and Persistent Pain After Breast Cancer Surgery,0.00028821630229109357,0.00018749288079958226
NCT03101683,Radiotherapy After Mastectomy for Breast Cancer Patients at Increased Risk of Local Recurrence,0.00030339859371988253,0.00034484130398329375
NCT03104595,Management of Severe Chemotherapy-induced Neutropenia in Advanced Breast Cancer,0.00027228484263945926,0.0003272118921722457
NCT03106350,Symptoms Experienced and Quality of Life in Breast Cancer Receiving Radiotherapy,0.0002593376912046274,0.0002708353035052039
NCT03102866,Aerobic and Strength Training Exercise in Improving Fitness and Arm Health During and After Radiation Therapy in Patients With Stage II-III Breast Cancer,0.00029498982055798994,0.00034416326833348426
NCT03105440,Innovation Oncological Rehabilitation: Applicability of the Different Techniques Physiotherapeutic Post Breast Cancer,0.00046131026299451575,0.00031148720452729933
NCT03105076,Impact of Decision Aids on Breast Cancer Surgery Choice: A Randomized Controlled Trial,0.0002874378332920238,0.0002461633452183476
NCT03100981,Online Mindfulness for Women Treated for Breast Cancer and Men Treated for Prostate Cancer,0.00032942417101453834,0.0003173564709749904
NCT01557478,Melatonin as Adjuvant Therapy in Breast Cancer Patients,0.00034784751075899064,0.0004068374826041307
NCT01545648,Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer,0.0003293673056805013,0.00033211597602021193
NCT01582685,Exercise in Breast Cancer Survivors,0.00046717801519213396,0.00018562065054327618
NCT01582971,Home-Based Symptom Management Via Reflexology for Breast Cancer Patients,0.00030895723907039353,0.00031249838752650056
NCT01528826,Salvage Chemotherapy of Vinorelbine Plus Oxaliplatin in Metastatic Triple-negative Breast Cancer:a Prospective Trial,0.0002545298911306903,0.000337051677719904
NCT01528345,"Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer",0.0003207628237817156,0.00026046521609421835
NCT01517945,Attention and Interpretation Modification (AIM) for Fear of Breast Cancer Recurrence: An Intervention Development Study,0.00026570170999851237,0.0002612047789496246
NCT01592825,PiA: Prognosis Used Every Day for Patients With Operable Breast Cancer - Comparison of Invasion Factors uPA/PAI-1 With Other Prognostic Factors,0.00028294134695893417,0.0003258598072955652
NCT01511276,The Effects of Equivalent Weight Loss With or Without Exercise Training on Breast Cancer Risk (SHAPE-2),0.00027796885757908177,0.00024521882123810737
NCT01580800,National Breast Cancer and Lymphedema Registry,0.00033197395381848546,0.00029733580490762446
NCT01560416,Fulvestrant With or Without Ganetespib in HR+ Breast Cancer,0.0003316840147012556,0.000355714375954866
NCT01577420,Reflexology: An Intervention for Advanced Breast Cancer,0.00030292710316761733,0.00026732003750485196
NCT01510964,The Involvement of Breast Cancer Patients During Oncological Consultations,0.00042411207769482446,0.0003348926891946975
NCT01599039,Study the Usefulness of Bio-impedance Spectroscopy in the Early Assessment of Breast Cancer Related Lymphoedema,0.0002715897111863787,0.000259630752168977
NCT01537536,Trial of Neoadjuvant EndoTAG-1 in Combination With Paclitaxel in HER2-negative Breast Cancer,0.0002731164749616448,0.0003159848035288903
NCT01542203,Impact of Body Weight on Pharmacokinetic Analysis of Doxorubicin + Cyclophosphamide in Breast Cancer,0.0002424933499498199,0.0002518574217143666
NCT01542216,Evaluation of Nutrition and Metabolism in Breast Cancer Patients,0.0003156720302008956,0.00029964781914671964
NCT01569087,Dose-finding Study of Empegfilgrastim for Neutropenia Prophylaxis in Patients With Breast Cancer,0.0003191654505737796,0.0003228485865018435
NCT01520103,Study to Compare Vinorelbine In Combination With the mTOR Inhibitor Everolimus vs. Vinorelbin Monotherapy for Second-line Treatment in Advanced Breast Cancer,0.00030654330711321376,0.00038517673831126937
NCT01596530,Evaluation of Drug Activity in Women With Breast Cancer and no Previous Herceptin Treatment,0.00026811558562778046,0.00036811575714872265
NCT01596439,A Prospective Study to Evaluate the Effect of Systemic Adjuvant Therapy on the Cognitive Function of Breast Cancer Patients,0.000334287515724958,0.00039632007414313166
NCT01559194,Low Fat Versus Protein Sparing Diet for Weight Loss & Impact on Biomarkers Associated With Breast Cancer Risk,0.0002369852255810524,0.0002691773997742417
NCT01583426,Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto),0.0002834870288071259,0.00035485878605317746
NCT01555645,Stress Management in Breast Cancer Patients,0.0003478970463138902,0.00031293195923536
NCT01521676,Predictive Clinical and Biological Parameters in Breast Cancer,0.0002744800480628057,0.0004099068440739005
NCT01521000,The Use of Bioimpedance to Determine Pre-Clinical Lymphedema in the Post-Operative Breast Cancer Patient,0.00029507662957333196,0.0003668637700987172
NCT01521741,Prospective Analysis of Symptoms and Lymphedema in Patients Following Treatment for Breast Cancer,0.0003363661719491223,0.00033474942732973243
NCT01506466,Weight Variation During Chemotherapy in Breast Cancer Patients,0.0003673521212403055,0.00032844084972334084
NCT01502592,"Pre-Operative, Single-Dose Ipilimumab and/or Cryoablation in Early Stage/Resectable Breast Cancer",0.0002570255708081002,0.0003265070185840013
NCT01566721,A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer),0.00032509210932854613,0.00029581965032774316
NCT01566799,Metformin Plus Neoadjuvant Chemotherapy in Breast Cancer,0.0003083536724861634,0.0003301687937012683
NCT01567137,MR Characterisation/Localisation of Breast Cancer,0.0008829212022672371,0.00019877529662890335
NCT01564368,DWI in Assessing Treatment Response in Patients With Breast Cancer Receiving Neoadjuvant Chemotherapy,0.000335123765052637,0.00038483569909018
NCT01562288,Studying Blood and DNA Samples From Patients With Breast Cancer Treated With Chemotherapy With or Without Trastuzumab,0.00033723825089264397,0.00040143542501723815
NCT01562873,Ruxolitinib in Patients With Breast Cancer,0.00042420274116987085,0.00031879438719463563
NCT01558258,A Mindfulness Meditation-Based Intervention for Younger Breast Cancer Survivors,0.00027846294515183526,0.00028981263149058
NCT01546649,A Phase 3 Comparative Study of TAP-144-SR(6M) in Postoperative and Hormone Therapy-naïve Patients With Premenopausal Breast Cancer,0.0003157796633297912,0.00029620865250936285
NCT01540955,Cognitive Rehabilitation Group Intervention for Breast Cancer Survivors,0.00027894906837111515,0.0002838820828831033
NCT01540110,Study of Neoadjuvant Docetaxel and Cyclophosphamide in Locally Advanced or Node Positive Primary Breast Cancer With Companion Pharmacokinetic and Pharmacogenomic Analyses,0.0003045124970130786,0.000314258640769773
NCT01565499,Neoadjuvant Treatment With Nab-paclitaxel for Patients With Stage II and III Luminal Breast Cancer,0.00030398930359194635,0.00035624132684391937
NCT01565083,A Study to Assess Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in Participants With Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer,0.00030439035788207654,0.0002780339297357976
NCT01500577,A Prevention Trial in Subjects at High Risk for Breast Cancer,0.000336827418629421,0.00022294111553311635
NCT01593020,Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2,0.00029669573467533145,0.0003076983497220041
NCT01591915,A Randomized Controlled Mindfulness Based Stress Reduction Intervention in Women With Breast Cancer,0.00023975895521366667,0.00030928674540557833
NCT01547741,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,0.0002755630109588345,0.0002841814275912039
NCT01563211,Predictive Model of Therapy Outcomes in Breast Cancer Patients,0.0003741073282463935,0.00037875190863294583
NCT01527487,Trial of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer,0.0002697166950768121,0.0003202277537529979
NCT01572883,Effect of Concomitant Radiotherapy and Trastuzumab on Cardiotoxicity of Patients Treated for Early Breast Cancer,0.0003093971034426038,0.00039566122518823585
NCT01572038,A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer (PERUSE),0.0002943614812224031,0.00032203944670252787
NCT01508546,Conservative Surgery With or Without Axillary Lymphnode Removal in Treating Women With T1N0 Breast Cancer,0.00028794644076993024,0.0002549346917295905
NCT01508572,VEGF-targeted Fluorescent Tracer Imaging in Breast Cancer,0.00027654257654796547,0.00026318397593813034
NCT01553903,Feasibility Study for the Determination of Oxysterols in Patients With Breast Cancer Receiving Hormonal Therapy With Tamoxifen or Not,0.0003002120465242122,0.0003490424955800697
NCT01530607,"Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer",0.00026399582049456443,0.0002643396686934415
NCT01530373,Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients,0.00030911665848849004,0.00028406333042320137
NCT01561443,LINE: Treatment Patterns in postmenopausaL Women With Hormone Receptor Positive Breast Cancer,0.0002933043557324307,0.000339342544877182
NCT01568346,Breast MRI for Newly Diagnosed Breast Cancer:Impact on Re-excision Lumpectomy,0.0002562459523335938,0.00028369074162329524
NCT01597921,A DB Randomized Study of R1 and R2 WaterJel / AloeVera Jell in Prevention of Radiation Dermatitis in Breast Cancer,0.0002902097331807178,0.000411483601346977
NCT01597999,Benefits of Breast MRI for Predicting of Histopathologic Cell Type of Small Breast Cancer,0.0002505004232050447,0.00029957979129110145
NCT01597193,Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer,0.0003908968494999233,0.00035508090560654973
NCT01598077,"A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer",0.0002854542517789307,0.0002603266838296882
NCT01581619,External-Beam Partial-Breast Irradiation for Early Breast Cancer 40 Gy QD Over 2 Weeks,0.0002718517196160892,0.0003379433670596378
NCT01544504,Exploratory Study of Topical Norepinephrine in Breast Cancer Patients Receiving Radiotherapy,0.00033419285738918176,0.00033184941851685886
NCT01554943,Late Cardiac Evaluation of the Three Arm Belgian Trial Involving Node-positive Early Breast Cancer Patients,0.0003001224730627406,0.0002669522287093589
NCT01589861,"Safety and Efficacy of BKM120 and Lapatinib in HER2+/PI3K-activated, Trastuzumab-resistant Advanced Breast Cancer",0.0002808966749171606,0.0003198271376697045
NCT01589367,Neoadjuvant Letrozole Plus Metformin vs Letrozole Plus Placebo for ER-positive Postmenopausal Breast Cancer,0.0002640646683947146,0.00023218592991179187
NCT01556243,Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer,0.00035663617349090834,0.00034366483183194754
NCT01552655,Breast Cancer Recurrence - the Accuracy of Dual-time PET/CT,0.00027801523775755697,0.00026939394963007915
NCT01503697,The Role of the Novel 99mTc-NC100692 Tracer in Patients at High Risk or Known Breast Cancer,0.00031381910489661165,0.0002871028168058909
NCT01503190,The Immune System's Response to Young Women's Breast Cancer,0.000336272336791006,0.0005428516829864952
NCT01503905,Neoadjuvant Chemotherapy for Operable Premenopausal Breast Cancer Patients,0.00034111668342290386,0.00037278674827391246
NCT01503034,Pregnant Women With a Breast Cancer Diagnosed Between 2000 and 2014,0.0003358867903341848,0.0004623248765990845
NCT01548209,Effects of a Dexmedetomidine on Quality of Recovery 40 and Postoperative Nausea and Vomiting in Breast Cancer Surgery,0.00025939886129844916,0.0002630558745561447
NCT01548677,Efficacy Study of Herceptin to Treat HER2-negative CTC Breast Cancer,0.0003912727521753287,0.0003212443654947755
NCT01594398,Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer,0.00028569722136608655,0.00028183858037316844
NCT01594177,Dual Blockage With Afatinib and Trastuzumab as Neoadjuvant Treatment for Patients With Locally Advanced or Operable Breast Cancer Receiving Taxane-anthracycline Containing Chemotherapy,0.00033170051417420347,0.0003912808904872557
NCT01594216,Ruxolitinib in Estrogen Receptor Positive Breast Cancer,0.0003296968121874585,0.0003188802778561466
NCT01501656,Epigenetic Testing for Breast Cancer Risk Stratification,0.0004607756726999687,0.00030338723417765455
NCT01539876,Tumour Necrosis Factor Release in Locally Advanced Breast Cancer Patients Receiving Neoadjuvant Docetaxel,0.0003167181350849038,0.00036290796119640956
NCT01539317,Therapy to Prevent Sexual Pain in Breast Cancer Survivors,0.0003020464058756581,0.00023991001522500992
NCT01504789,Part II: Exercise in Hispanic Breast Cancer Survivors,0.00046717801519213396,0.0003836012037347789
NCT01513408,Relevance of T Lymphocytes Tumor Infiltrates CD8 and Foxp3 as Immune Prognostic Biomarker in Breast Cancer Treated by Neo Adjuvant Chemotherapy,0.0002375751486059937,0.0003246438124026004
NCT01513356,Pharmacodynamic Study of BKM120 in Breast Cancer,0.0005475118996500432,0.00028244158315169086
NCT01513278,Study of APN201 (Liposomal Recombinant Human Cu/Zn-Superoxide Dismutase) for the Prevention of Radiation-induced Dermatitis in Women With Breast Cancer,0.0002730444419720845,0.0003094011376884177
NCT01532232,Tobacco Dependence in Breast Cancer Patients Trial of Varenicline (Chantix),0.00030807706377598127,0.00030969411159206047
NCT01532960,Pilot Study of a Breast Cancer Vaccine Plus Poly-ICLC for Breast Cancer,0.0002877883853320421,0.0003299755964774953
NCT02203552,Minocycline Hydrochloride in Reducing Chemotherapy Induced Depression and Anxiety in Patients With Stage I-III Breast Cancer,0.000308133386979834,0.00032205825301390314
NCT02203565,Dakin's Solution in Preventing Radiation Dermatitis in Patients With Breast Cancer Undergoing Radiation Therapy,0.0003564087489398286,0.00031024318549200926
NCT02299635,A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations,0.0003684650606246172,0.00040306598907894025
NCT02235051,Exercise Intervention in Preventing Breast Cancer Recurrence in Postmenopausal Breast Cancer Survivors,0.00028621779797015394,0.0002635506081238106
NCT02289365,Orally Administrated JBM-TC4 Prevents Acute Radiodermatitis in Breast Cancer Patients,0.00034605272524793274,0.00031308368968599985
NCT02257775,Evolution of Resistance to Systemic Therapies in Patients With Breast Cancer,0.0003742878754416103,0.0003405678191128651
NCT02216786,A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer,0.0002971374325476811,0.00035168224871473324
NCT02291913,Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer,0.00028082875556661356,0.0003522019031691272
NCT02251353,Intervention to Hepatic and Pulmonary Metastasis in Breast Cancer Patients,0.00029675745282667625,0.000250967321399773
NCT02271828,Omitting Sentinel Node Procedure in Breast Cancer Patients Undergoing Breast Conserving Therapy,0.0003225095230813972,0.0003463561905430748
NCT02255240,LEVEL UP: Video Games for Activity in Breast Cancer Survivors,0.0003309870905190493,0.00032074953055700003
NCT02222337,Nueva Vida Intervention for Latina Breast Cancer Survivors and Caregivers,0.0004701954466120917,0.0002785653042003645
NCT02249208,Sentinel Lymph Node Biopsy With Superparamagnetic Iron Oxide for Breast Cancer Patients After Neoadjuvant Treatment.,0.00032141460953943125,0.00032524943844909593
NCT02272335,Facilitating Adjustment in Low Income Black Women With Breast Cancer,0.00032952770992084285,0.00026061674034969645
NCT02215876,Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Eribulin Chemotherapy (ACE) in Operable HER2-negative Breast Cancer,0.0002771897616115508,0.00032433745971763485
NCT02215083,L-glutamine Supplementation to Alleviate Symptoms of Taxane-Induced Neuropathy in Patients With Breast Cancer,0.0002862463968623154,0.0003122827924683932
NCT02270931,A Prospective Longitudinal Breast Cancer Study,0.0005475118996500432,0.00042608590055112655
NCT02270372,Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer,0.0003070130343241327,0.0003012902371107883
NCT02270580,Komen Breast Cancer Survivor Health Screening Promotion Project: Staying Healthy,0.00032966069961342005,0.0002514577421848379
NCT02286362,An Observational Study of the Safety of Herceptin Given Subcutaneously in Patients With Early HER2-positive Breast Cancer,0.00035138142255000784,0.00034361505686832995
NCT02219789,Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery,0.000325326853087245,0.00037389303511086596
NCT02204098,Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy,0.0003028193219347436,0.00029942558361450446
NCT02204462,FBnTP Imaging of Breast Cancer,0.00046747653717039923,0.0002524036935522456
NCT02225652,"A Phase II Study of Dose Density Regimen With Fluorouracil, Epirubicin and Cyclophosphamide at Days 1, 4 Every 14 Days With Filgrastim Support Followed by Weekly Paclitaxel in Women With Primary Breast Cancer.",0.00027244044394445166,0.00036812301411135416
NCT02275403,Standard Care Alone or With Acupuncture for CIPN in Breast Cancer and Multiple Myeloma,0.000250717754885302,0.0003441269692094843
NCT02275871,Comparison of Contrast-enhanced Spectral Mammography (CESM) to MRI in Screening High Risk Women for Breast Cancer,0.0002421245675202726,0.00028636679369437593
NCT02252887,"Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based Therapy",0.00027339562331865766,0.0003555181576769775
NCT02276404,Preoperative Relaxation Training and Acupuncture to Minimize Perioperative Symptoms in Breast Cancer Patients,0.00031220367736924885,0.0003315952984429196
NCT02229084,Vaccination of High Risk Breast Cancer Patients,0.0003500599311738453,0.0003870185496284298
NCT02243397,Molecular and Cellular Analysis of Breast Cancer,0.00032895520858590503,0.0003423983253496367
NCT02243163,Effect of Yoga on Life Quality and Immunity in Breast Cancer Patients After Operation and or Chemotherapy,0.00032023084341635267,0.00039406481226750284
NCT02206984,Endocrine Response in Women With Invasive Lobular Breast Cancer,0.0003362679329132932,0.000372682090885012
NCT02278120,"Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer",0.0003027528807796198,0.0003313026662786863
NCT02278965,Metformin and Omega-3 Fatty Acids in Woman With a History of Early Stage Breast Cancer,0.0002575607805430959,0.00029463475511624937
NCT02244593,FAST MRI Study in Breast Cancer Survivors,0.0005475118996500432,0.00029793293503432757
NCT02244580,"Re-Evaluation of Tumor Samples From Women With Breast Cancer With the in Vitro Diagnostic Kit ""MammaTyperTM""",0.00024923632658974614,0.0002657808674283239
NCT02290782,TARGIT-C(Consolidation) Prospective Phase IV Study of IORT in Patients With Small Breast Cancer,0.0003906736818656815,0.00035045672359078865
NCT02290834,Chemotherapy-induced Cognitive and Brain Changes in Older Adults With Breast Cancer,0.0002960530102267624,0.00037358230239123094
NCT02279108,Study Assessing The Interest of Indocyanine Green Fluorescence Imaging With Radioisotope Method For Sentinel Lymph Node Biopsy in Patients With Breast Cancer,0.000314335392719161,0.0002582696990593984
NCT02227082,Olaparib and Radiotherapy in Inoperable Breast Cancer,0.0003414582764267887,0.0003542981712791248
NCT02297412,Minocycline Hydrochloride in Reducing Chemotherapy-Induced Peripheral Neuropathy and Acute Pain in Patients With Breast Cancer Undergoing Treatment With Paclitaxel,0.0003230973259095091,0.00035771287432929255
NCT02297438,A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4],0.0003130962207040941,0.0003277563759543436
NCT02297698,Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients,0.00030108575660784553,0.00037654775380264674
NCT02297230,Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics,0.00029656390538605493,0.00034851137797341686
NCT02236000,A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer,0.000282714596235989,0.00031887020027410493
NCT02236806,Cardiotoxicity Prevention in Breast Cancer Patients Treated With Anthracyclines and/or Trastuzumab,0.00030387167101948834,0.0003110975075475719
NCT02269813,PRospective Study to Measure the Impact of MammaPrint on Adjuvant Treatment in Hormone Receptor-positive HER2-negative Breast Cancer Patients (PRIMe),0.0003480741700170162,0.00036143699957376537
NCT02269696,"The Effect of Metoprolol on Anaesthesia, the Need for Analgesics, and Pain in Breast Cancer Patients",0.00029225748646628054,0.0003307098934645308
NCT02296801,A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer,0.00029379417599217217,0.00030898431948854396
NCT02266173,Observational Study of Pertuzumab Safety in Participants With Breast Cancer,0.00032054498508336636,0.00032505604445459544
NCT02266602,Intraoperative Radiation Therapy in Early Stage Breast Cancer,0.0003433263758760332,0.0003501270946111342
NCT02207335,Trial of Gemcitabine_Capecitabine Versus Gemcitabine_Carboplatin in Breast Cancer,0.00032750551540277256,0.0002791198882607902
NCT02207179,Breast Cancer Margin Delineation Using Polarization Subtraction Imaging Technology,0.00033233527095060875,0.0002842471038114873
NCT02260531,Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases,0.0003205264626980486,0.0003813621285664339
NCT02250118,Intrapleural Bevacizumab After Pleural Drainage in the Context of Breast Cancer,0.00024968764110998526,0.0003574525007301812
NCT02294565,VST-1001 (Dilute Fluorescein) for Lymphatic Mapping & Localization of Lymph Nodes in Patients With Breast Cancer,0.00029215343941059463,0.00030600965121508825
NCT02273973,A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI),0.00028150817852597734,0.0003430083874995592
NCT02261389,Follow-up of Early Breast Cancer by Dynamic Evaluation of CEA and CA 15.3 Followed by 18FDG-PET,0.00028401196594296545,0.000253204528527229
NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments.,0.00030089332329066957,0.00031424824200032927
NCT02240472,Sentinel Node Biopsy in Breast Cancer: Omission of Axillary Clearance After Macrometastases. A Randomized Trial.,0.0002338914727933872,0.0002848758968643316
NCT02240199,Perioperative Pregabalin and Lidocaine to Reduce Chronic Breast Cancer Pain,0.000247531700809915,0.0002577207665335451
NCT02240836,Energy Balance and Breast Cancer Aspects-II,0.00032759494039461787,0.0002951672395380773
NCT02224261,Effectiveness of Physical Therapy on Axillary Web Syndrome After Breast Cancer Surgery,0.0002487046521758534,0.00023458667634128073
NCT02284919,[18F]ISO-1 PET/CT in Breast Cancer,0.00046756837502362307,0.00034677386951117723
NCT02256670,Pilot for The Breast Cancer Endocrine Therapy Adherence (BETA) Trial,0.00047086475815400023,0.0003299253472851302
NCT02212834,Surveillance Imaging Modalities for Breast Cancer Assessment,0.00028158991007998333,0.0003084406279368394
NCT02213991,Intraoperative Radiotherapy for Korean Patients With Breast Cancer,0.0004246031435945524,0.000442600009567623
NCT02287675,Sentinel Lymph Node Biopsy Findings in Patients With Breast Cancer,0.0003467182083361562,0.0002030753140087124
NCT02295033,Randomized Boost Versus no Boost Irradiation of Early Breast Cancer,0.0003457036403238431,0.00030773144472585483
NCT02217033,"Effects of 'R' (Electro-kinetic Beverage) on Insomnia, Fatigue, and Depression in Breast Cancer Patients Having Adjuvant Chemo",0.00028697883887739324,0.00031194925363987815
NCT02281812,Radiofrequency Ablation in Breast Cancer,0.0004606322688816581,0.0003147442940367552
NCT02246621,A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer,0.00029812662347092437,0.0004399242495430478
NCT00590109,Germline BRCA1 and BRCA2 Mutations in Jewish Women Affected by Breast Cancer,0.00046131158196585805,0.00026968842223142845
NCT00590785,"Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394)",0.0003019057426824017,0.00024928620217914505
NCT00532285,Primary Paclitaxel Plus Gemcitabine in Patients With Stage II and III Breast Cancer,0.00031856619502872364,0.00033192368571718375
NCT00541086,"Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By Surgery",0.00029168147811228215,0.0002961820731208446
NCT00591747,Strength Training for Older Breast Cancer Survivors,0.0004609045801202636,0.0003026726686698899
NCT00591851,Phase II Study of Dose-Dense Doxurubicin and Cyclophosphamide (AC) Followed By Paclitaxel With Trastuzumab in HER2/ NEU-Amplified Breast Cancer: Feasibility,0.0002889036411016881,0.00035679585465623936
NCT00518583,Phase II Study in Patients With Operable Breast Cancer,0.0004827287424213841,0.000467705998421504
NCT00580333,"Preoperative Cisplatin and Bevacizumab in ER-, PR-, HER2 Negative Breast Cancer",0.00025193772382338706,0.0003116422241475644
NCT00534755,Prospective & Retrospective Data Collection of Breast Cancer Cases From 2000 to Present,0.0002720903913299482,0.00027688049317804627
NCT00570323,Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer,0.00026728661298309293,0.00034280974623752524
NCT00531973,A Study of Liposomal Doxorubicin in Women With Breast Cancer Exploiting Tissue Doppler Imaging,0.00027401102248601517,0.000291016297691627
NCT00542451,Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer,0.00026953684114019267,0.00036918103559098616
NCT00516243,Defined Green Tea Catechin Extract in Treating Women With Hormone Receptor Negative Stage I-III Breast Cancer,0.00026273465591589173,0.00029838311587635375
NCT00516698,Changes in Breast Density and Blood Hormone Levels in Postmenopausal Women Receiving Anastrozole or Exemestane for Breast Cancer,0.00024301561663511655,0.0003195062113051407
NCT00561119,Maintenance Versus Observation After 6 Cycles of Gemcitabine Plus Paclitaxel in Pts With Advanced Breast Cancer,0.0002762929266083362,0.00036889502215875047
NCT00574587,"Trial for Locally Advanced Her2 Positive Breast Cancer Using Paclitaxel, Trastuzumab, Doxorubicin and Cyclophasmide on a Weekly Basis",0.0002732938702594284,0.00033789793436381595
NCT00574301,Percutaneous Removal and Margin Ablation for Breast Cancer,0.00032809131792750374,0.00020049252420307594
NCT00574145,Healing Touch in Treating Fatigue in Women Undergoing Radiation Therapy for Breast Cancer,0.00028550266872413903,0.0003493619838622505
NCT00501332,"Evaluation of Maxy-G34 in Breast Cancer Patients Treated With TAC (Docetaxel, Adriamycin, Cyclophosphamide) Chemotherapy",0.0003100273158631386,0.00025664141539649937
NCT00539474,"""The Efficacy of 'Radioguided Occult Lesion Localization' (ROLL) Versus 'Wire-guided Localization' (WGL) in Breast Conserving Surgery for Non-palpable Breast Cancer: a Randomized Clinical Trial""",0.0002470973665523902,0.0004523797081024528
NCT00587925,Study of Bone Mineral Density in Postmenopausal Women After Treatment for Breast Cancer,0.000319146534837082,0.0003308049835910501
NCT00587340,A Survey of Sleep Problems in Survivors of Breast Cancer,0.0002724396588966219,0.0002735627891713607
NCT00510367,Primary Breast Cancer Occurring Concomitant With Pregnancy,0.00032826465880460146,0.00035905029218661195
NCT00502736,A Study of Loading Doses of Intravenous Bondronat (Ibandronate) in Patients With Breast Cancer and Malignant Bone Disease.,0.00031774234408951793,0.0002590696091312019
NCT00502684,Perioperative Administration of COX 2 Inhibitors and Beta Blockers to Women Undergoing Breast Cancer Surgery,0.0002596325269080061,0.00036657842720418094
NCT00572416,Fatigue in Breast Cancer: A Behavioral Sleep Intervention,0.0002540272048373372,0.00023316071029890574
NCT00584142,Mindfulness-based Stress Reduction in Breast Cancer Recovery,0.0002489269243553284,0.0003080723167368709
NCT00584753,Molecular Imaging of Breast Cancer With Breast PET/CT,0.00027948990365600176,0.00025249845155521567
NCT00581256,A Randomized Comparison of Radiation Therapy Techniques in the Management of Node Positive Breast Cancer,0.0002532955128797549,0.00030795383716217874
NCT00563407,Novel Surrogate Markers as Predictors of Radiation Toxicity in Breast Cancer Patients Undergoing Helical Tomotherapy Compared to Standard Radiation Therapy,0.0002930261346529836,0.00034856651321372984
NCT00563953,Caelyx as Primary Treatment for Patients With Breast Cancer and a History of Heart Disease and/or Age Over 65 Years,0.00030562642312880785,0.00040370004366821726
NCT00566085,New Technique as an Additional Diagnostic Tool for Women Undergoing Neoadjuvant Therapy for Breast Cancer,0.00035446777107200667,0.0002832543277953313
NCT00566618,Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis,0.0002658402624201382,0.0003310658258664541
NCT00540852,Monitoring the Response of Chemotherapy on Breast Cancer Tumor by Photon Migration Spectroscopy,0.00025309027478473726,0.0002707374732988115
NCT00540800,BREAST-10: Three-weekly Versus Weekly First-line Chemotherapy for Metastatic or Locally Advanced Breast Cancer,0.00032698497644038677,0.00033531233064199175
NCT00533364,Effect of SBG in Patients With Breast Cancer,0.000604818613718354,0.00039771842937014955
NCT00533338,Weight Gain Prevention for Breast Cancer Survivors,0.0003315199976803876,0.0003154261853155626
NCT00533663,Healing Touch During Chemotherapy Infusions for Women With Breast Cancer,0.0002933714676195636,0.0003192592789700499
NCT00533780,Effect of Healing Touch on the Experience of Women Undergoing Treatment for Breast Cancer,0.0003002207694335591,0.00023707832925975924
NCT00569049,Molecular Analysis of Breast Cancer,0.00046212792425593817,0.00030503088117651394
NCT00569543,Effect of Tamoxifen or an Aromatase Inhibitor on Estrogen Metabolism in Women Undergoing Treatment for Newly Diagnosed Breast Cancer,0.0002639804918575108,0.00026019910019528156
NCT00500383,Breast Cancer Risk Assessment Using Optical Breast Spectroscopy (OBS),0.00027624819957777194,0.0002473608912994848
NCT00537173,Predicting Response and Toxicity in Patients Receiving Paclitaxel and Avastin for Breast Cancer,0.0003034837871503089,0.00028712521654880374
NCT00594477,Intensity Modulated Radiotherapy for Breast Cancer,0.0003415550694316767,0.00027321717824466775
NCT00511459,Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients,0.00033562661096837176,0.0003578533087180768
NCT00559754,A Study of Avastin (Bevacizumab) and Sequential Chemotherapy in Patients With Primary HER2 Negative Operable Breast Cancer.,0.00033705240439923243,0.000299672214716799
NCT00559845,A Study of Avastin (Bevacizumab) in Patients With Inflammatory or Locally Advanced Breast Cancer.,0.00033855898426616145,0.00031881139470874546
NCT00559507,Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery,0.00031988994447882367,0.0002993246142481791
NCT00559858,Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine for Advanced Colorectal Cancer or Breast Cancer,0.000305683337324635,0.0002783198954516934
NCT00582244,Cognitive Behavioral Therapy (CBT) and Physical Exercise for Climacteric Symptoms in Breast Cancer Patients Experiencing Treatment-Induced Menopause: a Multicenter Randomized Trial,0.0003118780860601227,0.0004916468401287659
NCT00582478,Investigating Mechanisms to Explain Age Associated Differences in Quality of Life Among Breast Cancer Patients,0.0003489042326163871,0.0004166611547124276
NCT00582322,Genetic Studies in Breast Cancer,0.000462554440720925,0.000411842208099407
NCT00582920,Investigation of Changes in Bone Scan Imaging Before and After Intravenous Bisphosphonate Therapy for Osseous Metastases From Breast Cancer,0.0002596033708806808,0.0002781402600550191
NCT00505271,Safety and Efficacy Study Using Rexin-G for Breast Cancer,0.0005475118996500432,0.0003154309756436656
NCT00573495,Multipeptide Vaccine for Advanced Breast Cancer,0.0003628678273417118,0.0003763574019986574
NCT00525161,Study Adding Multikinase Inhibitor Sorafenib to Existing Endocrine Therapy in Patients With Advanced Breast Cancer,0.00033964347741271135,0.00037509005280106784
NCT00525759,Investigating the Biological Effects of the Addition of Zoledronic Acid to Pre-operative Chemotherapy in Breast Cancer,0.0002953704476692267,0.0003150461454668836
NCT00508794,Effects of Yoga in Breast Cancer Patients,0.0004252868324752444,0.00036499544473448444
NCT00508352,Post-operative Radiation With IMRT in the Management of Stage IIB-III Breast Cancer,0.0002955386409637835,0.00026810286409762314
NCT00556218,Meditation and Cognitive Function in Women With Breast Cancer,0.0003295585612151143,0.00029276638059098757
NCT00556374,Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy,0.00035095209929085855,0.00034262046738088624
NCT00546156,Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer,0.0002506102591131668,0.0003006234458610902
NCT00546104,Phase II Dasatinib Study in Advanced Breast Cancer,0.00034312374689146125,0.000589767357374137
NCT00571987,Pilot Study of Radiofrequency Ablation of Breast Cancer Lumpectomy Sites to Decrease Re-operation,0.0002700266097907057,0.00028507270617599104
NCT00551278,Validation Study Using the GeneSearch BLN Assay to Test Sentinel Lymph Nodes From Patients With Breast Cancer,0.00032803363684884334,0.0003870867870699697
NCT00519545,Prayer as a Possible Adjuvant Treatment for Breast Cancer,0.00036444763127759097,0.0003987624369557039
NCT00519168,"Sleep, Circadian Hormonal Dysregulation, and Breast Cancer Survival",0.0004609104270904101,0.0002964313809139197
NCT00589238,"Paclitaxel, Doxorubicin, and Cyclophosphamide With Or Without Carboplatin in Treating Women With Locally Advanced Breast Cancer That Can Be Removed by Surgery",0.00027218925200901114,0.00027897566004884115
NCT00513695,"Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer",0.00031015735448722015,0.00034792118706696517
NCT00513292,Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery,0.00026635494582837765,0.0002977256754265198
NCT00513136,Fatigue Intervention Trial for Breast Cancer Survivors,0.0003384199654696214,0.0001826779214029239
NCT00555503,Registry of Mastectomy for Breast Cancer Risk Reduction,0.0002741617986380911,0.00022442646989349823
NCT00555841,Safety and Efficacy of ALC in Breast Cancer in Subjects With Fatigue,0.0004663772083272083,0.00037010002326802065
NCT00555386,"Soy, Selenium and Breast Cancer Risk",0.0003277808228526156,0.00026990877386319945
NCT00555477,Aromatase Inhibitors in Premenopausal Breast Cancer Patients With Chemotherapy-Induced Ovarian Failure,0.00031267626344052884,0.00043837236747196835
NCT00550771,Phase II Trial to Compare the Safety of Two Chemotherapy Plus Trastuzumab Regimens as Adjuvant Therapy for HER2-positive Breast Cancer (Study P05048),0.0002974686197049869,0.000288737508842709
NCT00588705,The Communication of Genetic Risk to Adolescent Daughters of Women With Breast Cancer,0.00032919549922302783,0.0002562457237273879
NCT00588029,"Collection of Tissue, Blood, and Cells to Be Used For Studying the Causes, Prevention, Diagnosis, and Treatment of Breast Cancer",0.00025963493319405693,0.00031172737029923114
NCT00524459,Pegylated Liposomal Doxorubicin and Docetaxel in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery,0.00027263646266577465,0.0002731537982708349
NCT00524277,Vaccine Therapy in Treating Patients With Breast Cancer,0.0004250114303517305,0.0003018868485781406
NCT00524849,Zometa and Circulating Vascular Endothelial Growth Factor (VEGF) in Breast Cancer Patients With Bone Metastasis,0.0003094544543918062,0.00035912424181678583
NCT00544765,"Docetaxel, Doxorubicin and Cyclophosphamide Versus Vinorelbine and Capecitabine in Patients Not Sufficiently / Sufficiently Responding as Preoperative Treatment of Locally Advanced or Operable Primary Breast Cancer",0.0003325260110125624,0.0003504709315178725
NCT00544505,"Pre-operative Chemotherapy in Operable Breast Cancer, Phase III Study Comparing a Short Intensive Pre-operative Chemotherapy With the Same Therapy Initiated Shortly After Surgery(Peri-operatively)(POCOB)EORTC 10902)",0.0003666714614511311,0.0006366608017349494
NCT00544167,Adjuvant Doxorubicin/Cyclophosphamide and Paclitaxel Plus Sorafenib Breast Cancer,0.0002812083119344803,0.0003348325233685801
NCT00544986,"A Prospective,Open-label Study of Anastrozole in Post-menopausal Women With Hormone Sensitive Advanced Breast Cancer",0.0002854875355927739,0.0003665546364138198
NCT00535327,Test of Digital Breast Tomosynthesis vs. Regular Mammography in Detecting Breast Cancer in Women Undergoing Diagnostic Mammography,0.00024722430014312253,0.00024356940923488557
NCT00535067,Neuropathic Pain in Survivors of Breast Cancer,0.0004607717390098581,0.00033480875309603966
NCT00535678,Testing Digital Breast Tomosynthesis vs. Regular Mammogram in Detecting Breast Cancer in Women Having Screening Mammogram,0.000273653677156989,0.00021152682444970923
NCT00535184,Test of Digital Breast Tomosynthesis vs. Common Mammography to Detect Breast Cancer for Women Undergoing Breast Biopsy,0.00024722430014312253,0.00024424695358734114
NCT00535509,Phase II Trial of Neoadjuvant[FEC100]/Cisplatin-Docetaxel ± Trastuzumab in Women With Over Expressed or Amplified Her2/Neu With Locally Advanced Breast Cancer,0.0002838388002748909,0.0003308238691388464
NCT00530569,Evaluation of Clinical Significance of Circulating Markers in Breast Cancer Patients Undergoing Herceptin Therapy,0.00031750552611829605,0.0003247549622572981
NCT00530868,Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer,0.0002567464830971084,0.000333249200903802
NCT00575978,Hydralazine as Demethylating Agent in Breast Cancer,0.0003275967562530038,0.0003362368995430767
NCT00558272,Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease,0.0002815671316788636,0.00035823914422489255
NCT00558545,"A Phase 1-2, XIAP Antisense AEG35156 With Weekly Paclitaxel in Patients With Advanced Breast Cancer",0.0003170571963058013,0.00031887396242824323
NCT00597454,An Access Delivery Model That Eliminates Barriers to Breast Cancer Care Delivery,0.0002463550937488163,0.00029201036963163215
NCT00597597,"Phase II Open-Label Trial of Tarceva in Women With Metastatic, Hormone- and HER2-Negative Breast Cancer",0.0002806610897599062,0.0002862690016974345
NCT00506064,Melatonin Postoperative Sleep Study in Breast Cancer Patients,0.000345669894539609,0.0002252456130135788
NCT00567554,"Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer",0.00026788436739759393,0.00037392094501157276
NCT00567606,Prevention of Osteoporosis in Breast Cancer Survivors,0.000331522714152889,0.00030490476500882164
NCT00579800,"Newer Breast MRI Sequences for the Evaluation of Breast Cancer -FIESTA, Vibrant-DE and IDEAL: Feasibility Evaluation",0.0002839214556192313,0.00031975904935594416
NCT00599105,Angiogenesis in Early Breast Cancer for Prognosis Prediction,0.00032832957724023275,0.00039106277412809845
NCT00536939,"Trial of Paclitaxel, Bevacizumab, and Enzastaurin Versus Paclitaxel, Bevacizumab and Placebo for Breast Cancer",0.00025840040615296905,0.0003619598847319805
NCT00512993,Postoperative Use of Zoledronic Acid in Breast Cancer Patients After Neoadjuvant Chemotherapy,0.00033981823211152144,0.0004139133264074005
NCT00527293,Partial Breast Radiation Therapy in Treating Women Undergoing Breast-Conserving Therapy for Early Stage Breast Cancer,0.0002927230273350295,0.0003104610650443183
NCT00527449,Neoadjuvant Chemotherapy of Primary Breast Cancer With Epirubicin/Docetaxel and Carboplatin/Docetaxel,0.0002682299764194692,0.00040974536672866083
NCT00504699,Safety of Ovarian Stimulation With Letrozole and Gonadotropins in Breast Cancer Patients,0.0003140734795940011,0.0002900029424538429
NCT00548899,Neoadjuvant Chemotherapy Including Sorafenib in Women With Previously Untreated Primary Breast Cancer,0.00027676363788084165,0.0004081179883972645
NCT00562458,Non-interventional Study to Evaluate Arimidex in Postmenopausal Women With Advanced Breast Cancer,0.00030064455789336955,0.00036741556972695805
NCT00562718,Capecitabine and Radiation Therapy in Treating Patients With Nonmetastatic Breast Cancer After Surgery,0.0003346767852152558,0.00029261498073698757
NCT00538330,Post Operative Adjuvant Chemotherapy Followed by Adjuvant Tamoxifen vs Nil for Patients With Operable Breast Cancer,0.00035266400562502094,0.0004203710605415756
NCT00538525,Phase II Study of Neoadjuvant Chemotherapy With Doxorubicin Followed by Docetaxel-Cisplatin in Locally Advanced Breast Cancer,0.00030988057134894624,0.00042308402571240096
NCT00538343,RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain Metastases,0.0002931279877166273,0.0003976455901870007
NCT00538395,Intensive Sequential Chemotherapy With Adriamycin Taxol and Cytoxan in the Treatment of Locally Advanced Breast Cancer,0.00028605937638642856,0.00035736377673304445
NCT00576901,A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) and Docetaxel in Patients With Inflammatory or Locally Advanced Breast Cancer.,0.00034523656228727806,0.00034163777343243745
NCT02706964,Imaging the Patterns of Breast Cancer Early Metastases,0.00033444518589811597,0.00034212841909245917
NCT02762110,Imaging of In Vivo Sigma-2 Receptor Expression With [18F]ISO-1 Positron Emission Tomography (PET/CT) in Primary Breast Cancer,0.0002803362996651272,0.00021809861450395736
NCT02742051,"A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer",0.00027500111104873307,0.0002867178677077749
NCT02742168,99mTc-3PRGD2 SPECT/CT in Breast Cancer Patients,0.0003453276494615557,0.0003917696570839312
NCT02786797,Efficacy of MBSR Treatment of Cognitive Impairment Among Breast Cancer Survivors,0.0003645365081408466,0.00031779598389090587
NCT02786875,"Diet, Exercise and Vitamin D in Breast Cancer Recurrence",0.0002529602386279904,0.00025489788749775885
NCT02779751,A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer,0.0003176006336661104,0.00031552827818141625
NCT02763228,Physical Activity Intervention to Reduce Functional Health Disparities Among Breast Cancer Survivors,0.00024612912208331025,0.0002607545249601133
NCT02763566,A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer,0.0003870226376317102,0.00035459760728539824
NCT02704312,Dosimetric Comparison of Doses in Both Positions (Prone and Decubitus) for Patient With Breast Cancer,0.0003103509916112247,0.00029975739102273383
NCT02710058,Experience of Arab American Women With Breast Cancer: In-depth Interviews,0.0003277791064184543,0.0003903029993192889
NCT02760030,Fulvestrant and Palbociclib in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery,0.00029936372556883903,0.00035673270615307656
NCT02791581,"Cardiovascular Injury, Exercise Intolerance and Fatigue After Adjuvant Chemotherapy for Stage I-III Breast Cancer",0.0002458382736954085,0.000298520000862922
NCT02723877,PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO),0.0002590463250704852,0.0002886124166100633
NCT02734290,Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer,0.0002937976594701609,0.0003095091679295274
NCT02749019,Dual Integrin αvβ3 and GRPR Targeting PET Imaging in Breast Cancer Patients,0.0003152662775400767,0.00031841070967714337
NCT02794064,A Prototype Tri-modal Imaging Device for Breast Cancer,0.0004603590742105769,0.0003194733228230813
NCT02794493,Treatment of Hand and Foot Syndrome With Traditional Chinese Medicine Formula LC09 in Patients Who Are Receiving Capecitabine for Colorectal and/or Breast Cancer,0.0003037126177582926,0.0002658326715209264
NCT02740491,"Implementation of a ""Remission"" Consultation in the Management of Patients Treated for Localized Breast Cancer",0.0003097773362293555,0.00036017715130774703
NCT02754427,Pilot Study for a Prospective Surveillance Program for Rehabilitation Following Surgery for Breast Cancer,0.0002854976147994885,0.00032207095019647883
NCT02797652,Clinical Application of CTDNA in Operable Breast Cancer Patients,0.00034818998850711573,0.0003419642786114414
NCT02797223,"""Impact of Chemotherapy-induced Alopecia on the Quality of Life of Women With Breast Cancer""",0.00029619173551555136,0.0002724842452556774
NCT02716792,A Study to Evaluate Renal Safety of Intravenous Ibandronate (Bondronat) in Participants With Metastatic Bone Disease Due to Breast Cancer,0.0002704681672727712,0.0002546180669703538
NCT02716467,Effect of Intercessory Prayer in Patients With Breast Cancer in Radiotherapy Treatment: Clinical Trial,0.0003442938772685685,0.0003287299747907952
NCT02769104,Aromatase Inhibitors Plus Chemotherapy vs Chemotherapy as Neoadjuvant Treatment in Postmenopausal HR(+) Breast Cancer,0.0002893436854282956,0.0003930064600763151
NCT02712723,"Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer",0.0002722719928436071,0.0003475924414828717
NCT02712645,A Multicenter Breast Cancer Biospecimen Registry,0.00046131513084244306,0.0003013274325922512
NCT02712437,Prospective Study Evaluating the Use of PROSPECT to Reduce Insomnia in Patients With Early Stage Breast Cancer,0.0003569203355871181,0.00033541848555262294
NCT02748746,Early Detection of Lymphedema With Bio-Electrical Impedance Analysis in Patients After Breast Cancer Surgery,0.00030551661849330955,0.00032183201741590913
NCT02789657,BrUOG 308: Efficacy of wPCbTP and Switching to an AC in Non-responding Patients as Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.,0.00031261231101534855,0.00038868721369674555
NCT02789332,Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency,0.00031404214246041304,0.00029968948210739416
NCT02744079,Comparison of Healthy Diets on Breast Cancer Markers,0.00027968657719277005,0.00019702323707085476
NCT02750826,Breast Cancer WEight Loss Study (BWEL Study),0.0005475118996500432,0.0003386265934946876
NCT02750241,Pink Warrior—Support Group Toolkit for Breast Cancer Survivors,0.0003317511873153564,0.0002963684586254316
NCT02746666,Pharmacist's Influence on Breast Cancer Patient Quality of Life,0.00042798732017905857,0.0003101266182923726
NCT02732171,PENN-Surveillance Markers of Utility for Recurrence After (Neo)Adjuvant Therapy for Breast Cancer,0.00027779767388473044,0.00032393214021282787
NCT02781805,Pilot Study of Bisphosphonates for Breast Cancer,0.0003864812234273524,0.0002829874728063586
NCT02781051,Increasing Physical Activity Among Breast Cancer Survivors With Depression,0.0002798135213110897,0.0003354901319004491
NCT02781259,Selective Lymph Node Dissection Using Fluorescent Dye in Node-positive Breast Cancer,0.0002452768784630546,0.00025807384161288344
NCT02730858,Palliative And Oncology Care Model In Breast Cancer,0.0003337489212505972,0.000301144555415529
NCT02730091,"A Open Study of Metronomic Oral Vinorelbine in Combination With Aromatase Inhibitors for the Treatment of Postmenopausal Women With Hormone Receptor Positive,HER2-negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease",0.00032447787714029783,0.00034818833880511247
NCT02725489,Pilot Study of Durvalumab (MEDI4736) in Combination With Vigil™ in Advanced Breast Cancer,0.0002955254054381265,0.0002840291284549189
NCT02725541,Trial of Neoadjuvant Trastuzumab Emtansine in Patients With HER2-Equivocal Breast Cancer,0.0003603999433176985,0.0003879681926324865
NCT02725658,Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using DOSI,0.0002815890419582826,0.0003435994684720917
NCT02725840,Breast Cancer Lung Late Effects,0.00046131885547268103,0.0002487203274683279
NCT02725606,"Study to Assess the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of GW003 in Patients With Breast Cancer",0.0003916294400182825,0.0004022154325568513
NCT02771795,A Long-term Follow-up Study for Cardiac Safety in the Patients With HER2 (+) Breast Cancer Who Have Completed the SB3-G31-BC,0.00032646816077849274,0.0004172725164580965
NCT02771756,The Effect of Zhen Qi Shen Capsule Combined With Yu Yi Kang on Breast Cancer and Lung Cancer Patients With Chemotherapy,0.0003265546954268179,0.0003977291268064589
NCT02752659,Reliability and Validity of Self-measured Arm Circumference in Women With Breast Cancer,0.00032824131959353713,0.00022277219825639604
NCT02752893,Estrogen Receptor-Positive Breast Cancer Patient-Derived Xenografts,0.00030003596634006817,0.00031160374946700726
NCT02726477,Efficacy and Safety of Wuling San on Breast Cancer-related Lymphedema,0.00027780159625257975,0.00033827552577136977
NCT02776917,"Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer",0.0002929550987704823,0.00032374343697092205
NCT02702830,MRI and Cardio-Pulmonary Exercise Testing in Evaluating Exercise Intolerance in Patients With Stage I-III Breast Cancer After Chemotherapy Treatment,0.0003284027126091851,0.0003498630902640248
NCT02705859,Phase Ib/II Trial of coPANlisib in Combination With Trastuzumab in HER2-positive Breast Cancer. (Panther Study),0.0003383574800458642,0.00036851745823851436
NCT02780401,"Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission",0.00029371243872890944,0.00032142544845256693
NCT02780271,Diet and Physical Activity Changes Among Latina Breast Cancer Survivors,0.00025459953265587833,0.00020905491794465109
NCT02733601,Epidemiology of Breast Cancer in Women Based on Diagnosis Data From Oncologists and Breast Surgeons in Algeria,0.00028249462194818994,0.00027842152781149037
NCT02707471,Improving Well-Being for Breast Cancer Patients,0.00042411551835655714,0.0004104143098284785
NCT02707835,Edema Control in Patients With Breast Cancer-comparison of Manual Lymph Drainage and Epidermis Fascia Taping,0.00029103934882889154,0.00026441447938928275
NCT02790580,Dose-dense Doxorubicin/Cyclophosphamide With Intermittent Low-dose Sunitinib in Breast Cancer Patients,0.0002850950132927706,0.0004031270502995644
NCT02790320,Eribulin [Halaven] Use For the Treatment of Advanced Breast Cancer,0.00029272222473067155,0.0003943304316417467
NCT02790021,Lymphaticovenous Anastomosis for Breast Cancer-related Lymphedema,0.00027780159625257975,0.00035024849494588457
NCT02708511,Copper Cu 64-DOTA-B-Fab PET/CT in Imaging Patients With Ovarian and Breast Cancer,0.00029787374888355037,0.0003496159608920787
NCT02708680,Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In,0.0003190859431037145,0.00033669610141818325
NCT02777164,A Study of the MIRA System for Evaluating Women at High Risk of Breast Cancer,0.00039178990520458775,0.0002544207483435056
NCT02773004,"Prospective Study Assessing EndoPredict® Genomic Test Impact on Shared Decision of Adjuvant Chemotherapy in Patients With ER-positive, Her2-negative Early Breast Cancer",0.000327404419500929,0.000366804538832971
NCT02792114,T-Cell Therapy for Advanced Breast Cancer,0.0003616006938959774,0.00038002952172538673
NCT02761642,A Study of Recombinant Human Erythropoietin Beta (r-HuEPO) (NeoRecormon) in Anemic Participants With Breast Cancer Undergoing Chemotherapy,0.00027819396004922115,0.00034994302839560213
NCT02761616,A Study to Determine Biopsy Rate in Participants With a First Relapse of Breast Cancer,0.00031735823550310986,0.00034018426720379744
NCT02751606,Nano MRI on 7 Tesla in Rectal and Breast Cancer,0.0004603590742105769,0.0003073039998812945
NCT02751528,"QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer",0.0002957178070624037,0.00046413646901333905
NCT02721147,Pilot Study of an Intimacy Enhancement Intervention for Couples Facing Breast Cancer,0.0003223250833571091,0.0002640491926907471
NCT02770469,Culturally Tailored Educational and Support Program to Increase Quality of Life Among Korean Breast Cancer Survivors,0.00025478405192484304,0.00019168237539609915
NCT02770781,Feasibility Study of the Addition of a Personal Trainer to the Post-Treatment Regimen of Breast Cancer Survivors,0.00033068896940602636,0.00022259448556492586
NCT02718144,Assessment of Safety and Efficacy of Estetrol in Postmenopausal Women With Advanced Estrogen Receptor Positive (ER+) Breast Cancer,0.000283603768901496,0.00040233609008884415
NCT02793076,Physical and Emotional Benefits of Group Dance Intervention for Breast Cancer Survivors,0.0002568497783836409,0.0003194405007391466
NCT02774915,Outcome of Pregnancy and Breast Cancer,0.00046089923810156436,0.00019298358091667875
NCT02768415,Study of Apatinib Combined With Oral Vinorelbine in Metastatic HER2 Negative Breast Cancer,0.00027772488856867765,0.0003676976875230222
NCT02768714,Trial to Compare the Efficacy and Safety of Pegfilgrastim Biosimilar in Subjects With High Risk Stage Breast Cancer Receiving Chemotherapy,0.00026400254075499335,0.00021554267260836792
NCT02798796,Brazilian Randomized Study - Impact of MRI for Breast Cancer,0.00032045377106404465,0.0004687776606081119
NCT02753686,Treatment of Canadian Postmenopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy,0.00028257838523860845,0.00031229269305198113
NCT02778685,"Pembrolizumab, Letrozole, and Palbociclib in Treating Patients With Stage IV Estrogen Receptor Positive Breast Cancer With Stable Disease That Has Not Responded to Letrozole and Palbociclib",0.0002876890652960058,0.0003489885576312646
NCT02796755,Effects of Riluzole on CNS Glutamate and Fatigue in Breast Cancer Survivors With High Inflammation,0.0002401058676806759,0.00025433000572306193
NCT02772367,Generation of Heart Muscle Cells From Skin Cells of Breast Cancer Patients,0.00029334129149418423,0.0003296282460873995
NCT02772731,Shave Margins vs. Standard Partial Mastectomy in Breast Cancer Patients,0.00034807632406793547,0.00026703430005219195
NCT02765373,Effects of Adjuvant Endocrine Therapy With Aromatase Inhibitors on the Postoperative Lipid Levels in Postmenopausal Breast Cancer Patients,0.00030762095555705794,0.0003198524654756153
NCT02764541,Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS),0.00032375572927979926,0.00038400266809970066
NCT02741726,Efficiency of Acupuncture-assisted Anesthesia With Single Acupoint or Dual Acupoints in Patients Undergoing Radical Operation of Breast Cancer,0.000294160323107419,0.00028958536675464957
NCT02741232,Comparison of Perioperative Opioid Consumption Following Pectoral Nerve Block for Breast Cancer Surgery,0.00024345648496396078,0.00024285327704506328
NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,0.0003464164503927772,0.0003790245329469959
NCT02759549,Fatigue in Breast Cancer Patients Undergoing Radiotherapy-eSMART-MH,0.0003591611826711182,0.0003112212421760821
NCT02700386,Shorter Course Radiation for the Treatment of Breast Cancer That Has Spread to Lymph Nodes,0.00031151039039473724,0.00037217623198548355
NCT02738970,A Dose-Finding Study of Pertuzumab (Perjeta) in Combination With Trastuzumab (Herceptin) in Early Breast Cancer (EBC),0.00027792539169339966,0.0002529701821253883
NCT02745262,Overall Survival and Disease-free Survival in Breast Cancer Patients Under COS,0.00034660444115333297,0.00035464682277645034
NCT02766530,Integrated Positron Emission Tomography Magnetic Resonance (PET/MR) of Breast Cancer,0.00033271576874252805,0.0003193969726294516
NCT03041545,Tracking Physical Activity Throughout Chemotherapy for Breast Cancer,0.00030103820809476673,0.00021822652861696955
NCT03091842,Exercise Intervention in Targeting Adiposity and Inflammation With Movement to Improve Prognosis in Breast Cancer,0.000231830854256936,0.00027527923496117754
NCT03027063,Impact of Exercise on Mitigating the Cardio-toxic Effects of Adriamycin Among Women Newly Diagnosed With Breast Cancer.,0.00025674679494832616,0.00027847957161918134
NCT03014076,Immunotherapy Vaccine and Herceptin in Breast Cancer,0.00027677668603404983,0.0003345763928908006
NCT03079219,Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Chinese Breast Cancer Patients,0.00030957384215995885,0.0002912177220824564
NCT03005860,Effect of TIVA Propofol vs Sevoflurane Anaesthetic on Serum Biomarkers and on PBMCs in Breast Cancer Surgery,0.0002459637562946133,0.00019094606634062952
NCT03089918,A Study to Investigate the Regional Brain Kinetics of Brain Drug Transporters Using P-glycoprotein and Breast Cancer Resistance Protein Substrates and by Using the Positron Emission Tomography Ligand 11C-JNJ-63779586 in the Human Brain,0.00026530733305215074,0.0002268521484179895
NCT03089502,Efficacy of Cardio-Oncology Rehabilitation Exercise for Women With Breast Cancer and Treatment Related Cardiotoxicity,0.00026326007393109255,0.0002789717299702401
NCT03077841,Optimizing Preventative Adjuvant Linac-Based Radiation: the OPAL Trial - Study of Hypofractionated Partial Breast Irradiation in Women With Early Stage Breast Cancer,0.0003039643915544119,0.00035046241088433627
NCT03077776,Tracking Triple-negative Breast Cancer Evolution Through Therapy,0.00037037226021255896,0.00040371892965208054
NCT03087409,High-dose Chemotherapy With Hematopoietic Stem-cell Rescue for High-risk Breast Cancer: Long-term Follow-up,0.00025393925740811594,0.0002424694052208554
NCT03087461,Bridging the Gap: Incorporating Exercise Evidence Into Clinical Practice in Breast Cancer Care in Ontario,0.00027791793194482093,0.00035878366782173476
NCT03048942,Pilot Study of Cabazitaxel and Paclitaxel in HER2 Negative Breast Cancer,0.0002936924032664944,0.0003575435708123712
NCT03018080,Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast Cancer,0.00029872089851690903,0.0003409357978493525
NCT03006172,"To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer",0.0002645852739727736,0.0003402906024879991
NCT03006614,PERS Genetic Model Assistant Decision-making System of Neoadjuvant Chemotherapy for Breast Cancer,0.0002764540355355222,0.00030871771553936644
NCT03006055,The Detection of Circulating Tumor Cells (CTCs) in Breast Cancer With a Novel in Vivo Device,0.0002730659253573253,0.0002096617321333809
NCT03078751,Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer,0.0002816838468483875,0.0003516400011283787
NCT03078036,"International Breast Cancer Biomarker,Standard of Care and Real World Outcomes Study",0.0003226508475254156,0.0002850413349893464
NCT03036943,Fluciclovine (18F) Imaging of Breast Cancer,0.00033233527095060875,0.0002765507493005614
NCT03007979,Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer,0.00025270282038166716,0.00028407774604251855
NCT03007992,Metronomic Treatment With Daily Oral Vinorelbine as First-line Chemotherapy in Patients With Advanced/Metastatic Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Breast Cancer,0.0003508653000165318,0.00031095895944549616
NCT03046238,Efficacy and Safety of Dexmedetomidine Added to Modified Pectoral's Block in Breast Cancer Patients,0.0003459018810936628,0.0002624295074056686
NCT03088527,"A Phase 1, First-in-Human, Multi-Part Study of RAD140 in Postmenopausal Women With Hormone Receptor Positive Breast Cancer",0.0002901881573175621,0.00034003928158934655
NCT03050398,A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib,0.00027321782273885683,0.00033402706351352466
NCT03050463,Functional Magnetic Resonance Imaging in Assessing Affect Reactivity and Regulation in Patients With Stage 0-III Breast Cancer,0.00031813406219712107,0.00025036160702837217
NCT03051750,Comparison of Techniques for Breast Cancer-Related Lymphedema.,0.00028040583327808494,0.0004224229848423152
NCT03051659,A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer,0.00027792301833445734,0.00034007519130929215
NCT03051828,Physical Evaluation and Quality of Life in the Practice of Fencing in Breast Cancer Support,0.0002488141194282291,0.00023902992189389963
NCT03051776,Kinesio Taping Versus Compression Garments for Breast Cancer-Related Lymphedema,0.00027780159625257975,0.0003177403727247144
NCT03063619,Afimoxifene in Reducing the Risk of Breast Cancer in Women With Mammographically Dense Breast,0.0003275959036377162,0.0003540703100203126
NCT03000764,RNA and Heat Shock Protein Biomarkers in Radiation-induced Fibrosis in Breast Cancer,0.00024774093319589137,0.00024040010642911337
NCT03000036,Doxorubicin-associated Cardiac Remodeling Followed by CMR in Breast Cancer Patients,0.00034985941408881424,0.0002030409771795301
NCT03000920,Evaluation of the Short Message Service Effectiveness in the Screening Invitation Strategy for Breast Cancer (USIMaPI),0.00023566943740120836,0.00029437603405103825
NCT03022162,Prevalence of Paclitaxel Induced CIPN-Related Pain and CIPN in Indian Patients With Breast Cancer,0.00031976209171007445,0.00025505408603962237
NCT03081234,Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer,0.00027734530522950635,0.00034752414459195244
NCT03029182,Simulated-altitude to Optimize Aerobic Exercise Among Breast Cancer Survivors With Limited Mobility,0.0002461438858032921,0.000283278644668982
NCT03058939,Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast Cancer,0.0002867020111436137,0.0003134104238080173
NCT03072992,"""Curcumin"" in Combination With Chemotherapy in Advanced Breast Cancer",0.00029366650373138586,0.0003853488260606829
NCT03072966,Development of Distress Management Algorithms Using Mobile Device Based Health Logs in Breast Cancer Survivors,0.00023245776293470672,0.0002527031595452926
NCT03039140,Cardiac Rehabilitation Program in Improving Cardiorespiratory Fitness in Stage 0-III Breast Cancer Survivors,0.00025897488296404615,0.0002637725095067692
NCT03039127,Immunostimulating Interstitial Laser Thermotherapy in Breast Cancer,0.0002458875070730314,0.0002549844309215133
NCT03054025,Smart Phone Application in Increasing Physical Activity in Breast Cancer Survivors,0.0002532734692763024,0.00029086207901008935
NCT03054363,"Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer",0.00025112403600311475,0.00029779287081769016
NCT03017404,A Dose Increase Finding Study of Doxorubicin Hydrochloride Liposome Injection for Patients With Breast Cancer,0.00032601203922832874,0.00035884190849439846
NCT03017560,Treating Verbal Memory Deficits Following Chemotherapy for Breast Cancer,0.00029302872697024016,0.000294272534895145
NCT03074071,Enhancing Hope Among Patients With Poor-Prognosis Breast Cancer and Oncologists,0.0003087667677845853,0.00025400633718296545
NCT03011060,Sequential Neo-adjuvant Chemotherapy Followed by Capecitabine Vs. Conventional Adjuvant Chemotherapy in Breast Cancer,0.00027029772286430185,0.0003508857142558082
NCT03080155,A Study of the 3D MIRA System in Classifying Women at for Likelihood of Breast Cancer,0.0005475118996500432,0.0002924287032087229
NCT03080428,"Assessment of Genomic Test Impact on Shared Decision of Adjuvant Chemotherapy in ER-positive, Her2-negative Early Breast Cancer",0.00025028606364691045,0.00036366894963985627
NCT03085368,A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib vs Herceptin,0.0002968941053033311,0.00024160424211282843
NCT03095352,"A Randomized Phase II Study of Pembrolizumab, an Anti-PD (Programmed Cell Death)-1 Antibody, in Combination With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease",0.00032277999659031763,0.00036666969416021083
NCT03003611,Observational Trial on the Impact of Hypnose Used as a Sedation in Oncology Surgery in Breast Cancer,0.000250981030168277,0.0003234554156661291
NCT03093350,TUMOR-ASSOCIATED ANTIGEN (TAA)-SPECIFIC CYTOTOXIC T LYMPHOCYTES ADMINISTERED IN PATIENTS WITH BREAST CANCER,0.0002495530663131616,0.0003402784977701297
NCT03061773,Physical Training on Patients With Breast Cancer,0.0003522951496005545,0.0003998738515427225
NCT03061175,Web-Based Decision Aid in Improving Informed Decisions in Patients With Stage 0-IIIA Breast Cancer Considering Contralateral Prophylactic Mastectomy,0.00030089455023483806,0.00033727339065558467
NCT03010371,Presential Vs Online Group-based Psychosocial Treatment for Breast Cancer Survivors.,0.0003015813087122637,0.00027348417597372214
NCT03086785,"Prospective, Multicenter, Observational Study of Apatinib Single or Combined Capecitabine for Treatment of Patients With Metastatic Her-2 Negative Breast Cancer",0.0003441178914912966,0.0003879669245695168
NCT03043794,Study of Stereotactic Radiotherapy for Breast Cancer,0.0003863902133673511,0.0003999955961975408
NCT03052634,RC48-ADC Administered Intravenously to Subjects With HER2-Positive in Advanced Breast Cancer,0.00036160069389597747,0.0004618219314493976
NCT03012399,Biobehavioral Effects of Hypnosis During Breast Cancer Surgery,0.0003472702687782397,0.0002937463026251514
NCT03012477,CISPLATIN + AZD-1775 In Breast Cancer,0.0004621364396145226,0.0003793133432214522
NCT03025139,Mindfulness Meditation or Survivorship Education in Improving Behavioral Symptoms in Younger Stage 0-III Breast Cancer Survivors (Pathways to Wellness),0.0002461582781916662,0.0003010614540932056
NCT03025035,Pembrolizumab in Advanced BRCA-mutated Breast Cancer,0.0003623273057754221,0.00031065425746630966
NCT03004534,A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of ODM-201,0.0002785272605612847,0.000335678594076983
NCT03083288,Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Breast Cancer,0.0002764923891820967,0.0002698359094286305
NCT03075462,A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients,0.00032323893958958083,0.00033943225834927136
NCT03099174,This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer.,0.00034271723164044,0.00040287212518576765
NCT03045575,Objective Assessment of Physical Activity During Chemotherapy for Breast Cancer,0.00027073204696587513,0.0003143221923489552
NCT03045653,Efficacy of High Dose Tamoxifen to Advanced Hormone Receptor-High Expressed Breast Cancer,0.0002783916526058561,0.0002562124693540143
NCT03002532,Hippocampal-sparing Whole Brain Radiotherapy for Brain Metastases From Breast Cancer,0.00025837809313448593,0.0002762649867077113
NCT03002103,A Trial Evaluating the Efficacy and Safety of EndoTAG®-1 in Combination With Paclitaxel and Gemcitabine Compared With Paclitaxel and Gemcitabine as First-line Therapy in Patients With Visceral Metastatic Triple-negative Breast Cancer,0.0003195520042521992,0.0002759024949294971
NCT03094052,"Diarrhea Prophylaxis in Patients With HER2+ Breast Cancer Treated With Trastuzumab and Neratinib, Followed by Neratinib Monotherapy",0.00030268318591700866,0.00033283189568210743
NCT03067389,Combined Breast Cancer Risk Study,0.0005475118996500432,0.00028801904201417955
NCT03024580,A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer,0.0003001962822616557,0.0004081700462673078
NCT03024463,The Clinical Significance of Internal Mammary Lymph Node Irradiation in Axillary Lymph Node Positive Breast Cancer Patients,0.00030025254805573137,0.0003757872351837104
NCT03082456,Molecular Breast Imaging in Screening Breast Cancer,0.0003296195518615926,0.0002819344205917022
NCT03065478,Observational STudy to Evaluate the EFfectiveness of OnLife® in Improving CIPN in Patients With Colon or Breast Cancer After End of Adj. Therapy,0.0003207334076888211,0.00035599044483354406
NCT00284336,Caelyx Adjuvant in Elderly Breast Cancer,0.000460901640001601,0.00024328492623243707
NCT00203502,Primary Systemic Therapy in Operable/Locally Advanced Breast Cancer,0.00036196837145313626,0.00031114421338773843
NCT00271661,Presbyopia in Breast Cancer Survivors,0.0004603590742105769,0.0002689129356919775
NCT00296036,Pyridoxine and Topical Urea/Lactic Acid-Based Cream in Preventing Hand-Foot Syndrome in Patients Receiving Capecitabine for Breast Cancer or Other Cancer,0.00028432542187721533,0.00023442580751650667
NCT00296010,Liposomal Doxorubicin Compared With Observation or Cyclophosphamide and Methotrexate in Treating Older Women Who Have Undergone Surgery for Breast Cancer,0.0002510989154754508,0.0002707933249640679
NCT00220792,Group Therapy for Primary Breast Cancer,0.0004603590742105769,0.0002699662044178653
NCT00256243,Neoadjuvant Biweekly Treatment Followed by Weekly Treatment of Breast Cancer,0.0003829368033553994,0.0005032772791161625
NCT00256360,"Trial Exploring Feasibility of Densification and Optimal Sequencing of Postoperative Adjuvant Fluorouracil, Epirubicin Plus Cyclophosphamide (FEC) and Docetaxel Chemotherapy in Patients With High Risk Primary Operable Breast Cancer",0.00030776535189638865,0.0003174747879662925
NCT00291798,Neoadjuvant Endocrinotherapy of Breast Cancer (Mamma Carcinoma) With Exemestane,0.00026453856484397794,0.00025021323694669745
NCT00291759,ABCSG 8 - Adjuvant Treatment in Patients With Hormone Receptor-positive Breast Cancer With Good to Moderate Differentiation.,0.0003152996061976649,0.0003385044921430813
NCT00291135,Protocol for Women at Increased Risk of Developing Breast Cancer,0.000331455018899872,0.00029757077650554214
NCT00291122,An Examination of Predictors of Indicators of Response to Celecoxib in Women Who Have a Diagnosis of Early Breast Cancer,0.0002488773094894771,0.0002254174068940376
NCT00291083,Protocol for Postmenopausal Women at Increased Risk of Developing Breast Cancer,0.0002866304409922992,0.00018052497610067988
NCT00291694,Protocol for Women at Increased Risk of Developing Breast Cancer,0.000331455018899872,0.00021445142731239478
NCT00291096,Protocol for Women at Increased Risk of Developing Breast Cancer,0.000331455018899872,0.0002065669272136742
NCT00228943,The Role of Serotonin in Hot Flashes After Breast Cancer,0.00027355064524238904,0.0001674415134154287
NCT00255060,Comprehensive Screening for Women at High Genetic Risk for Developing Breast Cancer,0.0002778169003665074,0.00020213703112379204
NCT00243607,Hydrotherapy Against Menopausal Symptoms in Breast Cancer Survivors,0.00032768746942273875,0.0002764384901624296
NCT00204477,Soy Protein and Breast Cancer Risk Reduction,0.00032924824521206623,0.00019011473748482943
NCT00204490,Soy Isoflavones and Breast Cancer Risk Reduction,0.00027295864983337153,0.00018279100236987238
NCT00293540,Luteal vs Follicular Surgical Oophorectomy and Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor Positive Breast Cancer,0.0002590938357538392,0.0002841933817415209
NCT00293865,Study of Sentinel Lymph Node Assessment Following Previous Surgical Biopsy for Early Breast Cancer,0.0002874102981208759,0.00029640017848757324
NCT00235235,A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer,0.0003472731775053668,0.0003634838849433938
NCT00244959,Anastrozole in Treating Postmenopausal Women With DCIS or Stage I-III Breast Cancer,0.0002683625970868715,0.00024718694414749276
NCT00278837,Avon Foundation Program to Improve Quality of Life in Breast Cancer Survivors,0.0002791277156940743,0.00019694953334713325
NCT00212121,Radiation Dose Intensity Study in Breast Cancer in Young Women,0.0003997123848322345,0.0005777394381413376
NCT00212082,Gene Expression Profiles in Predicting Chemotherapy Response in Breast Cancer,0.0002695820087221879,0.0003569051271330772
NCT00212095,Docetaxel Combined With Ketoconazole in Treatment of Breast Cancer,0.0003068362058290545,0.0003585056907198503
NCT00212069,Serum Proteomics to Predict Gemcitabine Sensitivity in Breast Cancer,0.0002732938408143573,0.0002674043544673257
NCT00252811,A Study of ZD1839 Effects on Cell Proliferation in Breast Cancer,0.0002855780504021122,0.00028333167382980484
NCT00242203,Evaluation of Chemotherapy Prior to Surgery With or Without Zometa for Women With Locally Advanced Breast Cancer,0.0002887855617100426,0.0003629767150949857
NCT00208273,Concomitant and Sequential Radiohormonotherapy in Adjuvant Breast Cancer,0.00046076834526916695,0.00023195096739232396
NCT00208871,An Evaluation of Stereoscopic Digital Mammography for Earlier Detection of Breast Cancer and Reduced Rate of Recall,0.00025382194724654194,0.0002996290564176504
NCT00221221,Physical Activity Promotion in Breast Cancer Survivors,0.0003381573728039115,0.00032151651359592457
NCT00280930,Letrozole in Postmenopausal Women at Increased Risk for Breast Cancer,0.0002924470259709633,0.00030861516024357447
NCT00241046,Letrozole in the Treatment of 1st and 2nd Line Hormone Receptor Positive Breast Cancer: Pre-therapeutic Risk Assessment,0.00026692520108205286,0.0003541301686089272
NCT00241449,A Trial Comparing the Efficacy and Tolerability of Faslodex With Nolvadex in Postmenopausal Women With Advanced Breast Cancer,0.0002786089815725573,0.00036878399246876214
NCT00214292,Evaluation of Breast Cancer Surgical Margins Using Optical Spectroscopy,0.0002801496999277017,0.00026173748630142107
NCT00263198,PTK and Letrozole in Post-menopausal Women With Advanced Breast Cancer,0.00030726427341980195,0.00034890500308332547
NCT00263705,Adjuvant Capecitabine in Elderly Patients With Breast Cancer: a Phase II Study,0.0003956363365712682,0.0004517888161567551
NCT00263588,Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer,0.00033448381503793336,0.00033004422769320146
NCT00263211,A Study of the Effects of Inhibiting Platelet Function on Circulating Cancer Cells in Breast Cancer Patients,0.000328862302289481,0.00037186397320396094
NCT00263185,High Dose Vit D Musculoskeletal Symptoms & Bone Density in Anastrozole-Treated Breast Cancer With Marginal Vit D Status,0.00023430821255935406,0.0002825965931820962
NCT00288795,A Randomized Study of Polarity or Massage Therapy to Reduce Fatigue in Breast Cancer Patients During Radiation Therapy,0.00032972131700075615,0.0003513553115513657
NCT00260975,Study of the Effects of Chemotherapy on Memory and Other Mental Functions in Women With Breast Cancer,0.00027986709669948517,0.0002595518146540114
NCT00274469,A Clinical Trial to Compare Efficacy and Tolerability of Faslodex With Arimidex in Patients With Advanced Breast Cancer,0.0003141654186823426,0.00034744628522889314
NCT00209001,Efficacy of Acupuncture for Hot Flashes in Women Treated With Hormonal Therapy for Breast Cancer,0.00027954790326556656,0.0004327857743338985
NCT00209092,Randomized Phase II Trial Induction Therapy for Early Stage Breast Cancer,0.00030109565069499423,0.00033028789124598523
NCT00299286,Short-term Presurgical Study to Assess Molecular Predictors of Lapatinib's Effects in Primary Breast Cancer,0.00032072845429002725,0.00034903708178960483
NCT00299117,Brief Smoking Intervention for Women Undergoing Breast Cancer Surgery,0.00029201941152225553,0.0002740069505707404
NCT00247663,Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer,0.0003512452897653893,0.00040738331638616557
NCT00247975,Ability of L-carnitine to Prevent Heart Damage in Breast Cancer Patients Receiving Anthracycline Chemotherapy,0.00030101329854806896,0.00033881644609822393
NCT00247650,"Comparison Study of Letrozole Alone or Letrozole With Zoledronic Acid in Early Breast Cancer, Neoadjuvant Therapy",0.0002826295372210375,0.0003342134400683271
NCT00245024,Sulindac in Preventing Breast Cancer in Women at High Risk for Breast Cancer,0.00033308501771875035,0.00026155874681962893
NCT00245869,Ultrasound and Chemotherapy of Breast Cancer: Relationship Between Early Vascular Changes of the Tumor and Late Tumoral Response,0.0002522980675855285,0.0003120110318499464
NCT00246597,"A Phase III Clinical Trial of PROCRIT (Epoetin Alfa) Versus Placebo in Women Undergoing Adjuvant Chemotherapy for Stage I, II or III Breast Cancer",0.00024380642242590188,0.0003153056442729264
NCT00246571,Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer,0.0003685543886245379,0.00038870943695228994
NCT00246090,"A Phase II Study of E7389 in Patients With Breast Cancer, Previously Treated With Anthracycline, Taxane and Capecitabine",0.0003313692184962984,0.0003858451340774152
NCT00261313,ACCELERATE: Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Pegfilgrastim and Darbepoetin Alfa Support for the Treatment of Women With Breast Cancer,0.00026243099647588636,0.0003176409410574303
NCT00277004,Physiological Biomarkers of Cancer Treatment Related Fatigue in Women With Breast Cancer.,0.0002566255279831668,0.0003562838281921402
NCT00239343,Phase II Trial of Preoperative Therapy With Gefitinib and Chemotherapy in Patients With ERneg Breast Cancer,0.0003383976978391999,0.00038186261981222207
NCT00201942,PET Imaging to Determine the Role of PET in the Assessment of Regional Disease in Breast Cancer (PET PREDICT Trial),0.0002455377072523899,0.0003018090471338845
NCT00201773,"Exemestane With Celecoxib as Neoadjuvant Treatment in Postmenopausal Women With Stage II, III, and IV Breast Cancer",0.0002596065268199254,0.00022372525256860793
NCT00201890,"Trial of Decongestive Lymphatic Therapy for Lymphedema in Women With Breast Cancer ""DELTA STUDY""",0.00029409827499805494,0.000300361308091006
NCT00201929,A Decision Aid for Women With Early Stage Breast Cancer,0.0003432918674082705,0.0002947296451201653
NCT00201851,Adjuvant Oophorectomy and Tamoxifen in Premenopausal Women With Hormone Receptor-Positive Breast Cancer,0.00025240081381186464,0.00028997799021977745
NCT00201487,Choline Quantification in Breast Cancer by MRS,0.00032796187955158596,0.00032117988985496906
NCT00201864,Exemestane in Combination With Fulvestrant in Postmenopausal Women With Hormone Sensitive Advanced Breast Cancer,0.00026784136500275664,0.00025954497109100753
NCT00201708,Dose-Dense Docetaxel Before or After Doxorubicin/Cyclophosphamide in Axillary Node-Positive Breast Cancer,0.00026285373400525226,0.0003374798590854489
NCT00236275,PET and MRI in the Follow-up of Neoadjuvant Chemotherapy of Breast Cancer,0.00031117103281651356,0.0003013340817598636
NCT00237211,Study of High-dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer,0.0003539559723079134,0.00043039993538907765
NCT00237198,Study of Safety and Efficacy of Letrozole Monotherapy as Second-line Endocrine Therapy in Postmenopausal Patients With Advanced Breast Cancer Who Received Previous Anti-estrogen Treatment,0.00036693788056259107,0.0003474244316955656
NCT00237224,Open Label Study of Postmenopausal Women With ER and /or PgR Positive Breast Cancer Treated With Letrozole,0.000293113346731126,0.0003811606492051693
NCT00237133,Treatment of Locally Advanced Breast Cancer With Letrozole in Postmenopausal Women,0.0003079241338289242,0.0003279802551958219
NCT00210145,Socio-aesthetic Intervention on Body Image and Quality of Life in Women With Breast Cancer.,0.0002536901053838911,0.0003017951745717524
NCT00210236,Surgical Breast Resection With or Without Axillary Lymph Node Excision in Treating Women With Breast Cancer,0.0002639409248316325,0.0003023747365308602
NCT00210197,Hypercoagulability After Breast Cancer Surgery,0.0003469969432098194,0.00025493645454545313
NCT00253539,Arzoxifene or Tamoxifen in Preventing Breast Cancer in Premenopausal Women at High Risk for Breast Cancer,0.000256945228142116,0.00022099833333840766
NCT00259090,Anti-tumour Effects & Tolerability of Faslodex Alone or in Combination With Arimidex in Post Menopausal Women Prior to Surgery for Primary Breast Cancer,0.0002521106728786283,0.0002445713173155993
NCT00273208,An Intervention to Decrease Fatigue Among Breast Cancer Survivors,0.0002802518162856562,0.0003117532022004264
NCT00227656,Capecitabine and Pegylated Interferon Alfa-2a in Treating Patients With Recurrent or Progressive Brain Metastases Due to Breast Cancer,0.0003146091196263147,0.00028464553275938976
NCT00290758,Genistein in Preventing Breast Cancer in Women at High Risk for Breast Cancer,0.00033308501771875035,0.00026124073607236505
NCT00217815,Preliminary Study of Mycograb and Docetaxel in Advanced Breast Cancer,0.0003120088616941669,0.0004201049560433701
NCT00202046,Predictors of Lymphedema Following Breast Cancer Surgery,0.00035078732506112925,0.00032147617429009403
NCT00202059,Effects of Zometa and Physical Activity on Bone Density in Women Receiving Chemotherapy for Breast Cancer,0.0002574526093513072,0.00027627533831246114
NCT00232479,"Dose Dense Carboplatin, Taxotere and Herceptin As Primary Systemic Therapy in Breast Cancer",0.0002521125425099883,0.00031849026239501337
NCT00200174,Combined Estrogen Blockade of the Breast With Exemestane and Raloxifene in Postmenopausal Women With a History of Breast Cancer Who Have No Clinical Evidence of Disease,0.00024408201239297723,0.00035698725869745936
NCT00289432,Hospital Based Group Intervention for Breast Cancer Patients.,0.0003521649770428452,0.0003118024682541755
NCT00226928,Psychosocial Treatment for Improving Chances of Survival in Women With Breast Cancer,0.00036471744973082265,0.0004715353545201824
NCT00226967,"Stress, Diurnal Cortisol, and Breast Cancer Survival",0.0003287036152572046,0.0004075054820282896
NCT00249015,Trial of Combined Aerobic and Resistance Exercise in Breast Cancer Survivors,0.0003331298520329324,0.0002597533995521013
NCT00276120,Young Women's Breast Cancer Research Program,0.00046693538703530265,0.00035911449028365054
NCT00276822,Improving Communication With Patients With Breast Cancer,0.000604818613718354,0.0002488598312112313
NCT00238316,Letrozole in Preventing Breast Cancer in Postmenopausal Women Who Are at Increased Risk for Breast Cancer Due to High Breast Density,0.00025340506223570786,0.00022383043578400397
NCT00238290,Trastuzumab and Letrozole in Treating Postmenopausal Women With Progressive Advanced Breast Cancer,0.0002937970317550943,0.00026924531713173454
NCT00206492,Trial of ZD1839 (Iressa) and Tamoxifen in Breast Cancer Patients,0.00031278868963268493,0.00035152185726496234
NCT00206453,Extension Neoadjuvant Taxotere: Study of the Effects of Taxotere in Patients With Breast Cancer,0.00033711970872173287,0.0003953570326190567
NCT00206427,Neoadjuvant GW572016 to Treat Breast Cancer,0.00048803779357314917,0.0005417344795879004
NCT00206414,"Arimidex/Faslodex/Iressa Study: A Trial Using Arimidex, Faslodex and Iressa in Women With Breast Cancer",0.0002857738912454718,0.00039332444235183985
NCT00206518,Taxotere and Adriamycin/Cytoxan (AC) Validation in Breast Cancer Patients,0.00030933651229699655,0.00035930354015611764
NCT00267553,Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer,0.0003077002580211478,0.00031020471277566213
NCT00270894,Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients,0.0003147701187623229,0.00033414168838497737
NCT00234195,"Wellbutrin XL, Major Depressive Disorder and Breast Cancer",0.00032759652189812,0.0003568025706862044
NCT00234715,Psychosocial Study on Breast Cancer Risk Assessment,0.00031740238785906273,0.0002312443098471332
NCT00254592,Neoadjuvant Treatment of Breast Cancer,0.00048803779357314917,0.00033816028213136607
NCT00286117,ITA - Clinical Study Comparing ARIMIDEX™ With NOLVADEX™ in Women With Breast Cancer Treated With NOLVADEX for at Least 2 Years,0.0002867436168227001,0.0002763706764701501
NCT00286819,Dose Density FU 75 and FU 90 as Adjuvant Therapy for Early Breast Cancer,0.00046445057073026176,0.0003595347446682989
NCT00286247,Study to Determine the Efficacy and Safety of Docetaxel and Doxorubicin With INGN 201 in Locally Advanced Breast Cancer,0.00029669145510905035,0.0003669728250146729
NCT00282529,Identification of a Screening Tool and Treatment of Lymphedema Secondary to the Management of Breast Cancer Study,0.0002869759329626532,0.00034459236984387217
NCT00272740,SAKK - a Trial to Evaluate Antitumor Efficacy of Faslodex® After Aromatase Inhibitor Failure in Advanced Breast Cancer,0.00026369907989603336,0.00035128191499902127
NCT00248911,The Effect Of Meditation On Quality Of Life In Women With Breast Cancer And Other Gynecological Cancers,0.0002756474043401141,0.00020330669107334408
NCT00248170,Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer,0.00027562277276679516,0.000268772720608002
NCT00213980,Bone Mineral Density Effects of Zoledronate in Postmenopausal Women With Breast Cancer,0.0002845941946826922,0.00034351253151103535
NCT02366806,Impact of Individualized Radiotherapy Plan Review in Patients Receiving Adjuvant Radiotherapy for Breast Cancer,0.0002996373800566938,0.0003409195582101582
NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,0.0002590853618248351,0.0002438897878022218
NCT02334345,Skin Protection During Radiotherapy in Patients With Breast Cancer,0.0003179501905266475,0.0003313658706848614
NCT02352779,Omega-3 Fatty Acid in Reducing Cancer-Related Fatigue in Breast Cancer Survivors,0.000254376321735912,0.00037250594079252453
NCT02352883,MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ,0.00035245226335171067,0.0003214629939943414
NCT02328313,Impact of Physical Activity on Biomarker of Aging and Body Composition Among Breast Cancer Survivors Age 65 and Older,0.00024070338473914933,0.00020835735961324475
NCT02321527,Feasibility of Ultrasound Microbubble Contrast-Enhanced (CEUS) Sentinel Lymph Node Imaging With Guided Biopsy in Breast Cancer Patients,0.00028571740336820765,0.0002510996308566463
NCT02321358,Trial of a Behavior Change Intervention to Increase Aerobic and Resistance Exercise and Quality of Life in Older Prostate and Breast Cancer Survivors,0.0002401433812965168,0.0001867759680025678
NCT02380209,An Early Phase Clinical Trial to Evaluate the Feasibility of CEST MRI in Patients With Early Stage Breast Cancer,0.00032773951555348257,0.0002558318863172286
NCT02305641,An Observational Study of Kadcyla Safety in Breast Cancer,0.0003188420968813684,0.00030176177236060185
NCT02305628,An Observational Study of Herceptin SC Safety in Breast Cancer,0.00032250133547586805,0.00032503825850201394
NCT02312700,An Interactive Empowerment Tool for Breast Cancer Patients,0.000604818613718354,0.00042432200314615015
NCT02310464,"Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects",0.0002538806578753446,0.00027768825262681487
NCT02306096,Sweden Cancerome Analysis Network - Breast : Genomic Profiling of Breast Cancer,0.0003329489474777159,0.0002536569585095597
NCT02324101,Clinical Trial of Quantitative Detection Kit for Hsp90α in Breast Cancer,0.0002756821255719123,0.00024822308866814373
NCT02347449,The Impact of the Oncotype DX® Breast Cancer Assay on Treatment Decisions in a Canadian Population,0.00027128205860922335,0.0003195328258151202
NCT02322814,A Study of Cobimetinib in Combination With Paclitaxel as First-line Treatment for Patients With Metastatic Triple-negative Breast Cancer,0.00035122438210370596,0.00036412304032036277
NCT02349581,Ultrasound Guided Pectoral Nerves Blockade for Persistent Pain After Breast Cancer Surgery,0.0002439902315290785,0.00026420461363349485
NCT02336737,SentiMag® Intraoperative Comparison in Breast Cancer,0.0003312578060224473,0.00030177253129432853
NCT02336529,Nerveblocks for Persistent Pain After Breast Cancer Surgery,0.00034900872217819706,0.0003109875559587257
NCT02350582,e-CUIDACHEMO: Telerehabilitation During Chemotherapy in Breast Cancer,0.00035572326052648646,0.0003667581155555017
NCT02362230,Evaluation of Icotinib in Metastatic Triple-negative Breast Cancer After Second-line Therapy,0.0002873699459411179,0.00035163160357953995
NCT02300675,Therapeutic Education Intervention in Breast Cancer: PEPs Hormonotherapy,0.00030684136521705123,0.00036422466908565506
NCT02308020,"A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain",0.0002653587321160707,0.00029361588580161424
NCT02308085,Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer,0.0003644471023100312,0.0003019296827599024
NCT02375048,Randomized Study on Postmenopausal Women With Early Stage Breast Cancer: WBI Versus APBI,0.00030735885543523863,0.0003434912152559124
NCT02345772,"Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy (Taxotere, Trastuzumab and Pertuzumab) in Patients With HER2-positive and ER-Positive Breast Cancer",0.0003105185615243692,0.0002680291397871836
NCT02386371,Intraoperative Radiotherapy After Local Recurrence in Breast Cancer,0.0003309530563762464,0.00024101278055526008
NCT02344940,Safety of Toremifene and Tamoxifen Therapy in Premenopausal Patients With Operable Breast Cancer,0.00031988670085619726,0.0002514556208050317
NCT02365805,Randomized CT to Evaluate Efficacy of Neoadjuvant Chemotherapy Customized by Levels of BRCA1-HER2 Negative Breast Cancer,0.0002678188844302604,0.00030977907924854267
NCT02389686,Intra-operative Radiotherapy For Breast Cancer Women After NSM,0.0004804196347823597,0.00033026785713920936
NCT02389673,Intra-operative Radiotherapy For Women With Ductal Carcinoma in Situ Breast Cancer,0.00034100727763725514,0.00021831175187415972
NCT02379585,Study of Short-term Fasting on Neoadjuvant Chemotherapy in Patients With Newly Diagnosed Breast Cancer,0.00034802749172736634,0.0003725748987156195
NCT02379247,BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast Cancer,0.00029069866174176126,0.000301633601133896
NCT02391818,The Effect of Taxane Chemotherapy on Balance in Breast Cancer Patients,0.00032740214213613155,0.00031438583832312764
NCT02384733,Hypofractionated Loco-regional Adjuvant Radiation Therapy of Breast Cancer Combined With a Simultaneous Integrated Boost,0.0004603590742105769,0.00029380973402206667
NCT02338167,Praegnant Breast Cancer,0.0008829212022672371,0.00029979826448997386
NCT02338115,Defining an Exposure Target for Weekly Paclitaxel Infusion in Breast Cancer Patients,0.00031593679535685693,0.00037914340930197515
NCT02338349,"A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer",0.00029213840856509555,0.000366699830225503
NCT02315196,Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer,0.0003048619179332227,0.00039000820359641724
NCT02358837,Improving Breast Cancer Diagnostic by Novel sonographicTechniques Study,0.0003945917583006295,0.0002493757382140813
NCT02327442,68Ga-NOTA-NFB: Radiation Dosimetry in Healthy Volunteers and Applications in Glioma Patients or Breast Cancer Patients,0.00029139910648469126,0.0003664753543982704
NCT02327572,Age-related Changes in the Immune System and Their Impact on Elderly Breast Cancer,0.000251281191276842,0.00025739360086823393
NCT02340494,An Online Enhanced Education Tool for Young Women Newly Diagnosed With Breast Cancer,0.00033783907111608295,0.0002469070353391344
NCT02340858,Percutaneous Irreversible Electroportion for Unresectable Breast Cancer,0.00032814445410784464,0.0003011572610890083
NCT02304640,"Prevalence, Severity and Determinants of Cancer-related Fatigue (CRF) in Asian Breast Cancer Patients",0.00029808469804689964,0.00032274306835329504
NCT02364726,Acupuncture to Reduce Chemotherapy-induced Peripheral Neuropathy Severity During Neoadjuvant or Adjuvant Weekly Paclitaxel Chemotherapy in Breast Cancer Patients,0.00031744999790094187,0.0003130749037278527
NCT02364492,A Phase I Study of a Therapeutic Vaccine Candidate in Patients With Localized Breast Cancer at High-Risk of Relapse,0.00034170388010255014,0.00042797297304051897
NCT02303145,Breast Cancer Survivorship & Work-Related Cognitive Limitation,0.00046711290510665894,0.00026253758296481495
NCT02376413,Oncoplastic Breast-conserving Surgery in Non-metastatic Breast Cancer Patients,0.00033134860424734983,0.0003240513804372499
NCT02331212,Role of Hyaluronic Acid in Causing Cancer Stem Cell Growth in the Bones of Patients With Breast Cancer,0.0002842602143052517,0.0002961949612198824
NCT02370277,Effects of Chemotherapy on Intestinal Bacteria in Patients With Newly Diagnosed Breast Cancer,0.0003128416162627493,0.0003536278714777378
NCT02370264,Questionnaires in Identifying Upper Extremity Function and Quality of Life After Treatment in Patients With Breast Cancer,0.000308421487146093,0.0003470778647349876
NCT02333370,"A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer",0.00032881180410378457,0.00036523490018726927
NCT02333890,"A Phase 2 Randomized, Double-blind Trial Evaluating the Effects of Chloroquine in Breast Cancer",0.0002751543054852762,0.00027665576075901844
NCT02348320,Safety and Immunogenicity of a Personalized Polyepitope DNA Vaccine Strategy in Breast Cancer Patients With Persistent Triple-Negative Disease Following Neoadjuvant Chemotherapy,0.0003090708876080802,0.000323739832724402
NCT02387671,Weight Management Among Breast Cancer Survivors,0.0003304341397272755,0.0002112940359746324
NCT02387320,Evaluation of a Self-Care Toolkit in Surgical Breast Cancer Patients,0.00036880304560191386,0.0002986554133774601
NCT02313116,"Computed Optical Margin Assessment for Breast Cancer Surgery, Phase I (Part B)",0.00029227012426333244,0.00027509860647838947
NCT02313051,Everolimus trIal for Advanced prememopausaL Breast Cancer Patients,0.0003725312949950038,0.00029732946801091056
NCT02301767,MRI Background Parenchymal Enhancement as a Risk Factor for Breast Cancer: The IMAGINg and Epidemiology (IMAGINE) Study,0.0002702518644680251,0.00024060154988037255
NCT02316795,Fluorescence Imaging in Sentinel Lymph Node Biopsy for Breast Cancer and Melanoma,0.00027340357429410324,0.00025519758975285335
NCT02316509,Study of SRN-927 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer,0.0003046825621808721,0.00031625517595678233
NCT02390427,Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer,0.00029965217845777424,0.0003384849813914451
NCT02326857,Molecular Profiling of Stage II and III Breast Cancer in Latin American Women Receiving Standard-of-Care Treatment,0.00027478379678496165,0.0003595424721302893
NCT02311543,Impact of a Surgical Sealing Patch on Lymphatic Drainage After ALND for Breast Cancer,0.00025954747745576134,0.00017236898959224064
NCT02311647,Uterine Cavity Assessment and Endometrial Gene Expression in Tamoxifen Treated Breast Cancer Patients,0.0002917532194390714,0.0003341541647779961
NCT02311933,"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",0.00031193692269740255,0.0003218855285657205
NCT02360059,Metformin for Reduction of Paclitaxel-Related Neuropathy in Patients With Breast Cancer,0.0002943401318116842,0.0003515738194406358
NCT02360904,A Yoga Program for Breast Cancer Patients Undergoing Chemotherapy,0.0003304347234945836,0.00032121333115769484
NCT02393105,Sense of Hope Alleviates Fatigue in Breast Cancer Survivors,0.0003317366038209155,0.000347962662240097
NCT02339532,"Neoadjuvant Phase II Trial in Patients With T1c Operable, HER2-positive Breast Cancer According to TOP2A Status",0.0003206028412540362,0.000294234188226835
NCT02357927,A Single Session Intervention For Fear Of Recurrence In Breast Cancer Patients,0.0002983058717197939,0.00020532315522182447
NCT01396174,A Novel Prosocial Online Support Group for Distressed Breast Cancer Survivors,0.00027472620712942894,0.0002115812398567718
NCT01396655,PET in Breast Cancer Receiving Neoadjuvant Chemotherapy,0.00031117103281651356,0.00031124218739892975
NCT01308775,Comparing (SIS.NET) to Standard Care in Patients Who Have Completed the Acute Phase of Treatment for Early Breast Cancer,0.00031473646422001917,0.00037772835647374616
NCT01304797,Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer,0.00036930975469370663,0.000334286333048339
NCT01346579,Biomarkers in Tissue Samples From Older Women With Breast Cancer,0.0003372892987834606,0.0002838948560400004
NCT01301911,Study of Cipatinib in Patients With HER2 Positive or Uncertain Advanced Breast Cancer,0.0003460480115784458,0.0003277043839610015
NCT01301729,A Study of Herceptin (Trastuzumab) in Combination With a Taxane in Participants With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin Treatment,0.0002984392042889688,0.00032375396699046115
NCT01327781,Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast Cancer,0.00030556188526954933,0.00032286471013799427
NCT01351584,Tumour Registry Breast Cancer,0.00033387981384005473,0.0003381613373508243
NCT01351376,LLLT Combined With CDT in Breast Cancer-Related Lymphedema,0.00025134937270998093,0.0003089304312708962
NCT01351974,Sentinel Node Biopsy in Breast Cancer Patients,0.0004258481645939581,0.0002859803568976418
NCT01351844,The CEASE Study: Computer Based Educational Module for the Reduction of Arthralgia Syndrome Associated With Endocrine Therapy for Breast Cancer,0.0002670131314732507,0.0002977974240570039
NCT01340300,Exercise and Metformin in Colorectal and Breast Cancer Survivors,0.0002766989724205077,0.00030718246638790185
NCT01340430,"Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast Cancer",0.00026485894830138455,0.00031040624220191927
NCT01336257,Effectiveness of a Decision Support System in Improving the Diagnosis and Screening Rate of Breast Cancer,0.0002442054399078347,0.0002512753060081926
NCT01387373,Intra-hepatic Chemotherapy in Patient With Non-resectable Liver Metastases From Breast Cancer,0.00030771873350331653,0.0002820035322688926
NCT01387295,Intra-hepatic Chemotherapy in Patients With Liver Metastases From Breast Cancer and Limited Extrahepatic Disease,0.00030040072843796916,0.00027034933655424153
NCT01331629,Impact of Art Therapy on Fatigue and Quality of Life of Patients Treated With Adjuvant Radiotherapy for Breast Cancer,0.00029639290515031855,0.000409021899950625
NCT01331772,Impact of Nutritional Intervention in Women With Breast Cancer Under Adjuvant Chemotherapy,0.00033043950926041186,0.0002340280886767136
NCT01328249,Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer,0.00028494382852796023,0.0004423040625550304
NCT01339650,"Study of ABT-767 in Subjects With Breast Cancer 1 and Breast Cancer 2 (BRCA 1 and BRCA 2) Mutations and Solid Tumors or High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",0.0002665161039547754,0.00028267243798068924
NCT01339780,Imaging of Prostate and Breast Cancer Bone Metastases Using Magnetic Resonance Imaging and Nuclear Medicine Techniques,0.0002402121725079012,0.00035772567650329856
NCT01339351,Teleconference Group: Breast Cancer in African Americans (STORY),0.0004631012346473785,0.00025367113712072907
NCT01303419,Contrast-Enhanced Digital Mammography (CEDM) for Identifying a Change in Management of Women With Newly Diagnosed Breast Cancer,0.00024323661834047344,0.0002825146598433006
NCT01358877,A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer,0.00028977771419595657,0.00029709609683961554
NCT01320488,Breast Cancer in Young Women: Is it Different?,0.0008829212022672371,0.0002642782427042009
NCT01320592,PD0332991/Paclitaxel in Advanced Breast Cancer,0.0005113766994020161,0.0003159064462114995
NCT01320111,Breast Cancer Study: Paclitaxel Versus Paclitaxel Plus Sorafenib in Second- or Third-line Treatment,0.0003164067858519226,0.0003124506054862532
NCT01399359,Factors Influencing Decision-Making About the Use of Chemoprevention in Women at Increased Risk for Breast Cancer,0.0002741703016689989,0.00027828793224651284
NCT01321775,"Bevacizumab and Trastuzumab With Weekly Paclitaxel Followed, After Surgery, by Encapsuled Liposomal Doxorubicin, Cyclophosphamide and Trastuzumab as Adjuvant Treatment After Surgery on Women With Her2+ Breast Cancer",0.0002803860595736833,0.0003331184489309233
NCT01325207,Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer,0.00034358878998116683,0.00039526695184712685
NCT01311037,The Combination of GnRh Analogue and Aromatase Inhibitor in Receptor Positive Premenopausal Women With Advanced Breast Cancer,0.00027472541349015994,0.00033480606657893376
NCT01356862,Pasireotide LAR Administration in Lymphocele Prevention After Axillary Node Dissection for Breast Cancer,0.00023795542432093316,0.00026897056153373617
NCT01390064,Vaccination of High Risk Breast Cancer Patients,0.0003500599311738453,0.000272564904075286
NCT01302002,The Use of Metformin in Early Breast Cancer Patients Pre-Surgery,0.00036155401501376615,0.0004998574787052097
NCT01302379,Reach for Health Study: Obesity-related Mechanisms and Mortality in Breast Cancer Survivors,0.0002729922552363644,0.00031760724818990826
NCT01386411,Understanding Decision Making Processes for Undergoing Genetic Testing Among Women With Newly Diagnosed Breast Cancer,0.0002407856164378408,0.00027145836610025756
NCT01367028,A Phase II Study of Neoadjuvant Trastuzumab+Docetaxel+NPLD+/-Bevacizumab in Her2-pos. Early Breast Cancer,0.0004047910140414459,0.0003348980590929065
NCT01380912,Can Methylprednisoloneacetate Prevent Seroma After Mastectomy for Primary Breast Cancer,0.000247297599876089,0.00030824560278709564
NCT01380925,The Jewels in Our Genes Study - an African American Family Study of Breast Cancer,0.0003862087319208685,0.00045419723427800947
NCT01355393,Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer,0.00029187188637351194,0.0003627814829717869
NCT01355523,"The Effect of Melatonin on Depression, Anxiety, Cognitive Function and Sleep Disturbances in Breast Cancer Patients",0.0002852220236765644,0.0002697471191802869
NCT01359501,Evaluation of the Effects of Chinese Medical Treatment on Leucopenia After Chemotherapy in Breast Cancer Patients,0.0003263081600835342,0.00031588175604142744
NCT01310530,Partial Breast Proton Therapy for Early Stage Breast Cancer,0.0002876061217936878,0.00022147493696472858
NCT01366248,Integrative Oncology Outcomes Study in Breast Cancer,0.0003862087319208685,0.00031378536000317714
NCT01322412,Adapted Physical Activity Effect and Fatigue in Patients With Breast Cancer,0.0003176714211545449,0.0003067322647878572
NCT01391039,Diagnostic Study of Early Breast Cancer Using Ultrasound,0.00032446200895824097,0.0003045260420998831
NCT01391689,Diindolylmethane in Treating Patients With Breast Cancer,0.00042402168164967075,0.00046532716850996436
NCT01391806,The Impact of Preoperative Breast MRI in Patients With Breast Cancer Selected for Breast Conserving Surgery,0.00035019052193872955,0.0003131129010904354
NCT01344109,A Pilot Study of Tumor-Derived Exosomes as Diagnostic and Prognostic Markers in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy,0.0003487711700208747,0.0003758574412629895
NCT01334099,"Safety Study of Radiation and CP-675,206 Infusion for Breast Cancer Patients",0.00035590931004074976,0.00041556061995683206
NCT01334021,Genomic Testing for Primary Breast Cancer,0.0008829212022672371,0.00032879567629006046
NCT01361945,AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast Cancer,0.00030746352567039166,0.0003529962609450899
NCT01384838,Exercise Training in Postmenopausal Patients With Breast Cancer,0.00032308494928005914,0.00028620437509503595
NCT01342302,An Online Psychoeducational Intervention for Young Women With Breast Cancer and Their Partners,0.0004701954466120917,0.0002624537580000044
NCT01338753,Study to Evaluate Markers of Response in Locally Advanced Breast Cancer,0.0003039081759139037,0.0003175937368237364
NCT01333735,Impact on Cognitive Function and Quality of Life of Adjuvant Chemotherapy in Patients Aged Over 65 Years: Application to Breast Cancer or Colon,0.0002891529773479407,0.0003440754228305373
NCT01370239,HumanaH - Hu3s193 in the Treatment of Advanced Breast Cancer After Hormonal Therapy,0.00033131557821127486,0.0003114557373110864
NCT01370551,Clinical Study of Vaginal Lactobacilli and Estriol (Gynoflor®) for Atrophic Vaginitis in Breast Cancer Patients,0.00031465223353435343,0.0002808751738885817
NCT01316328,Determination of Predictive Genetic Markers of Toxicity After Hypofractionated Radiotherapy in Breast Cancer Patients Post-Conservative Surgery,0.00029860578218840597,0.0003362784496252773
NCT01305915,Getting Back on Track: An Educational Group for Women With Breast Cancer,0.00027453355875740957,0.0002845877873494194
NCT01305954,Study of the P16 Gene as a Predictor of Myelosuppression in Breast Cancer Patients,0.00039053642638535576,0.0002800852522070798
NCT01305239,A Survey Of Clinical Practice Of Adjuvant Treatment Of Breast Cancer Using Exemestane (Aromasin®) In Postmenopausal Hr+ Patients,0.0003127008803412061,0.00031824519585911683
NCT01305941,"A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases",0.0002823174929045703,0.00028327895123299903
NCT01368380,Hand in Hand. Psychological Support and Counseling to Breast Cancer Patients and Their Partners,0.0002929022886321481,0.0003719202226072655
NCT01368744,Clinical Evaluation of OSNA Breast Cancer System to Extensive Frozen Section Histopathology,0.0002717192204094475,0.00026050644573187944
NCT01368263,Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer,0.00029765843435804087,0.0003762887401010583
NCT01377363,Evaluation of Degree of Conversion of HER2 Receptor Between Primary Breast Cancer and Metastasis,0.0002813435490512332,0.00029844596278176837
NCT01382082,Assessment of Cognitive Function in Breast Cancer and Lymphoma Patients Receiving Chemotherapy,0.0003123191999344915,0.00032535597389217073
NCT01354041,Fear of Recurrence Pilot Intervention for Women With Breast Cancer,0.0002793236883660983,0.00032293870331206434
NCT01354522,TAC Versus TCX as Adjuvant Treatment for Node-Positive Her2-Negative Breast Cancer,0.00031498024286153906,0.0003026746284354782
NCT01392248,Prediction of Pain After Breast Cancer Surgery With EEG,0.00034900872217819706,0.0002959905146098871
NCT01343849,Blood Test for Breast Cancer Associated Auto Antibodies,0.00027225964272954446,0.0003267647050312204
NCT01300871,Alopecia Secondary to Endocrine Therapy in Postmenopausal Women With Breast Cancer,0.0002621447786000824,0.00027430637120288515
NCT01300351,Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Advanced Breast Cancer Women,0.00036559720341641886,0.0003742765465870958
NCT01362712,"Exploratory, Phase I,Open Label,Non-randomized Study of [F18]CP-18 PET in Normal and Breast Cancer Subjects",0.0002888979827707037,0.0003465483903648822
NCT01309607,Study of Preoperative Weekly Paclitaxel and Carboplatin With Lapatinib (Tykerb®) in Patients With ErbB2-Positive Stage I-III Breast Cancer,0.0003312906176289594,0.0004070242011165546
NCT01363986,A Study of Herceptin (Trastuzumab) in Combination With Whole Brain Radiotherapy in Patients With HER-2 Positive Breast Cancer,0.0003367444983961027,0.00032053740102640596
NCT01329640,Feasibility Study of Metronomic Chemotherapy for Locally Advanced Her2- Positive Breast Cancer (TraQ-Me 01),0.00027896381841732373,0.00037651493001590396
NCT01329627,Feasibility Study of Metronomic Chemotherapy for Locally Advanced HER2-Negative Breast Cancer,0.0002987369510679289,0.00036772115230195317
NCT01314833,Efficacy Study of Adjuvant Chemotherapy for Chinese Primary Breast Cancer Patients,0.000392850980077346,0.0003476520527320261
NCT01349959,Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer,0.0003302703795647828,0.0003714170148860598
NCT01313039,Evaluation of the Use of AZD6244 to Induce Increased ER Expression and Anti-Estrogen Response in ER-Negative/Low Breast Cancer,0.00024456808044401426,0.00032160830877600084
NCT01352494,Neoadjuvant Chemotherapy With Docetaxel and Gemcitabine in Locally Advanced Breast Cancer,0.00028765342925926287,0.000371356868080192
NCT01375023,"Allogenic Haematopoietic Cell Transplantation for Patients With Refractory ""Triple Negative"" Breast Cancer",0.00034990710561973995,0.0003145437175771625
NCT01335152,Online Stress Management and Coping Skills Training for Women With Breast Cancer,0.0002755279340554324,0.00031322706762795414
NCT01394575,Whole Breast Irradiation With Intensity Modulated Radiotherapy and Simultaneously Integrated Boost for Early Stage Breast Cancer Patients,0.0003087296168636902,0.00030855396326717554
NCT01394315,Diffuse Optical Tomography (DOT) for Monitoring Response to Neoadjuvant (Preoperative) Chemotherapy in Breast Cancer,0.00026667925240214934,0.00037021354001325903
NCT01394211,Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer,0.00027460437007564945,0.00033782944012823236
NCT01365845,Proton Therapy for Lymph Nodes in Breast Cancer,0.0003291514242544386,0.00029698446843686853
NCT00815555,CYP2D6 Genotyping by AmpliChipTM CYP450 for Tamoxifen-Treated Breast Cancer Patients,0.0003504403582526042,0.00032102003549020424
NCT00887536,"A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer",0.00025381106499419075,0.0003523778938041776
NCT00827307,Zoladex Plus Tamoxifen in Breast Cancer,0.00033432721489547553,0.000248815250509309
NCT00880009,Study Evaluating Bosutinib-Letrozole Combination Versus Letrozole Alone In Post Menopausal Women With Breast Cancer,0.0002770404348897388,0.0002955683407383301
NCT00880711,Faslodex International Observational Non-Interventional Study in Advanced Breast Cancer (BC),0.0002956417182224915,0.0003207929172681625
NCT00880022,Home-based Compression Therapy for Arm and Truncal Lymphedema in Breast Cancer,0.0002596937889170729,0.0002649929886154481
NCT00880464,"Autologous Vaccination With Lethally Irradiated, Autologous Breast Cancer Cells Engineered to Secrete GM-CSF in Women With Operable Breast Cancer",0.00023601920092225826,0.00023347029675330113
NCT00878709,Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer,0.00030507146812398377,0.0004327323361516635
NCT00878930,"Parameters of Acceptability, Compliance and Efficacy of Fulvestrant in Post-menopausal Patients With Advance Breast Cancer",0.00030647247809213973,0.0003615820036179486
NCT00813878,"Nipple Secretion Samples in Detecting Breast Cancer in Patients and Healthy Participants Undergoing Breast Cancer Screening, Breast Diagnostic Studies, or Treatment for Benign Breast Disease",0.0003081512475202297,0.00033400422009143146
NCT00871858,Anastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast Cancer,0.0003229934130785586,0.0002754799547808962
NCT00856492,"S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer",0.00026104327330005243,0.0003064213975650713
NCT00825682,The Effect of Reflexology on Radiation-related Fatigue in Breast Cancer Patients,0.00030459413020615173,0.00036151569204125793
NCT00853996,Acolbifene in Preventing Cancer in Premenopausal Women at High Risk of Breast Cancer,0.00028198791949154766,0.0002642362375514572
NCT00873600,Outpatient Health Care Program for Older Patients Receiving Chemotherapy for Newly Diagnosed Breast Cancer or Colon Cancer,0.0003042138333692138,0.0002855749859598765
NCT00873366,Breath Test for Women Receiving Tamoxifen in the Prevention or Treatment of Breast Cancer,0.00027696804242540926,0.0003509812345283013
NCT00873808,"S0307A, Long-Term Bone Quality in Women With Breast Cancer Enrolled on Clinical Trial SWOG-S0307",0.0002506033267043963,0.00022536507423619452
NCT00877188,Effect of Combined Aerobic and Resisted Exercise in Breast Cancer Survivors,0.00046717801519213396,0.00040187610866027166
NCT00811824,Effects of Physical Activity and Dietary Change in Minority Breast Cancer Survivors,0.0002812161430338532,0.0002654569500847269
NCT00811135,A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab) and Xeloda (Capecitabine) in Patients With HER2-Positive Breast Cancer,0.0003330696942024143,0.0003200241902035778
NCT00898131,Collecting Tissue Samples for Future Research From Women Undergoing Surgery for Breast Cancer,0.0003496025074167522,0.00041872857392541283
NCT00898976,Biomarkers in Native American Women With Breast Cancer,0.00033468405526139526,0.0002450773701067295
NCT00898898,Studying Tissue Samples From Women With Breast Cancer Who Were Treated on Clinical Trial NCCTG-N9831,0.00033416711937931244,0.0003658164243953592
NCT00898703,Studying Blood Samples in Women With Breast Cancer or a History of Breast Cancer,0.00032934014436442245,0.00031477638639833093
NCT00898573,Lapatinib Resistance in Patients With Breast Cancer,0.00034885019142817897,0.0003662522452072838
NCT00898690,Gene Expression in Predicting Response to Paclitaxel in Patients With Breast Cancer,0.0003208126577063372,0.00033295622281090474
NCT00898937,Gene Expression in Tumor Tissue From Women Undergoing Surgery for Breast Cancer or Core Biopsy of the Breast,0.000251616040166917,0.0002692669948788572
NCT00881010,Automated Pain Intervention for Underserved Minority Breast Cancer Patients,0.00035226093185511295,0.0003168585181269927
NCT00875238,Side Effects Involving the Heart in Women With Breast Cancer Receiving Doxorubicin and Trastuzumab,0.00026056516105789796,0.00022036344038804312
NCT00875355,Radiation Therapy With or Without Temozolomide in Treating Women With Brain Metastases and Breast Cancer,0.00028491073940561983,0.0002590493476487827
NCT00872625,Radiation Therapy and Docetaxel Followed by Standard Therapy in Treating Women With Breast Cancer,0.00028675462565625615,0.0002904669309022152
NCT00872677,Weight Loss Counseling for African American Women Who Are Breast Cancer Survivors,0.00032933513536782615,0.00020047486921982892
NCT00828854,"A Phase 2, Multicenter Study of the Effect of the Addition of SNDX-275 to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing",0.0003042851636406381,0.000346772195886301
NCT00884143,Observational Triveneto Study on the Use of Adjuvant Hormonal Therapies in the Treatment of Hormone-responsive Breast Cancer,0.0003101984619129012,0.0003131728983280906
NCT00807950,Phase II Study of Simvastatin in Primary Breast Cancer; Test of Its Potential Selectivity on Basal Subtype Breast Cancer,0.00031760482277229943,0.00026735373802718566
NCT00816244,Study of Statin as Neo-Adjuvant Therapy in Postmenopausal Breast Cancer,0.00029638060571056407,0.00033806990810689814
NCT00816985,Liposuction for Arm Lymphedema Following Breast Cancer Surgery,0.0002619721724725507,0.0003136715433036621
NCT00845078,Prospective Outcomes After Reconstruction and Radiotherapy for Breast Cancer,0.0003415562339136504,0.0003061897041516149
NCT00802932,Pilot Study to Validate Metallic Markers for Image Guided Radiation Therapy for Breast Cancer Tx,0.00032237909545890735,0.0003474047272107428
NCT00802945,Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Breast Cancer,0.0003570616690820953,0.0003684523190265675
NCT00821288,Post-treatment Care of Breast Cancer Survivors,0.0005152476714020549,0.0003631934758914804
NCT00821886,Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast Cancer,0.00027666031595513014,0.00036127426831217946
NCT00821964,Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer,0.00031121954273784095,0.0003164859468611552
NCT00821054,A Study to Examine the Effects of Low and High-fat Meals on Orally Administered Lapatinib in Metastatic ErbB2 Positive Breast Cancer Patients,0.0003284878894784917,0.00037807868922245814
NCT00837265,Neugranin in Breast Cancer Patients Receiving Doxorubicin/Docetaxel,0.00031699772333784124,0.0002600270244834967
NCT00810017,Phase 2 Study of Trastuzumab and Etoposide for Her2 Positive Breast Cancer,0.0003045877096710848,0.0003892002094203568
NCT00818051,Radiation Therapy in Treating Women Who Have Undergone Breast Conservation Surgery and Systemic Therapy for Early Breast Cancer,0.000271909575048299,0.0002341850883803188
NCT00814034,Coagulation Parameters in Postmenopausal Breast Cancer Patients Under Adjuvant Hormonal Therapy,0.00030437358866078194,0.00030635043533055323
NCT00882674,A Study to Evaluate the Biological Activity of R1507 in Women With Operable Breast Cancer,0.00029385221646023124,0.0003148132482064999
NCT00882089,"Use of the Contura™ Catheter in Intermediate-Risk, Pathological Stage 0, I, or II (Up to 3.0 cm) Breast Cancer Patients",0.00030829868187300894,0.0003231725029989196
NCT00882596,"Use of the Contura™ Catheter to Deliver Accelerated Partial Breast Irradiation to ""Low-risk"" Breast Cancer Patients",0.00029233563109036905,0.0003246542656361233
NCT00830544,Study of Neoadjuvant Chemotherapy of Breast Cancer,0.0003525369431927307,0.00033792618482448027
NCT00830635,Multimedia Educational Program for Patients With Early-Stage Prostate Cancer or Breast Cancer,0.0002965373551069921,0.0002630605250424946
NCT00860886,Premenopausal Hormone Concentrations in a Population of Women at Very Low Risk of Breast Cancer,0.00027475147769696814,0.00027587564564634837
NCT00866905,Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER-2 Negative Breast Cancer,0.0002649289415806085,0.00030739730665723015
NCT00842998,Efficacy Study of Single Agent Trastuzumab or Lapatinib to Treat HER2-Overexpressing Breast Cancer,0.0002816434132777733,0.00028301011133483424
NCT00859703,Study to Assess Efficacy of Risedronate in Preventing Bone Loss in Postmenopausal Women Treated for Breast Cancer,0.0002949490297764748,0.00029919147581955057
NCT00859651,Vitamin D in Postmenopausal Women at High Risk for Breast Cancer,0.00028901202177153326,0.0002828034433003829
NCT00892567,Evaluating the T Cell Response to a Peptide-based Vaccine in Patients With Breast Cancer,0.0002969231720573881,0.00035150436844293435
NCT00892515,Exercise Programs in Healthy Young Women at Increased Risk of Developing Breast Cancer,0.00028074154202887175,0.00019355035374737537
NCT00892268,Acupuncture or Medication in Reducing Pain in Postmenopausal Women With Breast Cancer and Joint Pain,0.00024699110839940003,0.00022929036999978496
NCT00892814,Partial Breast Versus Whole Breast Irradiation in Elderly Women Operated on for Early Breast Cancer,0.0003331301537287628,0.00025627929260681025
NCT00852332,Docetaxel With or Without a Phytochemical in Treating Patients With Breast Cancer,0.0004331883925932828,0.00029370679528568466
NCT00852683,The Effects of Peri-Operative Pregabalin on Post-Operative Pain Following Breast Cancer Surgery With Axillary Node Dissection: A Pilot Study,0.000282352229264652,0.00035004078675539356
NCT00870415,Breast-Conserving Surgery Techniques in Treating Women With Breast Cancer,0.0004617247985450961,0.00029319001816362114
NCT00862901,Safety Study Using Photodynamic Therapy Light Therapy for Patients With Chest Wall Progression of Breast Cancer and Satellite Metastases of Melanoma,0.0003128656950518383,0.00033235874746481676
NCT00891969,Treatment Decision Making Between Oncologists and Women With Newly Diagnosed Breast Cancer and Their Healthy Companions,0.0003069057366302852,0.0003588471259438201
NCT00891800,Brachytherapy Radiation Directly to the Liver in Breast Cancer Patients With Metastatic to Liver,0.00030537000528769813,0.0003645733111425277
NCT00861705,Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery,0.00030771618623028486,0.0003484377334185623
NCT00849472,Treatment With Pazopanib for Neoadjuvant Breast Cancer,0.000314339789816263,0.00036423509715385985
NCT00849758,"Gene Polymorphisms and Gene Products as Biological Markers of Aging and Correlation With Clinical Geriatric Assessment, Tolerance of Chemotherapy and Outcome in Elderly Breast Cancer Patients",0.0003018480658470006,0.00035712017710758364
NCT00849329,A Study to Examine the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Lapatinib in Subjects With Metastatic ErbB2 Positive Breast Cancer,0.0002753990222095285,0.00025054379700644943
NCT00855114,Everolimus in Treating Women With Breast Cancer That Can Be Removed by Surgery,0.0002895337198660303,0.00029711583331450803
NCT00854789,Safety and Efficacy Study of HER2/Neu (E75) Vaccine in Breast Cancer,0.00038747648005414757,0.00026675138563669935
NCT00895414,Enalapril Maleate and Doxorubicin Hydrochloride in Treating Women With Breast Cancer,0.000328051401048574,0.00024130526048355197
NCT00897065,Biomarkers in Predicting Response to Tamoxifen and Letrozole in Postmenopausal Women With Primary Breast Cancer Treated on Clinical Trial CAN-NCIC-MA17,0.000258160192191603,0.0002917145633451565
NCT00897884,Clinical and Biologic Effects of Metformin in Early Stage Breast Cancer,0.000258827964116943,0.0003437112081734261
NCT00897416,Identification of Biomarkers in Women at High Risk or Average Risk of Breast Cancer,0.000281993265908455,0.00022527079687135185
NCT00897338,Identifying Circulating Breast Cancer Cells in Women With Metastatic Breast Cancer,0.00032993001669797344,0.0002816348521669029
NCT00897845,Studying Tumor Samples From Women Who Have Undergone Chemotherapy for Breast Cancer,0.00036141973920279086,0.0003759305340486916
NCT00897455,Studying Breast Cancer Risk in Women Who Are BRCA1/BRCA2 Mutation Carriers,0.0004606286566507108,0.00035582226186287735
NCT00897728,Study of Tumor and Blood Samples From Women With Breast Cancer,0.0003220707022583826,0.00034405365304934657
NCT00897299,Identifying Genes That Predict Recurrence in Women With Breast Cancer Treated With Chemotherapy,0.00035859240037154605,0.000295844992643546
NCT00897208,"Studying Biomarkers in Nipple Fluid, Urine, and Blood Samples From Women With Newly Diagnosed Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer and in Women at Risk of Developing Breast Cancer",0.0002457158210958459,0.00020847914588715202
NCT00897702,Molecular Mechanisms of Clinical Resistance to Targeted Therapy Among Patients With Breast Cancer,0.000293949139387028,0.00033936651788777847
NCT00897091,"S8814A Biomarkers in Predicting Outcome in Postmenopausal Women With Hormone Receptor-Positive, Node-Positive Breast Cancer Treated With Tamoxifen With or Without Cyclophosphamide, Doxorubicin, and Fluorouracil",0.00026058400446501187,0.00028037424114912645
NCT00897468,Developing Mouse Models of Breast Cancer Using Tissue Samples From Women With Breast Cancer,0.00033065824358465066,0.0003661252045888717
NCT00826085,Phase 1/2 Study of ThermoDox With Approved Hyperthermia in Treatment of Breast Cancer Recurrence at the Chest Wall,0.0002858922515528747,0.00037678949076931726
NCT00826267,6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab,0.0002875736606258667,0.00027338276930706273
NCT00888082,Protection of Ovarian Function With Goserelin Acetate in Premenopausal Early Breast Cancer Patients With Chemotherapy,0.00029985604135588447,0.00037185245503297174
NCT00836186,Cytokine Expression During Radiation for Breast Cancer,0.0002831873778830141,0.0002810794715962413
NCT00820872,"Docetaxel, Carboplatin, Trastuzumab, and Lapatinib in Treating Patients With Early Stage Breast Cancer",0.0003096912181571398,0.0002868541265750208
NCT00820690,Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer,0.0003332094993595786,0.00034232824252965655
NCT00820924,Study of Lapatinib in Breast Cancer Patients With HER-2 Non-amplified Primary Tumors and HER-2 Positive or EGFR Positive Circulating Tumor Cells,0.0003186288595679739,0.0003738104815621224
NCT00806507,Early Detection and Prediction of Chemotherapy Induced Cardiac Toxicity in Breast Cancer Patients,0.0003274625387053784,0.0003099225141482965
NCT00885183,Adjuvant Acupuncture Care for Breast Cancer Patients Experiencing Side Effects From Chemotherapy,0.00032841987226305106,0.000353636481003628
NCT00885612,10 Year Coronary Heart Disease (CHD) Risk Evaluation and Its Treatment Pattern Analysis in Postmenopausal Early Breast Cancer (EBC) Patients Taking Aromatase Inhibitors (AI),0.0003216470697007647,0.00040053722968029054
NCT00841399,Safety and Efficacy Study of HER2/Neu (E75) Vaccine in Node-Positive Breast Cancer Patients,0.00033724649199564044,0.0003211418489208382
NCT00833963,"An Observational Study of Pregnancy And Pregnancy Outcomes in Women With Breast Cancer Treated With Herceptin, Perjeta In Combination With Herceptin, or Kadcyla During Pregnancy or Within 7 Months Prior To Conception (MotHER)",0.0002681635665063934,0.0002326436139097893
NCT00896324,Intellectual Impairment in Women With Breast Cancer,0.00032759891228912615,0.0002548901574158617
NCT00896857,Studying Cells Collected Through Ductal Lavage in Women Undergoing Surgery for Ductal Carcinoma In Situ or Other Breast Cancer,0.00024334955770383772,0.00021307322938132395
NCT00896818,Genes and Other Risk Factors for Second Primary Breast Cancer in Women With Breast Cancer and Their Female Family Members and Friends,0.0002728865091562762,0.0002898806953851238
NCT00896155,Trial of Concurrent Versus Sequential Tamoxifen With Radiotherapy in Breast Cancer Patients,0.00036097931185184463,0.0003024435509584577
NCT00896623,SWOG 8897-A DNA Analysis in Predicting Treatment Outcome in Women With Breast Cancer in SWOG 8897,0.00036435508150890067,0.0002706999735257934
NCT00896636,Study of Breast Tissue in Women Not Previously Diagnosed With Breast Cancer Who Are Undergoing Fine Needle Aspiration,0.00027955408063728743,0.0002958913189742266
NCT00896649,Positron Emission Mammography and Standard Mammography in Women at High Risk of Breast Cancer,0.0002522840229157048,0.0002587891367152374
NCT00899301,Collecting and Storing Tissue Samples From Women With or Without Breast Cancer,0.00046420489866979853,0.0003945021095486874
NCT00899288,Fingernails in Evaluating Bone Health in Postmenopausal Women With Breast Cancer Undergoing Hormone Therapy on Clinical Trial IBCSG-1-98,0.0002468700928230737,0.00021815831098751635
NCT00899418,Studying Tumor Tissue Samples to Learn More About DNA Changes and Response in Patients With Breast Cancer Treated With Bevacizumab on Clinical Trial ECOG-2100,0.0002951150622861463,0.00029814843094416147
NCT00899574,Imiquimod for Breast Cancer Patients With Chest Wall Recurrence or Skin Metastases,0.00029298951338255165,0.0002525260591856917
NCT00899145,Breast Cancer Risk in Women Who Are BRCA1/BRCA2 Mutation Carriers,0.0004606286566507108,0.00037962508290654857
NCT00899509,Gene Expression Profiling and Genetic Analysis of Tissues From Patients With Breast Cancer,0.00030991969916461485,0.0003783954432910262
NCT00839696,"Total Xenoestrogen Body Burden in Relation to Mammographic Density, a Marker of Breast Cancer Rlisk",0.00024291560016433459,0.0001955154337466312
NCT00851110,Adjuvant Breast Cancer Study of the Netherlands Working Party for Autotransplantation in Solid Tumors,0.00032115612438495255,0.0004243441070272841
NCT00851812,Exercise for Breast Cancer Patients (EXCAP),0.0004288298975541952,0.0003236718121053641
NCT00893061,"Letrozole, Anastrozole, Exemestane, or Tamoxifen Citrate in Treating Postmenopausal Women With Breast Cancer",0.0002538193664385881,0.00026772605613072374
NCT00801476,Pre-operative Magnetic Resonance Imaging (MRI) in Young Breast Cancer Patients,0.0004251553388299013,0.00034761980891858524
NCT00801411,Cyclophosphamide and Docetaxel or Doxorubicin in Treating Women With Newly Diagnosed Breast Cancer That Can Be Removed by Surgery,0.0002586268474844152,0.00027094133590169873
NCT00869466,Weight Control Programs in Women Who Have Undergone Surgery for Early Stage Breast Cancer,0.00027211530590127113,0.00021509036699535186
NCT00869973,Aprepitant in the Prevention of Delayed Emesis Induced by Cyclophosphamide Plus Anthracyclines in Breast Cancer Patients,0.00028681820217880423,0.00029652240633797603
NCT00805597,Clinical Trial of Postmastectomy Radiotherapy in Breast Cancer With One to Three Positive Nodes,0.00029751448075515815,0.0004279420287571416
NCT00823654,Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer or BRCA Mutations,0.0002646192794769042,0.00029834926619843184
NCT00879086,A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer,0.0003359653208469569,0.0003324338024111829
NCT00846027,A Study of Avastin (Bevacizumab) in Combination With Taxane-based Chemotherapy as First Line Treatment in Patients With HER-2 Negative Breast Cancer,0.0003370546735374497,0.0003353428431024792
NCT01644890,A Phase III Study of NK105 in Patients With Breast Cancer,0.0004827287424213841,0.0004715435721330559
NCT01628887,Feasibility of a Supportive Education Program for Latina Breast Cancer Survivors,0.0003339704601640725,0.000344781099273481
NCT01642511,Internal Mammary Sentinel Lymph Node Biopsy in Early Breast Cancer Patients With Clinically Axillary Node -Negative,0.00029303982141113457,0.00023272654402803624
NCT01642771,Comparative Study on Two Post-operative Adjuvant Chemotherapy Regimens for Treating Triple-negative Breast Cancer,0.00025307281984789163,0.0003199121292081937
NCT01634984,The Diagnostic Technology Applied Research of CDK5RAP2 in Breast Cancer,0.0004728040577709801,0.00032499304638412385
NCT01630226,Cisplatin-monotherapy in the Treatment of BRCA1 Positive Breast Cancer Patients in Poland,0.00034325076132281265,0.0004529170033936565
NCT01697345,"Breast Cancer, Aromatase Inhibitor Therapy, and Sexual Functioning: The Effects of Vaginal Testosterone Therapy",0.0002598077839437835,0.0003203230855151707
NCT01697293,"Triciribine Phosphate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer",0.0003021340337106347,0.0003823695416592809
NCT01690325,Imaging for Response Assessment of Neoadjuvant Chemotherapy in Primary Breast Cancer (GALADON),0.0002733062510296395,0.0004489730453371435
NCT01690702,Study of Nab-Paclitaxel in High Risk Early Breast Cancer,0.0003299339604078527,0.000578855223078146
NCT01676753,Phase 1b Dose De-escalation Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer,0.0002979115896643771,0.0002536692450648287
NCT01621529,Contribution of 18FDG PET-Scan in Tumour Volume Determination in Patients Operated of Breast Cancer,0.00028671890913215176,0.0003085287181120118
NCT01643148,"The Tetrad BMI, Leptin, Leptin/Adiponectin (L/A) Ratio and CA-15-3 is a Reliable Biomarker of Breast Cancer",0.0002388426668251417,0.00021756589088743335
NCT01698918,"Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer",0.00029735191739038144,0.00031022954384354846
NCT01698658,Ultrasound Tomography Using SoftVue in Diagnosing Women With Breast Cancer,0.0003358867903341848,0.0003457676667456753
NCT01620359,Study of ExAblate Focused Ultrasound Ablation of Breast Cancer,0.00031689357934386206,0.0003155085380698189
NCT01684579,Exercising Our ABC's (African- American Breast Cancer Survivors),0.0008829212022672371,0.00025948609578731787
NCT01684215,"A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer",0.0003513014456101119,0.00035719543489210636
NCT01647672,Efficacy and Safety With Albumin-bound Paclitaxel (Abraxane) in the TAC as Neoadjuvant Chemotherapy in Breast Cancer,0.00027705644886418174,0.00028699553606899124
NCT01647607,Young and Strong: An Education and Supportive Care Intervention Study for Young Women With Breast Cancer,0.0002764664455491982,0.0002500265972796626
NCT01627366,Study of Survivorship Care Plans and Outcomes in Underserved Breast Cancer Survivors,0.0005475118996500432,0.0003585152782307495
NCT01627704,Fluoroestradiol PET Imaging in Predicting Response to Hormone Therapy of Breast Cancer,0.0002493722881537497,0.00023094917366856866
NCT01602380,A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.,0.00034967314519375675,0.0003770943109486819
NCT01626950,Living Conditions and Breast Cancer,0.00032759667022032486,0.00027008048797223517
NCT01626781,"A Randomized, Open-label Phase III Trial of Mapisal® Versus an Urea Hand-foot Cream as Prophylaxis for Capecitabine-induced Hand-foot Syndrome in Patients With Gastrointestinal Tumors or Breast Cancer",0.00028958163907494484,0.000324457946483762
NCT01695226,Randomized Controlled Phase II Trial of Pre-operative Celecoxib Treatment in Breast Cancer,0.00027439233386271594,0.00031955349286474824
NCT01693731,Oral Health in Breast Cancer Survivors on Aromatase Inhibitors,0.00033270378936515755,0.0002936522305065871
NCT01699867,"Computed Optical Margin Assessment for Breast Cancer Surgery, Phase I (Part A)",0.00029227012426333244,0.00027536018372086143
NCT01606072,Perioperative Use of Desmopressin (DDAVP) in Breast Cancer,0.00032750551540277256,0.00041274166090310183
NCT01688609,"Lapatinib Ditosylate, Trastuzumab, Paclitaxel, and Surgery in Treating Patients With Breast Cancer",0.0003187531460313851,0.000362858191081181
NCT01688479,"Trial Comparing Calendula Officinalis With Aqueous Cream ""Essex"" to Treat Skin Reactions From Radiotherapy of Breast Cancer",0.0002558143540377657,0.0004119819422508509
NCT01622361,"Premenopausal Patient With Hormone Responsive, HER2 Negative, Lymph Node Positive Breast Cancer",0.0002963459130561571,0.0002895305381326529
NCT01622868,Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer,0.0002948413781110226,0.00033274523145628384
NCT01668914,Internal Mammary Sentinel Lymph Node Biopsy in Early Breast Cancer Patients With Clinically Axillary Node -Positive,0.00029783210190778385,0.00029221528006888575
NCT01664494,"An Observational Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer, Colon Cancer in the Adjuvant Setting, Advanced Gastric Cancer or Breast Cancer",0.0003381339272476588,0.00033051135840057145
NCT01641406,"""Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer""",0.0002968832416105197,0.0003326260188725497
NCT01641068,Memory and Thinking Skills Workshop to Improve Cognition in Gynecologic and Breast Cancer Survivors With Cognitive Symptoms,0.00023599961623030095,0.00025773274076581045
NCT01618357,Pre-Operative Radiation and Veliparib for Breast Cancer,0.0003413714547291861,0.0003706532552802939
NCT01645059,Multicenter Descriptive Study of the Patient Clinical Profile That Begins With Disseminated Her 2 + Breast Cancer or Develops a Metastasis After or During the Adjuvant Therapy,0.00031544028237858764,0.000345666293414547
NCT01645839,Interest of Intrathecal Chemotherapy With Liposomal Cytarabine (DepoCyte®) in Meningeal Metastasis of Breast Cancer,0.00023547839566531782,0.0003272647675059052
NCT01654367,Research of Zoledronic Acid and Aromatase Inhibitors as Adjuvant Therapy to Breast Cancer,0.000279197792660568,0.0002557406230825132
NCT01654432,A Randomized Controlled Comparative Study of Ultrasound-guided Paravertebral Blocks as Part of a Multimodal Regimen for Ambulatory Breast Cancer Surgery,0.00024314762420636307,0.00025516571871306314
NCT01613560,Clinical Study of Adjuvant Therapy on Post-menopausal Women With Breast Cancer Under the Guidance of the Results of Preoperative Endocrinotherapy,0.00026484411958073916,0.0002592250466922449
NCT01613352,Feasibility of Ambulatory Surgery for Early Breast Cancer,0.0004603590742105769,0.00021786641253537814
NCT01614704,Impact of Sequential Chemotherapy on Young Patients Breast Cancer Treated Fertility,0.0003669640689330265,0.00026790301442917525
NCT01614184,Fluorescein for Sentinel Lymph Node Biopsy (SLNB) in Breast Cancer,0.00032942060274323046,0.00030270720633453733
NCT01660529,Multi-peptide Vaccine With Basilixumab for Breast Cancer,0.00027330644596541815,0.00019594701093948074
NCT01660542,"An Open-label, Multi-center Phase Ⅳ Trial to Evaluate the Efficacy and Safety of Sequential Neoadjuvant Chemotherapy With Docetaxel(Monotaxel®) After Doxorubicin Plus Cyclophosphamide Combination Chemotherapy in Locally Advanced Breast Cancer",0.00028481551171749206,0.0002652653620416285
NCT01661816,Breast Cancer and Quality of Life,0.0004662423139961248,0.000329761682379769
NCT01694225,Adherence Rate of Monthly Bubble Package Among Patients Prescribed Adjuvant Endocrine Therapy in Breast Cancer Survivors,0.00031293685640771887,0.00038430947476526383
NCT01669252,Pharmacogenomic Study of Neoadjuvant Eribulin for HER2 Non-overexpressing Breast Cancer,0.000286750370597201,0.0003093432484409048
NCT01669265,Sentinel Lymph Node Total Tumoral Load as a Predictor of Non Sentinel Node Involvement in Early Breast Cancer,0.0004642105292565841,0.00027129111317813565
NCT01669239,"Study of Neoadjuvant Myocet®, Paclitaxel, Pertuzumab, and Trastuzumab in HER2-positive Breast Cancer",0.00028918806714974666,0.0003298204772807946
NCT01646346,4D Image-Guided Partial Breast Radiation in Stage 0 and l Breast Cancer,0.00024690735852629436,0.0002805173429823966
NCT01646034,High Dose Chemotherapy in Oligo-metastatic Homologous Recombination Deficient Breast Cancer,0.0002796746206593186,0.0003228882496198984
NCT01672021,Initial Assessment of 18FDG-PET/MRIin Determining the Extent of Systemic Disease in Breast Cancer Patients,0.0002983342048067849,0.00021286623928741449
NCT01648608,Efficacy and Safety of TAC and Exemestane as Neoadjuvant Chemotherapy in the Postmenopausal Women With Breast Cancer,0.00028923772433956865,0.0002652280878122089
NCT01648322,Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy,0.0003564473264124826,0.0004608121673714471
NCT01649258,Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy,0.0003073170896693649,0.0003415468372814011
NCT01649661,MRI Parenchymal Enhancement: A New Marker of Breast Cancer Risk,0.00027735689714093183,0.0002803945564301923
NCT01671943,Cryotherapy for Breast Cancer Trial,0.0004604955811995851,0.00035307798888922944
NCT01671319,Dose Dense TC + Pegfilgrastim Support for Breast Cancer,0.0003309781640412856,0.000349001891864445
NCT01677455,An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer,0.00031799483524764003,0.00036198545260744436
NCT01611051,A Study Comparing Pegylated rhG-CSF and rhG-CSF as Support to Breast Cancer Patients Receiving Chemotherapy,0.0003436201898620891,0.000307308614114101
NCT01662726,"A Study to Assess the Ability of a Novel Endocrine Treatment for Breast Cancer, Irosustat, to Slow Down Cancer Growth",0.0002937653552016882,0.00033356500812772806
NCT01662128,Efficacy and Safety Of Xeloda as Sequential Adjuvant Therapy After Chemotherapy in Breast Cancer,0.00029574818969140503,0.0002176257936579397
NCT01625429,Neoadjuvant Study of Nab-paclitaxel Plus Carboplatin in Breast Cancer,0.0002990112295365156,0.00031607418515171103
NCT01625286,"Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer Patients",0.0004356510684470095,0.00037447350966500714
NCT01663792,Dietary Seaweed and Early Breast Cancer: A Randomized Trial,0.00046734134015298897,0.00023821340481403538
NCT01608451,Randomized Controlled Trial of Neo-adjuvant Progesterone and Vitamin D3 in Women With Large Operable Breast Cancer and Locally Advanced Breast Cancer,0.000268225627534505,0.00045566893113680926
NCT01632956,Developing Culturally-Tailored Information-Based Support Groups for Chinese Immigrants With Breast Cancer,0.00027486345092391765,0.00030442650160776753
NCT01632332,Vaccine Therapy in Treating Patients With Previously Treated Stage II-III HER2-Positive Breast Cancer,0.0003485542207493621,0.00033458082716035595
NCT01609920,Nodal Staging in Breast Cancer With MRL,0.0008829212022672371,0.0002591665691994725
NCT01670877,Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer,0.00028337722567670423,0.0004274225803420474
NCT01637103,Treatment of Depressive Symptoms in Breast Cancer Patients: Comparison of Cognitive Therapy and Bright Light Therapy,0.00030653836366282525,0.0003310026587711927
NCT01605396,"A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064)",0.0002753453924838327,0.0003636246326193154
NCT01686737,Iyengar Yoga for Chemotherapy-induced Fatigue in Breast Cancer Patients,0.0003300562190893092,0.0003427776844041452
NCT01674140,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,0.00035211782329280897,0.0003073354753196389
NCT01674881,The Effectiveness of Mindfulness on Chronic Pain in Breast Cancer Survivors,0.0002743019432185425,0.00033022324839671247
NCT01639417,Pilot Functional Imaging Study to Evaluate Mechanisms Underlying Chronic Pain in Breast Cancer Patients,0.000322642551073306,0.0004000746601042587
NCT01612910,"Oral Microencapsulated Diindolylmethane in Treating Patients With Stage II-III Triple Negative, Androgen Receptor Positive Breast Cancer Who Have Undergone Chemotherapy and Surgery",0.00031201689807643524,0.0003287153368152207
NCT01612338,Interventions to Increase Screening by Breast Cancer Survivors and Their High Risk Female Relatives,0.00025138911715036864,0.00019431986492053814
NCT01612871,Circulating miRNAs as Biomarkers of Hormone Sensitivity in Breast Cancer,0.0003352332393381135,0.00032404446198678764
NCT01612728,Treatment for Joint Pains Due to Aromatase Inhibitor Therapy in Breast Cancer,0.0003041423396898947,0.00033962151227986194
NCT01612247,Low Dose Chemotherapy With Aspirin in Patients With Breast Cancer After Neoadjuvant Chemotherapy,0.00031932891695312944,0.0002679070980652755
NCT01658462,Phase II Study of Docetaxel +/- Nintedanib in Breast Cancer,0.00032372201861223326,0.0004721372823502907
NCT01658176,Study Of PF-04691502 (PI3K/mTOR Inhibitor) In Combination With Exemestane Compared With Exemestane Alone In Patients With Advanced Breast Cancer,0.0003403583036983562,0.0003457711211280687
NCT01652560,Observational Studies of the Application of Bevacizumab in HER2-negative Breast Cancer Neoadjuvant Chemotherapy,0.00026659152901755144,0.0003697377510820374
NCT01619514,Uncovering Potential Breast Cancer Biomarkers Amp; Possible Drug Targets Using Advanced Quantitative Mass Spectrometry,0.00025939582833251683,0.0003818133768911066
NCT01619306,Knowledge and Attitudes of Patients and Healthcare Professionals on a Spectrum of Genetic Tests Relevant to Breast Cancer Patients,0.0002808880377974213,0.00039155837798052895
NCT01012440,Role of Positron Emission Mammography (PEM) Flex Solo II Positron Emission Tomography (PET) Scanner in Evaluating Neoadjuvant Chemotherapy Response in Patients With Breast Cancer,0.0003130228811194697,0.0003327063403932168
NCT01082068,Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer,0.00033336716162747713,0.0003282592892838173
NCT01080170,The Effect of Aromatase Inhibitors on Cardiovascular Risk Factors in Women With Breast Cancer,0.00027627808694550215,0.00035988778605180907
NCT01042938,Curcumin for the Prevention of Radiation-induced Dermatitis in Breast Cancer Patients,0.00030171382807768753,0.0003198671285819753
NCT01042548,Proteomics Research of Breast Cancer Markers in Interstitial Fluid and Serum,0.0002774297308287397,0.0002873463992948583
NCT01042379,I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer,0.00028640719362887397,0.00034177095582644987
NCT01099436,Neo-Adjuvant Chemotherapy (TAC) With or Without Zoledronic Acid in Treating HER2-negative Breast Cancer Patients,0.0003493254819433919,0.000282162820749375
NCT01081106,Low Level Laser Therapy for Hair Preservation With Chemotherapy for Breast Cancer,0.00026445091259976014,0.0002977790422495969
NCT01081509,Survey Conducted Among Early Breast Cancer Patients Treated With Arimidex for Evaluation of Treatment Adherence,0.0003199121678021598,0.0004805033275805758
NCT01096901,Choose to Lose for Women-Weight Loss to Reduce Breast Cancer Risk Factors,0.0003297909923854181,0.0003565416841470714
NCT01035112,Magnetic Resonance Imaging of Breast Cancer,0.0004619943029632394,0.00031723736924626936
NCT01035268,Adipose Tissue Transfer for Moderate Breast Cancer Conservative Treatment Sequella,0.0002478963167819886,0.0002989395557948144
NCT01035099,RCT of Fixed vs Titrated Letrozole in Breast Cancer Patient Undergoing IVF,0.00031401728594519497,0.00033610080640324386
NCT01090128,"Study of Neoadjuvant Chemotherapy With Nanoparticle Albumin Bound Paclitaxel, Doxorubicin and Cyclophosphamide (NAC) in Patients With Stages II-III Breast Cancer",0.0003506975037274239,0.0003830983748975661
NCT01090687,Role of 3D Tomography in Breast Cancer,0.0003286963081406212,0.00029240796443130403
NCT01008150,Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer,0.00027742617401329373,0.00033090917763241426
NCT01072838,"Safety Study for Short-course Accelerated, Hypofractionated Partial Breast Radiotherapy (APBI) in Women With Early Stage Breast Cancer Using the Contura MLB",0.0003069443208994226,0.0003224260121505451
NCT01072318,Extended Adjuvant Treatment With Letrozole in Breast Cancer Who Complete 5 Years of Toremifene,0.0002624577868398434,0.00037490291468132383
NCT01018251,Positron Emission Tomography in Monitoring Treatment Response in Women With Newly Diagnosed Breast Cancer,0.00027019152203041903,0.0002863394231605859
NCT01018108,Visualization of the Effect of Acupuncture on Brain Serotonin in Breast Cancer Survivors,0.00024836351369182295,0.0002264691292420563
NCT01023802,The Use of Molecular Breast Imaging in the Evaluation of Tumor Response to Neoadjuvant Therapy in Women With Breast Cancer,0.00025931458647314855,0.00031145792353794687
NCT01023204,Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Breast Cancer,0.0003993905176413278,0.0005088968646141557
NCT01046929,Limonene Study in Women With Breast Cancer,0.0003862087319208685,0.0003292596543807199
NCT01086514,Digital Mammography for the Detection and Preoperative Staging of Breast Cancer,0.00032906688469742365,0.0002736998767204942
NCT01014715,Preoperative Accelerated Partial Breast Irradiation (APBI) for Women With Stage I and Select IIA Breast Cancer,0.0003433347554414497,0.0002940116634146982
NCT01091428,"MLN8237 in Patients With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer",0.0003375107849069012,0.00034739110659823583
NCT01043003,"Bilingual Breast Cancer Educational Intervention for Hispanic Women With Stage I, Stage II, or Stage III Breast Cancer and Their Families or Caregivers",0.00024533470987492576,0.00026535659835971514
NCT01043055,Evaluation the Diagnostic Ability of the Cancer Detection Technology (CDT) to Detect Breast Cancer Among Women Population Over Age 40,0.00024637321176475014,0.0003249998606495865
NCT01095003,Trial of Vinflunine Plus Capecitabine in Advanced Breast Cancer,0.0003025774714078869,0.0002746915313816249
NCT01045044,Magnetic Resonance Imaging (MRI) of Tumor Response and Cognitive Impairment in Breast Cancer Patients Undergoing Chemotherapy,0.0003070318447913941,0.00033523248641250406
NCT01064349,Breast Cancer With Over-expression of erbB2-BRAINSTORM,0.0004625577343011631,0.0003243782206541251
NCT01064635,"Letrozole in Treating Breast Cancer in Postmenopausal Women With Stage I, II, or III Breast Cancer Previously Treated With Tamoxifen (GIM4)",0.0002762050506477792,0.00022366279534712254
NCT01064427,Factors Correlated With Fatigue in Breast Cancer,0.0004663772083272083,0.00039854512096670127
NCT01051401,Rosuvastatin in Treating Women With Cardiovascular Complications Who Are Undergoing Chemotherapy For Breast Cancer,0.0002643066287585857,0.0003601019701175354
NCT01051609,"Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Non-Metastatic, Post Menopausal Breast Cancer Patients",0.0002893177644114694,0.00038294076050943523
NCT01051492,Development of Predictive Biomarkers and Novel Approached to Therapy in Breast Cancer,0.0003062525744686286,0.00025982508291759666
NCT01026116,A Randomized Trial Comparing Epirubicin/Cyclophosphamide Followed by Weekly Paclitaxel Versus Epirubicin/Paclitaxel Followed by Weekly Paclitaxel as Adjuvant Therapy for Operable Breast Cancer Patients Less Than 40 Years Old,0.0002937384205909905,0.0003022739999814148
NCT01027416,Analyzing a New Mechanism in Response to Tamoxifen Therapy in Breast Cancer Patients,0.00034162481969881393,0.00039412738043854295
NCT01000883,Correlation of Molecular Markers With Response to Therapy and Breast Cancer Behavior,0.00028024248228297846,0.00035083584872340544
NCT01034891,Women At Risk: The High Risk Breast Cancer Program,0.0003375980512831381,0.00032939399780139715
NCT01034215,Multi-Media Imagery Program for Breast Cancer Patients (Phase II),0.0002944185362114303,0.00030450508325877433
NCT01028352,Study to Assess Effect of 8 Wks of Duloxetine Therapy on Breast Cancer Patients With Aromatase-Inhibitor Associated Pain,0.0003415339550292655,0.00031692564107551035
NCT01010854,Valproic Acid in Combination With FEC100 for Primary Therapy in Patients With Breast Cancer,0.0003400897472869229,0.00039259650446757724
NCT01050634,Sequencing Of Endocrine Therapy In Post-Menopausal Women With Early Breast Cancer (FAST),0.0002801607534835649,0.0002761643445656797
NCT01070485,"BAY88-8223, Alpharadin, Breast Cancer Patients With Bone Dominant Disease",0.0003107595020416201,0.0003455123628710632
NCT01047774,The Effect of Soy Protein on Post- Breast Cancer Surgery Pain,0.0002882389991451551,0.0003138944528849001
NCT01047358,Post Marketing Surveillance Study To Observe Safety And Efficacy Of Aromasin In The Patients With Early Or Advanced Breast Cancer,0.0003461204456450375,0.0003473085452609321
NCT01097460,"MM-111 in Combination With Herceptin in Patients With Advanced Her2 Amplified, Heregulin Positive Breast Cancer",0.00031074792135205335,0.0003017976706588797
NCT01097278,S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer,0.000278495320326157,0.0003678921216446808
NCT01053468,Facilitating Physical Activity Behavior and Health Outcomes in Breast Cancer Patients Receiving Chemotherapy,0.0003051181729881866,0.0003186686340198051
NCT01031030,"Cyclophosphamide, Methotrexate, and Fluorouracil, With or Without Epirubicin Hydrochloride, in Treating Women Who Have Undergone Surgery for Breast Cancer (Group III Closed to New Patients as of 12/7/2009)",0.00029445228275666683,0.00028461196898746404
NCT01088893,Everolimus in Breast Cancer Patients After Pre-operative Chemotherapy,0.00036814626269951315,0.0003718279728994786
NCT01088477,Imaging of ER Density to Guide and Improve Tailored Therapy for Acquired Anti-hormonal Resistant Breast Cancer,0.0002556202607062467,0.0002582790604884886
NCT01049295,Omega-3 Fatty Acids and Chemotherapy-induced Neuropathy and Inflammation in Breast Cancer,0.0002650700242763711,0.0002764694036722923
NCT01049425,Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer,0.00031089687568528634,0.0002951417784291233
NCT01022086,Assessment of Cardiotoxicity by Cardiac Magnetic Resonance (CMR) in Breast Cancer Patients Receiving Trastuzumab,0.0002975044405519012,0.00031327093584478837
NCT01061359,Application Of Epirubicin Within A Neo-/Adjuvant Chemotherapy In Patients With Primary Breast Cancer,0.00032809347016876016,0.0002940688975750057
NCT01077154,Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE),0.0002999308563674732,0.00032834365103308935
NCT01077648,Brain Metastasis in Breast Cancer Patients,0.00042709534318825906,0.00038984917243238115
NCT01077726,A Study of Xeloda (Capecitabine) in Breast Cancer Patients With Central Nervous System (CNS) Progression,0.00031663468618322015,0.00030565937666637757
NCT01077453,Letrozole in Preventing Breast Cancer in Healthy Postmenopausal Women at High Risk for Breast Cancer,0.00029504148022166214,0.00033379120157172264
NCT01089933,Reducing Pain and Disability After Breast Cancer Surgery,0.0002882390390973735,0.00027359548016450864
NCT01089764,Couplelinks.ca - An Online Intervention for Couples Affected by Breast Cancer,0.0004701954466120917,0.00017562710921524734
NCT01089699,A Trial Testing Professional and Peer-led Support Online Support Groups for Young Canadian Breast Cancer Survivors,0.0002748630853834914,0.0003298629238274186
NCT01089998,"PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Safety and Tolerability in Healthy Volunteers and Safety, Tolerability and Diagnostic Performance of BAY86-9596 in Patients With Non-small Cell Lung Cancer, Breast Cancer, Head and Neck Cancer and Patients With Inflammations",0.0002939043518436795,0.00021130480462944702
NCT01005108,Acupuncture and Gabapentin for Hot Flashes Among Breast Cancer Survivors,0.0002742001561144439,0.0002685850750031998
NCT01005641,ELBA: Exemestane and Lapatinib in Advanced Breast Cancer,0.0003040893273358019,0.00025228029379180405
NCT01007695,Molecular Signature of Valproic Acid in Breast Cancer With Functional Imaging Assessment - a Pilot,0.00023984226455927887,0.0002758401384096527
NCT01007890,Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer,0.0003131714717321949,0.00034508108536254696
NCT01011218,Management of Insomnia in Breast Cancer Patients,0.0003474277902192909,0.000259326129765401
NCT01011946,Staging of Axillary Lymph Nodes Using the PEM Flex Solo II Pet Scanner in Patients With Breast Cancer,0.00034626706466253854,0.00030453264221369514
NCT01060514,Pazopanib + Vinorelbine in Non Small Cell Lung Cancer (NSCLC) and Breast Cancer,0.0002474948038822842,0.0003584155349010079
NCT01009918,Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab,0.00025678201309788914,0.000249826474916134
NCT01009788,ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer,0.0003284135279567488,0.00034994653786615934
NCT01009437,Ritonavir and Its Effects on Biomarkers in Women Undergoing Surgery for Newly Diagnosed Breast Cancer,0.0002698263534224204,0.0002846975505373105
NCT01079676,A Non-inferiority Study Comparing Two Filgrastim Preparations in Breast Cancer,0.00031735925086425653,0.0004516415754310169
NCT01015521,Efficacy Study of Aminoflavone Prodrug to Treat Breast Cancer,0.0003862087319208685,0.0006302969415319091
NCT01015131,18F-FLT-PET in Breast Cancer (MK-0000-139),0.00046756837502362307,0.0003028431718155528
NCT01015625,Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer,0.0004894700069833956,0.00032242726539795786
NCT01075802,Study of Tamoxifen Dose Escalation in Breast Cancer Patients With CYP2D6 Polymorphisms,0.00039565003707872653,0.0003408665048015598
NCT01019616,Alternative Non-cross-resistant Adjuvant Chemotherapy for Operable Breast Cancer Non-response to Primary Chemotherapy,0.00027143814199993247,0.0003355135092693157
NCT01019512,Flexitouch Lymphedema System in Treating Stage II Lymphedema in Patients With Breast Cancer,0.00035071179857633063,0.00037029131098718893
NCT01055678,To Evaluate the Characteristics of a Breast Cancer,0.0004767834760371071,0.0003157512964990666
NCT01073865,Study to Compare Zoladex™ 10.8 mg With Zoladex 3.6 mg in Pre-menopausal Women With Breast Cancer,0.0003196742863227415,0.0003279955423984075
NCT01004172,Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases,0.0002807253843149368,0.000325205168732662
NCT01004744,Feasibility of Pre-Surgical Intervention Studies for Evaluating Targeted Therapies for Breast Cancer,0.00032043151417415316,0.00035218643302149273
NCT01004796,Study of Biomarkers in Tissue Samples From Patients With Breast Cancer,0.0003533315094144385,0.0003827302565645885
NCT01071564,RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery,0.00030963775372708707,0.00038418860824852564
NCT01071109,The Clinical and Biochemical Effect of Therapeutic Massage on Fatigue and Insomnia in Women With Breast Cancer Receiving Radiation Therapy,0.00024757696162652293,0.0003081364398312815
NCT01093235,Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast Cancer,0.00035290021454480235,0.0002715026337338897
NCT01093612,Positron Emission Tomography in Women With Advanced HER2-Positive Breast Cancer,0.00036653645957488264,0.00028322015463394805
NCT02445482,SOLTI Breast Cancer Molecular Screening Program (AGATA),0.0002774965049812318,0.00028727913251750764
NCT02445586,Safety Study of Pertuzumab (In Combination With Trastuzumab and Docetaxel) in Indian Patients With Breast Cancer,0.0003371092472831472,0.00047280153715593287
NCT02411344,"Preoperative Study With Trastuzumab, Pertuzumab and Letrozole in Patients With Breast Cancer Sensitive to Hormonal Therapy",0.000331139897710108,0.00036466085386446985
NCT02416427,Targeting the Hippo Transducer TAZ in Breast Cancer With Statins,0.00032768649386685967,0.0003389051164939341
NCT02475174,Manual Lymphatic Drainage in the Superior Member in Women in Post-surgery for Breast Cancer,0.0003470879523906931,0.00022334648527596638
NCT02404506,Eribulin as 1st Line Treatment in Elderly Patients With Advanced Breast Cancer,0.00033382983566355,0.0003554543563268281
NCT02404844,"Trial of BKM120/Tamoxifen-combination in Patients With HR-pos, HER2-neg Breast Cancer",0.00042420370354204244,0.0002978003234291552
NCT02481128,Surgical Trial to Evaluate the Impact of a Lymphoscintigraphy Prior to Sentinel Node Biopsy in Early Breast Cancer,0.0002670616710538638,0.00030346128055563465
NCT02401685,POSNOC - A Trial Looking at Axillary Treatment in Early Breast Cancer,0.000365734600496797,0.000335271724251771
NCT02487524,Biomarkers of Neuropathic Pain in Women Treated for Breast Cancer,0.00033500054612385546,0.0002769572616443554
NCT02400060,Telephone-Based Intervention in Increasing Adherence to Adjuvant Hormonal Therapy in Patients With Breast Cancer,0.00035079621343720504,0.0003247199014721196
NCT02400476,A Study Looking the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide,0.00032567661667172785,0.00034560194023754224
NCT02400658,Efficacy of IORT With CT-Guided HDR Brachytherapy for Treatment of Breast Cancer,0.00030111525085544603,0.0003810043526711083
NCT02400567,"Efficacy of Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal Women",0.0002534511589124263,0.00033047379101820506
NCT02457039,Acupuncture Prevents Chemobrain in Breast Cancer Patients,0.00042592667634126606,0.00031720117661532374
NCT02479997,Clinical Application of Dual Sentinel Lymph Node Staining Method in Breast Cancer Patients,0.0002872763632922093,0.0002646409919721788
NCT02479607,Effects of an ICT-platform for Assessment and Management of Patient-reported Symptoms During Treatment for Breast Cancer,0.00031116274964519436,0.00036143463512369316
NCT02479347,Wound Infections in Breast Cancer Surgery After Preoperative Skin Preparation With Chlorhexidine vs. Povidone-iodine,0.0002416791537755811,0.0002243263972816637
NCT02444026,Feasibility and Efficacy of Internet-delivered CBT for Insomnia in a National Cohort of Danish Breast Cancer Survivors,0.0003280479469068639,0.0002549936885813715
NCT02419807,Comparison of Use of Indocyanine Green and 99mTc-labeled Radiotracer for Axillary Lymphatic Mapping in Patients With Breast Cancer,0.0002864458130541897,0.000361302716526973
NCT02488603,Decision Aids for Tamoxifen Treatment in Breast Cancer Patients,0.0003371724329529702,0.00033301089511131245
NCT02488187,Comparison of Preoperative ABUS and MRI in Newly Diagnosed Breast Cancer Patients,0.00035450952922113304,0.0003499835271202782
NCT02432950,Pancreatic Nutritional Program for Weight Loss in Overweight/Obese Patients With Stage I-III Breast Cancer,0.0002922052155314077,0.0003164844446473479
NCT02437318,Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.,0.0003120371455127589,0.0003278115957947621
NCT02441270,Evaluation of the Immunological Effects of a Combined Treatment With Radiation and Cyclophosphamide in Metastasized Breast Cancer Patients,0.00029873473829461684,0.00038266275014761674
NCT02441946,"A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer",0.0002908266824449923,0.00031863642351082706
NCT02423902,A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer,0.0003166720018995892,0.0002819095148288451
NCT02449824,MRI and Early Decision-making in Chemotherapy for Breast Cancer,0.000356270633265737,0.00029956480098478224
NCT02407613,Efficacy of MR-HIFU Ablation of Breast Cancer,0.0004606298421491506,0.0003683812573015722
NCT02429427,European Celecoxib Trial in Primary Breast Cancer,0.0004614620839729566,0.00039686353482322326
NCT02422641,Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis,0.0003003007680963225,0.0003347353563128481
NCT02422615,Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.,0.00035475908017030286,0.0003736455289427174
NCT02422199,"A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab",0.00032576169327081395,0.00030901997012707996
NCT02414776,Hydroxychloroquine in Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Hormonal Therapy,0.000253483486265529,0.0002644310328280965
NCT02414646,Trastuzumab Emtansine in Treating Older Patients With Human Epidermal Growth Factor Receptor 2-Positive Stage I-III Breast Cancer,0.0003099877484600776,0.00035253738079033903
NCT02462681,Ketamine as Adjunctive Analgesic With Bupivacaine in Paravertebral Analgesia for Breast Cancer Surgery,0.0002410259284733395,0.0002650311733808365
NCT02462226,Enhancing Management of Chronic Pain and Symptoms Among Women Treated for Breast Cancer (Lymph-Flow),0.00024913548666132766,0.00026902437787670495
NCT02402712,Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC With Perjeta and Docetaxel in Patients With HER2-positive Advanced Breast Cancer,0.00034210652487309785,0.00031777022143887997
NCT02455453,Assessment of Functional Status of Estrogen Receptors in Breast Cancer by Positron Emission Tomography,0.00025502176162625677,0.0003364713151909356
NCT02455791,Feasibility and Identification of Breast Cancer Patients for Potential Avoidance of Surgery,0.00032172272019351716,0.00036958622787013556
NCT02430103,Study of Preservation of Ovarian Reserve Function During Chemotherapy for Breast Cancer Patients at Reproductive Age,0.0003284325302326468,0.0003019637198759794
NCT02476539,Study Evaluating Hemay022 In Subjects With HER2-Positive Advanced Breast Cancer,0.0003426431031812981,0.00036967391383820503
NCT02472353,Use of Metformin to Reduce Cardiac Toxicity in Breast Cancer,0.0003302422430182504,0.0002775741312965996
NCT02491957,Impact of LOFT Therapy™ on Breast Cancer Survivors,0.0005152476714020549,0.0003254426000012334
NCT02491697,Immunotherapy Combined With Capecitabine Versus Capecitabine Monotherapy in Advanced Breast Cancer,0.00030294383346874646,0.0003344916587909258
NCT02499146,"Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer",0.00029976613269695924,0.00030647840471341393
NCT02499367,Nivolumab After Induction Treatment in Triple-negative Breast Cancer (TNBC) Patients,0.0003166150085106394,0.00033142587874198656
NCT02474641,Hypofractionation With Simultaneous Integrated Boost vs. Standard Fractionation in Early Breast Cancer,0.00027397549589623676,0.00032122483490025315
NCT02428114,A Multi Centre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Standard of Care Administration Schedules of G-CSF (Filgrastim) for Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia in Early Stage Breast Cancer (React-G Study),0.00027035837744303093,0.0003296153896265853
NCT02433067,Physical Activity Intervention on Myocardial Function in Patients With HER2 + Breast Cancer,0.00030259348037760416,0.00032590104926421545
NCT02480842,Clinical Trial With Two Physical Therapy Protocols After Breast Cancer Surgery and Immediate Reconstruction,0.00024527897609938565,0.00037497540209971127
NCT02480933,Silent Breast Cancer A Study of the Disease Prevalence Held by Imaging Guided Biopsies in Autopsy Specimens,0.0002636312580932688,0.00025560325770737624
NCT02480218,Cognitive Sequelae of Adjuvant Endocrine Therapy for the Treatment of Breast Cancer in Older Women,0.00030534426051642135,0.00034047828676132
NCT02467686,"Breast Cancer, Sexuality and Black Cohosh",0.00046049432384370504,0.00040759597191671027
NCT02454777,High-Intensity Interval Training in Improving Fitness in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy With Trastuzumab,0.00032538774966922704,0.0003307170425537416
NCT02486796,Immediate or Delayed Naturopathic Medicine in Combination With Neo-Adjuvant Chemotherapy for Breast Cancer,0.00024287052602172388,0.00029320922674478994
NCT02458391,Complete Decongestive Therapy in Breast Cancer-Related Lymphedema,0.0002617178649927712,0.0003133408979023001
NCT02494869,Dose-Response of Aerobic Training in Post-Menopausal Women at High-Risk for Development of Breast Cancer,0.00024546162266289085,0.00024695817070896604
NCT02494206,Immunotherapy for the Treatment of Breast Cancer Related Upper Extremity Lymphedema (BCRL),0.0002622049319329284,0.00030463800082800366
NCT02484131,Bone Health Management for Women Diagnosed With Breast Cancer,0.00025565542964727086,0.0002695826782347042
NCT02495155,Initial Assessment of an Internet-based Symptom Management Intervention in Early Stage Breast Cancer,0.00026565647582485117,0.00019294687535870603
NCT02434367,The Effect of Walking on Fatigue During Radiotherapy in Breast Cancer Patients 65 and Older,0.0003203191709542542,0.00027159366510100556
NCT02413008,A Clinical Trial to Assess the Safety of 0.005 % Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women With Early Stage Breast Cancer in Treatment With Aromatase Inhibitor in the Adjuvant Setting,0.00027853599492758027,0.00032594920838664536
NCT02463474,Mobile Health (mHealth) Black Women With Breast Cancer,0.0004603590742105769,0.0003321274340016566
NCT02463032,Efficacy and Safety of GTx-024 in Patients With ER+/AR+ Breast Cancer,0.00042402168164967075,0.0005173441740558287
NCT02439554,Risk Factors for Medium-term Adverse Outcomes and Predictive Modeling for Breast Cancer Patients,0.00034603698126920037,0.0003617217458975352
NCT02415387,Typhoid Vaccine in Testing Response to Immune Stress in Patients With Stage I-IIIA Breast Cancer Who Received Chemotherapy,0.0003083211680504795,0.00033050528237119005
NCT02493569,A Multicenter Study of Clinical Epidemiology of Breast Cancer in Shaanxi Province of China,0.0003192085420566682,0.00045347807568796853
NCT02450357,The Detection of Circulating Tumor Cells (CTCs) in Patients With Breast Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment,0.0003143938995831891,0.00024918883653680387
NCT02450058,Adjuvant FEC Versus EP in Breast Cancer (MIG5),0.0008829212022672371,0.00030593550372082326
NCT02448771,A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer,0.0002800103331677808,0.0003123658124626653
NCT02483871,Dose Optimization of Rosuvastatin in Early Stage and Metastatic Estrogen Receptor Positive Breast Cancer Patients on Endocrine Therapy,0.000302608634836791,0.00035806119022575514
NCT02483377,Patient Navigation and Tailored Treatment Planning in Latina Patients With Breast Cancer,0.0003326303451520855,0.00030499978734373987
NCT02483767,Gonadotropin-Releasing Hormone Agonist for the Preservation of Ovarian Function During Chemotherapy in Premenopausal Breast Cancer,0.00024943365697296883,0.00029932359386052385
NCT02403973,Trial Comparing Perioperative Care for Breast Cancer Patients at a Patient Hotel vs a General Surgical Ward,0.000321308596419159,0.0003438167975467559
NCT02438358,Feasibility Study of Intraoperative Imaging in Breast Cancer,0.00032877702236089876,0.00028607528435176886
NCT02440620,Cardiac Toxicity in Medical Treatment of Breast Cancer,0.00030113304447513503,0.0002876763786804632
NCT02440191,3DCRT vs. IMRT in Early Breast Cancer,0.0008829212022672371,0.0007102315174896992
NCT02440230,Safety of OFS Combined With AI Endocrine Therapy in Chinese Premenopausal Breast Cancer Patients,0.0003540358091417085,0.00035005535799815276
NCT02460744,2-weeks of Adjuvant Radiotherapy in Patients With Breast Cancer,0.00042456475581116484,0.00033567352988360643
NCT02453620,"Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer",0.0003166838168077068,0.00035742747438719056
NCT02482376,Preoperative Single-Fraction Radiotherapy in Early Stage Breast Cancer,0.00026605932130028875,0.00027992836502135747
NCT02482753,Trial of Chidamide in Combination With Exemestane in Patients With Advanced Breast Cancer,0.0003197963097629442,0.0003814558372218729
NCT02482506,Moving Forward: A Weight Loss Intervention for African-American Breast Cancer Survivors,0.00027798390979821115,0.00019398881056414066
NCT02426489,Improving Diagnosis of Breast Cancer by Using a Combined MRI and Positron Emission Mammography (MRI-PEM) System,0.00033643494240186714,0.00028522057693836333
NCT02408393,MIRs03: Paravertebral Block With Ropivacaine Before Breast Cancer Surgery,0.00028679981671464173,0.00023458858083747795
NCT02408107,A Home-based Physical Activity Intervention in Breast Cancer Survivors,0.0002578593938518937,0.0002652310978746158
NCT02408770,Breast Cancer - Anti-Progestin Prevention Study 1,0.0003195685828328304,0.00026745381011933166
NCT02406794,Effect of Kinesiotaping for the Treatment of Hormone-induced Myalgia in Women Given Breast Cancer Survivors,0.0003644481540813232,0.0003071531352506873
NCT02451735,Genetic Counseling for Breast Cancer Survivors (GC for BC),0.0004609021674493956,0.00029931000052387907
NCT02443428,Eribulin Use for the Treatment of Advanced Breast Cancer: A Prospective Observational Registry,0.0002788389963323482,0.0003453938535080496
NCT02443493,Laser Therapy for the Prevention of Radiodermatitis in Breast Cancer Patients,0.00031099487971489504,0.00029705116066666357
NCT02443467,A Study to Determine the Safety and Tolerability of Herceptin as an Adjuvant Therapy of Early Breast Cancer,0.0002896376256813428,0.0003516423133794739
NCT02420249,Qigong for Breast Cancer Survivors,0.00046076968661922034,0.0003090669031439862
NCT02485626,Identifying Subgroups With High Cardiovascular Risk in Breast Cancer Survivors,0.0003328566608892881,0.00028049336066345417
NCT02485678,A Pragmatic Trial of Ambulatory Toxicity Management in Patients Receiving Adjuvant or Neo-adjuvant Chemotherapy for Early Stage Breast Cancer,0.00030652778462609897,0.0002464205741740177
NCT02473159,Clinical Application of Near-infrared Fluorescence Guided Localization on Breast Surgery in Breast Cancer,0.000247151267117263,0.0002525784120459051
NCT02409316,[18F]FES PET/CT in Endocrine Refractory Breast Cancer,0.00046756837502362307,0.0003189360399758222
NCT02464982,Psycho-esthetic Impact of Tattoo Technology as Part of Mammary Reconstruction After Surgery Against Breast Cancer,0.0002500606874769109,0.00025142454299442594
NCT02424292,Evaluation of a Physical Activity Program in Overweight Breast Cancer Patients,0.0002982665279359624,0.0003211534469709913
NCT02468739,Effect of GM1 in Prevention of Taxanes Induced Neurotoxicity in Operable Breast Cancer,0.0002757052529489836,0.00024990278564119444
NCT00101400,BAY43-9006 - Phase II in Advanced Breast Cancer,0.0005113766994020161,0.00036926281462617856
NCT00165243,Tangential Radiation Therapy Without Axillary Dissection in Breast Cancer,0.0003424807158418479,0.0004089120756717716
NCT00121134,Bevacizumab With or Without Cyclophosphamide and Methotrexate: A Pilot Study in Women With Operable Breast Cancer,0.0002925398665313626,0.0003308835871239964
NCT00121992,Docetaxel in Combination With Doxorubicin and Cyclophosphamide (TAC) Versus 5-Fluorouracil in Combination With Doxorubicin and Cyclophosphamide (5 FAC) as Adjuvant Treatment of Breast Cancer Patients,0.0003180596564392115,0.00029235340909119264
NCT00102219,A Study of Pemetrexed Plus Doxorubicin Given to Patients With Advanced Breast Cancer,0.00034807054298727224,0.00038754065123215026
NCT00195013,Randomized Placebo-Controlled Trial of Glutamine for Breast Cancer Patients With Peripheral Neuropathy,0.0002881577141045992,0.0002593475980531405
NCT00195091,Phase II Study of Tetrathiomolybdate (TM) in Patients With Breast Cancer,0.00039053642638535576,0.0003302898255093901
NCT00190671,A Study of Pemetrexed and Cyclophosphamide Given Every 21 Days in Advanced Breast Cancer Patients,0.00034937990195755474,0.00038545269932345
NCT00184210,Magnetic Resonance (MR) Spectroscopy of Breast Cancer Tissue,0.0002739563399244685,0.00022732604111936854
NCT00179634,Study of Fine Art Photographs and Visualization Tapes to Improve Surgical Recovery in Breast Cancer,0.00027522621235506013,0.00025573526869442044
NCT00179309,Docetaxel Alone or in Combination With Vaccine to Treat Breast Cancer,0.00026212498242397114,0.0003858062317160684
NCT00110695,"Therapy With Abraxane and 5-Fluorouracil, Epirubicin, Cyclophosphamide (FEC) for Patients With Breast Cancer",0.0003102651483533808,0.00040963248702523877
NCT00185744,Accelerated Partial Breast Irradiation Following Lumpectomy for Breast Cancer,0.00032919595611471963,0.0002848260835164107
NCT00119262,Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer,0.0003063019573671677,0.0002897770877378666
NCT00124111,A Study of Cyclophosphamide/Methotrexate/5-Fluorouracil (CMF) With Pegfilgrastim in Subjects With Breast Cancer,0.00027383047247222603,0.0003105537312449313
NCT00109239,A Study of rhuMAb VEGF (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Treated Breast Cancer,0.00035154150043108836,0.0003375843737790637
NCT00109785,PET Scans in Patients With Locally Advanced Breast Cancer,0.0003751436573216825,0.00028802156436549207
NCT00171340,Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer.,0.00024708582850360196,0.00021490915894430718
NCT00171314,The Use of Zoledronic Acid to Prevent Cancer-treatment Bone Loss in Post-menopausal Women Receiving Adjuvant Letrozole for Breast Cancer,0.00025908251299628434,0.00021403559684049622
NCT00171704,A Study to Evaluate the Effect of Letrozole and Tamoxifen on Bone and Lipids in Postmenopausal Women With Breast Cancer,0.00028714401587944167,0.00029205972227982536
NCT00160901,Complementary Therapies for the Reduction of Side Effects During Chemotherapy for Breast Cancer,0.00026591759949172347,0.0002486439208837948
NCT00127205,S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer.,0.000330545315545963,0.00021529790632077842
NCT00133796,Neoadjuvant Herceptin in Patients With Breast Cancer,0.00036338096236246365,0.0004903326961081074
NCT00189644,6 FEC 100 Vs 4 FEC 100 Followed by 4 Taxol in N+ Breast Cancer,0.0004613175188562612,0.000253102138269976
NCT00189670,Randomized Phase II Trial of Dose Dense Docetaxel in N+ Breast Cancer,0.0003413659069335763,0.0002485022336309734
NCT00176046,"Mistletoe Extract in Early or Advanced Breast Cancer, A Feasibility Study",0.0002983210635224206,0.0003020978877934926
NCT00128856,"Gemcitabine, Doxorubicin and Paclitaxel (GAT) as Neoadjuvant Treatment of Breast Cancer Patients",0.0003119826885751625,0.0002466287359221871
NCT00128362,Sentinel Node Biopsy and Axillary Sampling in Operable Breast Cancer,0.000273912849091689,0.00031486219450671906
NCT00128297,Pamidronate Administration in Breast Cancer Patients With Bone Metastases,0.00031001844149561504,0.0003608960905251343
NCT00174343,Exemestane As Treatment In Neoadjuvant Setting For Operable Breast Cancer Patients,0.0003270363051212082,0.0003271001816266043
NCT00174707,Study of Docetaxel in Breast Cancer Patients,0.0003975880795927259,0.00035768024168276395
NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,0.0004739784354825977,0.00028935934973710163
NCT00199212,PS-341 in Combination With Herceptin in Advanced Breast Cancer That Overexpresses HER-2,0.0002785662314195775,0.0002951602702921403
NCT00193726,Estrogen Priming to Increase the Efficacy of Adjuvant Chemotherapy in Operable Breast Cancer,0.00033226608967764206,0.0003266001760079853
NCT00193011,Weekly Docetaxel and CMF in the Adjuvant Treatment of Elderly Women With High-Risk Breast Cancer,0.00027937168394860375,0.00027024569257567884
NCT00193115,Docetaxel Followed by Doxorubicin Plus Cyclophosphamide for Node Positive or High-Risk Primary Breast Cancer,0.0002532157091079232,0.0002385601344880262
NCT00193089,"Docetaxel, Vinorelbine and Trastuzumab in the Treatment of Patients With Metastatic Her-2 Positive Breast Cancer",0.0003278194954061941,0.00029946317777817345
NCT00166998,The Study of Infrared Imaging on Breast Cancer,0.00039104014466253146,0.00029345999346630665
NCT00166543,Three Doses of TAS-108 to Treat Recurrent or Recurrent Inoperable Breast Cancer,0.0004603590742105769,0.0006118640731675158
NCT00149214,Preoperative Treatment of Breast Cancer With Two Different Sequential Treatment Regimens,0.00030131018864971857,0.0003468935406397053
NCT00106145,A Notch Signalling Pathway Inhibitor for Patients With Advanced Breast Cancer (0752-014),0.0003712093242914406,0.0003500665276562865
NCT00155038,Imaging Characteristics of Breast Cancer in Women Under 40 Years of Age,0.0003330674170617619,0.00028401468027596313
NCT00155259,"Docetaxel, Cisplatin and Capecitabine as Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer",0.0002838426535699166,0.0002871948974484773
NCT00136539,Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer,0.0002900579273252853,0.00035558074747775063
NCT00196872,A Study to Compare ETC vs. EC-TX and Ibandronate vs. Observation in Patients With Node-positive Primary Breast Cancer (GAIN),0.0003268211433128054,0.0003831775183906474
NCT00196859,Study in Elderly Patients With Early Breast Cancer (ICE),0.00039053642638535576,0.00042052982406162064
NCT00196833,Breast Cancer in Pregnancy Register Study,0.00031716241053369104,0.0003267946131079976
NCT00148681,Preoperative Herceptin and Navelbine for Breast Cancer,0.0003326614103448408,0.00042534819693280907
NCT00148694,Preoperative Cisplatin in Early Stage Breast Cancer,0.000343973328515691,0.0003683149040578494
NCT00148668,Preoperative Herceptin/Navelbine Versus Taxotere/Carboplatin/Herceptin in HER-2 Positive Breast Cancer,0.00024057408771750082,0.00031210757790441594
NCT00148720,Capecitabine in Women With Operable Breast Cancer,0.0004704288307836469,0.0005922292722597796
NCT00191789,Neoadjuvant Sequential Administration of Two Gemcitabine Combinations in Operable Breast Cancer,0.00026727875624432435,0.00024991812029716303
NCT00191243,Docetaxel vs. Docetaxel-Gemcitabine in Breast Cancer,0.00033812779977230553,0.00034115724482678393
NCT00130533,Maintenance Treatment With Capecitabine Versus Observation in Breast Cancer Patients,0.0003368626932193454,0.00035999506757732877
NCT00130507,Benefit of Adding Trastuzumab to Second Line Chemotherapy in Breast Cancer Patients Previously Treated With Trastuzumab,0.00033691071991054074,0.00026451929105452207
NCT00118508,The Prevention of Osteoporosis in Premenopausal and Newly Postmenopausal (Up to 8 Years) Women With Breast Cancer Following Chemotherapy (REBBeCA Study),0.00029151273708650854,0.000314281306660287
NCT00161291,Open Label Trial for Post-Menopausal Women With Newly Diagnosed Operable Breast Cancer,0.0002819773665257994,0.00032615206585173646
NCT00161265,Tissue Procurement Protocol for Patients Undergoing Neoadjuvant Systemic Therapy for Breast Cancer,0.0003031457407740146,0.0004050822072512049
NCT00123812,Frequency of Portal Images Required to Enhance Quality Assurance for Breast Cancer Patients Treated With Radiotherapy,0.00029184089849064763,0.00025562922089684015
NCT00123929,Genetic Expression and Prediction of Response to Neoadjuvant Docetaxel or Doxorubicin in Locally Advanced Breast Cancer,0.00026939025099955805,0.00024784361689247973
NCT00123669,Primary Progesterone Therapy for Operable Breast Cancer,0.00036453885889008197,0.0003380963030219195
NCT00123799,Study of Fluorodeoxyglucose (FluGlucoScan) in Patients With Breast Cancer: Correlation With Histologic Findings of Sentinel Node Biopsies and Axillary Dissection,0.000315655976472538,0.00032571176015678806
NCT00156039,Randomized Trial of Follow-up Strategies in Breast Cancer,0.0003327505924655815,0.0002998530664441278
NCT00156260,Feasibility Study of Evaluating Breast Cancer Patients With Ductal Lavage,0.0003465610207477063,0.0002527275946939109
NCT00156806,Investigating the Therapeutic Effectiveness of Aloe Barbadensis in Reducing Cutaneous Side-Effects of Radiation Treatment for Breast Cancer.,0.00028035013167537634,0.00030345664107750577
NCT00156312,Evaluation of Tumor Factors in Breast Cancer Treated With Docetaxel and Capecitabine,0.00026652341219548815,0.0004426167668737943
NCT00156416,Menopause and Meditation for Breast Cancer Survivors,0.0003318182097326566,0.0003223898765912481
NCT00156052,Hypofractionated Radiotherapy Post-Lumpectomy in Women With Node Negative Breast Cancer,0.00025329740121424974,0.0002060177760299636
NCT00147550,"MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.",0.0002683244565917485,0.00033248127705010316
NCT00112749,Infliximab in Treating Cancer-Related Fatigue in Postmenopausal Women Who Have Undergone Treatment for Breast Cancer,0.00026637226358182956,0.00029863001175355704
NCT00144898,GF-GS 01: Comparing Conventional Axillary Dissection Versus Sentinel Node Resection in Clinically Node-negative Operable Breast Cancer,0.00023713905178846537,0.00025716592383859
NCT00153894,Effects of Exercise Intervention on Insulin Levels in Breast Cancer Survivors,0.0002726338096234996,0.00026756205301698744
NCT00146562,Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer,0.00025016917064212625,0.0002794375086454619
NCT00146601,Fulvestrant in Premenopausal Women With Hormone Receptor-Positive Breast Cancer,0.00026433231800813576,0.0003870838235067433
NCT00146588,"Cytoxan, Epirubicin and Capecitabine in Women With Breast Cancer",0.00027846137605656705,0.0003825926284812521
NCT00150917,RCT of a Group Intervention for Women With a Family History of Breast Cancer,0.00027843965756055316,0.0002460013678102192
NCT00188721,Breast Study to Learn More About the Application of Optical Transillumination Measurements to Assess Breast Cancer Risk and to Potentially Detect the Presence of Breast Cancer.,0.0002662635547573514,0.0002664908504246273
NCT00188604,The Use of Selenium to Treat Secondary Lymphedema - Breast Cancer,0.0003275957109891878,0.0003454807044684605
NCT00131963,A Pharmacogenomics Study for Breast Cancer Patients Undergoing Adjuvant Chemotherapy With Doxorubicin (A)/Cyclophosphamide ©) and/or Weekly Paclitaxel,0.0003304222798389408,0.000369347835042612
NCT00172068,Zoledronic Acid in the Treatment of Breast Cancer With Minimal Residual Disease in the Bone Marrow,0.00025921295001485225,0.00030499461398743164
NCT00172029,Study Comparing Full-dose Radiotherapy Versus Reduced Dose in the Management of Bone Metastasis in Patients With Breast Cancer Receiving Zoledronic Acid,0.00032815768183104896,0.00030085256006749303
NCT00115505,"Quality of Life, Employment, and Informal Care Costs in Women Who Are Receiving Chemotherapy for Breast Cancer",0.00035968732419621184,0.00035004485908086546
NCT00115713,Effects of Aerobic Exercise Versus Weight Training in Breast Cancer Survivors During Chemotherapy,0.0002658360996188667,0.000304558937340175
NCT00115414,Same Day Dosing of Pegfilgrastim in Breast Cancer Patients Undergoing Chemotherapy (TAC),0.0003676700623973178,0.0003407033787259156
NCT00198250,Venlafaxine for Hot Flashes After Breast Cancer,0.00032907086621435924,0.0003091039962803989
NCT00198237,Genomic & Proteomic Analysis of Docetaxel & Capecitabine as Primary Chemo for Stage II-III Breast Cancer,0.00025855206084933127,0.00035444542915784316
NCT00100893,IH636 Grape Seed Extract in Preventing Breast Cancer in Postmenopausal Women at Risk of Developing Breast Cancer,0.0003435732273532156,0.00024088144359126759
NCT00152178,The Comparative Trial of UFT + TAM With CMF + TAM in Adjuvant Therapy for Breast Cancer (CUBC),0.00033064332450887467,0.00035302142880979325
NCT00152191,A Randomized Controlled Study of Postoperative Adjuvant Therapy of Uracil-tegafur (UFT) Compared With Cyclophosphamide/Methotrexate/5-fluorouracil (CMF) in Breast Cancer (NSAS-BC),0.00026657323032152914,0.0003144865985403035
NCT00117910,Treatment for Elderly Patients With High Risk Breast Cancer,0.0003780609753752611,0.0003283705144836238
NCT00107497,Radiation Therapy in Treating Women With Localized Breast Cancer,0.0004804196347823597,0.00028358072438274825
NCT00107094,Study of Adriamycin Plus Cyclophosphamide Followed by Abraxane as Adjuvant Therapy for Patients With Breast Cancer,0.0003224850117048617,0.00039764369679809116
NCT00107484,Magnetic Resonance Imaging Using Ferumoxtran-10 in Finding Metastases to the Axillary Lymph Nodes in Patients With Breast Cancer,0.00028619426077178544,0.0002897144470322183
NCT00107016,Everolimus and Letrozole as Preoperative Therapy of Primary Breast Cancer in Post-menopausal Women,0.00026727964438328316,0.00035115130655808974
NCT00140140,"A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer",0.00032341418239356586,0.000301747642012922
NCT00140075,Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer,0.0002628693366800112,0.00033361585148978856
NCT00186602,Does a Peer Navigator Improve Quality of Life at Diagnosis for Women With Breast Cancer?,0.00028217500125507245,0.0003314734189530801
NCT00186524,Do Community Cancer Support Groups Reduce Physiological Stress in Women With Primary Breast Cancer?,0.00025122788245015285,0.0002912564823718566
NCT00186641,High Dose Chemotherapy and Autologous Transplant for Breast Cancer,0.00032768748239596964,0.0003761669591756277
NCT00177840,Acupuncture to Treat Cancer-Related Fatigue in Breast Cancer Patients,0.00029931445029462766,0.00044290600953070605
NCT00167414,Study for Using Radiosurgery on Limited Metastases of Breast Cancer,0.00028580256521441817,0.00036811143848525517
NCT00175344,Does Scar Massage Improve Postoperative Pain and Function in Women With Breast Cancer?,0.00023632240799145658,0.00034768741884353695
NCT00145743,Diagnostics and Therapy of Disease-Related Quality of Life of Patients With Breast Cancer,0.0003158930318192413,0.000404055726191138
NCT00129376,Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Docetaxel as Neoadjuvant Treatment of Breast Cancer Patients,0.0003136335895622527,0.00033651950944588925
NCT00129389,FAC Versus FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative High Risk Breast Cancer Patients,0.000319529968161954,0.00035553045819960034
NCT00129922,"Fluorouracil, Epirubicin, and Cyclophosphamide (FEC) Versus FEC Plus Paclitaxel as Adjuvant Treatment for Node Positive Breast Cancer Patients",0.0003197705934024905,0.0003465091771179537
NCT00129935,"EC (Epirubicin, Cyclophosphamide) Followed by T (Docetaxel) Versus ET (Epirubicin, Docetaxel) Followed by X (Capecitabine) as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer Patients",0.0003026962183646349,0.00027986986162668984
NCT00114816,"Docetaxel Followed by CEF (Cyclophosphamide, Epirubicin and 5-Fluorouracil) Compared to Docetaxel and Capecitabine Followed by CEX (Cyclophosphamide, Epirubicin and Capecitabine) as Adjuvant Treatment for Breast Cancer",0.0002644179153780687,0.00031254806760897045
NCT00114296,Omega-3 Fatty Acids in Preventing Breast Cancer in Women at High Risk of Developing Breast Cancer,0.0003337256184158141,0.00022093764107449749
NCT00194779,Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery,0.00030745116229565633,0.000384433411440186
NCT00194363,Strength Training Intervention for Breast Cancer Survivors and the Effects on Lymphedema Status,0.00025403200324306907,0.00029969801387987
NCT00194792,Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer,0.0003194149331731894,0.00032582728787324173
NCT00194571,Enhancing Connections: Helping the Mother With Breast Cancer Support Her Child,0.00032988183650156297,0.00020433728950839815
NCT00194337,"Digital Mammography, Ultrasound, MRI, and PET Scans in Women With Newly Diagnosed Breast Cancer",0.0002553699967846054,0.0002232963441133099
NCT00194753,Adjuvant Therapy for High-Risk Breast Cancer With Wkly Adriamycin & Oral Cytoxan With G-CSF for 12 Wks; Wkly Taxol x 12,0.00023994696918025452,0.00032557289488897184
NCT02139358,Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer,0.0002649823970537346,0.0003196730738793505
NCT02150525,Effect of Omega 3 on Atrophic Vaginitis in Breast Cancer Survivors,0.00046063483304663175,0.00020871623682256087
NCT02131506,A Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast Cancer,0.0003395776427933131,0.00034978765932961787
NCT02131064,A Study Comparing Kadcyla Plus Perjeta Treatment to Chemotherapy Combined With Herceptin Plus Perjeta in Patients With HER2-Positive Breast Cancer,0.0003516006119220415,0.00034594661434022444
NCT02163694,"A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer",0.0002618090950375143,0.0003112575241247593
NCT02102490,A Study Of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread,0.0003870226376317102,0.0006064012665897767
NCT02102282,Breast Cancer During Pregnancy,0.00046089923810156436,0.00026021079154347327
NCT02102568,Study the Impact of Chemo-induced Menopause on the Quality of Life in Young Women of Childbearing Age and Diagnosed With Non-metastatic Breast Cancer,0.0002752939455848154,0.0002843701883080873
NCT02178475,Prospective Observational Study of Febrile Neutropenia (FN) and Pegfilgrastim Primary Prophylaxis in Breast Cancer and Non-Hodgkin's Lymphoma Patients Receiving High (>20%) FN-risk Chemotherapy,0.0003321747815023414,0.00035196549575821674
NCT02162719,"A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors",0.0002919641902453735,0.00033528648831069794
NCT02162667,Efficacy and Safety Evaluating Study of CT-P6 in Her2 Positive Early Breast Cancer,0.00040255622405199835,0.00039068688147768317
NCT02104830,Study of the Efficacy and Safety of Empegfilgrastim for Neutropenia Prophylaxis in Breast Cancer Patients,0.00032811603885201794,0.0003480142095597407
NCT02122107,"Cognition in Older Breast Cancer Survivors: Treatment Exposure, APOE and Smoking History",0.0002712848198785303,0.0002985636250242257
NCT02168452,Clinical Application of Dual Sentinel Lymph Node Staining Method in Breast Cancer,0.00023842068335323414,0.00027005503524823483
NCT02168179,KeraStat Skin Therapy in Treating Radiation Dermatitis in Patients With Newly Diagnosed Stage 0-IIIA Breast Cancer,0.00031587721697616284,0.000335219494277914
NCT02177175,Carvedilol for the Prevention of Anthracycline/Anti-HER2 Therapy Associated Cardiotoxicity Among Women With HER2-Positive Breast Cancer Using Myocardial Strain Imaging for Early Risk Stratification,0.00025529437636756725,0.000302220533288123
NCT02188745,ER Reactivation Therapy for Breast Cancer,0.0005152476714020549,0.0002490091550296282
NCT02195076,Non Invasive Detection of Lung and Breast Cancer by Odor Signature,0.0002480800336505035,0.0002377879786884294
NCT02195960,Supplementation With Dietary Anthocyanins and Side Effects of Radiotherapy for Breast Cancer,0.0002835370672055487,0.00029042247479765755
NCT02134977,"Leuplin SR 11.25 mg Injection Kit Specified Drug-use Survey: ""QOL Survey in Premenopausal Breast Cancer Patients""",0.0002841223275606016,0.00023961438681566638
NCT02157051,Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer,0.00034625054381590874,0.00032889136888353645
NCT02125006,"The Effect of an Inter-Disciplinary Program, Including MBSR, in Breast Cancer Survivors With Chronic Neuropathic Pain",0.00027549351361313203,0.0002711083576444485
NCT02125344,"A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)",0.0003236505947495286,0.00031366066186449203
NCT02125630,Bone Metastasis and Surgery in Breast Cancer,0.00034872552652835047,0.0002628841944876703
NCT02125019,Longitudinal Evaluation of Taxane Induced Neuropathy in Early Stage Breast Cancer,0.00026417104036655233,0.00034285148113538433
NCT02112682,Omitting Completion Axillary Treatment in Sentinel Node Positive Breast Cancer Patients Undergoing a Mastectomy,0.0003155771333967072,0.00033540512820670826
NCT02166983,Cognitive Enhancement Program in Improving Cognitive Function in Breast Cancer Survivors,0.00027631164352283794,0.0003467902570476969
NCT02166281,Impact of Adjuvant Treatment With Aromatase Inhibitor on Sleep Disturbances in Postmenopausal Women With Endocrine Responsive Early Breast Cancer,0.0002836068599833024,0.0002863001743819005
NCT02183805,Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Metastatic Triple-negative Breast Cancer,0.0002752132032562373,0.0003044028935423139
NCT02159157,"A Randomized, Controlled Trial to Determine the Effects of an Exercise Intervention on Physical Activity During Chemotherapy for Patients With Early Stage Breast Cancer",0.0003116985086986742,0.00030478016104106296
NCT02127073,"Pilot Study of Oxytocin and microRNA Identification in NAF, Serum, and Tissue in Women With Breast Cancer",0.00027138939548807266,0.0002888649724478496
NCT02144012,A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus the Combination of Trastuzumab Plus Docetaxel in Patients With HER2-positive Breast Cancer,0.0003376054586407258,0.00037019179762638396
NCT02135159,Patients With Brain Metastases From HER2-positive Breast Cancer,0.00042709534318825906,0.00032118909301455384
NCT02129556,"Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast Cancer",0.00027845440346693713,0.0003525167443473274
NCT02129686,A Pilot Study of Acupuncture for Chemotherapy-induced Peripheral Neuropathy in Breast Cancer Patients,0.00034352999789180394,0.0003187803604783717
NCT02107703,A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer,0.00027730189459727146,0.00027389403272461285
NCT02154776,"Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer.",0.0002941057498980879,0.0003406848844855513
NCT02154139,"Leuprorelin Acetate SR 11.25 mg for Injection Specified Drug-use Survey ""Long-term Use Survey on Premenopausal Breast Cancer Patients (96 Weeks)""",0.00028710632967685783,0.0002584810558369944
NCT02152462,Exergaming Intervention and Breast Cancer Biomarkers in Black Women,0.00034145791382027854,0.0002607898694816807
NCT02190539,Homeopathic Protocol for Advanced Breast Cancer,0.00029874130732676055,0.00033805234314760797
NCT02120417,A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer,0.0002962095669949619,0.00033330466081618734
NCT02171078,Post-Treatment Surveillance in Breast Cancer: Bringing CER to the Alliance,0.00030059856595410363,0.0002057045686049604
NCT02133677,A Phase II Multi-center Pilot Study of Concurrent Temozolomide and Whole Brain Irradiation in Lung Cancer and Breast Cancer Patients With Brain Metastases,0.00032297340305008804,0.00029690190431031806
NCT02158299,Contrast The Role of Avitene And OK-432 in Reducing Seroma Formation After Axillary Lymphadenectomy for Breast Cancer,0.0002365524486438625,0.0002213022791426055
NCT02187718,Ambulatory SNP Under Local Anaesthesia in a Subgroup of Breast Cancer Patients - Trial,0.00034580590334018697,0.0003803896545518446
NCT02187289,A Study to See Whether Adding Night-time Compression to the Standard Care Will Result in Improved Control of Arm Swelling (Lymphedema) in Breast Cancer Subjects,0.000263243296651258,0.00028685291972122305
NCT02117011,Effects of a Structured Exercise Program on Cancer-Related Fatigue in Women Receiving Radiation Therapy for Breast Cancer,0.00025103107269559946,0.0003009011073395271
NCT02167932,The Impact of a Physical Activity Program on Biomarkers of Aging During Chemotherapy for Breast Cancer,0.0002585337879070478,0.00033783403520525854
NCT02167854,"Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer",0.000331131515760958,0.00036579838924182803
NCT02103140,An Exercise RCT Targeting African-American Women With Metabolic Syndrome and High Risk for Breast Cancer,0.00027980918892206734,0.000250532039481062
NCT02103634,NaF PET/MRI Evaluation for Bone Metastases in Breast Cancer,0.00028503346390664234,0.0002595251750890455
NCT02103387,Five Sessions Intervention to Facilitate Adaptation to Breast Cancer,0.0003343687877158681,0.00019673840788276547
NCT02199418,Addition of Cisplatin to Neoadjuvant Therapy for T Locally Advanced Breast Cancer,0.00031262016459910767,0.0003318779421373582
NCT02119481,Effects of Mindfulness Meditation and Stress Management After Breast Cancer,0.00024953415657053994,0.00023491809080701832
NCT02119715,A Phase II Study Comparing Pegylated rhG-CSF（HHPG-19K） and rhG-CSF in Breast Cancer Patients Receiving Chemotherapy,0.0003648536158142674,0.00031087555110297023
NCT02189278,Improving Adherence to Recommended Surveillance in Breast Cancer Survivors,0.0004617251646067236,0.0002953051330868627
NCT02186470,Intensity Modulated Accelerated Partial Breast Irradiation Before Surgery in Treating Older Patients With Hormone Responsive Stage 0-I Breast Cancer,0.0003045356441059868,0.00031198540564698863
NCT02194166,An Open-Label Randomized Study to Investigate the Tolerability of Subcutaneous (SC) Trastuzumab Administration in Patients With HER2-Positive Early Breast Cancer (eBC) Using Either a Single-Use Injection Device or Manual Administration,0.0003227414205620997,0.0002538479831527708
NCT02115984,"Study of the Safety and Leukostimulatory Activity of the Preparation ""Panagen"" in Patients With Breast Cancer",0.00032758923108392574,0.00041037831587990115
NCT02115594,Phase 2 Study of Fulvestrant With and Without Entinostat in Postmenopausal Women With ER+ Advanced Breast Cancer,0.00030047716521103236,0.0002767097953675078
NCT02115282,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,0.0003161314568653851,0.0003660889703021701
NCT02115152,Neoadjuvant Trial of Capecitabine for Axillary Lymph Node Positive Operable Breast Cancer,0.00027299634997076674,0.00023534821060221088
NCT02115048,Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone,0.00033940105485818735,0.00040021183563560626
NCT02148575,Integrating Palliative Care Into Self-Management of Breast Cancer,0.00032796358601869865,0.00026705354925501333
NCT02185352,"Bevacizumab, Etoposide and Cisplatin Followed by Whole Brain Radiotherapy in Breast Cancer With Brain Metastases",0.0002442937345146764,0.00035562084591335554
NCT02165605,HylaCare in the Treatment of Acute Skin Changes in Patients Undergoing Radiotherapy for Breast Cancer,0.000314812155285341,0.0003470532213876687
NCT02142868,"Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate",0.0003179850447174593,0.00039170999414986775
NCT02142010,Weekly Paclitaxel Liposome Injection Plus Cisplatin in Preoperative Treatment of Breast Cancer,0.00027127558187082883,0.0003431499571444455
NCT02161900,Randomized Controlled Trial Evaluating the Role of Exercise in Women Undergoing Treatment for Breast Cancer,0.0002747955684674677,0.00047417166187830093
NCT02161315,Steroid Aromatase Inhibitors Versus Progestogens for nSAID-resistanced Late Stage Breast Cancer,0.00024673109753797404,0.0002226016768700734
NCT02126800,Rapid Medical Donation Programme for Breast Cancer,0.00027526839093573415,0.000335183419158369
NCT02126449,DIetary REstriction as an Adjunct to Neoadjuvant ChemoTherapy for HER2 Negative Breast Cancer,0.00034928233899067263,0.00028842288318648953
NCT02132000,Efficacy and Tolerability of Toremifene or Tamoxifen Therapy in Premenopausal Estrogen and Progesterone Receptor Positive Breast Cancer Patients,0.00030864230367124915,0.0002643828846273241
NCT02132390,"Adjuvant Toremifene With or Without Goserrelin in Premenopausal Women With Stage I-IIIA, Hormonal Receptor Positive Breast Cancer Accompanied With or Without Chemotherapy Induced Amenorrhoea",0.00026458756179800237,0.0002502836011969502
NCT02132949,"A Study Evaluating Perjeta (Pertuzumab) Combined With Herceptin (Trastuzumab) and Standard Anthracycline-based Chemotherapy in Patients With HER2-positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer.",0.000364991127792933,0.00040081757875829165
NCT02108561,Breast Cancer Tumor Heterogeneity,0.0004688409607390491,0.0003095144614187622
NCT02137252,Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer,0.00032404509022887544,0.0003512880301812782
NCT02198118,Domiciliary Physiotherapy During Breast Cancer Radiation,0.00034147129946991435,0.00033365985527831804
NCT02141139,Perioperative Inflammation and Breast Cancer Outcome,0.0004610558748314623,0.0002503370159405597
NCT02141373,Effectivenes of Cyanoacrylate (Glubran 2®) in Reducing Seroma Formation in Breast Cancer Patients Post-Axillary Dissection,0.00029272452453036013,0.0003146202293278236
NCT01169792,"Study of Cytochrome P450 Polymorphisms (CYP2D6, CYP3A4/5 and CYP2C19) in Breast Cancer Patients",0.0004827287424213841,0.000421373007256212
NCT01187381,An Observational Study of the Mean Duration of Herceptin (Trastuzumab) Treatment in Patients With Early or Metastatic HER2-positive Breast Cancer (HERODOT),0.0003482265466025184,0.0003182859833785525
NCT01190566,PET-MR for Prediction and Monitoring of Response to Neoadjuvant Chemotherapy in Breast Cancer,0.00026997390857704315,0.0002738644673162992
NCT01190345,Anti Cancer Stem Cell Activity of Pre-operative Bevacizumab and Chemotherapy in Breast Cancer,0.00025285973874816526,0.0003404287376849551
NCT01175694,Dose Optimization for Pulsed-dose-rate (PDR)/High-dose-rate (HDR) Brachytherapy Alone for Early Breast Cancer,0.0002740450512992301,0.0002636877665069139
NCT01149083,Veliparib With or Without Carboplatin in Treating Patients With Stage III-IV Breast Cancer,0.00031090557180517747,0.00036092544706377045
NCT01181518,Tamoxifen Pharmacogenetics in Asian Breast Cancer Women,0.0004700563493012497,0.00040247189721461386
NCT01126190,Neugranin in Breast Cancer Patients Receiving Doxorubicin/Docetaxel (NEUGR-003),0.00031699772333784124,0.0002582708966317268
NCT01120158,Paclitaxel Plus Bevacizumab for Older Patients With Breast Cancer,0.00035806995949147675,0.00038911662195708437
NCT01120171,Myocet Plus Endoxan for Older Patients With Breast Cancer,0.00034537557953123754,0.0003459635188558867
NCT01106820,Progressive Resistance Training Versus Relaxation for Breast Cancer Patients During Chemotherapy: Biological Mechanisms and Effects on Fatigue and Quality of Life,0.00030479906541624915,0.0002512433639009495
NCT01140282,Exercise Program for Early Breast Cancer Survivors,0.00033682430248143053,0.00036158746192058345
NCT01140776,Clinical Evaluation of OSNA Breast Cancer System in Breast Cancer Patients Receiving Neoadjuvant Therapy,0.00035972306890566535,0.00030816644074871266
NCT01140763,Clinical Evaluation of Tissue Sampling Bias in Histologic Evaluation of Sentinel Lymph Nodes in Breast Cancer,0.00024389592587133256,0.00026617579493638555
NCT01171508,Circadian Disturbances After Breast Cancer Surgery,0.0004894700069833956,0.000273558815869449
NCT01171417,A Treatment With Fulvestrant and Exemestane in Postmenopausal Patients With Advanced Hormone Receptor-Positive (HR) + Breast Cancer,0.0003401699090907909,0.00026608557812281573
NCT01155063,Evaluating The Safety Of Exemestane Following 2-3 Years Of Adjuvant Tamoxifen Therapy In Postmenopausal Early Breast Cancer Patients,0.0003288779590623033,0.0002797520274119733
NCT01127373,Multi-Beam Intensity-Modulated Radiation Therapy for Node-Positive Breast Cancer,0.00024616303691785385,0.000282668887958328
NCT01127763,RAD001 Plus Carboplatin in Breast Cancer Patients,0.0004277641276355019,0.0004292059284881225
NCT01127295,Pharmacology of Adjuvant Hormonotherapy in Breast Cancer,0.0008829212022672371,0.00045895377127551514
NCT01159405,The Study of Biodistribution and Dosimetry of 99mTc-Glycopeptide(99mTc-GP) in Patients With Breast Cancer,0.0003908090955683192,0.00043025913731144103
NCT01159236,Molecular Triaging of Newly Diagnosed Breast Cancer,0.000337151224159934,0.0003899774025541762
NCT01154972,Preoperative Localisation of the Sentinel Lymph Node in Breast Cancer,0.0004642105292565841,0.0003097361307085575
NCT01189851,Intraoperative Radiotherapy for Early Stage Breast Cancer,0.0003433263758760332,0.00021094384750931078
NCT01116713,Effect of Dexamethasone in Postoperative Symptoms After Mastectomy for Breast Cancer,0.00027421279478989977,0.0003020661528814781
NCT01153035,Excision Followed by Radiofrequency Ablation for Breast Cancer,0.0003286928454533678,0.000280613872609225
NCT01153282,Physical Functional Side Effects of Taxane Chemotherapy for Breast Cancer,0.00025771727848463295,0.00021088043048681383
NCT01194427,A Study of Vorinostat and Tamoxifen in Newly Diagnosed Breast Cancer,0.0002946830671127823,0.00035776211512701536
NCT01194869,Preoperative Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Early Stage Breast Cancer,0.0002580089680202228,0.00036315308679221107
NCT01142778,A Study of Avastin (Bevacizumab) Added to Herceptin (Trastuzumab) Plus Docetaxel in the Neoadjuvant Setting in Patients With Early Stage HER2-Positive Breast Cancer,0.00034722733760101694,0.00034350458409826846
NCT01142661,Compassionate Use of Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Marketed Therapies,0.0002774496472662624,0.0003356850282433535
NCT01142141,Manual Therapy in Postoperative Breast Cancer,0.0004603590742105769,0.00019567524758976328
NCT01142479,Compound Herbal Formula (TPE-1) for Leukopenia and Cancer-related Fatigue in Breast Cancer Patients With Radiotherapy,0.0002934214814489469,0.0003181470382264049
NCT01148875,Mammography Reminders for Encouraging Women to Undergo Regular Mammography Screenings for Breast Cancer,0.00033017836450451585,0.00021763083843552282
NCT01172886,Metabolic Syndrome as Modifiable Risk Factor for Breast Cancer,0.00032851153780150306,0.00023519472865861263
NCT01172223,Primary Chemotherapy in Patients With HER2-positive Early Breast Cancer,0.0004522424875898522,0.00029273680273707477
NCT01196052,"A Study of Trastuzumab Emtansine (T-DM1) Sequentially With Anthracycline-based Chemotherapy, as Adjuvant or Neoadjuvant Therapy for Patients With Early Stage Herceptin (HER)2-positive Breast Cancer",0.0003487309447218644,0.0003334908982215219
NCT01196936,Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors,0.00027336712810523676,0.00032007510372203954
NCT01164930,Impact of Acceptance and Commitment Therapy on Early Stage Breast Cancer,0.0003427468263320214,0.000278174197061581
NCT01132664,Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast Cancer,0.00040267204588663994,0.0004322218235537908
NCT01141868,Evaluating an Internet-based Intervention for Insomnia in Breast Cancer Survivors,0.00033482163618466166,0.0002918961051930593
NCT01141530,Deep Sequencing of the Breast Cancer Transcriptome,0.0003281439513328424,0.0002482648034532377
NCT01138553,Preoperative Testing of the Anti-Progesterone Mifepristone in Early Stage Breast Cancer,0.00028353690651307715,0.00031850961872171104
NCT01138345,Biomarkers in Blood Samples From Older Breast Cancer Survivors,0.0003359638952202497,0.00032367948781647493
NCT01130259,"An Open-Label, Expanded Access Protocol of Iniparib Breast Cancer",0.000273864620605133,0.0003247345524179585
NCT01160718,Fulvestrant With or Without AZD6244 in Treating Patients With Advanced Breast Cancer That Progressed After Aromatase Inhibitor Therapy,0.0003377278556409002,0.00033461445404486524
NCT01177124,Mindfulness-Based Stress Reduction (MBSR) Symptom Cluster Trial for Breast Cancer Survivors,0.00024898130815841546,0.00026556700466739736
NCT01197456,Predictors of Ovarian Insufficiency in Young Breast Cancer Patients,0.00042429556837167746,0.0003793062632382208
NCT01108224,Psychotherapy to Patients With Primary Breast Cancer - Psycho-social and Survival Outcome From a Randomised Trial,0.00042402168164967075,0.00037541060016287763
NCT01191164,Pilot Study of Partial Breast Irradiation Utilizing Permanent Breast Seed Implant to Treat Breast Cancer,0.00027296051785347645,0.00038069557906885576
NCT01191580,Interpersonal Therapy for Depression in Breast Cancer,0.0003648090208327064,0.00023835932342510497
NCT01122342,Vaginal Testosterone Cream For Atrophic Vaginitis in Women Taking Aromatase Inhibitors for Breast Cancer.,0.00023796954157754115,0.0002973602483801006
NCT01192308,PharmacoKINEtics of TAMoxifen and Its Metabolites in Breast Cancer Patients: the Influence of a Dose Increase in Phenotypic Poor Metabolizers of CYP2D6 (KINETAM),0.00030855228411989604,0.0003449588836233747
NCT01121549,A Non-Interventional Study With Aromasin® As Adjuvant Treatment Of Invasive Early Breast Cancer,0.0002967840364604188,0.0003098121679008215
NCT01151215,Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer,0.00030137319513614744,0.0003151676448700731
NCT01151488,"Nutrition, Exercise, and Breast Cancer Survivorship",0.0003327688661654361,0.0002420412167271834
NCT01151046,Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer,0.00026573120900282287,0.0002493303904240203
NCT01134172,"Ethnic Differences in the Impact of Breast Cancer on Employment Status, Financial Situation, and Quality of Life",0.00027446937169347776,0.00029403549421182646
NCT01111201,"International Travel Patterns and Risk Behaviour of Breast Cancer, Lymphoma Patients and Bone Marrow Transplant Recipients",0.00030830860738386036,0.00027148700772438114
NCT01137136,Aromatase (CYP19) Polymorphism Between AI-responsive and AI-resistant Breast Cancer in Korea,0.0003286071411892229,0.0002788033134505824
NCT01152398,A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Breast Cancer After Adjuvant Therapy,0.00028615554554362423,0.00028836799129416474
NCT01152606,A Study of Cardiac Safety in Patients With HER2 Positive Early Breast Cancer Treated With Herceptin,0.00032991114526704357,0.0002825527077407174
NCT01144572,Quality of Life in Chinese Postmenopausal HR(+) Early Breast Cancer (EBC) Patients During Adjuvant Aromatase Inhibitors(AIs) Treatment,0.00032733787705432004,0.0003878952233195782
NCT01144481,Risk Factors for Skeletal Related Events in Breast Cancer Patients Receiving Bisphosphonates for Bone Metastases,0.0002876676969077804,0.00027242003012509567
NCT01157767,Exercise Program of Breast Cancer Patients Undergoing Chemotherapy With or Without Radiation,0.0003220487851920647,0.0003364844215916203
NCT01157026,A Pilot Clinical Trial With Tocotrienol on Breast Cancer,0.00033165348775520244,0.00024407632116458895
NCT01157130,Breast Cancer Patients: A Breast Cancer Rehabilitation and Exercise Laboratory,0.00031240161927223594,0.0003440841863641212
NCT01180335,Standard Neoadjuvant Chemotherapy Versus Genomic Driven Chemotherapy in Patients With Breast Cancer,0.00031974579335014087,0.0003851053829421559
NCT01166763,Modulation of Breast Cancer Risk Biomarkers by High Dose Vitamin D,0.0002820078353130224,0.0001984816282127584
NCT01156168,Biomarkers in Tissue Samples From Patients With Breast Cancer Treated With Bevacizumab,0.0003181618939816711,0.0004289998680021119
NCT01156753,A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer,0.0003684088795421933,0.0003676584294190975
NCT01156961,A Study of The Safety Profile of First-line Avastin (Bevacizumab) in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Her2-negative Breast Cancer (AVATAX),0.00033096046600136303,0.00032530583629804613
NCT01104935,Evaluation of Trastuzumab Without Chemotherapy as a Postoperative Adjuvant Therapy in HER2 Positive Elderly Breast Cancer Patients,0.00031565105147869106,0.00027284663558652697
NCT01104571,Trastuzumab or Lapatinib Ditosylate in Treating Women With Early Breast Cancer,0.00034367785204759174,0.00031914592546398123
NCT01186367,Trial Comparing the Effects of Linear Versus Nonlinear Aerobic Training in Women With Operable Breast Cancer,0.0004629595373387834,0.00031615163803549686
NCT01112826,Efficacy of Capecitabine Metronomic Chemotherapy to Triple-negative Breast Cancer,0.0002814894789904306,0.00033226537980781784
NCT01112839,Reducing Breast Cancer Recurrence With Weight Loss,0.00033174510614709674,0.00018158993990724132
NCT01112254,Evaluation of the Diagnostic Performance of MRI±Biopsy to Optimize Resection of Ductal Carcinoma In Situ (DCIS) Breast Cancer,0.0002595665399472648,0.000434856895082101
NCT01170143,"Efficacy and Safety Study of Trastuzumab, Paclitaxel and Carboplatin on HER2+ Preoperative Breast Cancer",0.0003041569928627321,0.0003625346572630468
NCT01110954,Fluorescence-guided Resection in Breast Cancer,0.0004617432943411507,0.0004368733857240067
NCT01162200,Cyberknife® Partial Breast Irradiation (PBI) for Early Stage Breast Cancer,0.00028388285217546003,0.0002299408963245548
NCT01199432,"Comparative Efficiency of Three Regimen, CEFci, CEF and EC as Neoadjuvant Chemotherapy for Primary Breast Cancer",0.0003087618527673731,0.00034885542783794543
NCT01118975,GCC 0845:Vorinostat and Lapatinib in Advanced Solid Tumors and Advanced Breast Cancer to Evaluate Response and Biomarkers,0.0002649254626144348,0.0002975615021417727
NCT01118624,Study of Pralatrexate in Female Patients With Previously-treated Breast Cancer,0.00034675885956181085,0.0003826407178486301
NCT01147016,Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery,0.00027694643940174944,0.00026081882978516344
NCT01182519,Lung Inflammation and Lung Metastases From Breast Cancer,0.00032750551540277256,0.00023486436580980955
NCT01182506,Rehabilitation of Cognitive Changes in Breast Cancer Survivors,0.0003282246049864109,0.0002615643433196284
NCT01185509,Trastuzumab and Vinorelbine in Advanced Breast Cancer,0.0003109086748475496,0.0003792653889082132
NCT01185132,Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy,0.00025325666309827804,0.00023623360417909377
NCT01105468,Breath Gas Analysis for the Diagnosis of Breast Cancer,0.00027818041718903543,0.00027422732945802135
NCT01176838,A 5 Year Follow-up on Newly Diagnosed Breast Cancer Patients,0.0004324054994519446,0.0003335106443906981
NCT01113554,Breast Cancer Rehabilitation Program in Improving Quality of Life in Breast Cancer Survivors,0.0002781538168810836,0.0003345346191872545
NCT01136369,Clinical Evaluation of OSNA Breast Cancer System to Test Sentinel Lymph Nodes From Patients With Breast Cancer,0.00031077720879623007,0.00031695363438613127
NCT01114464,Impact of Chemotherapy on Ovarian Reserve in Young Women With Breast Cancer,0.00035717756220377466,0.000325480693630191
NCT01101438,A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer,0.0002615326797813744,0.00032663197854863863
NCT01143974,Trial of Pemetrexed in Combined With Cisplatin for the Treatment of Advanced Breast Cancer,0.00029302978218965386,0.0002539842458801338
NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,0.0002652156045376673,0.0002524309114702246
NCT02089100,Trial of Superiority of Stereotactic Body Radiation Therapy in Patients With Breast Cancer,0.00042402168164967075,0.0003193813575037418
NCT02057029,Assessment of the Decision-making Impact of the Breast Cancer Index in Recommending Extended Adjuvant Endocrine Therapy for Patients With Early Stage ER-positive Breast Cancer,0.00030368504191699954,0.00022816584941579644
NCT02057133,A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread,0.00031676646815449375,0.00032792612088957366
NCT02057536,The Effect of an Exercise Program in Breast Cancer Patients With Joint Pain While Taking Aromatase Inhibitors.,0.00030032218997609454,0.00034485035337384967
NCT02000193,Maintenance Hormone Therapy for Postmenopausal HR Positive Advanced Breast Cancer,0.0002926012523707211,0.00038175666417015553
NCT02086578,Study Assessing the Potential for Reduced Rates of Implant Failure Using Multi-Beam Intensity-Modulated Radiation Therapy for Locally Advanced Breast Cancer Patients With Implant Reconstructions,0.0003293357128491442,0.0003492341373218955
NCT02017496,Safety of Breast Conserving Treatment in Locally Advanced Breast Cancer Receiving Neoadjuvant Treatment,0.0003075374648958896,0.00042015407165018346
NCT02022202,Breast Cancer Genome Guided Therapy Study (BEAUTY),0.0003460003455374039,0.00036305969230919803
NCT02022579,DCE-MRI and DWI for Detection and Diagnosis of Breast Cancer,0.00027913573333049286,0.00024283343043928678
NCT02068092,Olive Oil for Breast Cancer Prevention in Women at High Risk for Breast Cancer,0.00033308501771875035,0.0002748216761141245
NCT02054338,A Study of Vinflunine Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine in Patients With Advanced Breast Cancer,0.00034222299550791795,0.0003357240485353428
NCT02009150,Evaluation of a Novel Infra-red Breast Imaging System for Risk Assessment in Women at High Risk for Breast Cancer.,0.0002507048984537461,0.0002972832348594706
NCT02001506,Neoadjuvant Chemotherapy of 6 Cycles vs 8 Cycles in Node Positve Breast Cancer,0.0003101284281257924,0.00028725439980612497
NCT02066025,Blood Test for Breast Cancer Associated Auto Antibodies - Improvement of Octava Blood Test,0.00027225964272954446,0.00021146251861871328
NCT02046421,"Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer",0.00029981617892381045,0.00040271294997366153
NCT02046057,Evaluation of Needle Core Biopsy of Axillary Sentinel Lymph Node in Breast Cancer,0.0002428585710261134,0.00028253585585916115
NCT02062983,Early Predictor of Herceptin Cardio Toxicity in Breast Cancer Patients,0.00035039806513142535,0.00021551162666667796
NCT02062489,"Evaluation of Tamoxifen's Efficacy for ER/PR Negative,ER-beta Positive Operable Breast Cancer Patients",0.00031314722613973406,0.00037675502944487714
NCT02028221,Phase II Study of Metformin for Reduction of Obesity-Associated Breast Cancer Risk,0.00028682263336458154,0.0003089852022730613
NCT02024074,Evaluation of Magnetic Resonance Imaging (MRI) vs Molecular Breast Imaging (Tc-MBI) in Breast Cancer Patients,0.0003160955190108034,0.00031366573467407226
NCT02094495,Pilot Study About Tamoxifen Therapy for Breast Cancer Patients,0.000375211543605514,0.0003832504299014334
NCT02015676,A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Metastatic or Locally Advanced Breast Cancer,0.000349446400258288,0.00033391127479977007
NCT02031042,Sentinel Node Biopsy Before and/or After Neoadjuvant Chemotherapy in Breast Cancer,0.00030865037136702144,0.00029194475806754736
NCT02041338,Study of Optimizing Neoadjuvant Regimens in Subtypes of Breast Cancer,0.00033247432889601587,0.0004079267063003112
NCT02041364,Biomarkers of Fatigue Related to Adjuvant Chemotherapy for Breast Cancer,0.0002585066260349758,0.00033570098126386294
NCT02091765,RCT of an Internet-based CBT Program for Sexuality and Intimacy Problems in Women Treated for Breast Cancer,0.0003322940523417547,0.0004004249886033293
NCT02091960,"A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Subjects With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer",0.0002979609048563176,0.0003592269861243442
NCT02053597,TRIal evalUating the Menstrual and Ovarian Function of Young Breast Cancer Patients Treated With a cycloPHosphamide-free Regimen,0.0002938268333385844,0.00024333877791006347
NCT02011880,Standardization Research of TCM Syndrome Differentiation and Treatment on Advanced Breast Cancer,0.000292269437147199,0.00033988308475733486
NCT02078531,A Prospective Pilot Study to Evaluate the Effect of Systemic Adjuvant Therapy on the Cognitive and Brain Function of Breast Cancer Patients,0.0003256507178560719,0.00031848345409517514
NCT02078570,Breast Cancer Biomarker Sample Collection for the dtectDx v2 Assay Proof of Concept Protocol,0.00024057472471389357,0.00029348046233189856
NCT02078388,Correlation Between Genetic Variants and Long-term Cardiac Effects Induced by Doxorubicin in Breast Cancer Patients,0.0003129176495371906,0.00030927528297876815
NCT02060253,"Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer",0.0002564361046801932,0.0002923453936241265
NCT02065908,Circulating MicroRNA as Biomarker of Cardiotoxicity in Breast Cancer,0.0003360524593667811,0.00024936139508479927
NCT02065960,Feasibility Study of Stereotactic Body Radiotherapy for Early Breast Cancer,0.0003287777955450411,0.00035578506706022457
NCT02018458,Safety Study Of Chemotherapy Combined With Dendritic Cell Vaccine to Treat Breast Cancer,0.000338258173824332,0.00031400683193920094
NCT02056886,Medico-economic Study of Three Strategies of Sentinel Lymph Node Analysis in Operable Breast Cancer,0.00031922692150503193,0.0003011944148751504
NCT02056483,REBECCA - Research in Rehabilitation After Breast Cancer,0.00046131026299451575,0.00028091418384380915
NCT02079662,The Role of Lifestyle Factors in Breast Cancer-Related Outcomes,0.0003332400532500922,0.0002899924991031362
NCT02048059,ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases,0.00042709534318825906,0.0004964596003560226
NCT02081612,Comparison of Nutrition Education Alone or With Acupuncture for Weight Loss in Breast Cancer Patients Post-Chemotherapy,0.00030121443125699784,0.0003009340623085136
NCT02080390,Strain Imaging in Breast Cancer Patients Receiving Trastuzumab,0.00032170717581350743,0.0003433966178093175
NCT02004496,Randomized Controlled Single-blind Trial to Evaluate the Mobile Tracking of Symptoms in Ambulatory Breast Cancer Patients,0.0002895387576640047,0.0003117217618581981
NCT02008734,Randomized Phase II Study to Assess PD 0332991 in Breast Cancer,0.00039090625676167724,0.00037173979114097993
NCT02005926,The Accuracy of Sentinel Node Biopsy of Breast Cancer With Sonographic Abnormal Axillary Lymph Nodes,0.0002738152300656496,0.00027083991251763685
NCT02005549,A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Primary Breast Cancer,0.0003414864469506899,0.00037343807410866357
NCT02005770,Anesthesia and Circulating Tumor Cells in Breast Cancer,0.00032850550457618025,0.00020367853967376203
NCT02027818,Study of the ICG Distribution in the Margins of Breast Cancer After Tumorectomy,0.0003863017342748149,0.00033450674420419196
NCT02027376,Study With LDE225 in Combination With Docetaxel in Triple Negative (TN) Advanced Breast Cancer (ABC) Patients,0.00034929261296252103,0.0004980462492898528
NCT02037542,A Study of Lifestyle Intervention in Overweight or Obese Women With Early Stage Breast Cancer,0.00028365642095954524,0.00029143051008306896
NCT02037269,LightPathTM Imaging System for Ex-vivo Assessment of Margin and Lymph Node Status in Breast Cancer Surgical Specimens,0.0002494425766767424,0.00028148130085509717
NCT02051010,ABC Survey - do we Meet the Needs of Patients With Advanced Breast Cancer?,0.0003717087364397264,0.00036450014504510724
NCT02051751,A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer,0.0002944504213822133,0.0003748009888436358
NCT02058758,Quantitative Methods for Supplementing Contrast-Enhanced Magnetic Resonance Imaging of Breast Cancer,0.00024754098515730825,0.00015750500592071442
NCT02058667,Reirradiation With Concurrent Paclitaxel for Breast Cancer,0.00033913226553961587,0.0003303805200636471
NCT02010021,Presurgical Treatment With Letrozole in Patients With Early-stage Breast Cancer.,0.00034822866780126943,0.00037580409775840975
NCT02073045,Intensive Education in Increasing Understanding of Lymphedema in Patients With Breast Cancer Undergoing Surgery,0.0003065651200352704,0.00029127194160182197
NCT02050620,Self-Reported Exercise Behavior and Short-Term Patient Outcomes in Women Undergoing Radiation Treatment for Operable Breast Cancer,0.0002954947069957803,0.0003099850468836146
NCT02088710,Expectations and Side Effects of Endocrine Therapy in Women With Breast Cancer,0.00033605949146260725,0.0003391724270080192
NCT02088684,Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer,0.00034570761239687166,0.0002888818184281552
NCT02007512,Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer,0.0003438650498591139,0.00039900760284566276
NCT02095210,HER2 PET Imaging in Breast Cancer Patients Using [68GA]ABY-025,0.00035301707372728617,0.00032840446801568835
NCT02095743,Tolerance of PICC Line Versus Implanted Port for Adjuvant Chemotherapy in Early Breast Cancer,0.00023672972565651847,0.0003208911792843743
NCT02077569,AKT Inhibitor in Oestrogen Positive Breast Cancer,0.00028388573668612714,0.0002689844735877536
NCT02077933,"Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors",0.00033417766748648027,0.00033956693191560693
NCT02097459,Prognostic Evaluation of Changing Endocrine Therapy in Women With Breast Cancer,0.00025787221160612577,0.00026760093314597065
NCT02067416,PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer,0.00048803779357314917,0.00034678600375523383
NCT02067884,Contrast Enhanced Ultrasound and Shear Wave Elastography in Measuring Response in Patients With Breast Cancer Receiving Chemotherapy Before Surgery,0.00031102578710546044,0.0003489432157616533
NCT02067481,Effect of a Diet and Physical Activity Intervention in Breast Cancer Survivors,0.0002580333350659724,0.00027949213439546774
NCT02067351,Mindfulness-Based Intervention in Breast Cancer Patients Undergoing Chemotherapy,0.00033216914568391366,0.00025655981250980315
NCT02067741,CR1447 in Endocrine Responsive-HER2neg and TN-ARpos Breast Cancer,0.0008829212022672371,0.0004084270954409219
NCT02032823,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,0.0003103486544276905,0.00030909853571796505
NCT02084784,Application of Surgical Navigation System in Sentinel Lymph Node of Breast Cancer Research,0.00028938126207477194,0.0003056452952433927
NCT02030353,The Use of Smart Scales for Weight Gain Prevention in African American Breast Cancer Survivors,0.0002745199065622226,0.0002745429089221023
NCT02072512,The Study of Goserelin Plus Fulvestrant Comparing With Goserelin Plus Anastrozole for Advanced Breast Cancer,0.00029328617861816266,0.00036661221477027263
NCT02069093,"Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer",0.0002934630789611751,0.0002906534249239275
NCT02040935,A Study of Subcutaneous Herceptin (Trastuzumab) Administered at Home By Single-Use Injection Device in Patients With Early HER2-Positive Breast Cancer (HOMERUS),0.0003221246996977334,0.0002920924096639043
NCT02040493,Intra-Operative Radiation Therapy Immediately Following Resection of Early Stage Breast Cancer,0.000294579739334752,0.0003168750868001756
NCT02063893,Safety Study of Cancer Stem Cell Vaccinie to Treat Breast Cancer,0.0002724404406549418,0.0002389777534990873
NCT02063906,Prognostic Relevance of Biological Subtype in Breast Cancer,0.0003287877341891559,0.00034499107760159106
NCT02059876,Dose-dense (Biweekly) Carboplatin Plus Paclitaxel With or Without Trastuzumab as Neoadjuvant Treatment for Breast Cancer,0.0002634803066963261,0.00039484850151480614
NCT02076074,Single Fraction High-Gradient Partial Breast Irradiation in Treating Patients With Low-Risk Stage 0-I Breast Cancer,0.0002938466852381924,0.00035925614996276656
NCT02023008,Interactive Gentle Yoga in Improving Quality of Life in Patients With Stage I-III Breast Cancer Undergoing Radiation Therapy,0.00031174468090079406,0.0003689157334631565
NCT02002533,Brief Behavioral Therapy in Improving Sleep Disorders in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy,0.0003164301430177329,0.0003545576032180097
NCT02003209,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",0.0003225316816787435,0.00040601893178362835
NCT02003599,Laser InGaAlP (660Nm) to Prevent Radiodermatitis in Breast Cancer Patients Submitted to Radiation Therapy,0.0003001423449041264,0.000354031381633496
NCT00938171,Comparing Local Anesthesia With General Anesthesia for Breast Cancer Surgery,0.0002867101234598785,0.0005203139919981894
NCT00999557,Bimatoprost Ophthalmic Solution in Increasing Eyebrow and Eyelash Growth in Patients Who Have Undergone Chemotherapy for Breast Cancer and in Healthy Participants,0.0002992940341563328,0.0002333260385142338
NCT00999921,Effects of Tamoxifen in Premenopausal Women With Benign Breast Disease Not at High-Risk of Developing Breast Cancer,0.00025623316705546936,0.000303520144883053
NCT00959244,Study of Urine Samples From Women With Newly Diagnosed Breast Cancer Enrolled on Clinical Trial UNMC-08105,0.0002774743991799086,0.00035183764334435676
NCT00959556,Study of Blood Samples in Patients With Breast Cancer,0.00039154258962557833,0.00038785464818134435
NCT00959985,Early Detection and Intervention for Mild and Moderate Lymphedema in Patients Treated for Breast Cancer,0.00029077740216242406,0.00032070102115428455
NCT00902668,Lovastatin in Reducing Side Effects After Radiation Therapy in Women With Breast Cancer,0.000283058045754176,0.00025129261968943824
NCT00902954,Study of Exemestane After Anastrozole or Letrozole Treatment of Postmenopausal Women With Hormone Responsive Breast Cancer,0.0002982713905178054,0.00030624395210566714
NCT00902330,Cranial Stimulation for Chemotherapy Symptoms in Breast Cancer,0.00026550081523364573,0.00023861325517519048
NCT00964522,Trial of the Effectiveness of a Nurse Education and Care Program for Breast Cancer Patients Treated With Chemotherapy,0.0003125091627693399,0.00033564885322244666
NCT00965939,An Observational Study to Assess Response to Tamoxifen in Breast Cancer Patients,0.0003354618559580525,0.00032056632656808865
NCT00965276,Relationship of pAKT to Survival in Patients With Node-Positive Breast Cancer,0.00032069394744991045,0.0003655791045206798
NCT00945607,Guided Relaxation Training for the Reduction of Self-Reported Stress in Individuals With Newly Diagnosed Breast Cancer,0.00023854441672187796,0.0003126432446078888
NCT00983684,Comparison of Intra-operative Radiotherapy With Post-operative Radiotherapy for Women With Early Breast Cancer,0.00034439192789683276,0.000282913618774318
NCT00955890,Dexrazoxane as a Protective Agent in Anthracycline Treated Breast Cancer,0.0002728064311298456,0.00021650917492472825
NCT00989638,A Multi Modality Surveillance Program for Women At High Risk for Breast Cancer,0.00024216005386827225,0.00033016307831258213
NCT00998738,Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast Cancer,0.00029154349340950055,0.0003747003589783902
NCT00917735,Green Tea and Reduction of Breast Cancer Risk,0.00032924468495026005,0.0001950777252851353
NCT00948285,Importance of Magnetic Resonance Imaging (MRI) in Treating Breast Cancer,0.0003286368213833965,0.00041326050697944495
NCT00918892,Assessment of Candidate Protein Expression in Breast Cancer Specimens,0.00025203369296921313,0.00034155533327864026
NCT00944047,Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression,0.00032253860222172033,0.0003779859423794157
NCT00992602,Liposomal Cytarabine and High-Dose Methotrexate in Treating Patients With Central Nervous System Metastases From Breast Cancer,0.00029417073817103283,0.0003477491233881457
NCT00950742,Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With Herceptin® in Patients With HER2-positive Advanced Breast Cancer.,0.0003115959311575629,0.00035063745958296413
NCT00950300,A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer,0.0002784729343566221,0.0003253060136559833
NCT00910884,"Natural Supplements and a Special Diet in Eliminating Cancer-impacting Hormones From Sources Outside the Body in Patients With Early-Stage or Remission Prostate Cancer, Breast Cancer, or Uterine Cancer",0.0002897860587774,0.0002396045923761793
NCT00927511,"A Study, Comparing a Dose-Titration Regimen of Fulvestrant With the Approved Dosing Regimen in Postmenopausal Patients With Hormone-Responsive Advanced Breast Cancer (ABC)",0.0003424571431538024,0.0003716024280822907
NCT00958971,Safety and Efficacy of TKI258 in FGFR1 Amplified and Non-amplified Metastatic HER2 Negative Breast Cancer,0.0002820518322591033,0.00026517213744943485
NCT00949247,"Docetaxel,Carboplatin,Trastuzumab and Bevacizumab for Breast Cancer and Bone Marrow Micrometastases",0.000246667469457365,0.000238338336104117
NCT00949598,Letrozole or Tamoxifen Citrate in Treating Older Postmenopausal Women Undergoing Surgery for Breast Cancer,0.0002754549148459283,0.00024972673592914984
NCT00949923,Green Tea in Breast Cancer Patients,0.0004241118429495974,0.00025195149519450393
NCT00949871,Study of Support Groups for African-American Breast Cancer Survivors,0.00032002408218303595,0.000377050798692988
NCT00935558,Dendritic Cell Based Therapy for Breast Cancer Patients,0.00037494975487575703,0.0003496026280279799
NCT00967824,Tamoxifen Citrate Decision Aids for Women at Increased Risk of Breast Cancer,0.00027421006117628067,0.00031000629565883215
NCT00904410,Early Assessment of the Response to Neo-adjuvant Chemotherapy in Breast Cancer Patients With FDG-PET,0.0003188831290303927,0.0003737528084157672
NCT00957125,A Translational Trial on Molecular Markers and Functional Imaging to Predict Response of Preoperative Treatment of Breast Cancer Early,0.00026562131009132454,0.0003340130819633194
NCT00934856,"A Study of Trastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Participants With Advanced Breast Cancer",0.000293941990755531,0.00031701455068319816
NCT00934401,Positron Emission Mammography With Fluorothymidine (FLT) to Evaluate Treatment Response to Chemotherapy in Breast Cancer,0.0002767064727752186,0.00028250532213202847
NCT00972400,Fatigue in Breast Cancer Survivors,0.0004663772083272083,0.00024310145592898745
NCT00926315,Gene Expression Profile of Breast Cancer Samples After Vitamin D Supplementation,0.0002479682403717157,0.0003007068978325206
NCT00929591,SWOG-8814 Tamoxifen With or Without Combination Chemotherapy in Postmenopausal Women Who Have Undergone Surgery for Breast Cancer,0.00027672526741362945,0.0002736875027287402
NCT00929214,Aggressive Local Therapy for Limited Bone-only Metastasis to Improve Progression-Free Survival in Breast Cancer Patients,0.0002824119365552543,0.0003655420748767437
NCT00993642,ERB-B4 After Treatment With HDAC Inhibitor in ER+ Tamoxifen Refractory Breast Cancer,0.00030496787699536626,0.00032548511908219184
NCT00933309,The Impact of Obesity and Obesity Treatments on Breast Cancer,0.0003650905167228222,0.0003724807851383317
NCT00933088,Adolescent Daughters' Response and Adjustment to Maternal Breast Cancer,0.00025094541823500504,0.0002758575485157887
NCT00933517,"Assessment of the Efficacy of the Neoadjuvant Combination: ""Chemotherapy-Targeted Therapy"" in Breast Cancer.",0.0002726362030872672,0.0003136391475435204
NCT00963417,Study of Bone Mineral Density in Women With Breast Cancer Treated With Triptorelin and Tamoxifen or Exemestane on Protocol IBCSG 25-02,0.000270720143567889,0.00028256266674800727
NCT00963729,Chemotherapy or Letrozole Before Surgery in Treating Postmenopausal Women With Breast Cancer That Can Be Removed By Surgery,0.00027832088353739676,0.0002799171612840428
NCT00963209,Tamoxifen Citrate in Patients With Breast Cancer,0.00042475336025672006,0.0002966015341215554
NCT00923377,Breast Stem Cells in Women at Average Risk and Increased Risk for Breast Cancer,0.0002527063044679503,0.00019017728350255705
NCT00971945,Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced Breast Cancer,0.00037581513157855176,0.00041559898417786766
NCT00915018,Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer,0.0003045187743643789,0.0003480888597286297
NCT00915369,"A Clinical Trial to Study the Effects of Nanoparticle Based Paclitaxel Drug, Which Does Not Contain the Solvent Cremophor, in Advanced Breast Cancer",0.00029063865904422286,0.00033104324969502556
NCT00906321,Facilitating Web-based Patient Decision Support: Decision About Medication to Lower Breast Cancer Risk,0.00029367065155109243,0.00034394429794021867
NCT00978913,Transfected Dendritic Cell Based Therapy for Patients With Breast Cancer or Malignant Melanoma,0.00033382592682594303,0.00037687254002465834
NCT00978770,MRI in Predicting Early Response to Chemotherapy in Patients With Locally Advanced Breast Cancer,0.00035297345220874503,0.00032156921473051864
NCT00940277,Couple-Focused Intervention for Breast Cancer Patients,0.00035068443371661696,0.00035175554016332036
NCT00900367,Nutrition-Related Biomarkers in Predicting Breast Cancer Risk in Women,0.00028090864848051946,0.00023041314234205826
NCT00900133,"Study of Calgranulin A/B Levels in Patients With Newly Diagnosed Stage I,II,III Breast Cancer",0.0003407247421209045,0.00030564527248562863
NCT00900627,Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II),0.00033015140389390697,0.0004486046263895687
NCT00977379,A Study of Whole Brain Radiation Therapy and Capecitabine in Breast Cancer Participants With Newly Diagnosed Brain Metastasis,0.0002826737394556474,0.0003205910342854005
NCT00921115,Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.,0.00026416144632722947,0.00030994729437161696
NCT00932997,Survivorship Booklets With or Without Individual Telephone Sessions in Increasing Knowledge About the Impact of Breast Cancer in African American and Latina Breast Cancer Survivors,0.00027165596162759736,0.00016797726463986689
NCT00932035,Axillary Lymph Node Preservation Surgery in Reducing Lymphedema in Patients With Breast Cancer,0.00030608168593167446,0.0003250229385518462
NCT00976339,Study of Vitamin D for Premenopausal Women at High Risk for Breast Cancer,0.00029191104699432077,0.00027867912172032554
NCT00976131,Study of CoQ10 During One Cycle of Doxorubicin Treatment for Breast Cancer,0.0003114997306186406,0.00036719370826965086
NCT00976989,A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer,0.0002963068844604744,0.0003014823760652145
NCT00931450,Sunitinib Malate and Exemestane in Treating Postmenopausal Women With Breast Cancer,0.0002873948117309479,0.00023451656131475402
NCT00968214,Study of Tumor and Blood Samples From Postmenopausal Women With Primary Breast Cancer Enrolled on Clinical Trial CAN-NCIC-MA27,0.00027754352385298984,0.0003541014402372451
NCT00954135,Letrozole Plus Oral Cyclophosphamide Plus/Minus Sorafenib as Primary Systemic Treatment in Breast Cancer Patients,0.00032257966982886975,0.00039873573190363324
NCT00912080,Utilization of Genomic Signature as Decision-making for Adjuvant Treatment of Breast Cancer,0.0003006561492741767,0.0003513955563494829
NCT00912444,"Neoadjuvant Treatment of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docetaxel and Cyclophosphamide (TC) in Triple-Negative or Her2 Positive Breast Cancer",0.00026081877366131715,0.0003086807760011734
NCT00908531,Trial of Endocrine Against Locoregional Therapy First in Postmenopausal Women With Early Breast Cancer,0.00038033099897390486,0.00029439835260049825
NCT00908791,Proof of Principle Trial to Determine if Nutritional Supplement Conjugated Linoleic Acid (CLA) Can Modulate the Lipogenic Pathway in Breast Cancer Tissue,0.0002479681921823456,0.00028440470898906416
NCT00981305,Impact of Lactate-Containing Vaginal Lubricant on Sexual Dysfunction in Young Breast Cancer Survivors,0.00027195255443134686,0.0004299272004142843
NCT00981812,Positron Emission Mammography (PEM) Biopsy Accessory for the Diagnosis of Breast Cancer,0.0002791578346811171,0.0002796960717691596
NCT00990977,Mindfulness and Cancer Mamma - Clinical Trial MBSR Among Women Operated for Breast Cancer,0.000255516386300487,0.00038424203305151543
NCT00984399,Serum Estradiol Levels In Postmenopausal Women With Breast Cancer Receiving Adjuvant Aromatase Inhibitors and Vaginal Estrogen,0.00024054149531023322,0.00024613791186117604
NCT00909506,Efficacy and Safety of Adjuvant Metformin for Operable Breast Cancer Patients,0.00042539250848793754,0.000365860752299645
NCT00909662,Fatigue Caused by Chemotherapy in Women Who Have Undergone Surgery for Breast Cancer and in Healthy Volunteers,0.00031145290844415783,0.00029161588137038396
NCT00909818,Hypofractionated Versus Standard Fractionated Whole Breast Irradiation to Node-negative Breast Cancer Patients,0.00029779536876134427,0.0003207897653462783
NCT00909441,Sentinel Node Biopsy Following NeoAdjuvant Chemotherapy in Biopsy Proven Node Positive Breast Cancer,0.00026309824286943314,0.00032314048606275046
NCT00909909,Radiation Therapy in Treating Women With Early Stage Breast Cancer,0.0003562493582650302,0.0002682813319396781
NCT00986609,MUC1 Vaccine for Triple-negative Breast Cancer,0.0003347879496826843,0.0002255798394462234
NCT00960401,A Study of Atherosclerosis in Patients After Radiation Treatment for Breast Cancer,0.0003557981064968106,0.0003170066952278725
NCT00914017,Statins and Breast Cancer Biomarkers,0.0003348652245789752,0.0002635218251833027
NCT00925652,"Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise After Preoperative Chemotherapy for Breast Cancer",0.00024149293058890416,0.00040454727743269845
NCT00922961,Research for Predictive Biologic Parameters of Cutaneous Hypersensitivity After Brachytherapy in Breast Cancer,0.00024688050820167106,0.0002790534474139538
NCT00916825,Effectiveness of a Rehabilitation Programme for Mothers With Breast Cancer and Their Children,0.00025077225628380756,0.0002481825230129932
NCT00916162,Drug Withdrawal in Women With Progressive Breast Cancer While on Aromatase Inhibitor Therapy,0.000303660472720882,0.00033510605220315624
NCT00991978,VEGF Early Imaging for Breast Cancer,0.00046747653717039923,0.0003219116981486056
NCT00991263,Study of Tissue Samples From Women Treated With Paclitaxel for Breast Cancer on Clinical Trial CALGB-9344 or CALGB-9741,0.0002962129093806367,0.0003559080338697995
NCT00996632,The Use of a High-frequency Ultrasonic Knife in Breast Cancer Surgery,0.0002621658611340814,0.00022500728476343478
NCT00911911,Proteomic Signature in Breast Cancer: Correlation With Tumor Response to Neo-adjuvant Chemotherapy,0.00027281468782779084,0.0003226808501803831
NCT00937989,Study of Barriers to Beginning and Finishing Treatment for Patients With Breast Cancer,0.00037089721752554377,0.0004211902731515119
NCT00903162,Extended Endocrine Therapy for Premenopausal Women With Breast Cancer,0.00028051134664920185,0.00032992165793441284
NCT00903006,"Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer",0.0002540442834756981,0.0003494002366972224
NCT00913016,"Assessment of Quality of Life, Bone Density and Safety in Postmenopausal Breast Cancer Patients With Letrozole Therapy",0.00032117825189465816,0.0003082913076823439
NCT00952679,Computed Tomography (CT) Based Lymphatic Mapping and Localization of Sentinel Lymph Node in Breast Cancer Patients,0.00029283364854110883,0.0002589213771779516
NCT00975676,Study of Estrogen Levels in Premenopausal Women Who Have Undergone Surgery for Breast Cancer and Are Receiving Triptorelin and Tamoxifen Citrate or Exemestane on Clinical Trial IBCSG 24-02,0.0002784203698306069,0.00027719485936251174
NCT00919880,Comparison of Neo-adjuvant Weekly Paclitaxel With or Without Carboplatin in Early Breast Cancer,0.0002856803674414955,0.00028827085590724837
NCT00956813,Flaxseed in Treating Postmenopausal Women With Hot Flashes Who Have a History of Breast Cancer or Other Cancer or Who Do Not Wish to Take Estrogen Therapy,0.0002387701280806999,0.00021328577324456827
NCT00038402,Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer,0.00026588068838945375,0.00038373215666990515
NCT00038467,Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer,0.0002664631193623315,0.00022203006615871142
NCT00071383,"Analysis of Brain Metastasis in Patients With Breast Cancer, With and Without Over-Expression of HER-2",0.00034894839174697543,0.00040146631172346687
NCT00022204,Vitamin E and Pentoxifylline in Treating Women With Lymphedema After Radiation Therapy for Breast Cancer,0.00025754385654514205,0.00023977723035893087
NCT00022074,Gabapentin For the Control of Hot Flashes in Women With Breast Cancer,0.0002730747107184313,0.00036245750235950193
NCT00022516,Low-dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-negative Early Breast Cancer,0.00024571459514320047,0.0002455598042906947
NCT00022087,"Zoledronate, Calcium, and Vitamin D in Preventing Bone Loss in Women Receiving Adjuvant Chemotherapy for Breast Cancer",0.00023790535180510106,0.00021108123767911785
NCT00093795,Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer,0.0002746369335653258,0.0002729132196157741
NCT00093002,Fulvestrant (FASLODEX™) as a Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer,0.00026969803073533124,0.00032068948974512887
NCT00093145,Study of Albumin-bound Paclitaxel (Abraxane) in Combination With Carboplatin and Herceptin in Patients With Advanced Breast Cancer,0.00033976469801746094,0.00037314449638586373
NCT00064857,Pycnogenol for the Treatment of Lymphedema of the Arm in Breast Cancer Survivors,0.00027307373316859455,0.0003561079603032264
NCT00028964,Combination Chemotherapy After Surgery With or Without Chinese Herbal Therapy to Treat Symptoms in Women With Breast Cancer,0.00026366748026334877,0.0003016653626852813
NCT00028704,Breast-Conserving Therapy Compared With Mastectomy Followed By Radiation Therapy in Treating Women With Locally Advanced Breast Cancer Previously Treated With Chemotherapy,0.000297122763929437,0.0003125404030566321
NCT00006459,Paclitaxel With or Without Gemcitabine in Treating Women With Advanced Breast Cancer,0.00030733548975162375,0.00038558800298797973
NCT00006421,Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Annual Follow-Up Study,0.00027233401254471754,0.0003088115188782338
NCT00006425,Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Menstrual Cycle Study,0.00027233401254471754,0.0002646476285587436
NCT00006225,Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic Cancer,0.00034623774568443,0.00033512336346919837
NCT00006825,Liposomal Doxorubicin and Trastuzumab in Treating Women With Advanced Breast Cancer,0.000309753266246643,0.0003234811533650122
NCT00006433,Phase I/II Trial of Doxil and Hyperthermia for Breast Cancer Patients With Chest Wall Recurrence or Stage IV Disease With Locally Advanced Breast Cancer,0.00030033281252511555,0.0003814026627942199
NCT00084669,Venlafaxine With or Without Zolpidem in Treating Hot Flashes and Associated Sleep Disorders in Women With Breast Cancer OR at High Risk for Developing Breast Cancer,0.00023923191881394335,0.00022231953423055886
NCT00066586,Exemestane in Reducing Breast Density in Postmenopausal Women at Risk for Breast Cancer,0.00028762809697371433,0.00027350040254129227
NCT00066573,Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast Cancer,0.00027435609290629915,0.00023992490008486504
NCT00066690,Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer,0.0002386656361526281,0.00027013220752357506
NCT00066703,Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer,0.00024401594133195196,0.0002133001371698684
NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,0.0003395923235321873,0.0003841793167106176
NCT00041353,Comparison of Biomarkers Based on Fine-Needle Aspiration in Women at Increased or Normal Risk of Breast Cancer,0.00024259020102978914,0.00023817096085186336
NCT00041223,IH636 Grape Seed Extract in Treating Hardening of Breast Tissue in Women Who Have Undergone Radiation Therapy for Early Breast Cancer,0.0002477333171945344,0.0002992291297658615
NCT00041652,Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer,0.00028474809298515623,0.00046542268971775253
NCT00087347,Magnetic Resonance Imaging of Lymph Nodes Using Ferumoxytol in Patients With Primary Prostate or Breast Cancer,0.0002926301786451097,0.0002781602506913395
NCT00087958,"Intravenous RPR109881 in Male or Female Patients With Advanced Breast Cancer Who no Longer Respond to Anthracycline, Taxane and Capecitabine Treatment",0.00032513661019996045,0.00029218044344489903
NCT00087178,Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer,0.00027918516038484743,0.000264844626441807
NCT00087399,Gabapentin With or Without Antidepressants in Treating Hot Flashes in Women Who Have Had Breast Cancer or Have Concerns About Taking Hormone Therapy,0.0002518148137151303,0.0002706464387374887
NCT00083304,"Whole Brain Radiation Therapy With Oxygen, With or Without RSR13, in Women With Brain Metastases From Breast Cancer",0.00024585902158012166,0.0003459581572858398
NCT00083148,Irinotecan and Capecitabine in Treating Women With Advanced Breast Cancer,0.00030257816575891106,0.0003016809283498712
NCT00083993,Study Evaluating CCI-779 and Letrozole in Post-menopausal Women With Breast Cancer,0.0002925131231001808,0.0003180421709277819
NCT00083174,Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer,0.00026303653595719135,0.0002584770305096001
NCT00083044,Ductal Lavage in Assessing Women With Early Breast Cancer or at High Risk of Developing Breast Cancer and Who Are Eligible For Tamoxifen Therapy,0.0002786159483578741,0.0002784655293492985
NCT00083018,"Nipple Aspiration, Ductal Lavage, and Duct Endoscopy For Diagnostic Assessment in Women Undergoing Surgery for Breast Cancer",0.0002478639410432976,0.0002532697697396405
NCT00033683,Combination Chemotherapy in Treating Women With Resected Breast Cancer,0.0003323503863436423,0.0002832894126262204
NCT00033345,Indole-3-Carbinol in Preventing Breast Cancer in Nonsmoking Women Who Are at High Risk For Breast Cancer,0.00033308501771875035,0.0003623225427864749
NCT00033397,Diagnostic Procedures in Women With Locally Advanced Breast Cancer Who Are Receiving Chemotherapy Before Breast Cancer Surgery,0.0002926817090910116,0.00038674928343075806
NCT00060138,Monoclonal Antibody Compared With Zoledronate in Treating Women With Breast Cancer and Bone Metastases,0.0002480923113448443,0.0002039466343471287
NCT00060320,Black Cohosh in Treating Hot Flashes in Women Who Have or Who Are At Risk of Developing Breast Cancer,0.00032901472265152497,0.0002880410775877199
NCT00016406,"S0012 Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Filgrastim in Treating Women With Inflammatory or Locally Advanced Breast Cancer",0.00026098041550361335,0.00026596867022399636
NCT00016549,Bevacizumab to Treat Inflammatory Breast Cancer or Locally Advanced Breast Cancer,0.00030139059287655234,0.0005409186709674727
NCT00010153,ICI 182780 in Treating Women With Stage I or Stage II Primary Breast Cancer,0.000346032161241602,0.000327853246428985
NCT00010140,Epirubicin and Tamoxifen With or Without Docetaxel in Treating Postmenopausal Women With Breast Cancer,0.00026748953565670686,0.0002659247402866229
NCT00015886,Combination Chemotherapy in Treating Women With Breast Cancer That is Metastatic or Cannot be Treated With Surgery,0.0002983089317550652,0.0004011535019663359
NCT00063934,Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer,0.0003146320260155078,0.0003051533178443751
NCT00078832,Anastrozole in Preventing Breast Cancer in Postmenopausal Women at Increased Risk of Breast Cancer,0.00028800064349152196,0.0002661854402148231
NCT00012129,Chemotherapy in Treating Patients With Breast Cancer,0.0004522424875898522,0.00040325709057008503
NCT00074139,"Docetaxel, Doxorubicin, and Cyclophosphamide in Treating Women With Advanced Breast Cancer",0.00028107108764945,0.0002788347575217819
NCT00074152,Adjuvant Chemotherapy in Treating Women Who Have Undergone Resection for Relapsed Breast Cancer; Chemotherapy as Adjuvant for LOcally Recurrent Breast Cancer,0.00025365056338462553,0.00028445608560996274
NCT00014222,Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer,0.00033244213786994567,0.0002978044366074067
NCT00014430,Chemotherapy Plus Trastuzumab in Treating Patients With Breast Cancer,0.00037895956975799724,0.000351695849144352
NCT00030758,Filgrastim or Pegfilgrastim in Preventing Neutropenia in Women Receiving Chemotherapy Following Surgery for Breast Cancer,0.00026405673515937845,0.00022677060069420938
NCT00030823,Vaccine Therapy in Treating Patients at High Risk for Breast Cancer Recurrence,0.00031473572692099146,0.0003085559378089031
NCT00049114,"Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer",0.0002752225394181198,0.00035836806039159284
NCT00049452,Zoledronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy After Surgery For Early Stage Breast Cancer,0.0002686395496960252,0.0002695503725467885
NCT00029224,"Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions",0.0003063203862962027,0.00027243754893610344
NCT00047099,Combination Chemotherapy in Treating Women With Breast Cancer,0.0004668872382305032,0.00030860979240035524
NCT00047255,Docetaxel and Trastuzumab With or Without Carboplatin in Treating Women With HER2-Positive Breast Cancer,0.00029340668811844896,0.0003251812123660013
NCT00047970,The Sister Study: Genetic and Environmental Risk Factors for Breast Cancer,0.0003186091030530504,0.0004489715206675571
NCT00081510,Anastrozole Plus Lonafarnib (SCH 66336) or Plus Placebo for the Treatment of Advanced Breast Cancer (P03480),0.00027969503511053107,0.0002681060265301566
NCT00081796,Breast Cancer Trial of RPR109881 Versus Capecitabine in Male or Female Patients With Advanced Breast Cancer,0.000376308892738116,0.00035480069460127115
NCT00081003,"Nipple Aspiration, Ductal Lavage, and Duct Endoscopy in Screening Women at Moderate-to-High Risk of Developing Breast Cancer",0.0002321760494540362,0.000215200320176824
NCT00081965,Acupuncture in Treating Hot Flashes in Women With Breast Cancer,0.000330786036189794,0.00027476687954949115
NCT00019643,Factors Affecting Weight Gain in Women Receiving Adjuvant Chemotherapy for Breast Cancer,0.0003307118097559055,0.00024033906094434156
NCT00019500,Raloxifene in Preventing Breast Cancer in Premenopausal Women,0.000331891146515503,0.00034689864496889394
NCT00003013,Chemotherapy Plus Surgery in Treating Women With Breast Cancer,0.0003752159374869133,0.00043049907450994155
NCT00003000,Morphine for the Treatment of Pain in Patients With Breast Cancer,0.0003337168692473953,0.00025286552376780366
NCT00003771,Hormone Replacement Therapy and the Risk of Breast Cancer Recurrence in Women With Previous Early Stage Breast Cancer,0.00028554046736092745,0.00024208996603029866
NCT00003165,Doxorubicin in Treating Women With Advanced Breast Cancer,0.0003664357711743919,0.00040856957012009475
NCT00003455,Antineoplaston Therapy in Treating Women With Advanced Breast Cancer,0.00032582579225195373,0.00029025319077851297
NCT00003678,Tamoxifen in Treating Women With Breast Cancer,0.0004700563493012497,0.00026042996751654795
NCT00003736,MRI for Detecting Cancer in Women Who Are at High Risk of Developing Breast Cancer,0.00033701111166588744,0.00034626987002774317
NCT00003440,"Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is Inoperable, Recurrent, or Metastatic",0.00033217886694638266,0.0003330419401834023
NCT00003519,Combination Chemotherapy in Treating Women With Breast Cancer,0.0004668872382305032,0.00030860979240035524
NCT00003099,Chemoprevention Therapy Plus Surgery in Treating Women With Breast Cancer,0.0003150542300882304,0.00035299151970099056
NCT00003140,Letrozole After Tamoxifen in Treating Women With Breast Cancer,0.00034343135016425106,0.0002397484463151127
NCT00003016,Prolonged Tamoxifen Compared With Shorter Tamoxifen in Treating Patients Who Have Breast Cancer,0.00035041894387605866,0.0002738571514965389
NCT00003830,Surgery to Remove Sentinel Lymph Nodes With or Without Removing Lymph Nodes in the Armpit in Treating Women With Breast Cancer,0.0002507792509050574,0.0002288831624790921
NCT00003428,Hormone Therapy in Treating Women With Breast Cancer,0.00047086475815400023,0.0002796717584187435
NCT00003679,Combination Chemotherapy in Treating Women With Breast Cancer,0.0004668872382305032,0.00028055036175983754
NCT00003357,Vaccine Therapy Plus QS21 in Treating Women With Breast Cancer Who Have No Evidence of Disease,0.0003302247267781949,0.00030977355837355925
NCT00003418,Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Primary Breast Cancer,0.00029237006715374125,0.00024041376931025526
NCT00003536,Methotrexate With or Without Antineoplaston Therapy in Treating Postmenopausal Women With Advanced Refractory Breast Cancer,0.0002856728005365892,0.0003100860107519119
NCT00003035,Doxorubicin and Paclitaxel in Treating Women With Locally Advanced Breast Cancer,0.00030984499804988025,0.0003209790814029583
NCT00003088,Combination Chemotherapy in Treating Patients With Breast Cancer,0.0004285047757591136,0.00030644182958560953
NCT00003086,Repeated Bone Marrow Transplantation in Treating Women With Advanced Breast Cancer,0.0002974134780268432,0.0003092503138501014
NCT00003012,Combination Chemotherapy Following Surgery in Treating Women With Early Stage Breast Cancer,0.0003020553073373048,0.0003395669412902553
NCT00003782,"Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes",0.000257789292676343,0.00028009562578608577
NCT00065533,Pemetrexed as First Line Chemotherapy for Advanced Breast Cancer,0.0002866289991586466,0.00036005683795070387
NCT00065325,The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer,0.00027312261842019607,0.0003708020846399517
NCT00096343,"Paclitaxel and Carboplatin in Treating Women Who Are Undergoing Surgery for Newly Diagnosed, Locally Advanced Breast Cancer",0.0002804126392848239,0.0003383513694485186
NCT00096369,Tamoxifen in Preventing Breast Cancer in Women at Increased Risk for Breast Cancer,0.00033635512154079114,0.0002717000652072395
NCT00096291,Neoadjuvant Chemotherapy Using Doxorubicin and Paclitaxel in Treating Women With Large Breast Cancer,0.00028639472848063224,0.0003090497911200358
NCT00096356,Coenzyme Q10 in Relieving Treatment-Related Fatigue in Women With Breast Cancer,0.00027580911846183167,0.0003101702573895364
NCT00088972,"S0300, Celecoxib in Preventing Breast Cancer in Premenopausal Women",0.00033239046855536666,0.0002945985488765375
NCT00088010,Effects of Arzoxifene on Bone Fractures and Incidence of Breast Cancer,0.0003276903393007503,0.000244663156909151
NCT00088829,Genetic Testing in Predicting Response to Paclitaxel in Women With Breast Cancer,0.0002864310940683291,0.000296042322662331
NCT00062400,Assessing Women's Attitudes About the Risk of Infertility Related to Adjuvant Therapy for Early Breast Cancer,0.000250798994012298,0.0002614109028281574
NCT00091442,A Study of Docetaxel Monotherapy or DOXIL and Docetaxel in Patients With Advanced Breast Cancer,0.0003506226138111964,0.0003811270864013285
NCT00008034,Combination Chemotherapy Before Surgery in Treating Women With Breast Cancer,0.0003514782256561748,0.00040873394670918884
NCT00008346,Screening and Diagnostic Trial to Compare the Effectiveness of Two Types of Mammography in Detecting Breast Cancer in Women,0.0002547268720356235,0.0003128039660783026
NCT00057993,Trastuzumab and Exemestane in Treating Postmenopausal Women With Metastatic or Locally Advanced Breast Cancer,0.0002805245949996419,0.00033516132129627555
NCT00094133,Hypnosis in Treating Hot Flashes in Breast Cancer Survivors,0.0003291561787297064,0.0003220391689517621
NCT00055991,Bexarotene in Preventing Breast Cancer in Women at Genetic Risk,0.0003290102368091696,0.0003346488504435679
NCT00040430,Study of 111In-DAC as a Medical Imaging Agent for the Detection of Breast Cancer,0.00028902718709819536,0.0003605137077537672
NCT00058526,A Dose-escalation Vaccine Trial in HER2-overexpressing Patients With High-risk Breast Cancer,0.00035009125731817487,0.0003276801211228407
NCT00053911,Combination Chemotherapy Compared With Observation After Surgery in Treating Women With Relapsed Nonmetastatic Breast Cancer,0.0002630334581598886,0.00028763259364830246
NCT00099281,DPPE in Combination With Epirubicin and Cyclophosphamide in the Treatment of Breast Cancer,0.00028358231367942905,0.00031337904327285776
NCT00099437,Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.,0.000269541040168889,0.0003418613158792397
NCT00079625,Stem Cell Transplant With Th2/Tc2 Cells to Treat Advanced Breast Cancer,0.00029896893486482616,0.00044269918670457293
NCT00039546,Combination Chemotherapy in Treating Women With Breast Cancer Who Have Undergone Surgery,0.0003514782256561748,0.0002875668513137643
NCT00039052,"Intravenous Interleukin-4 PE38KDEL Cytotoxin in Treating Patients With Recurrent or Metastatic Kidney Cancer, Non-Small Cell Lung Cancer, or Breast Cancer",0.000286114869441788,0.00032540673481851374
NCT00052676,Technetium Tc 99m Sulfur Colloid and Blue Dye In Detecting Sentinel Lymph Nodes in Patients With Breast Cancer,0.0002848878401162601,0.00024092602509957487
NCT00052169,Therapy With Docetaxel and ZD1839 for Patients Who Have Advanced Breast Cancer,0.0003380023616728043,0.00046723499226290023
NCT00048633,"Phase II Study to Evaluate Tariquidar (XR9576), a Selective MDR-1 Inhibitor, in Chemotherapy Resistant Advanced Breast Cancer",0.00029973674002931874,0.0003547378740578498
NCT00046865,Acupressure in Treating Nausea in Women Receiving Combination Chemotherapy for Breast Cancer,0.00027519572200982915,0.0002704886250200926
NCT00046891,EGb761 in Maintaining Mental Clarity in Women Receiving Chemotherapy for Newly Diagnosed Breast Cancer,0.0002562864576085247,0.00027450397410807805
NCT00027118,Morbidity After Diagnosis and Treatment of Breast Cancer Patients,0.0003382828489831167,0.00036616894071708143
NCT00027105,Morbidity Following the Diagnosis and Treatment of Patients With Breast Cancer,0.0003382828489831167,0.0003218977590928427
NCT00027131,Vaccination Against High Risk Breast Cancer Using Tumor Derived Heat Shock Protein 70,0.0002415603719419105,0.00029436645719825447
NCT00027885,Phase II Bevacizumab + Tax In Advanced Breast Cancer,0.0003668767357199657,0.00029335132741372777
NCT00045032,Trastuzumab in Treating Women With Primary Breast Cancer,0.00048375288864420873,0.00022889030355316694
NCT00072501,Breast Ultrasound and Mammography in Screening Women at High Risk for Breast Cancer,0.000243802659502357,0.00026028947170883137
NCT00072293,Surgical Resection With or Without Axillary Lymph Node Dissection in Treating Women With Node-Negative Breast Cancer and Sentinel Lymph Node Micrometastases,0.000247001651905286,0.0002338581806434425
NCT00021255,Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer,0.00034779779826029256,0.00022000386874335964
NCT00020098,Complementary or Alternative Medicine Practices Used by Women at Increased Risk for Breast Cancer,0.0002746346302398971,0.00023060220184191276
NCT00092950,Exercise in Women at Risk for Breast Cancer,0.00046717801519213396,0.0002498968949662364
NCT00051051,A Phase II Study of CI-1033 in Treating Patients With Metastatic (Stage IV) Breast Cancer,0.00033147667189064873,0.00030503294360292713
NCT00051779,An Investigational Drug (CAL) Versus Zoledronic Acid (Zometa®) in Patients With Breast Cancer,0.0003097846268165929,0.00030588969375279815
NCT00068601,S0230 Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer,0.00029345862321282577,0.00022083341168398126
NCT00068328,Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer,0.00030053826325092257,0.0002941358176810966
NCT00068614,HER-2 Protein Vaccine in Treating Women With Breast Cancer,0.00032932732266199665,0.0003390099915426545
NCT00068341,Docetaxel and Carboplatin With or Without Trastuzumab Before Surgery in Treating Women With Locally Advanced Breast Cancer,0.00028257020981643425,0.000270885416095158
NCT00036621,"A Randomized, Placebo-Controlled Trial of BMS-275291 Given Daily for 12 Months to Women With Stage 1c-IIIA Breast Cancer Receiving Adjuvant Chemotherapy and/or Hormonal Therapy",0.0002486382902439101,0.00021767128428945646
NCT00036985,Combination Chemotherapy With or Without Microwave Thermotherapy Before Surgery in Treating Women With Locally Advanced Breast Cancer,0.00028412328724443327,0.0002677155353411004
NCT00036686,Isoflavones in Treating Women Who Have Breast Cancer and Are Planning to Undergo Mastectomy or Lumpectomy,0.0002477002007270765,0.0002658136403299025
NCT00082433,Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer,0.0003162027321016184,0.00032903680378531527
NCT00082979,Duct Endoscopy in Assessing Cellular Atypia in the Breast Duct Fluid of Women With a Genetic Risk for Breast Cancer,0.0002287942176873747,0.0002199565278396104
NCT00082277,Anastrozole Biphosphonate Study in Postmenopausal Women With Hormone-Receptor-Positive Early Breast Cancer,0.0002891204296712776,0.0002949302382454886
NCT00002707,Chemotherapy in Treating Women With Breast Cancer That Can Be Surgically Removed,0.00030979951644028326,0.0002876054144240509
NCT00002784,High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Combination Chemotherapy in Treating Women With High-Risk Breast Cancer,0.00025474645268193266,0.00026923655675373487
NCT00002942,Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer,0.00031058643411597647,0.0002735272877315948
NCT00002455,"Immunotherapy After Surgery in Treating Patients With Breast Cancer, Colon Cancer, or Melanoma",0.00030378950185287756,0.0003119391420495261
NCT00002509,High-Dose Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Poor-Prognosis Breast Cancer,0.0002904433232151763,0.00035510089931754926
NCT00002934,Evaluation of Breast Cancer Recurrence Rates Following Surgery in Women With Ductal Carcinoma In Situ,0.000268168731336064,0.00036226453701938914
NCT00002837,High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer,0.00031540627204436117,0.000379640372813473
NCT00002529,Hormone Therapy and Chemotherapy in Treating Perimenopausal or Postmenopausal Women With Node-Positive Breast Cancer,0.0002679052496350975,0.00031461469682191496
NCT00002836,Filgrastim Plus Chemotherapy Compared With Filgrastim Alone In Treating Women Undergoing Peripheral Stem Cell Transplantation For Breast Cancer,0.00026700356089921215,0.0002941711294744445
NCT00002646,Hormone Therapy in Treating Postmenopausal Women With Receptor-Positive Breast Cancer,0.00030135042881681136,0.0003098378545006041
NCT00002755,Standard Chemotherapy Compared With High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer,0.0002589506406496514,0.0002918752582738386
NCT00002920,"S9630, Medroxyprogesterone in Treating Women With Breast Cancer",0.0004603590742105769,0.0002713444423770511
NCT00002460,Adjuvant Hormone Therapy in Treating Women With Operable Breast Cancer,0.00047086475815400023,0.000217935246027914
NCT00002662,Paclitaxel or Docetaxel in Treating Women With Advanced Breast Cancer,0.00031324734435536877,0.00037319958120909713
NCT00002772,"S9623, Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer",0.00033325924254602875,0.00027982763362605924
NCT00002967,"Octreotide, Tamoxifen, and Chemotherapy in Treating Women With Breast Cancer",0.0002980722079949712,0.0003523056484170365
NCT00002627,Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer,0.00032196244181726796,0.00033524874359695795
NCT00002616,Biological Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Breast Cancer,0.00033093782572348374,0.00034733558350529594
NCT00002498,Combination Chemotherapy Compared With Mitoxantrone in Treating Older Patients With Advanced Breast Cancer,0.0003332299411720783,0.00029798255816138584
NCT00002564,Nutrition Intervention in Treating Women With Breast Cancer,0.00046049742277737835,0.00030300670365127953
NCT00002679,"Adjuvant High-Dose, Sequential Chemotherapy in Treating Patients With Resected Breast Cancer",0.000329725852374638,0.0003683093334378123
NCT00002542,Tamoxifen in Treating Women With High-Risk Breast Cancer,0.00033903610329642585,0.0003285318522699481
NCT00005879,LY353381 in Preventing Breast Cancer in Women With Hyperplasia,0.0004603590742105769,0.0003630472523346112
NCT00005587,Radiation Therapy After Surgery in Treating Women With Early Stage Breast Cancer,0.00030900082094682146,0.00025043658902007174
NCT00005058,Enhanced Ultrasound in Determining Extent of Disease in Women With Primary Breast Cancer,0.00033070692588830293,0.00038609561591519117
NCT00005970,"Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer",0.00025475084079788795,0.0003198360052907338
NCT00005588,Radiation Therapy After Surgery in Treating Women With Early Stage Breast Cancer,0.00030900082094682146,0.00025043658902007174
NCT00005886,Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer,0.0003424367408081027,0.00029424191888514906
NCT00005054,Temozolomide in Treating Women With Advanced Breast Cancer,0.00036205524228936735,0.00042786990828406243
NCT00005798,Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer,0.00033325924254602875,0.0003878505251350055
NCT00005908,Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer,0.00026634906218182813,0.0005309347450813814
NCT00005993,"Biological Therapies Following Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Advanced Breast Cancer",0.0003029647371314219,0.00034155731601522
NCT00005975,S9626: Megestrol in Treating Hot Flashes Following Treatment for Breast Cancer,0.00030090962941803763,0.0003448142640163694
NCT00086749,Effect of Tamoxifen on Breast Density in Premenopausal Women With Breast Cancer or High Risk for Breast Cancer,0.00025718146488753926,0.0002202891164246486
NCT00050141,Study of Letrozole Plus Tipifarnib or Placebo in the Treatment of Advanced Breast Cancer,0.00030879865569136616,0.00033841965247568444
NCT00050011,Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy,0.00024863466120303917,0.00020958166727142762
NCT00050427,A Study of ET-743 (Trabectedin) in Patients With Advanced Breast Cancer,0.0003451993503631282,0.000396244300777372
NCT00050167,Evaluation of Differing Taxanes/Taxane Combinations on the Outcome of Patients With Operable Breast Cancer,0.00030452302697380504,0.00029422691007387875
NCT00004565,Susceptibility to Breast Cancer,0.00046090866921910895,0.0002758380412264666
NCT00004156,Vaccine Therapy in Treating Patients With Breast Cancer,0.0004250114303517305,0.00032727193972768273
NCT00004038,Gene Therapy Plus Chemotherapy in Treating Patients With Breast Cancer,0.00036689220246255335,0.0004005994080681757
NCT00004205,Letrozole or Tamoxifen in Treating Postmenopausal Women With Breast Cancer,0.00029574426548833094,0.0002818020361891559
NCT00004157,"Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors",0.00028355277690619754,0.00030165915419106174
NCT00004092,Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer,0.00035273503023601775,0.00030676487549563243
NCT00004174,Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Advanced Breast Cancer,0.00033407946891014827,0.00037822491861391907
NCT00004067,Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2,0.00026017622690123606,0.0002559831219276336
NCT00080756,Deslorelin Combined With Low-Dose Add-Back Estradiol and Testosterone in Preventing Breast Cancer in Premenopausal Women Who Are at High Risk for This Disease,0.00023469771403006648,0.0002479454129739044
NCT00080613,Neoadjuvant and Adjuvant Exemestane in Treating Postmenopausal Women With Locally Advanced Hormone Receptor-Positive Breast Cancer,0.00028033978970688143,0.0003297584972593902
NCT00080626,Neoadjuvant Docetaxel in Treating Women With Newly Diagnosed Breast Cancer,0.0002993667294430961,0.0003567078893045366
NCT00080301,Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer,0.0003162027321016184,0.00035572991069171133
NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,0.0002657531869112523,0.00028817898872283065
NCT00054587,Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer,0.00034779779826029256,0.00024403788296725864
NCT00054418,Risedronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy for Primary Breast Cancer,0.00026731979732535013,0.000242625742121996
NCT00054028,Suramin and Paclitaxel in Treating Women With Stage IIIB-IV Breast Cancer,0.000292026394696568,0.0003688652739357873
NCT00001806,Methods in Education for Breast Cancer Genetics,0.00033000789587460166,0.00028806884349966757
NCT00001385,Positron Emission Tomography in Patients With Breast Cancer,0.0004289588534386335,0.0003840242389630485
NCT00001504,A Phase I Trial of Tamoxifen and 9-Cis-Retinoic Acid in Breast Cancer Patients,0.00035035016409051904,0.0003758157995587534
NCT00001496,Establishment of Normal Breast Epithelial Cell Lines From Patients at High Risk for Breast Cancer,0.00029866366518756715,0.00019541433231157153
NCT00001498,"A Pilot Trial of Sequential Chemotherapy With Antimetabolite Induction, High-Dose Alkylating Agent Consolidation With Peripheral Blood Progenitor Cell Support, and Intensification With Paclitaxel and Doxorubicin for Patients With High-Risk Breast Cancer",0.00030703422154430886,0.0002825048032840527
NCT00001378,A Pilot Trial of Tamoxifen and 4-HPR (4-N-Hydroxyphenyl Retinamide) in Persons at High Risk for Developing Breast Cancer,0.00025407102624046935,0.0002856623033931851
NCT00001193,A Multimodality Treatment Approach to Patients With Inflammatory Cancer of the Breast and Locally Advanced Non-Inflammatory Stage III Breast Cancer and Stage IV Breast Cancer,0.0003025420918750506,0.0003795138441441007
NCT00001338,"A Prospective, Randomized, Phase III Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Chemotherapy With GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) Versus PIXY 321 in Advanced Breast Cancer",0.00026292402086507767,0.00031305069735223487
NCT00001493,"Antimetabolite Induction, High-Dose Alkylating Agent Consolidation and Retroviral Transduction of the MDR1 Gene Into Peripheral Blood Progenitor Cells Followed by Intensification Therapy With Sequential Paclitaxel and Doxorubicin for Stage 4 Breast Cancer",0.00025953146850738503,0.0003920463237944851
NCT00001440,Autologous T-Cell Transplantation and the Immunotherapy of Residual Disease in Breast Cancer: Pilot Study of Vaccine-Driven T-Cell Expansion in Patients Treated With Dose-Intensive Chemotherapy,0.0003275201027914469,0.00036122601265391587
NCT00035594,Pegfilgrastim as Support to Advanced Breast Cancer Patients Receiving Chemotherapy,0.00032894752213901937,0.00033284508115956563
NCT00035126,EPO906 Therapy in Patients With Advanced Breast Cancer,0.00039962329126110285,0.00040102094083065777
NCT00044291,Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer,0.0002944473859872408,0.00029440398675756004
NCT00007904,Adjuvant Stage 2-3A Breast Cancer With Positive Lymph Nodes,0.00028728158041584144,0.00025395325214988795
NCT00026949,Study of Etoposide in Breast Cancer Patients,0.00039074277961187687,0.00031746877411221693
NCT00026286,Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer,0.0002448591603910317,0.0002461941842991151
NCT00026117,Shark Cartilage in Treating Patients With Advanced Colorectal or Breast Cancer,0.0003301775787101386,0.0002833978733292907
NCT00009997,Trastuzumab and Chemotherapy Followed by Surgery and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer,0.0002946045689052759,0.00037297794329600454
NCT00056082,Celecoxib in Preventing Breast Cancer in At-Risk Premenopausal Women,0.00033239046855536666,0.00036127817610200606
NCT00089479,A Study of Xeloda (Capecitabine) in Women With High-Risk Breast Cancer,0.0002922029019598067,0.00023632796621179768
NCT00089661,AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer,0.00028036938514118927,0.0004178671574862277
NCT00089973,Study Of Ispinesib In Subjects With Breast Cancer,0.0003862087319208685,0.00034422145807777024
NCT00073073,Exemestane and Celecoxib in Postmenopausal Women at High Risk for Breast Cancer,0.00026344452767464844,0.0003548543197370002
NCT00032136,Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Breast Cancer,0.00029237006715374125,0.00023878189897288032
NCT00090480,Vaccine Treatment for Advanced Breast Cancer,0.0003267964819923807,0.0004096107960979161
NCT00090974,"Quality of Life in Postmenopausal Women Who Are Receiving Either Exemestane or Anastrozole With or Without Celecoxib for Stage I, Stage II, or Stage IIIA Primary Breast Cancer",0.0002525612663891748,0.0002789247748072296
NCT00090857,Letrozole in Preventing Breast Cancer in Postmenopausal Women,0.00035285657604666016,0.0002705509254208902
NCT00097344,The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer,0.0002944473859872408,0.00028605841053205486
NCT00031850,Raloxifene and Goserelin in Preventing Breast Cancer in Women With a Family History of Breast Cancer,0.00027201735944351076,0.0003149078794894921
NCT00031681,7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007),0.000290154750989054,0.0002864500702656677
NCT00031811,Raloxifene With or Without Exercise Compared With Exercise Alone in Women Who Have Been Previously Treated for Breast Cancer,0.0002777276535442479,0.0002770190282214019
NCT00031772,S9832: Effectiveness of Telephone Counseling By Breast Cancer Survivors on the Well-Being of Women With Recurrent Breast Cancer,0.00023580320690612015,0.00031615920580767867
NCT00070564,"S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer",0.0003230097693444563,0.00030192817558902945
NCT00070278,"Neoadjuvant Epirubicin, Cyclophosphamide, and Paclitaxel With or Without Gemcitabine in Treating Women Who Are Undergoing Surgery for Early Breast Cancer",0.0002635284680875315,0.0002733651606494443
NCT01483196,Vascular and Cognitive Assessments in Patients With Breast Cancer Undergoing Chemotherapy After Surgery,0.0003194140266018073,0.0003548176005755481
NCT01463007,Partial Breast Irradiation Using Non Invasive Approach for Early Stage Breast Cancer,0.0002845178274640431,0.0003065989529777002
NCT01403779,Comparison of the Cosmetic Outcome of Hypofractionated Versus Normofractionated IMRT in Treatment of Breast Cancer,0.00036774033364862075,0.000364196269986266
NCT01459003,Evaluation of Beauty Care Before Chemotherapy in Women With Breast Cancer,0.0003667147021439533,0.0004891362026749827
NCT01471106,Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer,0.000253201293868496,0.00030059584424715213
NCT01471847,A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to Trastuzumab,0.00040267204588663994,0.0003295052300628303
NCT01427933,A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer,0.00029456712907661547,0.00040530559086096417
NCT01427166,Non-Invasive Imaging for Cording in Breast Cancer Patients,0.000349789351063171,0.0003211939003937574
NCT01417286,Accelerated Radiation Therapy After Surgery in Treating Patients With Breast Cancer,0.0003604372452957355,0.0004164753895893236
NCT01491737,A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer,0.000307898729096539,0.0003482153082736557
NCT01425476,Changes in Breast Cancer Biomarkers Using Synergistic Prostaglandin Inhibitors,0.0002788457856976106,0.00028546746298094375
NCT01450020,Peer Navigator Education in Improving Survivorship Care in African American Breast Cancer Survivors,0.000463225389290309,0.00033346306999839704
NCT01419197,A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy,0.00028320858956664585,0.0002976226509974146
NCT01419613,Promoting a Healthier Lifestyle Among Breast Cancer Survivors,0.0008829212022672371,0.0004604267657291667
NCT01437865,Gadofosveset for Axillary Staging in Breast Cancer Patients,0.0003462942308843919,0.000297030805862513
NCT01466972,Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib,0.0002976208509799776,0.0003097735807551421
NCT01409811,Biomarkers in Tissue Samples From Patients With Newly Diagnosed Breast Cancer Treated With Zoledronic Acid,0.00030382460948517377,0.0003833140601801294
NCT01431196,Trial With Autologous Dendritic Cell Vaccination in Patients With Stage II-III HER2 Negative Breast Cancer,0.00028803525138188153,0.0003665627739668708
NCT01431872,Systemic Dickkopf-related Protein 1 (DKK1)During Estrogen Level Changes in Post-menopausal Breast Cancer Patients Treated With Aromatase Inhibitors,0.00028869640921160624,0.0003134355193927028
NCT01431053,Study of Aspirin and Exemestane as Adjuvant Treatment in Breast Cancer,0.00031170103143585826,0.000544343090363435
NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ®) as Adjuvant for Breast Cancer,0.00032162009906311454,0.0002964313739810321
NCT01400399,Cosmetic Evaluation of Lumpectomy Versus Oncolytic Mammoplasty With Bilateral Breast Reduction for Early Stage Breast Cancer,0.0002501998933714758,0.00032646048688664086
NCT01421017,"Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases",0.0002468186855498224,0.0003422959187412407
NCT01421472,A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer,0.00047767251510476294,0.0004143806693132602
NCT01407770,Genetic Susceptibility to Radiation-Induced Skin Reactions in Racial/Ethnic Groups of Patients With Breast Cancer,0.0002932432516174418,0.0003324281763542693
NCT01433562,Efficacy and Safety of DLBS1425 as Neoadjuvant in Stage II or III Breast Cancer Patients,0.00036202558484457693,0.00034153634867608787
NCT01433926,"Characteristics of Disseminated Her2+ Breast Cancer Patients Treated With Trastuzumab That Have Reached Complete, Partial Remission or Stabilization of Disease During More Than 3 Years",0.00028971921825236645,0.0002265317561527513
NCT01482702,Impact of Weight Loss Interventions for Overweight Breast Cancer Survivors,0.0002735204294055137,0.0002688752826321695
NCT01426880,Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer,0.00029310242872206935,0.0003595674355770866
NCT01480674,An Observational Study of Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer Treated With Herceptin (Trastuzumab) in 1st Line and Without Progression For 3 Years,0.0003451894825580096,0.00035204494512944176
NCT01480583,GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases,0.0003101257496573861,0.00036127549408361824
NCT01480869,Study of Vitamin D Supplementation Tailored to Vitamin D Deficiency in Breast Cancer Patients,0.0003268954054644225,0.00033721203140202316
NCT01472445,Vitamin D and Breast Cancer: Does Weight Make a Difference?,0.0002730152341707075,0.0002829088176197233
NCT01472146,ZoNantax - Zolendronic Acid as Neoadjuvant Therapy Plus Anthracycline and Taxane in Locally Advanced Breast Cancer,0.00026700984951919606,0.0002981103673910293
NCT01494662,HKI-272 for HER2-Positive Breast Cancer and Brain Metastases,0.00046483868553141784,0.0002812843476467063
NCT01445054,111 Indium CHX-A DTPA Trastuzumab (Indium-Herceptin) for Imaging Breast Cancer,0.0002492124540927772,0.0003866086758762837
NCT01441947,Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer,0.00029179890084892244,0.00033592196606386637
NCT01441596,Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases,0.0002994651911930981,0.0003308374646665447
NCT01492101,The BEACON Study (Breast Cancer Outcomes With NKTR-102),0.0005475118996500432,0.0003151353102593513
NCT01411787,Bootcamp During Neoadjuvant Chemotherapy for Breast Cancer,0.0003743047592099143,0.0002949843943902441
NCT01411943,Epigenetics and Psychoneurologic Symptoms in Women With Breast Cancer,0.00046379701827968094,0.0002518670390427605
NCT01493310,Nab-paclitaxel (Abraxane) With or Without Mifepristone in Patients With Advanced Breast Cancer,0.00031146095600366214,0.00035624806602202496
NCT01495650,Effect of a Tailored Program of Physical Activity and Nutritional Counseling on Fatigue Reduction in Breast Cancer Patients Receiving an Adjuvant Treatment,0.00031173101165811527,0.00028759757762842285
NCT01452672,Resource-sparing Post-mastectomy Radiotherapy in Breast Cancer,0.0003422027842122395,0.0003172141428575993
NCT01452399,A Randomized Controlled Trial of Routine Shave Margins Versus Standard Partial Mastectomy in Breast Cancer Patients,0.0002931722885918946,0.0003159667659141967
NCT01432886,A Study of Eribulin Mesylate With Trastuzumab for Advanced or Recurrent Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast Cancer,0.00029864162440528577,0.00033656007586698404
NCT01432002,FDG-PET/CT for Simulation and Radiation Treatment Planning of Early Breast Cancer,0.000258878760804062,0.00027671299205471835
NCT01423123,Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer,0.0002630240551644228,0.0002977698843216441
NCT01423890,A Prospective Cohort Study to Evaluate the Oncotype DX® Test in Early Stage Breast Cancer,0.00028514067351174954,0.0003578036069372314
NCT01440010,TARGeted Intraoperative radioTherapy With INTRABEAM as a Boost for Breast Cancer - A Quality Control Registry,0.00027251739308866964,0.00036931495246970996
NCT01440413,Study of the Response to a Neoadjuvant Chemotherapy Based on the Antitumor Immune Response in Localized Breast Cancer,0.0002935318956774056,0.0003794755444583588
NCT01422551,Facilitating Positive Adaptation to Breast Cancer,0.0003439410803626722,0.0002781279833984609
NCT01422408,Fluocinonide Cream in Treating Symptoms of Vaginal Dryness and Painful Sexual Intercourse In Patients With Breast Cancer Undergoing Hormone Therapy,0.00028714440129203636,0.00034732225121268727
NCT01478477,"Omega-3 Fatty Acids in Preventing Joint Symptoms in Patients With Stage I-III Breast Cancer Receiving Anastrozole, Exemestane, or Letrozole",0.00029955316061545045,0.0003096015166564115
NCT01439945,Magnesium Oxide in Treating Postmenopausal Women With Hot Flashes and a History of Breast Cancer,0.0002572820696807753,0.0002718752262527091
NCT01439282,Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer,0.0002749222539741192,0.00024597151279254974
NCT01416389,A Study of LY2523355 in Patients With Breast Cancer,0.0004827287424213841,0.0003967961263356765
NCT01404377,Wound Infiltration and Breast Cancer Surgery,0.0002867828140387592,0.0002195976538483382
NCT01424865,Cancer Stem Cell Biomarkers as a Predictor of Response to Trastuzumab in Samples From Patients With Breast Cancer Previously Treated in the NSABP-B-31 Trial,0.0002999706736927075,0.0003489805061752148
NCT01497015,Memory Training Intervention for Breast Cancer Survivors,0.0003342790016475592,0.00017824606365494098
NCT01415336,AX Versus AC as Adjuvant Treatment for Node-Negative Breast Cancer,0.0003072780602289155,0.0002685397062008266
NCT01446185,"Treatment Decision Impact of OncotypeDX™ in HR+, N- Breast Cancer Patients",0.00037456501839720156,0.00039701091808800205
NCT01487954,Alkaline Water in Reducing Skin Toxicity in Women With Breast Cancer Undergoing Radiation Therapy,0.0002566685590275423,0.0002596608724104262
NCT01420185,Identification of Genes That Predict Local Recurrence in Samples From Patients With Breast Cancer Treated on NSABP-B-28,0.0003480391105736103,0.0003205758948773612
NCT01401166,Participant Preference of Subcutaneous (SC) Versus Intravenous (IV) Herceptin (Trastuzumab) in Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer,0.00024617510801179667,0.0003018579397225161
NCT01428739,Correlation Between MRS (Magnetic Resonance Spectroscopy) and Tumor Response to Radiation Therapy in Breast Cancer,0.00026386714861002466,0.0004456274086002871
NCT01428414,Efficacy and Safety Study of Trastuzumab and Paclitaxel Based Regimens to Treat HER2-positive Breast Cancer,0.00030309244262274995,0.0003532643843510684
NCT01458457,Life Quality and Mental State in Patients With Breast Cancer,0.0004242059420745484,0.00034277326122703045
NCT01473680,Neuropsychologic and Electrophysiological Features of Cancer-Related Cognitive Side Effects in Racial and Ethnic Minority Breast Cancer Patients,0.0002885695143614338,0.00033631942099126953
NCT01461070,Intestine Bacteria and Breast Cancer Risk,0.0003277785003668991,0.00028802024728623516
NCT01461044,An Observational Study of Avastin (Bevacizumab) in Patients With HER2-metastatic or Locally Advanced Breast Cancer,0.0003396955346050361,0.0003628994836849455
NCT01447771,Decision Support for Women With Breast Cancer,0.00033106983988567514,0.0003051062692446448
NCT01484483,An Observational Study to Register the Incidence of Breast Cancer and Current Clinical Care Patterns in Kenya,0.00028783831946457963,0.0003388513328992476
NCT01484704,The Significance of MRI in the Development of Diagnostics and Treatment of Breast Cancer,0.0003072107102606619,0.0005029438383212551
NCT01484080,Neoadjuvant Paclitaxel Versus BIBF 1120 Priming Followed by BIBF 1120 Plus Paclitaxel in Early HER-2 Negative Breast Cancer With Proteomic and Dynamic Imaging Correlates,0.0002706254381773917,0.00031435236687489543
NCT01499160,GCC 0901 - Study of How Well Letrozole Works in Combination With Lapatinib Followed by an Addition of Everolimus in Postmenopausal Women With Advanced Endocrine Resistant Breast Cancer,0.0002981788970743931,0.00034282073996918
NCT01499836,Quality Study of Anesthetic Technique on Breast Cancer Surgery,0.0003320804666495936,0.00027811882641119994
NCT01430585,Pre-Operative Study of PF-4691502 With Letrozole Compared To Letrozole Alone In Patients With Early Breast Cancer,0.0003542612556468749,0.0003190461665014794
NCT01435005,Breast Cancer and Exercise Trial in Alberta,0.00046717801519213396,0.00019210832686804793
NCT01413828,Trastuzumab Administered Concurrently or Sequentially to Anthracycline-containing Adjuvant Regimen for Breast Cancer,0.00028646201061638334,0.0002397006623057777
NCT01468766,Effects of a Supervised Progressive Resistance Training With Breast Cancer Patients During Adjuvant Radiotherapy,0.00034600264506731113,0.00022405893582090906
NCT01468649,Real-Time Near-infrared (NIR) Mapping of Sentinel Lymph Nodes in Breast Cancer,0.0004642105292565841,0.000340219726062963
NCT01468883,"The Treatment of Stage I and II Breast Cancer With Mastectomy and Axillary Dissection vs. Excisional Biopsy, Axillary Dissection, and Radiotherapy",0.0002692522761145689,0.00033443584994255417
NCT01468246,The Young Women's Breast Cancer Study,0.0005475118996500432,0.0002535707664280389
NCT01498536,Effect of Diet and Exercise in Breast Cancer Survivors,0.00033314346976076614,0.0003152335039872847
NCT01498588,"Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer",0.00027600529747358234,0.00036106934177574274
NCT01479036,"Trial of Neoadjuvant Endostar, Docetaxel and Epirubicin for Patients With Breast Cancer",0.00030827166590685797,0.00038568658433319424
NCT01479244,Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence,0.00026576388191915345,0.00028043596326082386
NCT01479946,Electrochemotherapy For The Treatment Of Breast Cancer That Has Spread to the Skin,0.0003006092903570401,0.0003368743555658036
NCT01414933,High Throughput Technologies to Drive Breast Cancer Patients to Specific Phase I/II Trials of Targeted Agents,0.0002941585986623732,0.0003094667506688663
NCT01485926,"A Phase II Neo-adjuvant Study Assessing TCH (Docetaxel, Carboplatin and Trastuzumab) and TCHL (Docetaxel, Carboplatin, Trastuzumab and Lapatinib) in HER-2 Positive Breast Cancer Patients.",0.00033045086886850604,0.00034914394543508347
NCT01249456,Safety and Efficacy Study of Femara(Letrozole) as an Extended Adjuvant Treatment in Breast Cancer Patients,0.0003710731386019582,0.000357072997350424
NCT01296555,A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer,0.00030298706617224645,0.0003110172112401897
NCT01284751,The Use of Major Depression Inventory (MDI) in Measuring Preoperative Depressive Symptoms in Breast Cancer Patients,0.0002910145688871129,0.00029501929926721397
NCT01284153,Potential Benefits of Radiotherapy in Prone Position for Breast Cancer Patients: a Planning Study,0.0003343669048484035,0.0003265232257480339
NCT01243541,Cryotherapy in Preventing Peripheral Neuropathy and Nail Toxicity in Patients With Breast Cancer Who Are Receiving Paclitaxel,0.0002910191785123073,0.00037157589702677195
NCT01221688,Sentinel Lymph Node Detection After Neoadjuvant Chemotherapy for Large Operable Breast Cancer,0.00027870657995581117,0.0003367360136155449
NCT01236417,Exercise Intervention in Breast Cancer Patients With Treatment-Induced Arthralgia,0.0003331259199407008,0.0004460609213140942
NCT01275807,Effectiveness and Safety of Acupuncture for Climacteric Syndrome in Patients With Breast Cancer,0.0002932890539978259,0.00032632773708667035
NCT01275859,Neoadjuvant Combined Endocrine and HER2 Target Therapy in Postmenopausal Women With ER and Her2 Positive Breast Cancer,0.00030227605571685423,0.00025032031618903535
NCT01267552,Study of Axillary Lymphadenectomy Without Drainage for Breast Cancer,0.00031807589383353943,0.0003367019644850403
NCT01222416,PET/CT Evaluation of Treatment Response in Breast Cancer,0.0002853029609543668,0.00037367038046768166
NCT01222052,6xFU/Epirubicin/Cyclophosphamide (FEC) Compared to 3xFEC-3xDocetaxel in High-risk Node-negative Breast Cancer Patients,0.00029918898115959946,0.00032091412305014613
NCT01222377,Endoscopic Breast Surgery in Treating Patients With Breast Cancer,0.00032493751235858494,0.0003382682997991188
NCT01266486,Effect of Metformin on Breast Cancer Metabolism,0.00032932909038834514,0.00040414137844560206
NCT01254136,Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer,0.0003259584896983099,0.0004830631867430074
NCT01259076,Effect of Weight Loss on Breast Density Using Digital Mammography and MRI in Women Who Are At Increased Risk For Breast Cancer,0.00024908622228303636,0.00021543336859108358
NCT01225328,Participation Restrictions in Breast Cancer Survivors,0.00046035907421057695,0.00032039223859587826
NCT01225172,Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors,0.00032864095034733327,0.00035947650255146264
NCT01248897,Study of Biomarker Profiles in Asia Pacific erb2+/HER2 Breast Cancer Patients Treated With Lapatinib,0.0003326757809622734,0.0003646675713018449
NCT01210768,A Study of Pegylated Liposomal Doxorubicin and Cyclophosphamide in Her2-negative Stage I and II Breast Cancer Patients,0.000338680186392204,0.00039719623570184703
NCT01223833,A Prospective Assessment of Loss of Grip Strength by Baseline BMI in Breast Cancer Patients Receiving Adjuvant Aromatase Inhibitors and Tamoxifen,0.000294058548001563,0.00032572690369932965
NCT01220960,Art Therapy Intervention for Breast Cancer Patients,0.0003508893528853461,0.00029757658515827337
NCT01220570,The Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer (MK-8669-050),0.0002885900919839047,0.0002725173711674156
NCT01220076,Biological Response to Tamoxifen (TAM) in Patients With Breast Cancer Non Metastatic RH+,0.00030540741647031033,0.00034362705523717453
NCT01219075,Soy Isoflavones Supplementation in Treating Women at High Risk For or With Breast Cancer,0.0002503278786904694,0.00027798407473346264
NCT01227408,"Neoadjuvant Doxorubicin, Polyglutamate Paclitaxel, Capecitabine and Metronomic Chemotherapy in Breast Cancer",0.0002587898087877142,0.00031770397830124483
NCT01216033,Exploratory Study of Breast Cancer With ABY025,0.0005475118996500432,0.0006532910249261078
NCT01216176,A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer,0.0003123085314653735,0.0003911546177196546
NCT01203839,Partial Breast Irradiation (PBI) Using 40 Gy for Select Patients With Early Invasive or Noninvasive Breast Cancer,0.0003465835670106734,0.0003786051024724095
NCT01203267,Weekly Paclitaxel Plus Carboplatin in Preoperative Treatment of Breast Cancer,0.0003114878153746661,0.00040058143533658303
NCT01256801,Gene Expression Profiling of Breast Cancer Cells Predict the Response of Malignant Pleural Effusion,0.00025205600771185087,0.00021725333002411867
NCT01256008,Intervention Study of Depression in Breast Cancer Patients,0.0003488100202354979,0.00044679679736347116
NCT01256567,A Study of Ramucirumab (IMC-1121B) in Participants With Breast Cancer,0.0005475118996500432,0.0003263487401653109
NCT01277926,"Patterns of Care in Hormone-receptor Positive, Advanced Breast Cancer",0.0003097843425418109,0.0003519546467761433
NCT01277757,Akt Inhibitor MK2206 in Treating Patients With Advanced Breast Cancer,0.00037134519868224115,0.0004188136190540052
NCT01268150,A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer,0.00026900606895081936,0.0003241793542902296
NCT01245205,Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer,0.00031247094664258894,0.0003384060963982704
NCT01215162,Phase II Study of Intra-Operative Electron Irradiation and External Beam Irradiation After Lumpectomy in Patients With T1N0M0 and T2N0M0 Breast Cancer,0.00032551169838332324,0.0003925017330032102
NCT01281696,Bevacizumab With Etoposide and Cisplatin in Breast Cancer Patients With Brain and/or Leptomeningeal Metastasis,0.0002880064148386352,0.00033066477393895214
NCT01281137,Study of Changes in Estrogen Levels and Grip Strength in Postmenopausal Women Who Have Received 4 to 6 Years of Hormone Therapy for Breast Cancer and Are Currently Receiving Letrozole on Clinical Trial IBCSG-35-07,0.0002804837801390088,0.00032519608368485726
NCT01239745,"Aromasin® As Adjuvant Treatment In Postmenopausal Women With Invasive, Estrogen Receptor Positive Early Breast Cancer",0.00026744843388290074,0.00030285968026286795
NCT01239251,GlowCap Reminder System in Patients With Early Stage Breast Cancer Receiving Adjuvant Endocrine Therapy,0.00032284939866643336,0.000309669323770016
NCT01291082,Whole-body MR in Staging Bone and Soft Tissue Metastases in Breast Cancer Patients(MetaMaRBo),0.000276837480417101,0.00030716062920036554
NCT01262274,Randomized Phase II Trial of Anastrozole Plus Metronomic Tegafur-uracil as Neo-adjuvant Therapy in Postmenopausal Breast Cancer,0.00027022432171765095,0.00033098393656402493
NCT01262716,A Novel Therapy for the Treatment of Chest Wall Progression of Breast Cancer,0.00030060505666283557,0.0003181429258947858
NCT01204801,Randomized Study of Combination Chemotherapy With or Without Focused Microwave Thermotherapy Before Surgery in Treating Women With Large Breast Cancer Tumors,0.00028274227218401767,0.0003545753388782661
NCT01204242,IRB-HSR# 13957: IV Lidocaine for Patients Undergoing Primary Breast Cancer Surgery: Effects on Postoperative Recovery and Cancer Recurrence,0.00029903739657082467,0.00030501780198307634
NCT01204957,Brown Seaweed as a Breast Cancer Preventive,0.0008829212022672371,0.0002167372621960378
NCT01233947,Study of AFP464 +/- Faslodex in ER + Breast Cancer,0.0003874851554644591,0.0005077889132035742
NCT01205217,Lapatinib or Trastuzumab Given Prior to Surgery With Chemotherapy in Patients With Early Breast Cancer,0.000330479811267896,0.0003871021483121447
NCT01240928,MK-2206+Endocrine Therapy in Patients With Hormone Receptor-Positive Breast Cancer,0.00034550925477604393,0.0003072700277866337
NCT01240941,Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer,0.00034550925477604393,0.0003859627734805561
NCT01240681,Blood Oxygen Level Dependent Magnetic Resonance Imaging (BOLD MRI) and Fluorothymidine Positron Emission Tomography (FLT PET) in Patients With Locally Advanced Breast Cancer Undergoing Neoadjuvant Chemotherapy,0.00032675500305615957,0.0003517375690482516
NCT01240421,"An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory",0.0002716102170036405,0.0003203192686471256
NCT01263366,Exploratory Study of Norepinephrine to Prevent Radiodermatitis in Breast Cancer Patients,0.00032646404042497104,0.0003365668737259528
NCT01263613,Feasibility Study of Biomarkers of Response to Neoadjuvant Paclitaxel in Locally Advanced Breast Cancer,0.0002745228608937285,0.00034354583105675575
NCT01247233,Standard or Hypofractionated Radiotherapy Versus Accelerated Partial Breast Irradiation (APBI)for Breast Cancer,0.0002744926246860702,0.0003441371625252157
NCT01247480,Analysis of Prognostic and Predictive Genomic Signatures Using Archival Paraffin-embedded Tumor Specimens in Breast Cancer,0.00023825241693663368,0.0003297123742304377
NCT01241721,Pre-Surgery Positron Emission Mammography in Patients With Newly Diagnosed Breast Cancer,0.000327506122864546,0.00036889302666535343
NCT01202591,Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients,0.00032015484908898907,0.00044278877406419984
NCT01202851,Relaxation for Women With Breast Cancer Undergoing Radiotherapy,0.0004804196347823597,0.0002799342167037017
NCT01224678,Vitamin D and Breast Cancer Biomarkers in Female Patients,0.0003520603752861391,0.00034377913726857043
NCT01224873,"Diagnosis of Bone Metastases in Breast Cancer: Bone Scintigraphy, Fluoride-PET and FDG-PET",0.00024038460875458494,0.00028744337181099434
NCT01252277,Breast Cancer Risk Biomarkers in Premenopausal Women,0.00033879266231923736,0.00028465989562759654
NCT01252290,Breast Cancer Risk Biomarkers in Postmenopausal Women,0.0003506591920750359,0.0002915780286490127
NCT01272401,Quality of Life in Breast Cancer Patients and Survivors,0.00042798732017905857,0.00035116390315431326
NCT01272037,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",0.0003057704745615215,0.00033989423955012814
NCT01272570,Oral Health and Oral Health-Related Quality of Life in Early Stage Breast Cancer Survivors,0.0002614101506386969,0.0003162215742323787
NCT01244087,Pilot Clinical Trial (Phase II) of Inquiry-based Stress Reduction (IBSR) Program for Survivors of Breast Cancer,0.0002536739687511569,0.0001835242426434121
NCT01231386,MIRNA Profiling of Breast Cancer in Patients Undergoing Neoadjuvant or Adjuvant Treatment for Locally Advanced & Inflammatory Breast Cancer,0.00034372225221888594,0.0002804293732988678
NCT01257932,Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging,0.00026369549618820526,0.00025033951306166534
NCT01207635,Evaluation of Antiproliferative Effects of Arimidex in Ductal Lavage Fluid in Patients With Breast Cancer,0.0002974664367781165,0.00033655546173333114
NCT01276769,Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast Cancer,0.0003021585889173106,0.0003353371096430886
NCT01276704,Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer,0.0002431347090118803,0.000189552455596238
NCT01276041,"Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer",0.00027918990765288476,0.0003521051315125432
NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,0.0004611660033411331,0.00040373745912850354
NCT01229605,Cyclophosphamide and Docetaxel Every 3 Weeks as Neoadjuvant Therapy in Locally Advanced Breast Cancer,0.000290211857273759,0.00037154128130710627
NCT01273415,Usefulness of Ki67 Index in Hormone Receptor-positive Breast Cancer,0.00028767393467933004,0.0002518566810010355
NCT01209091,Utility and Work Productivity Data for Economic Evaluation of Breast Cancer Therapies in the Netherlands and Sweden,0.00037534674628943854,0.00032891827759583037
NCT01250379,A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Breast Cancer Progressing After First-Line Therapy With Avastin and Chemotherapy (TANIA),0.00033745598011022466,0.00030843888587405664
NCT01230671,The Physical and Psychological Benefits of Yoga and Breast Cancer,0.0002782672399018077,0.00028383830721593587
NCT01230970,Exploratory Study to Assess the Short Term Intratumoural and Peripheral Effects of BN83495 in Postmenopausal Women With Newly Diagnosed Breast Cancer,0.0003005782309675879,0.00031110423374683085
NCT01292408,Autophagy Inhibition Using Hydrochloroquine in Breast Cancer Patients,0.00042411421183547647,0.00036715172964964655
NCT01293032,Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer,0.00032403893373802664,0.0002962402034889972
NCT01293682,Effects of High Dose Calcitriol in Breast Cancer Patients,0.00034905142299407376,0.00036683069855433895
NCT01208779,Epidemiology Study in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer,0.00029585434155270356,0.0003050896982707788
NCT01271920,Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab,0.0003477745982492876,0.0003540235555924623
NCT01271738,Evaluating and Comparing Two Surgical Methods for Treatment of Early Stage Breast Cancer,0.00029352779325070435,0.0003273082640283382
NCT01206881,Neoadjuvant Pegylated Liposomal Doxorubicin and Cyclophosphamide +/- Trastuzumab Followed by Docetaxel in Breast Cancer,0.0002637431260654014,0.00029438093732601765
NCT01264562,Cognition in Breast Cancer Patients: The Impact of Cancer-related Stress,0.0002970938508085378,0.00035009474813496653
NCT01232881,Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer,0.0003140864041912825,0.00044095155039445937
NCT01278212,Accelerated Hypofractionated Radiotherapy (AHF-RT) for the Treatment of Breast Cancer,0.0003003996507224771,0.0003445308283000019
NCT01278810,Phase I Study of Novel Estrogen Receptor(ER) a36 Modifier Icaritin in Advanced Breast Cancer Patients,0.0003461897175128242,0.00047175426043121024
NCT01234402,Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients,0.0003585233413855369,0.000353099415010862
NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,0.0002827200962309212,0.0003831954542811919
NCT01234857,A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3),0.0003385980779916034,0.0003555671406082836
NCT01265927,A Study Inhibiting Telomerase to Reverse Trastuzumab Resistance in HER2+ Breast Cancer,0.00029490848339549646,0.00038199584631936863
NCT01265654,Reasons for Changing HOrmonal Therapy of Advanced Breast Cancer,0.00032582675012798515,0.000366591729388082
NCT01299987,Prospective Phase II Study of Intraoperative Radiotherapy (IORT) in Elderly Patients With Small Breast Cancer,0.0003910944050113731,0.00031488545251131666
NCT01217385,Diffuse Optical Spectroscopy Imaging in Monitoring and Predicting Response in Patients With Locally Advanced Breast Cancer Undergoing Chemotherapy Before Surgery,0.00033129472271283146,0.00038583093086515914
NCT01217411,RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer,0.00030241125611910974,0.00031223164657658665
NCT01290354,Exploratory Lapatinib (Positron Emission Tomography) PET Study in Subjects With Breast Cancer,0.00032358034319012537,0.00033259111508749105
NCT01290835,Conformal Partial Breast Irradiation With CyberKnife After Resection for Early Stage Breast Cancer,0.0002570600389174753,0.0003104594953315409
NCT01290718,A Study of Herceptin (Trastuzumab) in Combination With Xeloda (Capecitabine) in Patients With Metastatic or Recurrent HER2-positive Breast Cancer After First-Line or (Neo)Adjuvant Therapy.,0.000355418012747269,0.0003390081489966064
NCT01298362,Impact of Chemotherapy Followed by Aromatase Inhibitors on Bone Health of Women With ER-positive Early Breast Cancer,0.00026443313987985114,0.0003267106206646042
NCT01298193,Incidence of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With the Docetaxel-Cyclophosphamide Regimen in Early Breast Cancer Patients,0.0003085589729817098,0.00036905651329882953
NCT02941614,Implementing Systematic Distress Screening in Breast Cancer,0.00032944199681501376,0.0003333014814254206
NCT02941536,Correlation Between Circulating Tumor Cells and Brain Disease Control After Focal Radiotherapy for Metastases of Breast Cancer,0.0002446283059885774,0.0002662865865613051
NCT02934815,Relational and Emotional Mechanisms of a Supportive-expressive Group Intervention in Breast Cancer,0.00027843748851628567,0.0002598729707947182
NCT02934828,Study of Preoperative Chemotherapy for Early Triple Negative or HER2-positive Operable Breast Cancer,0.00032141374767241497,0.0004104328919120183
NCT02934126,The Development of a Personalized Decision Aid: Perspectives of Patients and Health Care Professionals on Shared Decision Making and Informational Needs on Radiotherapy for Breast Cancer,0.00028812622680510886,0.0003185358165023457
NCT02934880,Impact of Adapted Physical Activity on Cognitive Functions in Breast Cancer,0.0002805655902951858,0.0003505870485182482
NCT02969291,A Home-Based Study to Enhance Activity in Breast Cancer Survivors,0.0003196708292313603,0.0002605580971926505
NCT02921152,Bone Marrow Micrometastases in Patients With Early Stage Breast Cancer,0.00030134052562693525,0.0002963149800870168
NCT02921191,"Descriptive Analysis of G-CSF Use in Patients With Breast Cancer, Lung Cancer, or Lymphoma Treated",0.0003086220537489366,0.00029677001786289906
NCT02917005,PalbocIclib in PreMenopausal Women With ER Positive/HER-2 Negative MetAstatic Breast Cancer,0.0002781000135214881,0.0003209161051409556
NCT02907918,Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer,0.0002917954926687654,0.00027601071655895235
NCT02997995,Durvalumab and Endocrine Therapy in ER+/Her2- Breast Cancer After CD8+ Infiltration Effective Immune-Attractant Exposure,0.00023970994354780006,0.00026697519880544284
NCT02997384,Feasibility of Breast Cancer Risk Evaluation in Women From the General Population,0.000338585981017013,0.0002789311887631305
NCT02964234,Empowering Latinas to Obtain Breast Cancer Screenings,0.0003292543251314971,0.0001744319003594421
NCT02964507,Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Subjects With Estrogen Receptor Positive (ER+) Breast Cancer,0.00029579415257245277,0.000338037009703232
NCT02980965,"Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast Cancer",0.0002869138386192365,0.00031169639165402137
NCT02938780,Using Behavioral Economics to Achieve Improved Healthy Behavior Outcomes in Breast Cancer Survivors,0.0002729701331962792,0.000262132661571098
NCT02958852,A Clinical Trial to Compare Efficacy and Tolerability of Atorvastatin in Addition to Endocrine Treatment With Focus on Mechanisms of Resistance to Endocrine Treatment (Fulvestrant/Aromatase Inhibitors) in Patients With Advanced Breast Cancer,0.0003252704096156241,0.0003503515024461071
NCT02958774,Hypofractionated Radiation Therapy for Patients With Breast Cancer Receiving Regional Nodal Irradiation,0.00035648063528527773,0.0003871985613589559
NCT02958332,Effects of a Videogame-based Program on Women With Lymphedema Secondary to Breast Cancer,0.0002795602333552041,0.0002691955885302035
NCT02924584,"Clinical Outcome Of Hormonal Receptor Positive, Her-2 Negative Breast Cancer In Taiwan",0.0002905414574708199,0.00021694917107027754
NCT02948478,Economic and Social Disparities and Breast Cancer,0.0008829212022672371,0.00028541365854514554
NCT02948764,Diagnosis of Pathological Complete Response by Vacuum-assisted Biopsy After Neoadjuvant Chemotherapy in Breast Cancer,0.00026779180754668265,0.000305753825415306
NCT02902991,The Study on the Clinical Utility of Liquid Biopsy in Breast Cancer,0.00031893484635928094,0.00032075984052600903
NCT02970344,I HEAL for Breast Cancer Survivors With Diabetes,0.00032750551540277256,0.00018255893634818452
NCT02952729,Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2,0.00034652677245506855,0.00031732803893313083
NCT02956473,Supine MRI in Breast Cancer Patients Receiving Neoadjuvant Therapy,0.00044260475519276095,0.00033747524188763016
NCT02992730,Predictors of Adjuvant Endocrine Therapy in Women With Breast Cancer,0.00047086475815400023,0.0003706945299451661
NCT02992769,Predict the Risk of Axillary Metastases in Breast Cancer Patients With Axillary Ultrasound,0.00030993925194030934,0.0003020385725349236
NCT02992067,CK19 Combined With Contrast-enhanced Ultrasound: a Prediction System on Axillary Lymph Node Metastasis in Breast Cancer,0.00024939739019904034,0.00020872428902510428
NCT02992574,Trial Evaluating Role of Post Mastectomy Radiotherapy in Women With Node Negative Early Breast Cancer,0.0002497883863687618,0.00025877984878412913
NCT02909361,Fulvestrant 500mg in Patients With Advanced Breast Cancer,0.0003742744099113529,0.0005391394952823765
NCT02909751,Tocotrienol in Combination With Neoadjuvant Chemotherapy for Women With Breast Cancer,0.00028383031210367217,0.0003593090790082933
NCT02900469,Presurgical Trial of Denosumab in Breast Cancer,0.00046116888150390516,0.00045389134784879127
NCT02900118,Imaging Evaluation of the Therapeutic Response of Breast Cancer Bone Metastasis (EMOS),0.00027106431140459737,0.00035063534393976764
NCT02900326,Mindfulness-based Stress Reduction (MBSR) Program Combined With Endurance Exercise Training: a Help in Treatment for Breast Cancer?,0.0002575782145193985,0.000289263659594783
NCT02939274,"An Open Label, Phase II Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin (Visudyne®) for the Treatment of Cutaneous Metastases of Breast Cancer",0.00025123377880065874,0.00032871386591305915
NCT02994914,GEriatric Determinants of Curative RAdiotherapy Scheme Choice for Breast Cancer ELderly Patient Treatment Compliance and Tolerance,0.00031320308640290915,0.0003241338683779083
NCT02936206,Examination of Breast Cancer Cells of Pre-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant.,0.00024300382488214313,0.00031443828354385723
NCT02923037,Hatha Yoga in Breast Cancer Survivors,0.00046212586113425665,0.00025090046108007465
NCT02923401,High-Intensity Interval Training for Women at Heightened Risk for Breast Cancer,0.00046049393953570637,0.00029412305218331635
NCT02903524,Doxorubicin Hydrochloride Liposome Injection Combination With Cyclophosphamide vs Pirarubicin Combination With Cyclophosphamide in Patients With Locally Advanced Breast Cancer,0.0003116206282847191,0.0003119642680648184
NCT02940470,Weight Loss Pilot Study in Postmenopausal Breast Cancer Survivors,0.00032995089682699886,0.00030290710704292595
NCT02931864,Effects of an e-Home Based Symptom Management and Mindfulness Training Programme on QoL in Breast Cancer Survivors,0.00024023896588418195,0.0003511473172563666
NCT02963740,Feasibility of High Levels of Energy Expenditure From Physical Activity for Breast Cancer Survivors,0.00024380351761232852,0.00029548475097046365
NCT02963363,Adapted Physical Activity for Breast Cancer HER2 Positive Patient,0.00031581062000807513,0.0004216701356305356
NCT02918084,CONcurrent vs SEqueNTial Adjuvant Treatments in Early Breast Cancer,0.0005152476714020549,0.0003765305574560059
NCT02926690,Safety and Efficacy Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer,0.000345337098188559,0.00040668664531445597
NCT02926729,Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy,0.0002513165756216216,0.0002849055893832227
NCT02926547,New Approaches for the Identification and Characterization of Functional Markers of the Risk of Extension of Breast Cancer Without Lymph Node Involvement,0.00024044740223812434,0.00023829952175287493
NCT02965950,The p53 Breast Cancer Trial,0.0008829212022672371,0.0003320979684067665
NCT02982980,Upper Limb Muscular Strengthening in the Rehabilitation of Patients Submitted to the Breast Cancer Surgical Treatment,0.0003172122674631307,0.00032587265500368134
NCT02982564,Effect of Low vs Moderate-intensity Endurance Exercise on Physical Functioning Among Breast Cancer Survivors,0.00024310635340829705,0.00028120242893400706
NCT02982421,The Effect of Art Therapy on Physical and Psychological Symptoms of Breast Cancer Survivors,0.0002522848026398168,0.0002836220074342348
NCT02982148,Methylene Blue Intradermal Injection for Sentinel Lymph Node Biopsy for Breast Cancer Patients,0.0003093110067708306,0.00036947101406186036
NCT02946294,Modified Pectoral Nerves Block Versus Serratus Plane Block in Major Breast Cancer Surgery,0.00028723845037218604,0.0003037451519313702
NCT02946619,Health Benefits of Expressive Writing Among Chinese Breast Cancer Survivors,0.0003290160807330141,0.00036198382190418053
NCT02993159,Tamoxifen Citrate or Afimoxifene in Treating Patients With Estrogen Receptor Positive Breast Cancer,0.0003099246919219252,0.00033907933821436705
NCT02993198,A Prospective Study of Breast Cancer Patients With Abnormal Strain Imaging,0.0003288134544740619,0.0003741118855622591
NCT02988986,"TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer",0.0003626548574274302,0.00033436630481689574
NCT02927249,"Aspirin in Preventing Recurrence of Cancer in Patients With Node Positive HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy",0.00032912464502937624,0.00034252460486415516
NCT02927912,Intraoperative Electron Beam Radiotherapy Boost in Treating Patients With Stage I-II Breast Cancer Undergoing Surgery With Reconstruction,0.0003010460785626427,0.0003236118495198804
NCT02949310,Effectiveness of Nefopam in Breast Cancer Surgery,0.00028795105216658235,0.00022280974887137455
NCT02944604,The Efficacy and Safety of PEG-rhG-CSF（Pegylated Recombinant Human Granulocyte Colony Stimulating Factor)in Patients With Breast Cancer Who Were Treated With Intensive Chemotherapy,0.00030736492269506404,0.0003341710884405798
NCT02944721,"Genetic, Neurophysiological and Psychological Predictive Factors of Chronic Neuropathic Pain After Surgery for Breast Cancer",0.00024797960722281327,0.000240996214871249
NCT02999074,Exercise Interventions for Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy,0.00032201017194134356,0.0003954099975915233
NCT02999477,A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer,0.0002977043737086142,0.0003201216982632061
NCT02915445,EpCAM CAR-T for Treatment of Nasopharyngeal Carcinoma and Breast Cancer,0.00036435508150890067,0.0003277502384696528
NCT02922244,Effects of Herbal Products on Reduction of Radiation-induced Dermatitis in Breast Cancer Patients,0.0003003877572023313,0.00031688947386025436
NCT02995772,Neoadjuvant Hormonal Therapy Compared to Neoadjuvant Chemotherapy in Stage IIIB/C and IV Breast Cancer Patients,0.00033171709922980654,0.0004589130338238046
NCT02942615,The Safety Management of Cardiac Toxicity in Breast Cancer Patients Under Multidiscipline Therapy.,0.00033477168157451464,0.00022035301728065188
NCT02942355,Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer,0.00028364966065851744,0.0003126584592127226
NCT02955394,Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer,0.0003319498043402379,0.00039778111846579137
NCT02947061,S1 Plus Docetaxel Versus Capecitabine Plus Docetaxel First-line Treatment in Patients With Advanced Breast Cancer,0.0003417354318624036,0.0004310733095760967
NCT02983604,GS-5829 in Combination With Exemestane or Fulvestrant Comparing With Exemestane or Fulvestrant Alone in Women With Advanced Estrogen Receptor Positive HER2- Breast Cancer,0.00026138643203085386,0.00031408001122773196
NCT02983279,"Caloric Restriction Before Surgery in Treating Patients With Endometrial, Prostate, or Breast Cancer",0.00030320935524088085,0.0002938520123498643
NCT02967146,"Anti-adhesive Effect and Safety of a Mixed Solid of Poloxamer, Gelatin and Chitosan(Mediclore®) After Axillary Dissection for Breast Cancer",0.00024685086200827575,0.00025561314410704283
NCT02935920,A Study on Optimizing Follow-up for Postmenopausal Women With Breast Cancer Treated With Adjuvant Endocrine Therapy,0.00033434560846810793,0.00040314919511304096
NCT02979678,European Organisation of Research and Treatment (EORTC) Quality of Life Questionnaire (QLQ) Breast Cancer Module Update,0.00027287818930295905,0.0003201608367410784
NCT02950259,Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC),0.0004831600663302357,0.0004316668867013892
NCT02953860,Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast Cancer,0.0003007674503657434,0.00035644324123470746
NCT02945579,Eliminating Breast Cancer Surgery in Exceptional Responders With Neoadjuvant Systemic Therapy,0.000271274860289762,0.00036455676483695113
NCT02544945,Comparing 3-D Printed vs Standard Bolus for Breast Cancer Chest Wall Radiotherapy,0.00025700779196039653,0.00028071768348699263
NCT02569489,Dose Escalation Study of HBI-8000 in Combination With Paclitaxel and Trastuzumab in Women With Advanced or Metastatic HER2+ Breast Cancer,0.000307224940872512,0.00032839323792956284
NCT02569294,Feasibility and Impact of Group Interventions on Breast Cancer Patients Well-being,0.0003472201312713259,0.00031208070900273977
NCT02566408,"Attitudes, Beliefs, and Preferences of Older Stage I-III Breast Cancer Survivors Towards Physical Activity",0.0002497541160201702,0.000290829987167285
NCT02526498,Accelerated Partial Breast Radiation Therapy Using High-Dose Rate Brachytherapy in Treating Patients With Early Stage Breast Cancer After Surgery,0.0003150290269478058,0.00037912352015759027
NCT02570100,Research and Analysis of the Mechanisms Involved in the Emergence of Breast Cancer Stem Cells (RepriM),0.0002734154208673528,0.0003078555450381746
NCT02530008,Breast Cancer 2-PREVENT Translational Center of Excellence (TCE) - Metastatic Markers of Recurrent Tumor Phenotype for Breast Cancer,0.00023948921688719558,0.0003045163843399217
NCT02530411,Fulvestrant +/- Vandetanib in Advanced Aromatase Inhibitor Resistant Breast Cancer,0.0002596782338757897,0.00033078797300489077
NCT02561832,"A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer",0.00033912086032552316,0.0002951156270421623
NCT02598557,Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast Cancer,0.00031954827749263945,0.00033937889619117497
NCT02556632,Prophylactic Topical Agents in Reducing Radiation-Induced Dermatitis in Patients With Non-inflammatory Breast Cancer or Breast Cancer In Situ,0.0002843378204488177,0.0002764015365242144
NCT02556684,Breast-Specific Gamma Imaging and Locally Advanced Breast Cancer Undergoing Neoadjuvant Chemotherapy,0.0002981627674821801,0.00035055120014389446
NCT02583828,Study in Letrozole Combined With Metronomic Oral Cyclophosphamide in Elderly Metastasis Breast Cancer Patients,0.00033593061335421764,0.0004094251923953452
NCT02583204,Taxane Chemotherapy and Nail Toxicity in Women With Breast Cancer; Stage Two: Evaluation of Interventions,0.00025942794116309587,0.0002944796072744917
NCT02583568,Fluorescence Guided Surgery in Breast Cancer,0.0003481883692774935,0.0002737753498519483
NCT02502864,Multicenter Study of Pharmacokinetic-Guided Docetaxel in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide,0.000326312740764815,0.0003578747984685451
NCT02505906,Late Toxicity in Breast Cancer Patients Treated With Breast-conserving Surgical Procedures and Radiotherapy Using the Simultaneous Integrated Boost Technique,0.0003072253902523929,0.0003697367484417885
NCT02586025,"A Randomized, Double-Blind, Placebo-Controlled Study in Patients With Early-Stage or Locally Advanced HER2-positive Breast Cancer to Evaluate Treatment With Trastuzumab + Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel",0.000380088304022583,0.0003834957748720543
NCT02586675,TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer,0.00029494478567454387,0.0002928071531316115
NCT02582801,Clinical Research of 18F-Alfatide Ⅱ PET/CT in Breast Cancer,0.000277570120848767,0.0004124522431427024
NCT02560662,PhysSurg-B : Physical Activity in Relation to Surgical Operations - Breast Cancer,0.00026853811655412434,0.00033940268617066476
NCT02520063,"Preoperative Combination of Letrozole, Everolimus, and TRC105 in Postmenopausal Hormone-Receptor Positive and Her2 Negative Breast Cancer",0.0002612876990178302,0.00031357025686319314
NCT02584712,Effect of Exercise Training in Autonomic Modulation in Breast Cancer Patients,0.0003506712822700189,0.00034618975779092187
NCT02541435,Acute and Long-term Cardiovascular Toxicity After Modern Radiotherapy for Breast Cancer,0.0002565410990044729,0.0002943604296588074
NCT02541188,Genotype and Phenotype in Early Onset Breast Cancer in Young Women on the Two Shores of the Mediterranean Sea,0.00032796227844899824,0.00019887610658403526
NCT02513394,PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer,0.00027839662281060217,0.0003197127567716683
NCT02513329,Stellate Ganglion Block (SGB) For Women for Breast Cancer,0.0003281459749570465,0.0002543944870846773
NCT02518477,Preventive Intervention Against Lymphedema After Breast Cancer Surgery,0.00029243344358857476,0.00026695578554682765
NCT02545023,"Supportive Care Questionnaires in Gathering Data on Unmet Needs and Health-Related Quality of Life in Latina Breast Cancer Survivors After Surgery, Chemotherapy, or Radiation Therapy",0.0002675877815117063,0.00030862809818937983
NCT02596867,Neoadjuvant Propanolol in Breast Cancer,0.0003461750017886549,0.00037368595817319314
NCT02553707,A Study to Assess the Short Term Efficacy of Intravenous Ibandronate (Bondronat) in Participants With Metastatic Bone Pain Due to Breast Cancer,0.00026613652558810433,0.00021583259383462332
NCT02553850,An Observational Study in Patients With Breast Cancer and Bone Metastases Receiving Ibandronate (Bondronat),0.00031915003429481734,0.0002938333630550435
NCT02547961,Chimeric Antigen Receptor-Modified T Cells for Breast Cancer,0.0003294755902144267,0.00043870555368311716
NCT02510781,A Study on Neoadjuvant Therapy for Her-2 Positive Breast Cancer and the Prognosis by Detecting CTCs,0.00030683224674656,0.000306465568416514
NCT02510430,The Plan and Stand Study: Reducing Sitting Time in Breast Cancer Survivors,0.0003168082158438533,0.00026955797032340937
NCT02510456,Monitoring Neoadjuvant Chemotherapy Response in Breast Cancer Patients Using Diffuse Optical Spectroscopic Imaging,0.00031394322541135187,0.00035584535591443
NCT02548338,Argon Plasma Coagulation Scalpel on Surgical Treatment of Breast Cancer,0.0002831597489904528,0.00024585091115731587
NCT02535221,Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ & HER2- Breast Cancer,0.0003251630006307889,0.000352445504957474
NCT02549534,Early Detection of Taxane-Induced Neuropathy in Women With Breast Cancer,0.00027356304081856684,0.0003096275024148561
NCT02549677,"Epirubicin Versus Docetaxel Plus Cyclophosphamide in Lymph Node Negative, ER-positive, Her2-negative Breast Cancer",0.0002511278988031669,0.0002929577109362745
NCT02522234,A Pharmacokinetics/Dynamics Ib Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy,0.0003393501663751584,0.00031806291010301284
NCT02522260,OptiTrain - Optimal Training Women With Breast Cancer,0.0004629595373387834,0.0003114854332454543
NCT02532400,Neoadjuvant Aromatase Inhibitor(AI) With Ovarian Suppression Versus Chemotherapy in Premenopausal Breast Cancer Patients,0.00031191791066304605,0.00027816021514337236
NCT02515487,An Investigation of Chemotherapy Induced Cognitive Impairments in Breast Cancer Survivors,0.0003014819518637756,0.00031700599815779386
NCT02515110,Hypofractionated Regional Nodal Irradiation Clinical Trial for Women With Breast Cancer,0.00034506418784317083,0.00033002184857596395
NCT02521961,Support Group Program in Improving Quality of Life in Underserved Urban Latina Breast Cancer Survivors,0.0002547358508533511,0.0002780190427135379
NCT02521441,"A Phase II, Dose-finding Study of F-627 in Patients With Breast Cancer Receiving Myelotoxic Chemotherapy.",0.00036516224049308246,0.00037113622725684615
NCT02521077,Intravenous Ascorbic Acid in Women Receiving Adjuvant or Neo-Adjuvant Chemotherapy for Early Stage Breast Cancer,0.0002585557729640248,0.0003061595595593827
NCT02574780,Lymphedema Upper Limb of Breast Cancer Through Muscle Strengthening Associated With Complex Physical Therapy,0.00023737980435625501,0.0002847943034194444
NCT02574546,Markers for Predicting Risk of Breast Cancer in Women of Different Races,0.0004709342382672909,0.00033770352893836654
NCT02574507,Behavioral Weight and Symptom Management for Breast Cancer Survivors and Partners,0.0002724280170283743,0.00030709445913417973
NCT02564848,IIT2015-06-Chung: Safety and Efficacy of Omission of Sentinel Node Biopsy in Patients With Clinical T1-2 Estrogen-Positive Breast Cancer Over Age 70,0.0002919282700303057,0.0002699586714374816
NCT02514837,Microwave Radiometry for the Diagnosis and Monitoring of Breast Cancer,0.0002791303856316834,0.00027466461212083767
NCT02514499,"Multiplex Testing for Evaluation of Breast Cancer Risk, Longitudinal Study",0.00039720095697548497,0.000323686238604333
NCT02528747,A Survey of Breast Cancer Patients With Metastatic Bone Disease Receiving Oral Ibandronate,0.00029748767560045967,0.00028142735815982363
NCT02528539,Prevention of Lymphedema Among Breast Cancer Patients Through Implementation of an Integrative Therapy Program (ITP),0.00031200035526894577,0.00036314144199655143
NCT02509871,Study of Body Composition in Patients Treated by Adjuvant Hormonal Therapy for Breast Cancer (MetaCa2),0.0003518373578240997,0.00035508257932892256
NCT02592070,Activity & Cognition After Treatment for Breast Cancer,0.0003034188610449097,0.0002963687821631353
NCT02567929,Assessment of the Anesthetic Effect on the Activity of Immune Cell in Patient With Breast Cancer,0.0002905065142629475,0.0002865775736910445
NCT02599363,A Trial of Ribocilcib (LEE011) and Weekly Paclitaxel in Patients With Rb+ Advanced Breast Cancer,0.0003800630738081759,0.00037142719228813666
NCT02599467,EMG at Performing ULTN 1 in Breast Cancer Patients,0.000604818613718354,0.0002955478215038277
NCT02599974,PET-CT in the Initial Staging of Breast Cancer and in the Early Assessment of Response to Neoadjuvant Chemotherapy,0.0002735097226890457,0.00038318126150751325
NCT02595138,Zoledronic Acid as Adjuvant Treatment of Triple-negative Breast Cancer,0.00030616107716189975,0.0003318867619418798
NCT02595905,Cisplatin With or Without Veliparib in Treating Patients With Stage IV Triple-Negative and/or BRCA Mutation-Associated Breast Cancer,0.00029542849145489363,0.00034838722439068694
NCT02580799,Study of Human Epidermal Growth Receptor (HER2) Status Evaluation in Breast Cancer Pathology Samples,0.0002759872647679179,0.0003084573539984111
NCT02580396,Evaluation Of CanADVICE+®M-Health System To Support Breast Cancer Patients Receiving Capecitabine,0.0003030783534245269,0.00022469168561150014
NCT02580279,Study of Epigallocatechin-3-gallate (EGCG) for Skin Prevention in Patients With Breast Cancer Receiving Adjuvant Radiotherapy,0.0003193224717371119,0.0003115911049577387
NCT02506790,Neoadjuvant Toremifene With Melatonin or Metformin in Locally Advanced Breast Cancer,0.0002666711308440102,0.00041552170373781127
NCT02506361,Evaluation of the Relationship of TOP2α Expression and Effect of Non Dose-dense Chemotherapy for Breast Cancer,0.0002539266156365558,0.0002895769151183361
NCT02506530,"Treatment Pathway of Patients Suffering From a Breast Cancer Related Lymphoedema, During an Intensive Decongestive Treatment",0.0003095944338211742,0.00041015742356893613
NCT02506556,Phosphatidylinositol 3-kinase (PI3K) Alpha iNhibition In Advanced Breast Cancer,0.00029741345030751156,0.00035419038643960156
NCT02506777,Neoadjuvant FDC With Melatonin or Metformin for Locally Advanced Breast Cancer.,0.0002811527279519697,0.0003728368908268548
NCT02550795,Dexmedetomidine or Dexmedetomidine Combined With Dexamethasone on Postoperative Nausea and Vomiting in Breast Cancer,0.0002717201159522877,0.00029154883233444397
NCT02536794,MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer,0.0003166511907257437,0.0003218858550199918
NCT02590458,Feasibility of Short Breast MRI (SBMRI) for Screening Patients at High Risk for Breast Cancer,0.0003167819604664635,0.0003203897053173658
NCT02581839,Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate,0.00030278805211977276,0.0003409595724562221
NCT02581670,Study on SBRT for Inoperable Lung and Liver Oligometastases From Breast Cancer,0.00028484430039307405,0.0003600689343219584
NCT02581956,Walking Affecting Immunology and Quality of Life of Breast Cancer Patients,0.00031102577082812587,0.00041251504170927543
NCT02559362,Study on Breast Cancer Patient Perspectives of Exercise,0.00039447359701399553,0.0003760339568226442
NCT02571894,The Cardio-Oncology Breast Cancer Study,0.0003919059940343226,0.00032166887013059247
NCT02571530,Super-selective Intra-arterial Cerebral Infusion of Trastuzumab for the Treatment of Cerebral Metastases of HER2/Neu Positive Breast Cancer,0.00025852859956287786,0.0003346609505788712
NCT02527746,Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy,0.0004144287464385372,0.0003160592164825021
NCT02527889,The Effect of Resistive Exercise on Forearm Blood Flow and Tissue Oxygenation Among Breast Cancer Survivors With or at Risk for Breast Cancer-related Lymphoedema (BCRL),0.00023924241177529016,0.000318745335241573
NCT02527317,Dose Dense Chemotherapy With Lipegfilgrastim Support in Early Breast Cancer,0.0002948324751201384,0.00030884007116964456
NCT02517086,Vascular Changes Due to Different Treatments of Lymphedema Secondary to Postoperative Breast Cancer,0.0002616223167508578,0.000328065835331287
NCT02517593,Genetic Risk Estimation of Breast Cancer Prior to Preventive Medication Uptake,0.00024788895444506853,0.0003110196381488487
NCT02562118,Neoadjuvant Lenvatinib Combined With Letrozole in Hormone Receptor Positive Breast Cancer,0.00026204139300443734,0.00036805887991558467
NCT02575612,Diagnosis of Pathological Complete Response by Minimal Invasive Biopsy After Neoadjuvant Chemotherapy in Breast Cancer,0.000262211219956891,0.00035838468086327754
NCT02597179,Genome Sequencing in Refractory Breast Cancer to Molecular Targeted Therapy and Young Breast Cancer,0.00032805053003616966,0.00042372133169500046
NCT02591316,"Nutrition, Physical Activity, and Cognition in Breast Cancer Survivors",0.00025382695356795986,0.00028434109451991487
NCT02591966,Genetic Alteration After Systemic Treatment in Breast Cancer,0.0003644455742068834,0.0004435295188146954
NCT02523417,HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA）for Breast Cancer,0.0003053710139133032,0.0005144997036168752
NCT02587663,Extent of Breast Cancer and the Role of Pre-Operative Sonography and MRI,0.0003286963081406212,0.00027155989752059283
NCT02557776,Written Genetic Counseling and Mutation Analysis of BRCA1 and BRCA2 to Patients With Breast Cancer,0.00034557331257482605,0.0003320265633903344
NCT00616967,Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer,0.00026159504777965273,0.0002667597742875185
NCT00670644,Self-Care for Lymphedema in Patients With Breast Cancer,0.0004278138751640682,0.0004513499122976529
NCT00670878,"Studying the Benefits of Adjuvant Sequential vs. Combined Taxane Based Chemotherapy, Followed by Different Biological Treatment Strategies in Early, HER2-positive Breast Cancer",0.00027474371225131216,0.0003593949729569212
NCT00667121,"Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline",0.00023453955774235046,0.0002053489015584207
NCT00678626,"Phase 2 Trial Of CP-751,871 And Docetaxel In Advanced Breast Cancer",0.000370765998729532,0.0003562825418599308
NCT00678509,Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Breast Cancer,0.0003129949290708422,0.000393824343242772
NCT00695916,MRI in Women With Newly Diagnosed Breast Cancer Prior to Breast Conserving Surgery,0.00033683868722494677,0.0002770405024964966
NCT00676663,Study to Evaluate Exemestane With and Without SNDX-275 in Treatment of Postmenopausal Women With Advanced Breast Cancer,0.0003193316880855422,0.00045147291164171553
NCT00623519,Assessment of Endometrial Changes in Postmenopausal Women With Breast Cancer in Adjuvant Treatment With Anastrozole,0.0002665587881240716,0.00030311200034486625
NCT00617539,Irinotecan and Temozolomide in Treating Patients With Breast Cancer Who Have Received Previous Treatment for Brain Metastases,0.0003075545096921398,0.00031584386336658916
NCT00617968,GETNA2 Neoadj. TAX+Femara vs Femara in g I/II Breast Cancer,0.0004606325542987772,0.00032996685552730525
NCT00617370,Dose-Dense Epirubicin and Cyclophosphamide (EC) Followed by Paclitaxel in Breast Cancer: Feasibility,0.00028749024523887185,0.00033688250627550204
NCT00617942,"Neoadjuvant Carboplatin, Weekly Abraxane and Trastuzumab in HER2+ Breast Cancer",0.00027114773250713455,0.00028548479027843933
NCT00614172,Proton Therapy for Early Stage Breast Cancer,0.0003430211479059622,0.0004308733339385363
NCT00614978,Lapatinib and Temozolomide for the Treatment of Progressive Brain Disease in HER-2 Positive Breast Cancer,0.00025986261568813917,0.0003579347293401916
NCT00633750,Erlotinib in Treating Patients With Breast Cancer That Can Be Removed by Surgery,0.00032262724061412154,0.0002905381359142682
NCT00662025,Study Of Sunitinib With Capecitabine In Breast Cancer,0.00032213041909844226,0.00043168848068993046
NCT00631852,A Phase II Biomarker Trial of Gelatin Encapsulated Extract of American Ginseng Root (LEAG) in Breast Cancer,0.00023399913320882275,0.000280994991035362
NCT00652678,Predictive Blood Tests for Severe Radiation Reactions in Breast Cancer Patients,0.0003176791536697704,0.00035711881946438
NCT00636441,Trial to Evaluate Genomic Expression Profiles to Direct Preoperative Chemotherapy in Early Stage Breast Cancer,0.00024527200076117974,0.00030131612113608097
NCT00673335,Letrozole in Preventing Breast Cancer in Postmenopausal Women With a BRCA1 or BRCA2 Mutation,0.00035285657604666016,0.00035220170041195485
NCT00610181,Magnetic Resonance Imaging in Patients With Breast Cancer,0.0004251553388299013,0.0003334695333096325
NCT00650910,Study To Examine The Effects Of Lapatinib On The Pharmacokinetics Of Digoxin In Subjects w/ ErbB2 Positive Breast Cancer,0.00027346467123536526,0.0002918973525711581
NCT00600275,A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer,0.00037082884583971844,0.0003455631170524388
NCT00600249,"Assessment of the Efficacy of a Neoadjuvant Combination: ""Chemotherapy-targeted Therapy"" in Breast Cancer.",0.0002947535475278483,0.0003659095264678534
NCT00659906,Optimizing Body Composition & Health After Breast Cancer,0.0003296594521816792,0.0002354551792086371
NCT00696527,National Survey on Infiltrative Breast Cancer,0.000328139926349992,0.0003947303465490139
NCT00696072,"Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic",0.00027100669021779943,0.00030740014459170725
NCT00611715,"Ph II Letrozole + OSI-774 (Tarceva) in Post-menopausal, w/ ER and/or PR-positive Met Breast Cancer.",0.00024194251001524714,0.0002132629697783675
NCT00637481,A Phase I Prevention Study of Atorvastatin in Women at Increased Risk for Breast Cancer,0.00028843942733865186,0.00030071621003528964
NCT00637325,Trastuzumab Optimization Trial in Breast Cancer,0.00048375288864420873,0.0003975440277395681
NCT00657137,APRiCOT-B: Study to Evaluate Apricoxib in Combination With Lapatinib and Capecitabine in the Treatment of HER2/Neu+ Breast Cancer (TP2001-202),0.0002976706880842413,0.00032734666982526985
NCT00681369,Observational Usage Study of Faslodex in Patients Suffering From Initial Breast Cancer in France,0.0003278120178205883,0.0004032803702265305
NCT00682253,"Use of Bone Scintigraphy, CT and MRI in Breast Cancer",0.00032997797205676154,0.0002700059436448983
NCT00684216,Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast Cancer,0.0003235278044920058,0.00035568459816309755
NCT00684983,Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer,0.00032256443202637546,0.0003519648673461002
NCT00665899,A Couples Approach to Enhance Breast Cancer Survivorship,0.0008829212022672371,0.0003178683327567787
NCT00668616,Adjuvant Treatment of Breast Cancer With 1-3 Aflicted Lymph Nodes,0.00036572804036529466,0.00045311267483470427
NCT00669773,Validate Gene Expression and Proteomic Signatures Predictive of Treatment for Response for Breast Cancer Patient,0.0003179699141081701,0.00034061927866218687
NCT00669565,Safety and Efficacy Study of Bavituximab Plus Paclitaxel and Carboplatin to Treat Breast Cancer,0.0002941485842898378,0.00033198223214147844
NCT00669591,A Safety and Efficacy Study of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer,0.00035063160786204126,0.0004355933427817656
NCT00653718,"Musculoskeletal Pain in Postmenopausal, Early Breast Cancer Patients Receiving Aromatase Inhibitor Therapy - A Pilot Study",0.0003488627522983457,0.0004348699180192272
NCT00634634,Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer,0.0002819082356953512,0.0002783914116779805
NCT00634088,Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer,0.00029056174448297635,0.000331215974427875
NCT00649090,A Study to Evaluate the Safety of Adjuvant Treatment With Exemestane Following Previous Treatment With Tamoxifen in Postmenopausal Women With Estrogen Sensitive Primary Breast Cancer,0.00030068489183736986,0.00037707470308001167
NCT00660803,Retrospective Brazilian Study of Fulvestrant in Advanced Breast Cancer,0.00030881484355689234,0.00041648400972604544
NCT00660244,Breast Cancer Tumor Care Observational Programme,0.0002813504565955946,0.0004505690875214547
NCT00635596,"Phase I Study of MT110 in Lung Cancer (Adenocarcinoma and Small Cell), Gastric Cancer or Adenocarcinoma of the Gastro-Esophageal Junction, Colorectal Cancer, Breast Cancer, Hormone-Refractory Prostate Cancer, and Ovarian Cancer",0.0002597611839573374,0.00023925727240599602
NCT00635713,Second Line Breast Cancer Trial,0.0004615825292633765,0.00036649620395377966
NCT00635050,"Therapy for Locally Advanced Breast Cancer Using Doxil, Paclitaxel, and Cyclophosphamide With Avastin",0.0002799708153870586,0.0003394279212647431
NCT00658281,Setup Variation in the Supraclavicular Lymph Nodes Treatment in Breast Cancer Patients,0.00037371982466283526,0.000325819437439863
NCT00656019,Development of Vitamin D as a Therapy for Breast Cancer - Phase II,0.00030165972568768574,0.000358904515925576
NCT00656669,Exploratory Study of Sunitinib Malate as a Component of Neoadjuvant Therapy for Breast Cancer,0.0002964648912087086,0.000345278883425111
NCT00656604,"Evaluation of Patients With Breast Cancer Using DCE-MRI, MRS, and Proteomics",0.0003539909391432316,0.00032561170239981654
NCT00646633,Improving Fatigue: A Pilot Study of Acupuncture and Patient Education for Breast Cancer Survivors,0.0003307527148856816,0.0002869385590259479
NCT00620594,A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer,0.00037082884583971844,0.000374174195529199
NCT00691509,"Dietary Phytoestrogens, Complementary and Alternative Medicine, and Lifestyle in Predicting Survival of Women With Breast Cancer",0.00032750551540277256,0.00024216483215062012
NCT00691119,Relaxation and Visualization Therapy for Breast Cancer Patients,0.0003737891330688514,0.0003365343130065826
NCT00691678,Glucosamine and Chondroitin for Aromatase Inhibitor Induced Joint Symptoms in Women With Breast Cancer,0.0002504590158347421,0.00020814419151003543
NCT00639210,BREAST CANCER AND EXERCISE,0.00032759788482961664,0.0003275508081891423
NCT00639366,Radiation Therapy to the Head in Preventing Brain Metastases in Women Receiving Trastuzumab and Chemotherapy for Metastatic or Locally Advanced Breast Cancer,0.0002845670038143235,0.0002511362614275397
NCT00604435,Neoadjuvant Endostatin and Chemotherapy for Breast Cancer,0.0003072381542495302,0.00033455506706580804
NCT00651976,"Letrozole in Treating Postmenopausal Women With Stage I, II or III Breast Cancer That Can Be Removed by Surgery",0.0002709997507251565,0.0003183273210719233
NCT00689156,Epirubicin or Not in Patients With TOP2A (Topoisomerase (DNA) II Alpha (170kD)) Normal Early Breast Cancer,0.0003095990051460711,0.0002516620644966772
NCT00612443,Healing Touch and Health-Related Quality of Life in Women With Breast Cancer Receiving Radiation Therapy,0.0002489569189486004,0.00034917893872175605
NCT00647790,Positron Emission Tomography (PET) Using Hormone Receptor Ligands in Breast Cancer,0.0003375553239193558,0.00037926987818406584
NCT00647075,Yunzhi as Dietary Supplement in Breast Cancer,0.00046077190001823286,0.0006573661123913896
NCT00675259,Phase II NCT (Neoadjuvant Chemotherapy) w/ Weekly Abraxane in Combination With Carboplatin & Bevacizumab in Breast Cancer,0.0002672775663472849,0.00027766162655498846
NCT00605267,Arimidex/Tamoxifen Neo Adjuvant Study in Premenopausal Patients With Breast Cancer Under Anti Hormonal Treatment,0.00034448811050663894,0.0003136742048770059
NCT00688909,Rheumatological Evaluation of Anastrozole and Letrozole as Adjuvant Treatment in Post-menopausal Women With Breast Cancer,0.00027193853563812023,0.00031304912958460675
NCT00688740,Docetaxel in Node Positive Adjuvant Breast Cancer,0.0002936175873600099,0.00035700115044945885
NCT00688246,Bone Mineral Density in Postmenopausal Women at Increased Risk of Developing Breast Cancer And Who Are Receiving Exemestane on Clinical Trial CAN-NCIC-MAP3,0.0002507123859550585,0.0002844072497648792
NCT00688337,Correlation Between Fluorodeoxyglucose (FDG) and FLT Uptake and Gene-Expression Oncotype Assay in Patients With Breast Cancer,0.0002922923353419961,0.0002975945080747547
NCT00690196,Tai Chi Effects on Chronic Insomnia in Breast Cancer Survivors: Immune Mechanisms,0.0003285085449125777,0.0003050506097563933
NCT00601406,"Study of DNA Mutations in Predicting the Effect of External-Beam Radiation Therapy in Patients With Early Breast Cancer, Localized Prostate Cancer, or Gynecological Cancer",0.00032136777093674297,0.0003469843389476582
NCT00630591,DAMES: Daughters And MothErS Against Breast Cancer,0.0008829212022672371,0.00025279094763936105
NCT00630032,Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer,0.00024247375188579022,0.00025816651352630405
NCT00630695,Prevention of Lymphorrhea by Lanreotide in Axillary Dissection for Breast Cancer,0.0002753979155507465,0.0003280248301458636
NCT00607295,Efficacy and Safety of Clino-san on Vaginal Dryness of Breast Cancer Patients,0.00042429337727395764,0.00025537224212754563
NCT00645138,Comparison of Paravertebral Block With General Anesthesia in Patients Undergoing Breast Cancer Surgery,0.00030497053901459213,0.00023118231373568535
NCT00629278,"Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast Cancer",0.00025754762017623616,0.00025607036474344726
NCT00629616,"Efficacy of Anastrozole and Fulvestrant in Patients With ER Positive, HER2 Negative, Operable Breast Cancer",0.00029787855673939743,0.000306560679683098
NCT00602316,Multifunctional Magnetic Resonance Imaging in Predicting Breast Lesions in Women Undergoing Mastectomy for Breast Cancer,0.00025116062642272896,0.0002684574201628605
NCT00615524,Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast Cancer,0.0002863344131633982,0.0003241770359056349
NCT00615316,Guaraná for Radiation Related Fatigue in Breast Cancer Patients,0.0003230044680487517,0.00027915464020417824
NCT00615602,Six vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer,0.00031897003999703635,0.00032209936183400303
NCT00615901,"Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer",0.00024276978115661551,0.00033379604182183183
NCT00679185,Expressive Writing in Improving Quality of Life in Patients With Breast Cancer and Lymphedema,0.0003134419706999359,0.0003092366413196852
NCT00679783,Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast Cancer,0.0003259822916487809,0.0003008368734191432
NCT00679341,A Study of the Efficacy and Safety of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) vs. Trastuzumab (Herceptin®) and Docetaxel (Taxotere®) in Patients With Metastatic HER2-positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease,0.0003310743745172209,0.0003079697964654946
NCT00679874,Assessment of Cardiotoxicity After Chemotherapy for Breast Cancer by Cardio-vascular Magnetic Resonance (MR),0.0002560833890926133,0.00031922747251300913
NCT00677326,Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Breast Cancer,0.0003129949290708422,0.000393824343242772
NCT00622401,Vaccination of Patients With Breast Cancer With Dendritic Cell/Tumor Fusions and IL-12,0.00029514097431855297,0.0003192276954298677
NCT00638599,Comparison of Laryngeal Mask Airway (LMA®) and Tracheal Tube in Modified Radical Mastectomy on Breast Cancer,0.0002361826168461608,0.00019354999329556255
NCT00638391,Ax-003/Arimidex (Anastrozole) in the Adjuvant Therapy of Early Breast Cancer,0.0003338410500240365,0.0005145070293704958
NCT00632723,IRESSA™ (Gefitinib) in Breast Cancer Patients,0.00034551103793627587,0.0002940607433106714
NCT00632489,LBH589 in Combination With Capecitabine Plus/Minus (±) Lapatinib in Breast Cancer Patients,0.0003225553112603941,0.00029083685658922034
NCT00698035,Vaginal Testosterone Cream vs ESTRING for Vaginal Dryness or Decreased Libido in Early Stage Breast Cancer Patients,0.00028821049018633115,0.0003388411952867152
NCT00666913,Menopausal Symptoms in Women With Breast Cancer or At High Risk of Breast Cancer Treated on Another Clinical Trial,0.00027917298640784305,0.0002675079167078684
NCT00666822,Compliance to a Hormone Therapy Regimen in Breast Cancer,0.0002787289994935006,0.0002657069231852167
NCT00666731,Breast Cancer Registry for Participants With Breast Cancer or Characteristics of Hereditary Breast Cancer,0.0002755580431251391,0.0003887305041056737
NCT00674557,Exemestane With or Without ATN-224 in Treating Postmenopausal Women With Recurrent or Advanced Breast Cancer,0.00031322959777291417,0.000249860297026458
NCT00674414,Trastuzumab With or Without Everolimus in Treating Women With Breast Cancer That Can Be Removed By Surgery,0.00027151308415834026,0.0002270270637676491
NCT00674830,Self-help Treatment for Insomnia in Breast Cancer Patients,0.0003327313986739546,0.0003262335712205688
NCT00674011,Hypertension in Breast Cancer Patients Receiving Bevacizumab,0.00034928496251448966,0.0003147244188047872
NCT00627627,A Study to Evaluate the Antitumor Activity and Safety of IPI-504 in Patients With Advanced Breast Cancer,0.0003427435209002581,0.000532594005024135
NCT00627614,Vibro-Acoustography Imaging in Diagnosing Breast Masses in Women With a Breast Mass or Breast Cancer,0.0002460961238532491,0.0002232129100046724
NCT00686127,Symptom Management After Breast Cancer Surgery,0.00034745553185005584,0.00027249100200069234
NCT00671918,Trial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and Melanoma,0.00023592992871989107,0.00019542801492148664
NCT00692458,A Study to Assess the Effects of MK0822 in Reducing the Risk of Bone Metastasis in Women With Breast Cancer (0822-029),0.00038793833547997426,0.0006444208445340239
NCT00692289,Quality of Life Analysis of Arimidex Treatment in Postmenopausal Patients With Breast Cancer,0.0003249935826795974,0.000344524326713445
NCT00694252,Lapatinib and Circulating Tumor Cells in Breast Cancer,0.0003319603257766273,0.00041077562774551025
NCT00694200,Vinorelbine Metronomic Plus Bevacizumab as Salvage Therapy for Breast Cancer,0.00027678258425324625,0.00030605327250559863
NCT00680667,Clinical Trial of Trametes Versicolor in Women With Breast Cancer,0.00046638215272680125,0.0003178349941391197
NCT00378313,"A Study of Gemcitabine, Epirubicin, and Paclitaxel Combination Chemotherapy Given Before Surgery to Patients With Locally Advanced Breast Cancer",0.00035121764995810884,0.000407771385840978
NCT00378638,Dose-Dense Chemotherapy Plus Bevacizumab in High Risk Lymph Node Positive Breast Cancer: A Pilot Study,0.0002932377647823354,0.0003288675768861711
NCT00382070,Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer,0.00025824394876692615,0.00022695669869682403
NCT00398567,A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer,0.0002989041940242746,0.00036321220023024386
NCT00398489,"Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery",0.0002757475196156232,0.00030104695767661104
NCT00369850,Bone Density and Bone Loss in Postmenopausal Women With Breast Cancer Receiving Treatment in Clinical Trial IBCSG-1-98,0.0002691065203616239,0.00027888633507949985
NCT00349011,Genetic Counseling for Menopausal Therapy Decision-Making for Women at Increased Risk for Breast Cancer,0.000261077295452737,0.0003191962175388951
NCT00338728,Letrozole (Femara) Plus Imatinib Mesylate (Gleevec) for Breast Cancer Patients,0.0002961301463324043,0.00034254591469619485
NCT00383500,Lymphedema Prophylaxis in Breast Cancer Survivors Who Show Early Evidence of High-risk Status,0.0002544259015797874,0.00022439163412584114
NCT00373256,A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer,0.0003548191929390231,0.0005268918702670826
NCT00308178,Dose Dense Abraxane in Adjuvant Chemotherapy for Breast Cancer,0.0003316193522580511,0.00026373409980257344
NCT00328783,Using the Active Breathing Control Device to Reduce Radiation Side Effects to Critical Structures in Breast Cancer,0.0002437530445278488,0.00030226817527518603
NCT00328432,"A Study of Women With an Early Diagnosis of Breast Cancer, Taking Celecoxib Between the Biopsy and Lumpectomy/Mastectomy",0.000265045135906633,0.0003051460054637886
NCT00347568,BC-DAISY: A Breast Cancer Decision Aid System,0.00032805013543450533,0.00025740797458246147
NCT00347438,Capecitabine as NeoAdjuvant Therapy in Locally Advanced Breast Cancer,0.0003308558187868383,0.00038349452599207516
NCT00301106,Biological Therapy in Treating Women With Breast Cancer That Has Spread to the Liver,0.00032786772771370166,0.00027961379506589925
NCT00301925,Combination Chemotherapy in Treating Patients With Early Stage Breast Cancer That Has Been Removed By Surgery,0.0003161637412409382,0.0003039202589106803
NCT00301457,Different Durations of Adjuvant Anastrozole Therapy After 2 to 3 Years Tamoxifen Therapy in Breast Cancer,0.00027672629864727773,0.00037635682072707067
NCT00301730,Cellular Adoptive Immunotherapy in Treating a Patient Who Has Undergone a Donor Stem Cell Transplant for Breast Cancer That Has Spread to the Lung,0.0002838226003065837,0.0002805406048463128
NCT00301548,Perioperative Chemotherapy After Primary Chemotherapy for Locally Advanced Breast Cancer,0.0003898200937261012,0.0003150146065731518
NCT00343382,Pilocarpine in Treating Vaginal Dryness in Patients With Breast Cancer,0.00034546202916000877,0.0002983693560968841
NCT00343616,Cognitive Function in Postmenopausal Women With Breast Cancer Receiving Hormone Therapy on Clinical Trial IBCSG-1-98,0.0002644509821074648,0.00023093470421259443
NCT00343863,Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer,0.00029131093333119887,0.00032117769596885104
NCT00343109,Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer,0.0003289000187647535,0.0002782428168005468
NCT00326820,Ibandronate or Zoledronate in Treating Patients With Newly Diagnosed Bone Metastases From Breast Cancer,0.00029792033612546006,0.0002810407682713367
NCT00370552,A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer,0.00025724323096314834,0.0003497007342686662
NCT00370240,Chlorhydrate of Ropivacaine and Breast Cancer Surgery,0.0003470884405078149,0.00037650241382807296
NCT00337233,Yoga in Controlling Symptoms and Reducing Stress in Women With Ovarian Cancer or Breast Cancer,0.00024926898081622487,0.00023435392025778713
NCT00337272,Treating Chronic Insomnia in Breast Cancer Patients,0.0004241118608812653,0.0004604930797468323
NCT00314977,Sequential vs Upfront Intensified Neoadjuvant Chemotherapy in Patients With Large Resectable or Locally Advanced Breast Cancer.,0.00036019871285308705,0.0003739764809565747
NCT00319254,Study Evaluating SKI-606 (Bosutinib) In Subjects With Breast Cancer,0.0003863921764408248,0.00043486578292995773
NCT00399802,A Study to Examine the Effects of an Experimental Drug on Women With Breast Cancer and Metastatic Bone Disease (MBD)(0822-016)(COMPLETED),0.0002760409383421626,0.000336380724714638
NCT00399321,A Pilot Study of Bone Mineral Density in Postmenopausal Women After Treatment for Breast Cancer,0.000319146534837082,0.00036164320008873717
NCT00375427,Safety and Efficacy of Zoledronic Acid in Patients With Breast Cancer With Metastatic Bone Lesions,0.0002992299549540523,0.000324583698418638
NCT00375752,Efficacy and Safety of Letrozole vs. Letrozole Plus Zoledronic Acid as Endocrine Therapy Before Surgery in Postmenopausal Patients With Breast Cancer,0.00031401163936151653,0.00036685340708755273
NCT00362973,PET Scans in Assessing Response To Treatment in Patients Receiving Hormone Therapy or Trastuzumab for Breast Cancer,0.0003246195686916545,0.0002888834993928794
NCT00304941,Insulin Resistance and Breast Cancer,0.0004603590742105769,0.00025126530706841705
NCT00334139,Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer,0.0002874123583254293,0.0003321628975176833
NCT00334542,Simvastatin in Preventing a New Breast Cancer in Women at High Risk for a New Breast Cancer,0.00033317532211319284,0.000237510893514526
NCT00360152,Testing of Different Methods for Determining Whether Breast Cancer Has Spread to the Lymph Nodes,0.0003294278328404206,0.000282820641474027
NCT00397501,BBBD Followed By Methotrexate and Carboplatin With or Without Trastuzumab in Treating Women With Breast Cancer That Has Spread to the Brain,0.000259823411846254,0.00024148031127938692
NCT00372476,Efficacy and Safety of Imatinib and Vinorelbine in Patients With Advanced Breast Cancer,0.00033112907387609756,0.0003951793317721364
NCT00372710,Safety/Efficacy of Intravenous Zoledronic Acid When Added to Standard Therapies in Patients With Breast Cancer and Metastatic Bone Lesions,0.0003090149232246877,0.0003594292772131839
NCT00372424,Study Of SU011248 In Combination With Docetaxel And Trastuzumab In Patients With Advanced Breast Cancer HER-2 Positive,0.0003572891972018056,0.00039256256108212683
NCT00372996,"Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer",0.0003046273860743654,0.00040374046783674355
NCT00310089,AZD2171 and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer,0.00036608238189536266,0.00025306180434107357
NCT00310180,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),0.00025936694016358405,0.0003442145228676336
NCT00310882,Involvement of Endogenous Digitalis-like Compounds in Breast Cancer,0.00032759873274834124,0.0001895132839397676
NCT00381368,Safety and Efficacy Study of Intravenous Loading Dose of Ibandronate in Breast Cancer Patients,0.0003477974643543396,0.00039464225912123766
NCT00381901,Trastuzumab for 6 Months or 1 Year in Treating Women With Nonmetastatic Breast Cancer That Can Be Removed By Surgery,0.0003003470269245144,0.00022623005858322378
NCT00381927,Effect of Counseling on Psychological Stress Amongst Women Felt to be at High Risk for Breast Cancer Development,0.000250603913239736,0.0002021141220532154
NCT00316407,Lapatinib/Carboplatin/Paclitaxel in Previously Treated Ovarian or Breast Cancer Patients,0.0003114819955277852,0.00034298583837273855
NCT00394251,Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer,0.0003160364354811661,0.0003119410418423995
NCT00365417,"Therapy With Bevacizumab (BEV), Doxorubicin, and Cyclophosphamide Followed by BEV, Docetaxel, and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer",0.00029397633360208047,0.0004006286300022718
NCT00365105,"Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer",0.00028232135899868504,0.0001979765426470331
NCT00365599,Phase II Trial of SAHA & Tamoxifen for Patients With Breast Cancer,0.0004305737249288571,0.0004027396854620062
NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,0.00033339645882773825,0.0003689773777445402
NCT00392392,Preoperative Bevacizumab and Trastuzumab With ABI-007 and Carboplatin in HER2+ Breast Cancer,0.0002903350619069236,0.0002318513711808131
NCT00392184,Partial Breast Irradiation With Multi-Catheter Brachytherapy for pT1-2pN0 Breast Cancer After Breast Conserving Surgery,0.0002315624103352502,0.0002886932011129029
NCT00318513,Safety Study of Bevacizumab to Treat Women With a History of Breast Cancer and Suffering From Upper Extremity Lymphedema,0.0002682364743434566,0.00031084388040709753
NCT00329940,Safety and Rheumatologic Tolerability of Letrozole in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer,0.00031653522859437146,0.0004029951452996596
NCT00329017,Protocol for Postmenopausal Women at Increased Risk of Developing Breast Cancer,0.0002866304409922992,0.0002980305936923753
NCT00356681,"A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast Cancer",0.00031450131906335345,0.00035401808029838036
NCT00356148,The Efficacy of Prophylactic Antibiotic Administration During Breast Cancer Surgery in Overweight Patients.,0.00029586569459333714,0.00022700527532761716
NCT00309556,Randomized Neoadjuvant Study of Epirubicin and Docetaxel With/Without Capecitabine in Early Breast Cancer,0.0002852896844592496,0.00030231801969054074
NCT00313248,Evaluation of a New Agent for Treatment of Advanced Stage Breast Cancer,0.00029186060404062873,0.0003501392592292433
NCT00332852,Letrozole as Early Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer,0.0003483612607225766,0.000359641703334121
NCT00332709,Safety/Efficacy of Letrozole Monotherapy or in Combination With Zoledronic Acid as Extended Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer,0.0003216047310060158,0.0003114240846932417
NCT00359060,Physical Activity and Breast Cancer Risk in Postmenopausal Women:the SHAPE Study,0.0003010775959089541,0.00028281036728104264
NCT00359190,Pharmacokinetics And Pharmacodynamics Of Lapatinib In Two Dosing Regimens In Treatment-naive Patients With Breast Cancer,0.0003171436033744429,0.0003702964696691209
NCT00336791,Randomized Clinical Trial to Evaluate the Predictive Accuracy of a Gene Expression for Stage I-II Breast Cancer,0.0002632718067837153,0.0002922565660144719
NCT00336089,Exercise Program or Health Education Program in Reducing Fatigue and Pain in Breast Cancer Survivors,0.00024172105448210708,0.00019044716105195823
NCT00336102,Thyroid Dysfunction in Women With Newly Diagnosed Breast Cancer Compared to Healthy Volunteers,0.00027819960004065667,0.00022717030737015397
NCT00320541,"A Trial of Paclitaxel and Bevacizumab vs. Gemcitabine, Paclitaxel, and Bevacizumab in Advanced Breast Cancer",0.00027931482317620354,0.00040887759317584463
NCT00320710,Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast Cancer,0.0003349650207496212,0.0003380625145561664
NCT00325598,Partial Breast Irradiation (PBI) for Selected Patients With Early Breast Cancer,0.00042484722541227793,0.0004642659790417778
NCT00325234,Pemetrexed-Carboplatin and Gemcitabine-Vinorelbine in Advanced Breast Cancer,0.0002582879366696194,0.00033071333383205076
NCT00367666,Using Diagnostic Tools to Stage Breast Cancer,0.00035112873173342524,0.000217961073829333
NCT00330317,Safety and Efficacy of Hormone Therapy With Letrozole in Postmenopausal Women With Breast Cancer,0.0002961903244053091,0.00031628281118611446
NCT00321464,A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects.,0.0002940400235035149,0.0004328779054704515
NCT00321633,Carboplatin or Docetaxel in Treating Women With Metastatic Genetic Breast Cancer,0.00026170771763580584,0.00027288793982742273
NCT00312208,Docetaxel in Breast Cancer,0.0004739784354825977,0.000293539181291957
NCT00312637,Using Magnetic Resonance Spectroscopy With MRI to Non-invasively Determine Breast Cancer Extent of Disease,0.0003296936723816572,0.0002710936884773506
NCT00393939,Study Of Sunitinib In Combination With Docetaxel Vs Docetaxel In Patients With Advanced Breast Cancer,0.00034635141417779016,0.0004057488845009288
NCT00393406,The Influence of Breast Cancer Risk and Risk Perception on Lifestyle Behaviors Among Women With a Family History: A Mixed Method Approach,0.00023514239839759134,0.00023084516374522577
NCT00393783,Xenogeneic HER2/Neu DNA Immunization for Patients With Metastatic and High Risk Breast Cancer: A Phase I Study to Assess Safety and Immunogenicity,0.00032518671536741595,0.00031886267587506804
NCT00393341,Quantitation of Endothelial Progenitor Cells as Markers of Tumor Angiogenesis in Breast Cancer,0.000278794627926562,0.0003391534456910946
NCT00371488,GW572016 Combined With Trastuzumab For The Treatment Of Previously Trastuzumab-Treated Breast Cancer,0.0003801675542365163,0.0004421244970234833
NCT00371254,A Study of Dasatinib (BMS-354825) in Patients With Advanced 'Triple-negative' Breast Cancer,0.000349003189754048,0.0004037036884243918
NCT00341458,Breast Cancer in Poland: An Expanded Study to Assess Occupational and Environmental Factors and Interactions With Genetics,0.0003862087319208685,0.00026518857127425606
NCT00341315,"Breast Cancer, Breast Disease, and Pesticides",0.00027692313387444944,0.00027031863514628195
NCT00331097,ELDA: Elderly Breast Cancer - Docetaxel in Adjuvant Treatment,0.0003735204407559213,0.00041520206708337476
NCT00331942,Breast Cancer Associated Antibodies,0.0004615886006494667,0.0002193482380544104
NCT00357487,Evaluation of Two New Medical Instruments Dedicated to the Sentinel Lymph Node Technique in Case of Breast Cancer,0.00023706528248493356,0.00022750800398065263
NCT00357110,Anastrozole and Fulvestrant Compared to Anastrozole as Adjuvant Treatment of Postmenopausal Patients With Breast Cancer,0.00032630457120316146,0.00027178099833859387
NCT00386087,Enzastaurin For Breast Cancer Patients Who Previously Received an Anthracycline and a Taxane Chemotherapy,0.00030150578927743945,0.00039290742237980264
NCT00354302,Bone Mineral Density in Postmenopausal Women With Primary Breast Cancer Who Are Receiving Treatment on Clinical Trial CAN-NCIC-MA27,0.00028346439257781627,0.0002741209940656469
NCT00354900,Phase I Study of Aprotinin in Advanced Breast Cancer,0.0003426431031812981,0.0002878989290829459
NCT00322348,Study of Zoladex Given Every 12 Weeks Versus Given Every Month in Advanced Breast Cancer (ABC) Pre-menopausal Women,0.00030865244303156,0.0002835579695964826
NCT00322400,Phase1b to Evaluate Safety of AMG706 in Combination With Paclitaxel or Docetaxel for Breast Cancer,0.00027370653949024244,0.0003814890119280953
NCT00322504,Acupuncture for Anxiety in Women With Breast Cancer: A Feasibility Study,0.00027404813841434096,0.000318941471955557
NCT00395655,Hydralazine and Valproate Added to Chemotherapy for Breast Cancer,0.0002930510986059969,0.00026059358271522833
NCT00300508,3 Years of Anastrozole vs. no Treatment as Extended Adjuvant Therapy for Postmenopausal Women With Breast Cancer,0.0002694662293006262,0.00034728132806691945
NCT00300781,Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer,0.0003435302572444876,0.0004641042167954445
NCT00390169,Randomized Controlled Trial Comparing MBSR to SET in Breast Cancer Patients,0.0003456502968620462,0.00030960567335863677
NCT00390377,Use of Hair to Diagnose Breast Cancer,0.00033616094016557506,0.000258338564351688
NCT00376909,"A Telephone-Based Prevention Care Manager in Increasing Screening Rates for Breast Cancer, Cervical Cancer, and Colorectal Cancer in Minority and Low-Income Women",0.00023399554154708034,0.00019962028504121038
NCT00376740,Effectiveness of Zoledronic Acid in the Prevention of Osteoporosis in Early Breast Cancer Patients Receiving Letrozole,0.0002927639638493908,0.0003011954611170556
NCT00317720,Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer,0.00035792020611217937,0.0003857841462073976
NCT00317603,Vaccination With Autologous Breast Cancer Cells Engineered to Secrete Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Metastatic Breast Cancer Patients,0.0002806529766084032,0.0002553309557988284
NCT00327769,Faslodex Advanced Breast Cancer Local Chinese Study,0.0003436219068252648,0.00038394491201529195
NCT00339248,Markers for Breast Cancer,0.0004709342382672909,0.00032151442301600136
NCT00388713,Radiation Induced Atherosclerosis in Breast Cancer Patients,0.00035593311309221935,0.00028775184064695807
NCT00352378,Primary Chemotherapy With Adriamycin/Cyclophosphamide(AC) vs Taxotere/Xeloda(TX) for Stage II and III Breast Cancer,0.0002572734935794906,0.00029783111433101604
NCT00352872,Pharmacogenetics as a Predictor of Toxicity in Pre-Menopausal Women Receiving Doxorubicin and Cyclophosphamide in Early Breast Cancer,0.00025671042461949544,0.0003004318157208731
NCT00355316,A Study to Determine the Clinical Significance of Molecular Detection of Breast Cancer in the Blood of Stage IV Breast Cancer Patients,0.00031547040936720993,0.00027814484744629215
NCT00323479,Arthralgia During Anastrozole Therapy for Breast Cancer,0.000302965423097443,0.00042127940719811755
NCT00323908,Protocol to Examine Methylation of Tumor Suppression Genes in Women at High Risk of Developing Breast Cancer,0.00024250585547859403,0.00026606452256939487
NCT00766454,Studying Urine and Blood Samples in Women With Newly Diagnosed Breast Cancer,0.0002791827204658539,0.00031354640449139486
NCT00793546,Study Evaluating Bosutinib-Exemestane Combination Vs Exemestane Alone in Post Menopausal Women With Breast Cancer,0.0002746018416181949,0.0002914933265589032
NCT00793962,A Phase Ⅲ Randomized Clinical Trial of Postmastectomy Hypofractionation Radiotherapy in High-risk Breast Cancer,0.000258896344512493,0.0002911538185385293
NCT00793377,Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-Doc) Versus Dose-Dense Doxorubicin and Docetaxel (ADoc) in Breast Cancer,0.000253550827987797,0.00042771686200671717
NCT00760370,Comparison of Zometa Retention and Effect in Multiple Myeloma and Breast Cancer,0.0002484343149239376,0.00017541036566104713
NCT00760123,Lymphedema Prevention in Breast Cancer,0.0003350376474375862,0.00031411698697824135
NCT00780000,Clinical Trial of Intravenous Alvespimycin in Patients With Her2 Positive Breast Cancer,0.00030270194028019675,0.0003516481987946656
NCT00785382,Pregabalin for Postoperative Pain in Women Undergoing Breast Cancer Surgery,0.0002869884125314574,0.00018330758881724606
NCT00784888,Research Of Quality Of Life And Safety Outcomes Of Postmenopausal Breast Cancer Patients Switching From Tamoxifen Therapy To Aromatase Inhibitor Therapy,0.0003198951277163281,0.0004583733096452869
NCT00723125,"Carboplatin, Abraxane, Avastin as Neoadjuvant Therapy for Her2-Negative Breast Cancer",0.0002619513888538223,0.0002816444946631543
NCT00723294,Cryoablation Therapy in Treating Patients With Invasive Ductal Breast Cancer,0.0003332314594971136,0.00038311717469718005
NCT00794989,Flaxseed in Preventing Breast Cancer in Premenopausal Women at Risk of Developing Breast Cancer,0.00033170750281735333,0.00031602061331112495
NCT00741260,Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer,0.0002834859825723823,0.0003516680164841881
NCT00756717,Study Of MK-0752 In Combination With Tamoxifen Or Letrozole to Treat Early Stage Breast Cancer,0.0002942928426703286,0.00031767574802481403
NCT00774371,Weight Reduction Intervention for Breast Cancer Survivors,0.00033565038234921316,0.00031297908203833615
NCT00774878,Study of AVE1642 (IGF-1R/CD221) in Combination With Fulvestrant (Faslodex®) in Postmenopausal Patients With Advanced Hormono-dependent Breast Cancer,0.0003456536577620371,0.000371511847074943
NCT00767520,Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer,0.0002728827345461423,0.0003401811669554087
NCT00767585,An Open Label Non-Interventional Evaluation of the Effect of Adjuvant Hormonal Treatment of Postmenopausal Women Wih Early Breast Cancer With Aromatase Inhibitors on Bone Mineral Density and Bone Fracture Rate in Daily Practice,0.00026958423153486367,0.00035333896757373795
NCT00744653,Electrochemotherapy for Chest Wall Recurrence af Breast Cancer: Present Challenges and Future Prospects.,0.00023178881585794156,0.00022269980335055633
NCT00783822,Effects of Rapid Genetic Counseling and Testing in Newly Diagnosed Breast Cancer Patients,0.0003522393435875606,0.0003304483159418854
NCT00783757,TOBI to Monitor Response to Neoadjuvant Therapy in Breast Cancer,0.00026286676317754476,0.00028988051066821297
NCT00746694,A Study to Determine the Management of Palmar-plantar Erythrodysesthesia (PPE) in Patients With Metastatic Ovarian or Breast Cancer Treated With Caelyx (Study P05020),0.00031798785379476264,0.0003499401569223452
NCT00749255,Collect Breast Cancer Patients' Digital Mammography Images With Corresponding Reports for the Development of Software,0.00028132333623292815,0.00018815008571615013
NCT00725374,A Study to Investigate the Effects of Tibolone (Livial®) on Breast Tissue in Postmenopausal Women With Breast Cancer (Study 32971)(P06469),0.0002759138459450477,0.0003086356689807419
NCT00738777,Pre-operative Hormonal Treatment for Hormone Receptor Positive Breast Cancer,0.00031594825682607986,0.00048677520588786313
NCT00738998,Longitudinal Assessment of Arthralgia and Related Symptoms in Breast Cancer,0.0002551417523638054,0.00030698325350750366
NCT00792077,A Pilot Study to Investigate the Effect of Cytotoxic Therapy and/or Radiotherapy on Cancer Related Sleep Disturbances in CLL and Breast Cancer Patients Experiencing Fatigue,0.00032538947251707466,0.0003430523904136689
NCT00726180,"Use of Trastuzumab to Induce Increased ER Expression in ER-negative/Low, Her-2/Neu Positive Breast Cancer",0.00025258702671252355,0.0002604774083876917
NCT00700778,Recombinant Human Chorionic Gonadotropin in Preventing Breast Cancer in Premenopausal Women With BRCA1 Mutations,0.0003316138277226941,0.00025971974412463636
NCT00709020,White Button Mushroom Extract in Preventing the Recurrence of Breast Cancer in Postmenopausal Breast Cancer Survivors,0.0002857857227121215,0.00026895752459109637
NCT00775645,"S0715: Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, II, or IIIA Breast Cancer Undergoing Chemo",0.0002565833467191623,0.0002450738144116671
NCT00769080,The Performance of Patient Support Program in Early Stage Breast Cancer,0.00032291543106674687,0.0003137248552535386
NCT00769821,The Impact of Lymphedema on Breast Cancer Survivors,0.00046598214202236147,0.000226160331269448
NCT00772824,Study of the Effect of Glutamine Supplementation on Chemotherapy Induced Toxicities in Breast Cancer Patients,0.0003333215043152753,0.0002609794409231111
NCT00724386,Concomitant Chemoradiotherapy With Weekly Paclitaxel and Vinorelbine and Granulocyte Colony Stimulating Factor (GCSF) Support in Patients With Advanced Breast Cancer,0.0003070563106118722,0.000304400332813624
NCT00734838,Optical Spectroscopy During Breast Cancer Surgery and Core Needle Biopsy,0.00028698535708797666,0.00029729857463072764
NCT00777101,Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer,0.00029543510679490813,0.0003158806260563793
NCT00796107,A Study of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer,0.0003098554207185152,0.00034371543633667813
NCT00798070,Panther: A Study Comparing Biweekly and Tailored EC-T Versus Three Weekly FEC-T in Breast Cancer Patients,0.0004827287424213841,0.00038764281731947463
NCT00712140,Trastuzumab in Treating Women With HER2-Positive Early Breast Cancer,0.00048375288864420873,0.00023023575497432464
NCT00712569,Physician-Patient Communication About Breast Cancer-Related Internet Information and Its Effect on Patient Satisfaction and Anxiety,0.00028616716083477533,0.0002689125095460298
NCT00712881,Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Patients With HER2-Positive Breast Cancer,0.0003115335278229435,0.0003400442479132434
NCT00712621,"Determining Quality of Life in Breast Cancer Patient After Completing Radiation,Chemotherapy,Surgery or Combination",0.0003274002817325047,0.00037318224017133253
NCT00768859,Trastuzumab in a Neo-adjuvant Regimen for HER2+ Breast Cancer - the TRAIN Study,0.00029585100514656945,0.00036637855617256937
NCT00768222,Coated VICRYL* Plus Suture Compared to Chinese Silk in Scheduled Breast Cancer Surgery,0.00025919328551560515,0.0003332936357104126
NCT00757211,Study of Genes and Environment in Patients With Breast Cancer in the East Anglia Region of the United Kingdom,0.0004827287424213841,0.0003608101222001052
NCT00757302,Intraoperative Gamma Camera for Breast Cancer Surgery,0.00028687158535775593,0.00030756838718460716
NCT00719173,Effect of Aprepitant on Cyclophosphamide Pharmacokinetics in Patients With Breast Cancer,0.0003135959734221588,0.0002653667264485933
NCT00719875,HDAC Inhibitor Vorinostat (SAHA) With Capecitabine (Xeloda) Using a New Weekly Dose Regimen for Advanced Breast Cancer,0.0002522010293979596,0.00026281771609927194
NCT00719966,Effect of Aromatase Inhibitor Therapy on Blood Vessel Function in Postmenopausal Women With Breast Cancer,0.00026967969904379284,0.00028285584747627236
NCT00788489,"A Prospective Study to Evaluate FDG-PET, Breast MRI, and Breast Ultrasonography in Monitoring Tumour Responses in Patients With Locally Advanced Breast Cancer (LABC) Undergoing Neoadjuvant Chemotherapy",0.0003722867325078257,0.00040282620314944297
NCT00788333,Combination Study of BMS-754807 and Herceptin® in Patients With Advanced or Metastatic Her-2-positive Breast Cancer,0.0003488764257428014,0.0003374837765965974
NCT00739063,"Phase II Study of Erlotinib, an EGFR Inhibitor in Metastatic EGFR-positive 'Triple Receptor-negative' Breast Cancer",0.0002789482211669182,0.00031879727334961226
NCT00739544,Chronic Pain After Operation for Breast Cancer,0.0003475456818952909,0.00036598674147661053
NCT00742222,Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer,0.00031199990086566676,0.0003662634903348025
NCT00773695,A Study of Avastin (Bevacizumab) in Combination With Neoadjuvant Treatment Regimens in Patients With Primary HER2 Negative Breast Cancer,0.0003328978527298457,0.0003633637534462293
NCT00727662,A Yoga and Wellness Program for Breast Cancer Survivors With Persistent Fatigue,0.0002757253144632291,0.00020719365228252538
NCT00727883,Retrospective Observational Trial on Reasons for Withdraw of Adjuvant Tamoxifen in Breast Cancer Patients,0.00031412886892031905,0.00040154354889345296
NCT00754845,Letrozole in Treating Women With Primary Breast Cancer Who Have Received 5 Years of Aromatase Inhibitor Therapy,0.0002798823648794971,0.000259380962064938
NCT00754312,"A Phase I, Multicenter, Open Label Study on the Effects of SNDX-275 on Expression of Biomarkers in Subjects With Newly Diagnosed Breast Cancer",0.00028112052297065896,0.00035792299811181644
NCT00754325,Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor,0.0002701321409526285,0.0002927257175232698
NCT00702858,Trial of Blue Citrus Compared to Placebo in Patients Receiving Aromatase Inhibitor Therapy for Estrogen Receptor Positive Post-Menopausal Breast Cancer,0.00030806557699430666,0.0003390369880029915
NCT00770354,Phase II Study of AS1402 Combined With Letrozole to Treat Breast Cancer,0.00039558636765677787,0.00039771612589639514
NCT00713141,Evaluation of Brain Function Before and After Standard Chemotherapy for Early Breast Cancer,0.0002603265513829198,0.00023423513661641212
NCT00771433,G-CSF in Preventing Neutropenia in Women Receiving Chemotherapy for Breast Cancer,0.00035626775164186947,0.0003409149115202813
NCT00771381,A Study to Determine the Value of 18F-FAZA PET Imaging in Patients With Breast Cancer,0.00033198705257045727,0.0003304007021185076
NCT00759785,A Study of Dalotuzumab (MK0646) in Breast Cancer Patients (0646-013),0.0003906724768407871,0.0004387196207493221
NCT00728949,A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer,0.0003181188010676231,0.000311726695765017
NCT00728442,Impact of OncoDoc2 on Guideline Compliance in the Management of Breast Cancer,0.0002733852666289021,0.00028183098230149893
NCT00752986,ZACtima FASlodex Trial in Postmenopausal Advance Breast Cancer Patients Instead of ZACtima FASlodex Trial,0.0003833258776847841,0.0003350604200333822
NCT00717886,Upper Extremity Lymphatic Mapping for Breast Cancer Patients,0.0003461988522716179,0.000293444406926045
NCT00717405,A Study of Avastin (Bevacizumab) Plus Herceptin (Trastuzumab) in Patients With Primary Inflammatory HER2-Positive Breast Cancer.,0.0003266564261769348,0.0003334108126793631
NCT00717951,"A Randomised,Multi-Center Study of Docetaxol Plus Capecitabine or Cisplatin in Anthracycline-Pretreated Patients With Advanced Breast Cancer",0.00033844554974062866,0.0002980311105877305
NCT00717015,Tamoxifen Pharmacokinetics and CYP2D6 Polymorphisms in Asian Women With Hormone Receptor Positive Breast Cancer,0.00026428571073770394,0.00027528276854174523
NCT00776724,Tailored Neoadjuvant Chemotherapy for Stage II/III Breast Cancer With Tumor Size More Than 2 cm,0.0002818036562596127,0.00026925905132786074
NCT00776308,Use of Molecular Breast Imaging (MBI) to Detect Additional Disease in Women With Breast Cancer Who Are About to go to Surgery,0.0002882349498557828,0.00027011152455601024
NCT00776659,An Observational Study Of Indian Breast Cancer Patients Receiving Adjuvant Therapy With Aromasin,0.00032887026781848987,0.0003864958294413645
NCT00703326,Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer,0.0003257711538879931,0.00030057138419972186
NCT00701584,The Role of Diet and Lifestyle in Breast Cancer Survival,0.00032952839521765265,0.00030039176204460293
NCT00740961,Older Patients With Newly Diagnosed Breast Cancer or Colon Cancer,0.0003521754244863374,0.0003366697832639598
NCT00748267,Hypnosis in Reducing Pain and Other Side Effects in Women Undergoing Surgery for Breast Cancer,0.00024930134482773,0.00026551751486658686
NCT00748553,A Phase I/II Clinical Trial of Vidaza With Abraxane in the Treatment of Patients With Advanced or Metastatic Solid Tumors and Breast Cancer,0.0003283451084833923,0.0003600908590480852
NCT00764322,Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen,0.0002778386552664178,0.0002761902099407123
NCT00721903,Three Dimensional (3D) Ultrasound in Predicting Response to Breast Cancer Therapies,0.0003068440190008601,0.00040803005162140174
NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,0.00028366872310161656,0.00036300319009625285
NCT00721409,Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer,0.0002955070484444357,0.0003528503421252693
NCT00721565,An Exercise Intervention for Breast Cancer Patients: Feasibility and Effectiveness (BEAT Cancer Trial; Pilot Study),0.00032901355542501015,0.0002991999974724989
NCT00721747,"Taxotere®, Followed by Myocet® and Cyclophosphamide First Line Treatment in HER2 Neg Breast Cancer",0.00025153559316078275,0.0003557637486995516
NCT00721370,Near-Infrared Fluorescent Sentinel Lymph Node Mapping for Breast Cancer,0.0003276907332899458,0.0002621143291609118
NCT00705315,Docetaxel/Epirubicin/Bevacizumab as First Line Therapy for Metastatic HER2 Negative Breast Cancer,0.0002451014081323291,0.00033129087582087473
NCT00445458,A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer,0.0002789244611218506,0.0003735187734500437
NCT00445445,Changes in Breast Density and Breast Cancer Risk in Women With Breast Cancer and in Healthy Women,0.00033026268954232347,0.0003549077330799277
NCT00425672,ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment,0.0003541878185032088,0.0002995067246474851
NCT00425776,Treatment of Hot Flushes in Breast Cancer Patients With Acupuncture,0.0003751450017982054,0.0003384337176545874
NCT00425516,Breast Cancer Treated by Neoadjuvant Chemotherapy,0.0003743047592099143,0.00033603789492272937
NCT00451555,Enzastaurin Plus Fulvestrant vs. Placebo Plus Fulvestrant in Breast Cancer,0.00027669309132191065,0.0003681191067792233
NCT00407888,"Doxorubicin Hydrochloride, Cyclophosphamide, and Filgrastim Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation With or Without Trastuzumab in Treating Patients With Breast Cancer Previously Treated With Surgery",0.00030759860390520435,0.0002918621623553142
NCT00407706,Using Test of SCM for Detection Breast Cancer,0.000329789891287566,0.00024508042825969323
NCT00466830,Psychological and Social Factors That May Increase the Risk of Developing Chronic Pain After Surgery in Women With Breast Cancer,0.000287283340445713,0.00027658742459074577
NCT00466102,Efficacy of RAD001 in Breast Cancer Patients With Bone Metastases,0.0004257520766312893,0.00037126181843903964
NCT00465673,Liposomal Doxorubicin (Lipo-Dox) in Patients With Brain Metastasis From Breast Cancer,0.00034803783000228943,0.0002892420563143329
NCT00403182,Chemotherapy and Hormone Therapy as First-Line Therapy in Treating Postmenopausal Women With Metastatic or Locally Advanced Breast Cancer,0.00028231433967320187,0.00027763055105740203
NCT00477139,A Pilot Study Evaluating the Immunologic Status of Patients With HER2+ Breast Cancer,0.00034701827980883603,0.0003125127709874938
NCT00450762,Gemcitabine + Carboplatin in Breast Cancer,0.0003327035348145245,0.00026732307335510007
NCT00450866,Epothilone B in Treating Patients With CNS Metastases From Breast Cancer,0.000345442012211778,0.0003209274336384909
NCT00450892,Phase I/II Study of Neoadjuvant Lapatinib in Breast Cancer,0.0003339254588711456,0.0003730831590256045
NCT00428896,A Feasibility Study With Iressa in Resistant Cytokeratin-Positive Tumor Cells Circulating in the Blood of Women With Breast Cancer,0.00024046897587117331,0.0002256520889271156
NCT00464516,Preoperative Estetrol in Breast Cancer,0.0008829212022672371,0.0003172097136690499
NCT00435409,A Study Of Sunitinib In Combination With Capecitabine Compared With Capecitabine In Patients With Breast Cancer,0.0003363292744155152,0.00040856799583147217
NCT00421447,Bone Geometry and Muscle Density Changes in Postmenopausal Women and Breast Cancer Patients Prescribed Anastrozole,0.00029315831138536147,0.0002884791490602771
NCT00417885,A Clinical Trial Assessing Efficacy and Safety of Sunitinib and Exemestane in Patients With ER [Estrogen Receptor] + and/or PgR [Progesterone Receptor] + Breast Cancer,0.0002889589233294592,0.0003285489752745125
NCT00412022,"HOBOE: A Phase 3 Study of Adjuvant Triptorelin and Tamoxifen, Letrozole, or Letrozole and Zoledronic Acid in Premenopausal Patients With Breast Cancer.",0.0003250471549233972,0.0003260945516122169
NCT00481884,Comparing RadiaPlexRx Hydrogel and Standard-of-Care for Radiation Dermatitis in Breast Cancer Patients,0.00031018187158416745,0.00024335395130467905
NCT00481845,Phase 2 Anastrozole and Vandetanib (ZD6474) in Neoadjuvant Treatment of Postmenopausal Hormone Receptor-Positive Breast Cancer,0.000258348966909796,0.0002682255513487673
NCT00437879,Pilot Investigation of Ultrasound Imaging and Spectroscopy and Ultrasound Imaging of Vascular Blood Flow as Early Indicators of Locally-Advanced Breast Cancer Response to Neoadjuvant Treatment,0.00026546083504875266,0.000352439795564767
NCT00437853,Neoadjuvant Hormonal Treatment of Postmenopausal Women Who Have Operable Breast Cancer,0.0003261794528714615,0.00028206780273464785
NCT00437294,Enzastaurin in Combination of Capecitabine to Treat Breast Cancer,0.00028622993401263057,0.0003071319272632442
NCT00437073,Brain Metastases In ErbB2-Positive Breast Cancer,0.00046483868553141784,0.00032692419428827186
NCT00437359,Antiestrogen vs Aromatase Inhibitor After Adjuvant Chemotherapy for Breast Cancer,0.0002776291949681938,0.00021817638273722613
NCT00433095,Vinorelbine (Oral) Plus Trastuzumab for 1st-line Treatment of HER2/Neu Overexpressing Breast Cancer,0.00031334984224390514,0.0005458649928703376
NCT00433589,Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes,0.000257582246061786,0.0002730266490510796
NCT00433511,"Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer",0.0003045987724804862,0.0003746829525096928
NCT00433420,Combination Chemotherapy With or Without Fluorouracil and/or Pegfilgrastim in Treating Women With Node-Positive Breast Cancer,0.0002493172083728537,0.0002659729013353735
NCT00431704,"VinCaT: Vinorelbine, Carboplatin and Trastuzumab in Advanced Her-2 Positive Breast Cancer",0.0002749453360822471,0.00035741820729502443
NCT00431080,Randomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast Cancer,0.00024626682830902264,0.00032535401931082543
NCT00448305,EndoTAG-1 in Triple Receptor Negative Breast Cancer Patients,0.0003499763273341311,0.0003563113532147695
NCT00409071,Placebo-controlled Evaluation of Cocculine® Efficacy in the Management of Nausea After Chemotherapy in Breast Cancer.,0.0002519676959907297,0.00028573384562774484
NCT00476203,Yoga Study in Breast Cancer Patients,0.00039159512831846757,0.0004011625463730419
NCT00484614,Study the Role of Positron Emission Mammography in Pre-surgical Planning for Breast Cancer,0.0002826198435671187,0.00025786883068674814
NCT00446030,Pilot Study of the Safety & Efficacy of Two Docetaxel-Based Regimens Plus Bevacizumab for the Adjuvant Treatment of Subjects With Node Positive or High Risk Node Negative Breast Cancer,0.0003030374127050748,0.00033006844308375674
NCT00478257,Effect of Increased Light Exposure on Fatigue in Breast Cancer,0.00025062938257037625,0.00020492367706659043
NCT00478283,Views and Attitudes of Oncologists and Geriatricians on the Use of Chemotherapy and Hormone Therapy in Treating Older and/or Frail Women With Breast Cancer,0.0002689521812747951,0.0002451695685146458
NCT00478270,A Study of Loading Doses of Intravenous Bondronat (Ibandronate) in Patients With Breast Cancer and Metastatic Bone Disease.,0.0003189064158642374,0.00026337650595208427
NCT00429286,Preserving Function in Breast Cancer Patients,0.0004261334865610265,0.0003913212985269371
NCT00429299,"Neoadjuvant Study With Chemotherapy, Lapatinib And Trastuzumab In Breast Cancer",0.00030785340778834017,0.0004268451253011336
NCT00429507,Sm-EDTMP and Autologous Peripheral Blood Stem Cell Transplantation for Breast Cancer Patients With Bone Only Metastases,0.0002865719625193085,0.0002387051369769523
NCT00429403,Goserelin Acetate Study for Ovarian Function in Patients With Primary Breast Cancer,0.00032747659618981897,0.0003235332051984568
NCT00429247,Randomized Trial With Trastuzumab Versus Observation in Breast Cancer Patients,0.0003215219094690922,0.0002849496500215072
NCT00429988,Study of Ductal Lavage in Women at High Risk for Breast Cancer,0.0003214275848472843,0.0002811479234638218
NCT00440089,Effects of Hands-on-Healing vs. Touch for Fatigued Breast Cancer Survivors,0.00033191874394730985,0.00021214044990512098
NCT00459628,Trial of Tomotherapy in Breast Cancer,0.0004604954805249314,0.00028033532533588805
NCT00415285,Docetaxel Followed by Capecitabine Versus Concomitant Docetaxel/Capecitabine for Early Stage Breast Cancer,0.00026618808418186536,0.00033234465007197015
NCT00422903,Letrozole In Combination With Lapatinib In Neoadjuvant Treatment Of Early Breast Cancer,0.00027402694387260174,0.0002690380904400168
NCT00427726,Follow-up of Breast Cancer and Multiple Myeloma Patients Previously Enrolled in NIH Gene Therapy Studies,0.00030858444400742147,0.0003448507465793797
NCT00427427,Delayed Adjuvant Herceptin® Treatment in Patients With HER-2 Positive Breast Cancer,0.0003166237779823376,0.000347241333095539
NCT00418210,Accelerated Partial Breast Irradiation for Early Breast Cancer,0.0004611785708990071,0.0002597318636373014
NCT00418457,Regional Anesthesia and Breast Cancer Recurrence,0.00033037383343678596,0.00017688842499505737
NCT00418028,Standard Versus Continuous Capecitabine in Advanced Breast Cancer,0.0003044308799036525,0.0002453615412441095
NCT00418444,Body Image and Psychosocial Functioning in Women With Breast Cancer: Can We Fix What We've Broken?,0.0003279597860040121,0.0003447068861184024
NCT00473096,Efficacy Study of an Educational Program for Decision Support for Breast Cancer,0.0002756983142703229,0.0003064081791883524
NCT00472589,A Biological Sample Collection Protocol of Women With and Without Breast Cancer,0.00027375361001666154,0.0002244071451999455
NCT00496379,ZK219477 (Sagopilone) in Patients With Breast Cancer and Brain Metastases,0.00042709534318825906,0.00034448006203792507
NCT00496665,ZD6474 (Zactima) and Metronomic Chemotherapy in Advanced Breast Cancer,0.00026805806535808066,0.0003016002220850876
NCT00496366,Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2/Neu-positive Breast Cancer,0.0002648037012427401,0.000388293026076003
NCT00496613,Chemotherapy-Induced Changes to Cognition and DNA in Breast Cancer Survivors,0.00029583810277014746,0.00028256529455833115
NCT00496288,Prophylactic Irradiation to the Contralateral Breast for BRCA Mutation Carriers Undergoing Treatment for Breast Cancer,0.0002685477214582287,0.0002011683639055176
NCT00496795,Predictors for Response to Dose-dense Docetaxel and Epirubicin Breast Cancer,0.00025811839672339426,0.00034755105694551935
NCT00452673,Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Women With Advanced Breast Cancer,0.000310770544330267,0.00036211684648512597
NCT00497458,Androgen Therapy for Breast Cancer Patients With Aromatase Inhibitor Induced Side-Effects,0.0003491124129181919,0.00034067066039703816
NCT00488722,"A Prospective, Single-Arm Study to Evaluate the Efficacy and Safety of Zoladex 3.6mg Combined With CEF Chemotherapy as Neo-Adjuvant Therapy in Hormone Responsive, Premenopausal, Operable Breast Cancer",0.0002842148907110018,0.00029061141186052005
NCT00402519,APBI Versus EBRT Therapy After Breast Conserving Surgery for Low-risk Breast Cancer,0.0003019787801629686,0.00022160334337327674
NCT00463489,Lifestyle Intervention Study in Adjuvant Treatment of Early Breast Cancer,0.0003684125935949588,0.00028535389866759294
NCT00424983,Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year,0.000348248952689178,0.0003668061032345873
NCT00424606,Epirubicin and Docetaxel Combination (ET) or Epirubicin Followed by Docetaxel (E/T) for Node Negative (N0) High Risk Breast Cancer Patients,0.000300488739753657,0.00027019283495577785
NCT00499525,Phase 2b Study of Taxol Plus Sorafenib or Placebo in Patients With Advanced Breast Cancer,0.0003372611730943329,0.000353512144903421
NCT00499603,Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer,0.00047767251510476294,0.0003801946241146735
NCT00436566,"Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery",0.00032094132466471784,0.0003025476017537996
NCT00436917,"Zoledronate in Treating Osteopenia or Osteoporosis in Postmenopausal Women Receiving Letrozole for Stage I, Stage II, or Stage IIIA Primary Breast Cancer",0.0002518937361020008,0.0002363647833103787
NCT00436254,Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer,0.00029236022957946056,0.000287100913474072
NCT00419900,Use of Hair to Diagnose the Presence of Breast Cancer,0.00027849840596555394,0.00022972073622689622
NCT00419822,Acupuncture in the Management of Post Operative Symptoms in Breast Cancer Patients,0.0003123488530967929,0.00035407080348951733
NCT00419679,Use of Hair to Diagnose Breast Cancer,0.00033616094016557506,0.00027594977295089854
NCT00458588,Long-Term Effect of Adolescent Diet on Hormones and Breast Cancer Risk in Women Previously Enrolled in the Dietary Intervention Study in Children,0.0002636877492518201,0.00025249126981281226
NCT00458796,Comparison of Two Schedules of Zoledronic Acid in Treating Patients With Breast Cancer That Has Spread to the Bone,0.0002955610027107213,0.00021487038204033468
NCT00462865,Trial of Chemotherapy and Avastin as Treatment for Women With Breast Cancer at High Risk for Relapse,0.00027775681891086895,0.00032546305768211425
NCT00462696,MRI in Evaluating Early Response to Chemotherapy in Women Receiving Chemotherapy for Infiltrating Breast Cancer,0.00029910282249328353,0.00029500904684409045
NCT00462410,Effect of Advertisements on Treatment Compliance in Women With Breast Cancer,0.00030006010215098797,0.00031865241245896856
NCT00479856,Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer,0.00027469247817830613,0.00034764512472979013
NCT00490503,Non-Invasive Magnetic Resonance Imaging (MRI) and Magnetic Resonance Spectroscopy Techniques (MRS) for Assessing Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer,0.00027607783120641544,0.0003460206132923922
NCT00432172,Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients,0.00032217519354046286,0.0003195431551529849
NCT00416130,Clinical Trial of SAHA in Patients With Breast Cancer,0.00042808054543232036,0.00036057040774779153
NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",0.0002497321139065989,0.00022873944735537862
NCT00416689,Nausea or Vomiting in Patients Who Are Receiving Chemotherapy for Breast Cancer or Lung Cancer,0.0003075346210169474,0.000309876482749925
NCT00404066,Phase II Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer,0.00025504033205593765,0.0003269239493277726
NCT00454805,AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.,0.0003742744099113529,0.0003669996756240703
NCT00470119,Effect of a Low-Calorie Diet and/or Exercise Program on Risk Factors for Developing Breast Cancer in Overweight or Obese Postmenopausal Women,0.00024355034255597234,0.00019014711215644672
NCT00470847,Lapatinib in Combination With Radiation Therapy in Patients With Brain Metastases From HER2-Positive Breast Cancer,0.00031023198738287366,0.0003133770689605679
NCT00493870,TAC Versus TC for Adjuvant Breast Cancer,0.0008829212022672371,0.0006991869922726951
NCT00493649,Adj TC + Herceptin Early Stage Breast Cancer,0.0003478097256081246,0.0003154546721902152
NCT00434369,5-Fluorouracil Combined With CoFactor (5-10 Methylenetetrahydrofolate) in Treating Advanced Breast Cancer Patients,0.0003023503747054457,0.00025092127602658677
NCT00434031,CETRA: Neoadjuvant Caelyx and Trastuzumab in Her-2 Positive Breast Cancer,0.00027834331790312035,0.0003396704780040217
NCT00434941,Administration of Capecitabine Simultaneous to Radiotherapy for Local Relapse Breast Cancer Patients With Negative Her2 Tumours,0.0002988963175046615,0.0003319191381619353
NCT00461253,Case-Control-Study on the Breast Cancer Risk of Mirena® Compared With Copper IUDs,0.00026942522218340357,0.000340810291722116
NCT00461773,Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer,0.0002819427616416812,0.0003029962044828536
NCT00461344,Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer,0.0003261313572793144,0.00032929230152414107
NCT00438074,A Pilot Study To Evaluate the Effectiveness of Pulsed Time-Domain Optical Spectroscopy for Monitoring the Responses in Neoadjuvant Treatments of Locally-Advanced Breast Cancer,0.0002976505140024027,0.00033969437640157726
NCT00471159,A Study Of Docetaxel Or Docetaxel Plus PF-3512676 To Treat Patients With Advanced Breast Cancer.,0.0003743135767771977,0.0005815039513261906
NCT00471276,Efficacy And Safety Of Sunitinib In Women With Advanced Breast Cancer,0.0003620519515471349,0.00037707108275250096
NCT00471601,Development of a Questionnaire to Evaluate Patient Expectations for Breast Reconstruction in Women With Breast Cancer or Other Conditions,0.00028727062597452564,0.0002641044299466343
NCT00408863,"Livial Intervention Following Breast Cancer; Efficacy, Recurrence and Tolerability Endpoints (LIBERATE)(COMPLETED)(P05885)",0.0002791856915375866,0.00027285080609821985
NCT00498771,Aquatic Exercise Study for Breast Cancer Patients With Lymphedema,0.0003526714187391602,0.00040900651805771387
NCT00485953,Effect of Bisphosphonate on Bone Loss in Postmenopausal Women With Breast Cancer Initiating Aromatase Inhibitor Therapy,0.0002688879372070134,0.00021233887874893344
NCT00485979,"Treatment of Larotaxel/Docetaxel, +/- Trastuzumab, After Anthracycline-cyclophosphamide in Breast Cancer Patients",0.00031846929672908427,0.0003400463592226478
NCT00455273,Dynamic Breast MRI in Assessing Locally Advanced Breast Cancer,0.0003670451784542722,0.0002655937347758625
NCT00455039,INST 0514C- Biologic Correlative Study: Trial of GW572016 in HER2 Overexpressing Breast Cancer Patients,0.0003907434408554873,0.0003943106055970981
NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,0.0002910613710601737,0.000332848893626439
NCT00489125,Strength and Range of Motion in Women Undergoing Surgery for Breast Cancer,0.00034709021713493654,0.0002873562999545722
NCT00494234,Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Breast Cancer,0.0003196935648600327,0.00040168391931300594
NCT00494481,E3 Breast Cancer Taxotere Combination,0.0003409425914916481,0.0002942477360766203
NCT00474604,Breast MRI in Women With Known or Suspected Breast Cancer and in Healthy Participants,0.00046846270813881544,0.00027743607208399485
NCT00482391,"Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer",0.0003061991577747416,0.000425195161106277
NCT00495209,Pre-Surgical Qigong Therapy for Women With Breast Cancer,0.0003152765996082218,0.0003177047185835423
NCT00486525,"Hatha Yoga in Improving Physical Activity, Inflammation, Fatigue, and Distress in Breast Cancer Survivors",0.00023925356387948264,0.0001922942914021532
NCT00426335,Evaluation of Group CBT Programme With Breast Cancer Patients,0.0003196184258362123,0.0003883390394628534
NCT01840293,Breast Cancer Proteomics and Molecular Heterogeneity,0.00046212792425593817,0.00023720911433443306
NCT01862900,Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic Lesions,0.0002895640685228243,0.00028721039971810777
NCT01879189,PROSPR/PCIPS Project 3: Communication of Personalized Breast Cancer Risk,0.0004609067803268478,0.0001888440254674073
NCT01888419,Investigation of the Pain Relieving Properties of Lipotransplantation After Treatment for Breast Cancer,0.00027693009823397916,0.0003738426581976384
NCT01893944,Applicability of Video Games and Vibrational Therapy in Reducing Pain Secondary to Breast Cancer,0.0002590768185159666,0.00025358753948634334
NCT01824745,Survivorship Care Planning in Improving the Quality of Life in Breast Cancer Survivors,0.00033192527637498014,0.0003377871105181141
NCT01824498,"Dietary Fat, Eicosanoids and Breast Cancer Risk",0.0004607711993515514,0.0001928923056341054
NCT01848197,Paclitaxol Every 2 Week Versus Paclitaxol Every 1 Week in the Adjuvant Treatment of Breast Cancer,0.0005152476714020549,0.00025187976086593074
NCT01804309,Functional Anatomical Examination of Axillary Sentinel Lymph Node Drainage in the Axillary Subregions in Early Breast Cancer,0.0002420942377869289,0.0002494927458330768
NCT01843608,Effect of Combined Exercise Post-treatment Intervention in Lean Mass Recovery in Breast Cancer Survival.,0.0002647668768645978,0.0004331450831951959
NCT01864798,A Study to Evaluate Denosumab in Young Patients With Primary Breast Cancer,0.0003538915591315712,0.0004040472039044965
NCT01864083,FACBC PET and PEM as a Staging Tool and Indicator of Therapeutic Response in Breast Cancer Patients,0.00032061513827494944,0.00045352640556973274
NCT01869764,Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer,0.00035754172272469195,0.00036555705967873133
NCT01856543,Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation,0.00028892950858102067,0.0003103216459252663
NCT01856452,Comparison Study of Sentinel Lymph Node Biopsy by Multimodal Method in Breast Cancer,0.00027259683354120904,0.0002385221346046169
NCT01842321,Abiraterone Acetate in Molecular Apocrine Breast Cancer,0.00027252701997670643,0.0004091898895150882
NCT01891227,Capecitabine + Bendamustine in Women With Pretreated Locally Advanced or Metastatic Her2-negative Breast Cancer,0.0002784883128743211,0.000371549382392687
NCT01891357,Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer,0.00032803325875131647,0.00041953466490582
NCT01831778,Breast Cancer Surveillance Consortium,0.0004617251646067236,0.00015836323440085716
NCT01874184,Group-Based Lifestyle Intervention in Measuring Biomarker Levels in Participants at High Risk for Breast Cancer,0.0002441932424847572,0.0002669041556447882
NCT01830933,Breast Cancer Risk Reduction: A Patient Doctor Intervention,0.00035196868944121254,0.00021077184969984898
NCT01830244,IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer,0.0002932238120560502,0.0004318158738142603
NCT01815242,Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer - Triple Negative Breast Cancer,0.00026589021203895455,0.00028901735402960855
NCT01828021,Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer,0.00033183919007293304,0.00040205575308492565
NCT01811264,Improving Psychosocial Quality of Life in Women With Advanced Breast Cancer,0.000300754373827336,0.00021740339520010297
NCT01857193,Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer,0.0002815296739048217,0.0003116614886424629
NCT01890824,Fat Metabolism Following Chemotherapy in Breast Cancer,0.0002936155332260754,0.000277329464424494
NCT01894711,Real World Efficiency of Trastuzumab in Early Breast Cancer,0.00048375288864420873,0.0002765292670594008
NCT01836640,Developing Plasma DNA as a Surrogate for Tumor Biopsy to Identify Tumor Genetic Alterations in Patients With Advanced Breast Cancer,0.0003054968654080323,0.00046079557746841034
NCT01818713,Clinical and Pharmacological Study With 2B3-101 in Patients With Breast Cancer and Leptomeningeal Metastases,0.00031018163755905257,0.0003394086592477762
NCT01818063,Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer,0.0003053063243941113,0.0003510132191362512
NCT01855503,Breast Cancer Molecular Analysis Protocol,0.00033041934699592736,0.00030759174251221075
NCT01819324,A Lifestyle Intervention for Breast Cancer Survivors,0.0004701954466120917,0.0003152087267086176
NCT01819233,Caloric Restriction in Treating Patients With Stage 0-I Breast Cancer Undergoing Surgery and Radiation Therapy,0.0003204214001474591,0.00034448497466767794
NCT01819948,Changes in Biomarkers of Cancer in Women With Breast Cancer and Without Evidence of Disease Who Were Given PhytoMed™,0.00025589741208848084,0.0003152702899115217
NCT01814865,Anti-Proliferative Effects and Genomic Alterations of Abiraterone Acetate Compared to an Aromatase Inhibitor in Post-menopausal HR+ Operable Breast Cancer,0.00023941128549133462,0.0003258550702493463
NCT01814449,Relationship Between Hypoxia and Endocrine Response in Human Breast Cancer,0.0002775157599517536,0.0003211213144103634
NCT01814397,Pilot Study to Evaluate the Effect of Aromatase Inhibitor Therapy on Pain Threshold in Breast Cancer Patients,0.0003460538622480531,0.00036754818618235907
NCT01809171,Placebo-controlled Trial With Vitamin D to Prevent Worsening/Relieve Aromatase Inhibitor-induced Musculoskeletal Symptoms in Breast Cancer Patients,0.00028616160810950416,0.0002350554118067044
NCT01880853,Ultrasound and Mammography for Screening Breast Cancer in Chinese Women,0.000274637233548959,0.00019444927658107157
NCT01880541,Assessment of Cognitive Function After Surgery in Two Types of Anesthesia in Patients Operated for Breast Cancer,0.0003081269769428486,0.0001996133067360599
NCT01805076,MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer,0.0003318042607375306,0.0003549869933012379
NCT01805908,Imaging With 111 Indium (111In)-Pertuzumab (PmAb) to Predict Response to Trastuzumab (TmAb) in Human Epidermal Growth Factor-2 (HER2) Positive Metastatic Breast Cancer (MBC) or Locally Advanced Breast Cancer (LABC),0.0002678006169930877,0.00031871792111743834
NCT01805089,Melatonin Versus Placebo in Breast Cancer,0.0003306937214700145,0.00027370872104776756
NCT01805271,"Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy",0.00027268885064224804,0.00035412830573748095
NCT01897441,Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer,0.00032126175336382,0.0003967966838125915
NCT01867229,Breast Cancer and Chemo-amennorhea,0.00046132192545348614,0.00047201852503679696
NCT01895491,Safety Study of VM206RY in Subjects With Expression of HER2 in Breast Cancer,0.00038771721663480974,0.0006013750802804893
NCT01816594,NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast Cancer,0.00028311138350114177,0.00024066391274782896
NCT01816035,Ado-Trastuzumab Emtansine in Treating Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed by Surgery,0.00031645782515784984,0.0003666923728880357
NCT01861054,Pilot Study to Evaluate the Safety and Biological Effects of Orally Administered Reparixin in Early Breast Cancer Patients,0.0003321851546841035,0.00032291530244339954
NCT01829984,Verbal and Written Instruction Versus Verbal and Written Plus Simulation in Patients With Breast Cancer and Their Caregivers,0.00030825645074641884,0.00027454979076192037
NCT01823549,Nutritional Supplements & Complementary/Alternative Medicine by Prostate & Breast Cancer Patients,0.0002921176943816685,0.0003143242011684863
NCT01823835,A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer,0.000289045764585936,0.00035050327320574037
NCT01823991,COGNUTRIN in Breast Cancer Survivors,0.0008829212022672371,0.00033070620946477853
NCT01827163,Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer,0.0002757589114080954,0.0004550129934657296
NCT01803958,Breast Cancer With Low Risk Of Local Recurrence: Partial and Accelerated Radiation With Three-Dimensional Conformal Radiotherapy (3DCRT) Vs. Standard Radiotherapy After Conserving Surgery (Phase III Study,0.0002827689694613479,0.0003976197253368083
NCT01803516,QOL Assessment in Breast Cancer Patients With Radiation-Induced Telangiectasias Treated With the Pulsed Dye Laser,0.0003033027613964671,0.0003167939676485713
NCT01845519,Step by Step: A Tailored Walking Intervention for Breast Cancer Survivors,0.00033454974202975417,0.0004350987367529062
NCT01878695,Pilot Study of Anti-oxidant Supplementation With N-Acetyl Cysteine in Stage 0/I Breast Cancer,0.0002946028522399842,0.00024263497583474014
NCT01896050,"Loss of Grip Strength, BMI, and Adjuvant Endocrine Therapy Breast Cancer",0.00033486389810674687,0.00037370083269139823
NCT01881022,An Internet-based Psychosexual Intervention for Couples Following Treatment for Breast Cancer,0.00037112972071914744,0.0002864109131963035
NCT01859936,Will Preoperative MRI Breast in Women Under 56 Years With Breast Cancer Change Primary Treatment,0.0002751917989550775,0.0003743783982689372
NCT01822314,Neoadjuvant Chemotherapy With Nab-paclitaxel in Women With HER2-negative High-risk Breast Cancer,0.0002794933712415999,0.0002734041192489007
NCT01866202,Study of Circulating and Tumor Biomarkers in Breast Cancer Patients,0.000355211903233513,0.0004069150160370931
NCT01866813,Internet-Delivered Cognitive Training For Breast Cancer Survivors With Cognitive Complaints,0.0003293240736220756,0.0002354793512528398
NCT01866631,Using National University Cancer Institute of Singapore (NCIS) Registry to Measure Time Trends in Quality of Care for Breast Cancer Patients in a National Cancer Centre,0.0002933190702356212,0.0002344418725067963
NCT01847001,Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy,0.0003481171991561196,0.00040070594516114765
NCT01875367,A Phase III Clinical Trial to Evaluate Patient´s Preference of Subcutaneous Trastuzumab (SC) Versus Intravenous (IV) Administration in Patients With HER2 Positive Advanced Breast Cancer (ABC).,0.0003140936129941902,0.0003258856611565022
NCT01875666,"Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib",0.00025220149892852113,0.00039926327795292713
NCT01892540,PET/CT or PET/MRI in Measuring Tumors in Patients Undergoing Clinical Imaging or With Newly Diagnosed Breast Cancer,0.00029635129296094097,0.00031921754385403104
NCT01871116,POWER-remote Weight Loss Program in Early Stage Breast Cancer,0.00034283701274105124,0.0002847691690862541
NCT01806259,Ketorolac in Breast Cancer Surgery,0.00034699694320981935,0.0002719158996418349
NCT01872260,"Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer",0.0003497874861206196,0.00032999172813424926
NCT01887925,The Effects of Circadian Gene on Sleep and Associated Symptoms in Breast Cancer Patients Under Chemotherapy,0.0003280049114954027,0.0004270192727319951
NCT01837563,Monitoring of Neoadjuvant Therapy in Locally-Advanced Breast Cancer,0.00031244382100601857,0.0003235172614208072
NCT01837602,cMet CAR RNA T Cells Targeting Breast Cancer,0.000463252489934321,0.00021022683932312583
NCT01839045,Breast Cancer Biomarker Sample Collection for the dtectDx Assay Verification,0.0002514118523555229,0.0003001572881027121
NCT01849250,Docosahexaenoic Acid in Preventing Recurrence in Breast Cancer Survivors,0.00033037383343678596,0.0003702108038857638
NCT01849614,Assessment of Ability of Breath Hold for Left-sided Breast Cancer Radiation Therapy to Reduce Side Effects to Heart,0.0002485386653508555,0.0002696158168812243
NCT01849328,Testing Spectrosense EVA System for Detection of Breast Cancer by Analyzing Volatile Organic Compounds (VOCs) in Exhaled Air,0.0002723359786325096,0.00018163139181289804
NCT01849978,Enhancing Exercise in Breast Cancer Survivors,0.00046717801519213396,0.00034867759356788097
NCT01849380,Neoadjuvant ECS Versus ECF in Local Advanced Breast Cancer,0.00031162305975855023,0.00026570943011487393
NCT01858116,PET Study of Breast Cancer Patients Using [68Ga]ABY-025,0.00035003752045591885,0.000443416261857622
NCT01876238,Feasibility of a Team Approach for Discussing Prognosis and Treatment Goals in Breast Cancer,0.00030035912275239846,0.0003046830114777563
NCT01876251,A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer,0.00035722943217945675,0.00043527331460006986
NCT01817231,Epidemiological Analysis of Vitamin D and Breast Cancer Risk in Saudi Arabian Women,0.0004624165934661497,0.0003175717497408789
NCT01817452,"A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pertuzumab With or Without Concurrent Taxane Chemotherapy Given for Twelve Weeks in Patients With Operable HER2+/HR- Breast Cancer Within the ADAPT Protocol",0.0003142069391823244,0.0002731138507196344
NCT01801527,Telehealth System to Improve Quality of Life in Breast Cancer Survivors,0.00027551086311533536,0.00036938608552263436
NCT01800422,Oral CDB-4124 vs. Placebo in Stage I-II Primary Breast Cancer,0.00034538964717142727,0.00031176855271094394
NCT01821768,Axillary Ultrasound With or Without Sentinel Lymph Node Biopsy in Detecting the Spread of Breast Cancer in Patients Receiving Breast Conservation Therapy,0.0002941555447472438,0.0003570490159083179
NCT01969253,A Prospective Observational Study of Lymphedema in Breast Cancer With Axillary Lymph Node Dissection,0.00028940413598565134,0.00029273159260048974
NCT01969643,A Safety Study of SGN-LIV1A in Breast Cancer Patients,0.0004827287424213841,0.0003831785592961897
NCT01980823,Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer,0.0002595932979243211,0.000331252690768475
NCT01980277,Phase Ib/II Study of LY2780301 in Combination With Weekly PACLITAXEL in HER2-metastatic Breast Cancer,0.000335075951800552,0.0002632108117646082
NCT01937052,Johns Hopkins Breast Cancer Program Hormone Therapy Longitudinal Database,0.00028090317040591794,0.00020199599938588048
NCT01937507,Hepatic Artery Infusion With FOLFOX in Liver Metastasis From Breast Cancer,0.00032768662868549954,0.00019987288873785078
NCT01937689,Study of Pyrotinib in Patients With Human Epidermalgrowth Factor Receptor 2 (HER2) Positive Advanced Breast Cancer,0.00034296781868089284,0.0003249328642087465
NCT01937039,Johns Hopkins Breast Cancer Program Longitudinal Repository,0.00046693538703530265,0.00030064103689346266
NCT01937117,Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer,0.0003318371933127334,0.00028012526702773363
NCT01908270,Effects of Yoga on Menopausal Symptoms in Women With Breast Cancer,0.0003289503075050877,0.0003117596475509619
NCT01950182,Trastuzumab Combined With Chemotherapy or Endocrine Therapy to Treat Metastatic Luminal B2 Breast Cancer,0.0002699103586348008,0.0004021258863947259
NCT01952054,Denosumab for Breast Cancer With Bone Mets,0.0003303743825900949,0.00037183245693953244
NCT01954706,Exercise to Prevent Aromatase Inhibitor Side Effects in Breast Cancer Patients,0.0002982109074302158,0.0003183419966763738
NCT01954654,Effectiveness of Accelerated Intervention With Compression Sleeve in Mild and Moderate Breast Cancer-related Lymphedema,0.00023823070552509378,0.000315322677289982
NCT01919229,A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1),0.00040573728572033344,0.0005600674822045812
NCT01982591,Heavy Metal Exposure in Predicting Peripheral Neuropathy in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy,0.0003168218852408637,0.00035321713123452776
NCT01921296,Pilot Study of Cyclobenzaprine for Treatment of Sleep Disturbance in Aromatase Inhibitor-treated Breast Cancer Patients,0.00033636987128912694,0.0003215781009724724
NCT01924078,Capecitabine Metronomic Chemotherapy Plus Aromatase Inhibitor for Postmenopausal Hormone Receptor Positive Breast Cancer,0.00025513201378904666,0.0003097918754739618
NCT01924351,HER2-positive Breast Cancer With Brain Metastasis (GCC 1345),0.0003307599311919418,0.00024432098881024903
NCT01989780,Bevacizumab Plus Paclitaxel Optimization Study With Interventional Maintenance Endocrine Therapy in Advanced or Metastatic ER-positive Human Epidermal Growth Factor Receptor 2(HER2)-Negative Breast Cancer,0.0003061140132749824,0.00029313831960928535
NCT01914614,A Pilot Study of Working Women and Breast Cancer,0.0005475118996500432,0.00030469184387360766
NCT01956513,Contribution of MRI in the Evaluation of Apparent Diffusion Coefficient and Prediction of Response to Neoadjuvant Chemotherapy in Breast Cancer,0.00028781712876606384,0.00039807995703031705
NCT01994369,Intraoperative Imagery of Breast Cancer With Folate-FITC (EC17),0.0002717421499788446,0.00026272227407414273
NCT01996046,FDG PET/CT in Breast Cancer Bone Mets,0.00032997594051261173,0.0003192789012626963
NCT01996410,The Efficacy of Acupuncture in Treating Chemotherapy Side Effects in Breast Cancer Patients,0.00032841987226305106,0.00030058538659709865
NCT01992952,Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer,0.0002597197912507854,0.00036127987993552375
NCT01992471,Multiplex Testing for Breast Cancer Susceptibility: A Pilot Study of Subject Preferences for Information and Responses After Testing,0.00027393249791769336,0.00029208358395210054
NCT01992250,Cryoablation of Small Breast Tumors in Early Stage Breast Cancer,0.0002835164003903797,0.00035669581053467906
NCT01992432,Brain Functional MRI in Older Women With Breast Cancer (Brain fMRI-BC),0.0003293375806355753,0.00031167705696393076
NCT01963572,A Continuing Cancer Service Model Emphasizing on Functional Restoration: Model for Breast Cancer,0.00023278644942064216,0.00039897710993579426
NCT01927939,18F-FDG PET Metabolic Phenotype in Evaluating Therapeutic Response for Breast Cancer Patients With Bone Metastases.,0.00030820271856847007,0.00034869725282444733
NCT01927081,Self-management Interventions for Advanced Breast Cancer,0.0002995833210232408,0.00030414331558147815
NCT01990430,Behavioural Changes in Breast Cancer Patients,0.0004263175454746863,0.0003339464342617879
NCT01959490,Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer,0.0003005068023172555,0.0003496609292745231
NCT01901146,Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Subjects With HER2 Positive Early Breast Cancer,0.00033003109743288907,0.0005402618072701733
NCT01901094,Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy,0.0003150691611025527,0.00038060110205467303
NCT01926964,Adjuvant Treatment Recommendation and Oncotype DX® in Early Breast Cancer,0.00036463195633461493,0.00034071793467977616
NCT01926886,A Study of Subcutaneous At Home Administration of Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer,0.0003242501272859464,0.000323337292819239
NCT01928186,"FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer",0.0003277616811083906,0.0003438174573954034
NCT01928615,A Study of Subcutaneously Administered Herceptin (Trastuzumab) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer,0.00032823273821611467,0.0003490821662775939
NCT01928589,Partial Irradiation and Sequential vs. Concurrent Chemo Early Breast Cancer,0.0003416907350237202,0.00030146621706707196
NCT01945476,Effect of Midazolam Premedication Before Induction on the Functional Recovery After General Anesthesia in the Patients Undergoing Breast Surgery Due to Breast Cancer,0.0002943987494571983,0.00034710332034684657
NCT01913067,Evaluation of Cabazitaxel in Patients With Brain Metastasis Secondary to Breast Cancer and NSCLC,0.0002923794583169181,0.00034005660876379527
NCT01913990,Prevention of Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients.,0.00032895595713550933,0.00024089375821767975
NCT01907438,Transformation Potential of E2 Exposed Breast Cancer Susceptibility Gene Mutation Heterozygous Epithelial Breast Cells,0.0002509684774136321,0.00022995297247103898
NCT01907880,The ODYSSEY TRIAL Phase IV Trial Evaluating the Palliative Benefit of Pamidronate or Zoledronic Acid in Breast Cancer,0.0002732854716663229,0.0002465341187839549
NCT01907529,A Trail of Neoadjuvant Endostar in Combination With Chemotherapy in Breast Cancer,0.00028379447515852854,0.00030399174217222844
NCT01943695,Supervised Aerobic Training During or After Chemotherapy for Operable Breast Cancer,0.00035754261266246874,0.00035601583779397894
NCT01943032,Discordant Hormonal Status of Breast Cancer.,0.00032823949173259163,0.000330357946404105
NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,0.00027492202151898596,0.00029071656191037907
NCT01948128,Effects of Vitamin D in Patients With Breast Cancer,0.00042543686435278966,0.000263592134955763
NCT01948726,Hypofractionation With Simultaneous Integrated Boost for Early Breast Cancer,0.00046145869323399515,0.000420056617948356
NCT01998906,A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Women With Locally Advanced Breast Cancer,0.0003037432751073228,0.00028048407414628954
NCT01965522,Anti-proliferative Effects of Vitamin D and Melatonin in Breast Cancer,0.00027312715231074585,0.0003227566730917585
NCT01965483,Phase 2 Study of Adjuvant Radiotherapy in Breast Cancer Using a Once a Week Hypofractionated Regimen,0.0003186234604516748,0.0002983210223709181
NCT01929811,NeoMET Study in Neoadjuvant Treatment of Breast Cancer,0.0004047910140414459,0.0002995875373657581
NCT01993576,ICG Distribution Using NIF Imaging After IV Injection of ICG in Benign and Malignant Breast Cancer Tissue.,0.0002513836290245183,0.00030475353352889636
NCT01993498,Breast Cancer Toxicity,0.00046282263863925297,0.0002873719168126062
NCT01991340,H.E.R.O.S. Study: An Observational Study of the Cardiac Safety of Herceptin (Trastuzumab) in Patients With HER2-Positive Breast Cancer,0.0003294453677217898,0.0003650936182154225
NCT01912612,Mechanistic Study of Duloxetine Versus Placebo in Breast Cancer Patients With Chronic Pain,0.00032747733958866584,0.00036348870355708637
NCT01912963,"Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer",0.00029288941266086973,0.00043202661549769655
NCT01940497,SCHEARLY Study: A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer,0.0002930193322530789,0.00027219919561589185
NCT01940107,Domiciliary Physiotherapy in Women Undergoing Treatment for Breast Cancer Radiation,0.0003107842134521921,0.000238670990886564
NCT01972984,Feasibility Study of Presurgical Hormone Therapy (Anastrozole) in Breast Cancer Patients,0.00031602012407091037,0.0003553717896851987
NCT01973660,PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer,0.00025142067968519916,0.0002949148066280561
NCT01936064,The Safety and Efficacy of Jobelyn in the Treatment of Breast Cancer Patients,0.0003736504562771746,0.0003507597955020105
NCT01975363,Pilot Study of Curcumin for Women With Obesity and High Risk for Breast Cancer,0.00028874753441056637,0.0002788829970588702
NCT01935739,Discordant HER2/Neu Status of Breast Cancer.,0.00032759569931932843,0.0003300559815186136
NCT01925651,Clinical Trial of The Use of Bolus in Post Mastectomy Irradiation in Breast Cancer,0.00025858263933704396,0.0003384653954758037
NCT01949376,Mild Cognitive Impairment in Breast Cancer Patients,0.00042402168164967075,0.0003735490518316693
NCT01961128,RPFNA Assessment of Exercise Effect in Breast Cancer,0.0003396643359633293,0.0002676210257469383
NCT01961544,Eribulin Mesylate Phase IV Clinical Trial in Korean Patients With Metastatic or Locally Advanced Breast Cancer,0.0003190004405520131,0.0003462419407487664
NCT01941784,Health Education Intervention in Reducing Weight Gain in Patients With Newly Diagnosed Stage I-IV Breast Cancer Undergoing Chemotherapy,0.0003149412630594738,0.0003464999229934854
NCT01983501,A Phase 1b Study of ONT-380 Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer,0.0003465409221214245,0.0004206756098326484
NCT01934478,Radiotherapy Alternates Human Epidermal Growth Factor 2 (Her2) Expression in Human Breast Cancer,0.0002833233417831394,0.00037072765199377565
NCT01905046,Metformin Hydrochloride in Patients With Atypical Hyperplasia or In Situ Breast Cancer to Placebo in Decreasing Atypical Cells in Patients With Atypical Hyperplasia or in Situ Breast Cancer,0.00028295488945176807,0.0003234292755602786
NCT01905592,"A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients",0.00029006505559890693,0.0003255266137116474
NCT01970670,Contrast-Enhanced Digital Mammography(CEDM) vs Contrast-Enhanced Breast MRI(CE-MRI) in Breast Cancer,0.0002763191959175393,0.000231997021285449
NCT01904331,Breast Cancer Long-term Outcome of Cardiac Dysfunction,0.00032895635008716297,0.00028945525229625847
NCT01904266,Paravertebral Blocks for Breast Cancer Surgery,0.0003476379257486892,0.00031565695403163585
NCT01904903,Cardiac Safety Study in Patients With HER2 + Breast Cancer,0.00039151069233262875,0.00035192595572382945
NCT01931709,FDG PET and DCE-MRI in Predicting Response to Treatment in Patients With Breast Cancer,0.0003373450556626268,0.0003484781328339138
NCT01931943,A Phase Ib Study of Selatinib Ditosilate Tablets in Patients With Advanced Breast Cancer,0.0003684088795421933,0.0003862445001799011
NCT01931163,NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer,0.0003304628074445275,0.00032121877978205963
NCT01942759,The Prognostic Value of FDG PET/CT and Diffusion-weighed Imaging on Breast Cancer,0.00024969105222735706,0.0002511927653823348
NCT01942980,Evaluation of the Efficacy of Hippocampal Avoidance on the Cognitive Toxicity of Whole-Brain Radiation Therapy After Surgical Resection of Single Brain Metastasis of Breast Cancer,0.0002564116579022313,0.00033184522824649174
NCT01964391,A Study of Participant Satisfaction and Safety With Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer,0.0002713103416683766,0.0002684619031553641
NCT01917578,Study of Breast Cancer Shrinkage Modes After Neoadjuvant Chemotherapy With Whole-mount Serial Sections and Three-dimensional Pathological and MRI Reconstruction,0.00028596970349021976,0.00026984206809739443
NCT01988870,IORT (Intra-operative Radiation Therapy) in Early Stage Breast Cancer,0.0003562493582650302,0.0003478872272657387
NCT01985841,Bevacizumab in Combination With Chemotherapy in the Neo-adjuvant Setting for HER2 (-) Breast Cancer,0.0002753145880214759,0.0003393762083297753
NCT01985724,"Sequential Administration of FE75C and Docetaxel Versus Docetaxel/Cyclophosphamide in HER-2 Negative, Node Positive Breast Cancer",0.0002466502404727456,0.00022614622520797666
NCT01985945,Yoga for Breast Cancer,0.00046212586113425665,0.00031210779280031216
NCT01985971,F18 EF5 PET/CT Imaging in Patients With Brain Metastases From Breast Cancer,0.00031718672393464553,0.0002337262583865018
NCT01984866,CPR Prediction After Neoadjuvant Using Excisional Biopsy By Radiofrequency In Breast Cancer From II-III UICC Stages.,0.0002975210175927279,0.0002124611647839788
NCT01939054,Nimotuzumab Plus Docetaxel and Capecitabine Versus Docetaxel and Capecitabine in the Treatment of Breast Cancer Patients,0.00032203280814124797,0.000246410177399454
NCT01939483,A Pilot Study of Irinotecan in Patients With Breast Cancer and CNS Metastases,0.00034684048991463995,0.0003263949744357155
NCT01938651,Ultra High Field MRI and MRS Techniques in Diagnosing Breast Cancer,0.00025523597102182065,0.00025974140957645036
NCT01938157,Diffusion Weighted MR Imaging of the Breasts in Women at High Risk of Breast Cancer: A Pilot Study,0.0002791718806602926,0.0002638222513965658
NCT01953003,Phase III Study of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer,0.0003400928614103882,0.00038374792916409585
NCT01953588,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,0.0003094355156427266,0.000356663755594242
NCT01953445,Paclitaxel and BKM120 Before Surgery in Treating Patients With Stage II or III Estrogen Receptor-Positive and HER2-Negative Breast Cancer,0.00031137484509855754,0.00040536565499355937
NCT01916837,Genomic Grade Index (GGI): Feasibility in Routine Practice and Impact on Treatment Decisions in Early Breast Cancer,0.0002517553841901364,0.0003639920156940272
NCT01916317,Randomized Controlled Trial to Assess Blockade of Voltage Gated Sodium Channels During Surgery in Operable Breast Cancer,0.0002467770610946094,0.0003589463864416221
NCT02652975,Anticancer Treatment of Breast Cancer Related to Cardiotoxicity and Dysfunctional Endothelium,0.00027400716958736113,0.00031673450164554395
NCT02615054,Assessment for Long-Term Cardiovascular Impairment Associated With Trastuzumab Cardiotoxicity in HER2-Positive Breast Cancer Survivors,0.000243366512958725,0.0002808917602675091
NCT02615678,Acupuncture for CIPN in Breast Cancer Patients,0.00042592667634126606,0.0004458618087861125
NCT02694029,Active Breathing Coordinator-based vs VisionRT-based Deep Inspiration Breath-hold for Radiation for Breast Cancer,0.00024291060585443074,0.00023769137529296185
NCT02630368,A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX),0.0003684088795421933,0.00034096613577487187
NCT02626507,Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer,0.00032408685807859967,0.0003673908651521876
NCT02692755,Palbociclib / Letrozole in African American Women With HR+ HER2- Breast Cancer,0.0003388858322972579,0.000337965274845976
NCT02605915,Safety and Pharmacokinetics of Atezolizumab in Combination With Trastuzumab Emtansine or With Trastuzumab and Pertuzumab (With and Without Docetaxel) in Participants With HER2-Positive Breast Cancer and Atezolizumab With Doxorubicin and Cyclophosphamide in HER2-Negative Breast Cancer,0.0002527043863937367,0.0003257133235958082
NCT02619292,Mindful Movement for Breast Cancer Survivors,0.00046063984328790326,0.00028592740706311553
NCT02619162,Nintedanib+Letrozole in Postmenopausal Women With Breast Cancer: Clinical Trial Safety and Pharmacodynamics,0.00034753701267088764,0.0002829339063967793
NCT02619669,Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer,0.0003054762369729634,0.00029349290310336636
NCT02651142,"A Randomized, Controlled Trial of Sentinel Lymph Node Biopsy With or Without Para-Sentinel Lymph Node Dissection in Breast Cancer",0.00023872273241481046,0.00018073282766000877
NCT02651844,Mifepristone for Breast Cancer Patients With Higher Levels of Progesterone Receptor Isoform A Than Isoform B.,0.00030898404187684346,0.0004045369090410954
NCT02651519,Sleep Quality After Stellate-ganglion Block of Patients Undergoing Breast Cancer Operation,0.00030321580582958054,0.0003047572474336823
NCT02649101,Thalidomide Plus Chemotherapy Versus Chemotherapy Alone for Advanced Breast Cancer,0.0002875692682847808,0.00026766154052459203
NCT02611544,Investigation of Three Approaches to Address Fear of Recurrence Among Breast Cancer Survivors,0.0002549152211847279,0.00023986962451484698
NCT02696759,Gut Microbiome & Gastrointestinal Toxicities as Determinants of Response to Neoadjuvant Chemo for Advanced Breast Cancer,0.0002617578798227329,0.00019088362218834418
NCT02696707,An Integrated Consent Model Study to Compare Two Standard of Care Schedules for Monitoring Cardiac Function in Patients Receiving Trastuzumab for Early Stage Breast Cancer,0.00032907548603815944,0.00030373497643656474
NCT02680236,Art Therapy for Pain Relief in Breast Cancer Patients,0.00034544226502092573,0.0003023837386657971
NCT02654119,"Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Patients With Stage I-II HER2/Neu Positive Breast Cancer After Surgery",0.00031871209431118177,0.0004032076379542335
NCT02672189,Internet-based Cognitive Behavioral Therapy for Breast Cancer Patients With Climacteric Symptoms,0.00030976029592181707,0.0003176626920452887
NCT02628613,Neoadjuvant Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Epirubicin for TEKT4 Variation Breast Cancer Patients,0.00030433025964723645,0.0003712721086266461
NCT02612012,Axillary Radiotherapy for Early Stage Breast Cancer With Limited Positive Sentinel Lymph Nodes,0.0002568952449219562,0.0003083868844024772
NCT02639832,A Pilot Surveillance Study to Monitor Natural Killer Cells and Circulating Tumor Cells in Women With Previously Treated Non-metastatic Triple Negative Breast Cancer and Women With Previously Treated Non-metastatic Breast Cancer With a Confirmed BRCA Mutation.,0.0002647426045998918,0.00031438046309014735
NCT02644382,Improving Surgical Decision-making in Young Women With Breast Cancer,0.000347544079145645,0.00027357900393540786
NCT02669576,Mind-Body Medicine Day Care Clinic in Breast Cancer Patients Undergoing Endocrine Therapy,0.0003128822823540098,0.00029611304502377955
NCT02669745,The Study of Molecular Risk Panels (70-gene Assay) in Chinese Breast Cancer Patients,0.0003267309182283645,0.00035360516732588264
NCT02688257,Assessing Treatment Response in Breast Cancer With Functional Imaging,0.0003059265409152962,0.0003635843429876391
NCT02688725,Post-Mastectomy Surveillance to Detect Recurrence in Breast Cancer Patients,0.00031163659459070264,0.00031539338524202423
NCT02616133,HER2+ Breast Cancer Neo-Adjuvant Coordination of Care Program,0.00046693538703530265,0.00028017821320835626
NCT02664103,Study of Capecitabine and Cyclophosphamide Administered as a Single Pill in Patients With Advanced Breast Cancer,0.0003383077015048117,0.0003777034257183495
NCT02664662,The Validation of Tailored Rehabilitated Education in Breast Cancer Survivors After Surgery,0.0003489495051338985,0.0003056029930634363
NCT02647216,Mindfulness for Breast Cancer,0.00046229057229774123,0.0003183119232896508
NCT02661932,Fertility Preservation in Breast Cancer Patients,0.00042402168164967075,0.0003696352789748778
NCT02671097,"Drug-drug Interaction Study Using Rosuvastatin as a Breast Cancer Resistant Protein (Efflux Transporter), Organic Anion-transporting Polypeptide (OATP)1B1, and OATP1B3 (Uptake Transporters) Probe Substrate",0.0002596298390331581,0.00027542327801699426
NCT02663973,Prospective Evaluation of Breast Cancer at Brazilian Institutions - Project AMAZONA III,0.00025319153226221,0.0003888238629606139
NCT02620735,Smart-phone Health Coaching Intervention to Promote Maintenance of Exercise in Breast Cancer Survivors:Protocol,0.0002564512753586939,0.00029875986069037537
NCT02620280,Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1,0.00035210248366998224,0.00032982873459169184
NCT02685111,"Intermittent G-CSF in Patients With Breast Cancer Receiving Adjuvant Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)",0.00030258692762430314,0.00021687709358354874
NCT02685306,A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer,0.0002939306998817109,0.00034303426655634686
NCT02621437,Impact of Osteopathy on Pain After Breast Cancer Surgery,0.00028862814854271174,0.0003256751376777867
NCT02613923,A Sleep Intervention to Improve Outcomes Among Women at High Risk of Breast Cancer,0.00025580697190605745,0.00028719485607199774
NCT02613026,Comparative Analysis of the Efficacies in Neoadjuvant Chemotherapy of Breast Cancer,0.0003743047592099143,0.0003884409800923281
NCT02610426,Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer,0.0003056076507149451,0.0003528177555090853
NCT02610920,Sentinel Lymph Node Identification in the Axilla of Women With Breast Cancer Using Ultrasound and Iron Injection,0.00023326795486218682,0.000248617294429432
NCT02610439,Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Peripheral Neuropathy Receiving Paclitaxel for Breast Cancer,0.00029098987904418707,0.00032969052995276185
NCT02610413,Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer,0.0002871113888211226,0.0003118541232594007
NCT02610621,Safety and Efficacy of Sentinel Node Biopsy Omission for Breast Cancer Patients Who Plan to Have Adjuvant Chemotherapy,0.00029389146769767015,0.000276166344646443
NCT02666378,Imaging Markers of Subclinical Cardiotoxicity in Breast Cancer,0.0002819962864939766,0.0002970783378012057
NCT02666261,A Study on the Epidemiology and Testing of Human Epidermal Growth Factor-Receptor 2 (HER2) in Breast Cancer in Germany,0.0003170825862083313,0.00035064038469577425
NCT02666079,Randomised Trial of LightPath Imaging in Breast Cancer Surgery,0.0003518273357109076,0.0002860710018074829
NCT02679586,Imaging Biomarker for Early Detection of Treatment Efficacy During Breast Cancer Neoadjuvant Chemotherapy,0.00028474957035428853,0.00029986144393685706
NCT02679755,"Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR+, HER2- Advanced Breast Cancer",0.0002833343200397209,0.0003817866289498841
NCT02679638,Factors and Perceptions Affecting Treatment Choices of Breast Cancer Patients,0.000373720860679541,0.0003319907030128255
NCT02674204,STOP Heart Disease in Breast Cancer Survivors Trial,0.00046049479959635954,0.00036337029115977816
NCT02689921,NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer,0.00033261126594176353,0.0002938236082770938
NCT02627248,Neoadjuvant Chemotherapy With or Without Huaier Granule in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery,0.0002871397265361436,0.000297968534196032
NCT02627703,(Oncotype DX®) in Estrogen Receptor Positive (ER+) HER-2 Negative (HER 2-) 1-3 Node Positive (pN1) Breast Cancer,0.00024223897339853125,0.00027441470067833914
NCT02691624,Study of the Change of Breast Cancer Patients' Upper Limb Lymphatic Drainage Pathway After Operation,0.0003261124397851725,0.0002893003716189308
NCT02601794,A Study of Delivering a Mindfulness App Intervention to Accompany Supportive Care Among Women With Breast Cancer,0.00029042659174259415,0.0002655498293356078
NCT02636582,Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer,0.0003461141552047403,0.0003131938398643947
NCT02670577,Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry,0.0003025562823962876,0.0003670466788042423
NCT02670668,Mutation of BRCA1/2 and Other Potential Genes in Triple-negative Breast Cancer,0.00033453401219621983,0.00035509927331466105
NCT02625441,"Adjuvant Trastuzumab, Pertuzumab Plus Docetaxel in the Treatment of Early HER2-positive Breast Cancer",0.000287576359165726,0.00031676868844790533
NCT02625935,Prospective Observational Study Evaluating Treatment Decision Impact of Prosigna® in Early Stage Breast Cancer Patients,0.0003438956627342418,0.0003096079219554535
NCT02653105,Women at Risk of Breast Cancer and OLFM4,0.0008829212022672371,0.0002723812955174168
NCT02653755,The PRECISION Trial (Profiling Early Breast Cancer for Radiotherapy Omission): A Phase II Study of Breast-Conserving Surgery Without Adjuvant Radiotherapy for Favorable-Risk Breast Cancer,0.00027181916784753196,0.0003253344006789477
NCT02690636,Conventional Versus Hypofractionated Radiotherapy in Node Positive Breast Cancer,0.0002588935193750366,0.00019209509425521714
NCT02690116,Effects of Meditative Movement (Qigong/Tai Chi Easy) on Fatigued Breast Cancer Survivors,0.00024910861091203445,0.00029454481450504397
NCT02698891,Avoiding Growth Factor During Paclitaxel Treatment in Breast Cancer,0.0002778734792771812,0.00031061401090484535
NCT02650193,A Study Of The Safety And Effects Of One Or More Doses Of HSP-130 Injected Under The Skin In Women With Breast Cancer That Has Not Spread To Distant Sites In The Body.,0.0003179972081518552,0.0002986578372834699
NCT02646735,Fulvestrant 500mg With Exemestane Endocrine Therapy for Postmenopausal Advanced Breast Cancer Patients,0.0003195179658957143,0.0003271144375330074
NCT02632045,Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ H2N- Advanced Breast Cancer,0.0003354915128983636,0.00031786922469300756
NCT02676986,Phase II Window of Opportunity Study of Short-term Preoperative Treatment With Enzalutamide (Alone or in Combination With Exemestane) in Patients With Primary Breast Cancer,0.00034328129797253295,0.0003925766145267836
NCT02676531,Walking Meditation Exercise in Breast Cancer Patients,0.00031230965614140806,0.0003654538600811404
NCT02614794,Phase 2 Study of Tucatinib vs Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer,0.00034741317111578097,0.00032675965469990305
NCT02600923,Palbociclib Plus Letrozole For Postmenopausal Women With HR(+) HER2(-) Advanced Breast Cancer For Whom Letrozole Is Deemed Appropriate,0.00028494576995113973,0.0003933205110078695
NCT02600442,Assessment of Breast Cancer Response to Neoadjuvant Anthracycline-based Chemotherapy by FDG-PET and Molecular Markers,0.00026989721914999216,0.00036956529109730975
NCT02600299,Effectiveness of a Psycho-educational Group (PEG) Intervention on Supportive Care and Survivorship Issues in Early-stage Breast Cancer Survivors Who Have Received Systemic Treatment,0.00026299874597278665,0.0003544404460113127
NCT02617264,Spot tm Tattooing of Biopsied Axillary Lymph Nodes With Ultrasound Guided in Breast Cancer Patients Prior to Surgery,0.0002942324078529268,0.0002962834192420521
NCT02657343,"An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.",0.0002669195500688893,0.00032302801371583624
NCT02657889,Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Triple-negative Breast Cancer or Ovarian Cancer,0.00032213136286337175,0.00036347734841465755
NCT02604030,"Surgical Intervention and Physiotherapy in Breast Cancer: Effects in Scapular Kinematics, Pain and Upper Limb Function",0.00024637833374168317,0.00022014584279834672
NCT02677714,99mTc-rhAnnexin V-128 Imaging and Cardiotoxicity in Patients With Early Breast Cancer,0.0003501549777404428,0.00029027200890159073
NCT02677857,Developing a Healthy Lifestyle in Breast Cancer Survivors,0.0008829212022672371,0.0002807661235164302
NCT02668666,Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer,0.00025369163632670623,0.0003168353830089779
NCT02699983,Virtual Weight Loss Program in Maintaining Weight in African American Breast Cancer Survivors,0.00032823757147094435,0.0002515391288735181
NCT02681965,A Mail and Video-based Weight Loss Trial in Breast Cancer Survivors,0.0003290593494896748,0.0002724328610684229
NCT02681562,"Olaparib in Locally Advanced ER, PgR and HER2 Negative (Triple Negative) and in Locally Advanced Germline BRCA Mutation-positive Breast Cancer Patients",0.00031140010597392384,0.0003973521069103037
NCT02681640,uPAR PET/CT for Preoperative Staging of Breast Cancer Patients,0.0004289588534386335,0.0003535307311052492
NCT02681523,ALERT: A Phase II Study of Alternating Eribulin and Hormonal Therapy in Pre-treated ER+ve Breast Cancer.,0.0002744190393415452,0.00030864327448732094
NCT02681120,Effect of Weight Loss on Breast Tissue and Blood Biomarkers in Women at Increased Risk for Breast Cancer,0.0002420351825588296,0.0002562308022790123
NCT02681107,APBI: 27Gy in 5 Fractions for Early Breast Cancer,0.00046063390108542725,0.00028925030301481605
NCT02609321,Efficacy of Thoracic Paravertebral Block in the Reduction of Acute Post-surgical Pain in Patients With Breast Cancer,0.000294234650981036,0.00026682562203084377
NCT02673918,The Breast Cancer Online Rehabilitation Program,0.0003327375167383948,0.00026925206103719384
NCT02673398,Neratinib in Treating Older Patients With Metastatic HER2-Positive Breast Cancer,0.0003541791809777321,0.0003545451955669851
NCT02658461,An Observational Time and Motion Study of Trastuzumab Subcutaneous (SC) and Intravenous (IV) Formulations in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (EBC),0.00027080621736629186,0.0002754187716893585
NCT02658812,Talimogene Laherparepvec (T-VEC) for Breast Cancer Local Recurrence,0.0004645999129676211,0.00035161898056465345
NCT02658708,Bright Light on Fatigue in Women Being Treated for Breast Cancer,0.00033173922229358307,0.0003295599262962538
NCT02622711,Promoting Weight Loss Through Diet and Exercise in Overweight Women With Breast Cancer,0.00025138701472129113,0.0002032416315751966
NCT02606110,Pilot Study Investigating the Use of the ReBuilder to Treat Chemotherapy Induced Peripheral Neuropathy in Patients With Breast Cancer,0.0003651258919352495,0.0005463786820624178
NCT02683083,"Study to Evaluate the Safety, Biodistribution, Radiation Dosimetry and Tumor Imaging Potential of [131I]-SGMIB Anti-HER2 VHH1 in Healthy Volunteers and Breast Cancer Patients",0.00032425097400889,0.00038643809584938893
NCT02648802,Cavity Shaving in Breast Conserving Surgery for Breast Cancer Patients,0.0003460071023674492,0.0002930840773537286
NCT02662335,Computerized Cognitive Retraining in Improving Cognitive Function in Breast Cancer Survivors,0.0004624147497205726,0.00027575085443949795
